



# Summary Tables by Region, Health Area, Country and Product

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Region**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	26,543	-	-	-	4,910,842	5,024	1,178,400	79,241	1,625	457	-	86,390
East Africa	69,776	14	-	-	5,346,738	3,978	1,395,117	26,013	990	3,345	-	36,938
Southern Africa	145,071	16	-	3	2,782,990	1,212	562,866	18,061	514	1,777	-	21,299
Americas	2,842	18	-	648	661,549	68	144,456	34	112	-	-	825
Asia and Eastern Europe	8,948	-	85	4,200	6,200,107	1,354	1,586,933	2,501	620	-	-	8,962
<b>Total</b>	<b>253,180</b>	<b>48</b>	<b>85</b>	<b>4,851</b>	<b>19,902,226</b>	<b>11,637</b>	<b>4,867,772</b>	<b>125,851</b>	<b>3,862</b>	<b>5,579</b>	<b>-</b>	<b>154,414</b>

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Region**  
**Period: 12**  
**Year: 2017**

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>4,218,273</b>	<b>38,115,982</b>	<b>30,499,631</b>	<b>(20%)</b>		<b>29,529,513</b>	<b>103%</b>
<b>West and Central Africa</b>	<b>1,621,010</b>	<b>20,138,152</b>	<b>10,783,165</b>	<b>(46)%</b>	<b>100 %</b>	<b>10,124,875</b>	<b>107%</b>
Family Planning	220,631	2,738,708	2,655,826	(3)%	25%	2,434,357	109%
HIV & STIs	131,934	1,542,724	1,062,413	(31)%	10%	1,434,900	74%
Malaria	1,085,581	15,565,001	6,599,183	(58)%	61%	5,926,969	111%
Maternal, Newborn, and Child Health	5,160	148,628	184,940	24%	2%	149,686	124%
Non-communicable diseases	4	683	513	(25)%	0%	326	158%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	177,230	122,137	273,235	124%	3%	174,275	157%
Tuberculosis	-	14,311	-	(100)%	0%	-	0%
WASH	468	5,961	7,056	18%	0%	4,364	162%
<b>East Africa</b>	<b>1,084,291</b>	<b>8,591,386</b>	<b>8,264,313</b>	<b>(4)%</b>	<b>100 %</b>	<b>8,579,902</b>	<b>96%</b>
Family Planning	191,036	2,212,175	2,585,377	17%	31%	2,436,560	106%
HIV & STIs	248,227	3,613,556	2,840,680	(21)%	34%	3,150,257	90%
Malaria	329,100	2,339,040	2,087,372	(11)%	25%	1,760,498	119%
Maternal, Newborn, and Child Health	(1,349)	319,107	373,587	17%	5%	866,929	43%
Non-communicable diseases	20	748	380	(49)%	0%	894	42%
Nutrition	-	31,989	20,370	(36)%	0%	-	0%
Safe Abortion	315,349	45,735	337,646	638%	4%	344,144	98%
Tuberculosis	-	29	-	(100)%	0%	-	0%
WASH	1,908	29,007	18,903	(35)%	0%	20,620	92%
<b>Southern Africa</b>	<b>1,275,790</b>	<b>7,533,480</b>	<b>9,082,432</b>	<b>21%</b>	<b>100 %</b>	<b>8,054,990</b>	<b>113%</b>
Family Planning	146,281	659,923	814,507	23%	9%	819,499	99%
HIV & STIs	795,023	6,034,822	6,572,941	9%	72%	6,106,101	108%
Malaria	323,406	643,322	1,459,816	127%	16%	921,962	158%
Maternal, Newborn, and Child Health	8,927	165,099	159,854	(3)%	2%	165,421	97%
Non-communicable diseases	10	401	239	(40)%	0%	159	151%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	416	1,744	49,318	2,728%	1%	3,049	1,618%
Tuberculosis	31	289	277	(4)%	0%	166	167%
WASH	1,696	27,881	25,480	(9)%	0%	38,634	66%
<b>Americas</b>	<b>12,958</b>	<b>176,655</b>	<b>232,360</b>	<b>32%</b>	<b>100 %</b>	<b>219,289</b>	<b>106%</b>
Family Planning	4,557	39,884	49,867	25%	21%	53,376	93%
HIV & STIs	5,936	90,163	132,637	47%	57%	114,251	116%
Malaria	2,338	-	2,338	0%	1%	2,258	104%
Maternal, Newborn, and Child Health	-	12,121	10,301	(15)%	4%	14,123	73%
Non-communicable diseases	-	-	7	0%	0%	-	0%
Nutrition	13	132	162	23%	0%	183	89%
Safe Abortion	114	137	640	369%	0%	870	74%
Tuberculosis	-	34,218	36,409	6%	16%	34,228	106%
<b>Asia and Eastern Europe</b>	<b>224,224</b>	<b>1,676,309</b>	<b>2,137,361</b>	<b>28%</b>	<b>100 %</b>	<b>2,550,456</b>	<b>84%</b>
Family Planning	90,930	948,572	1,164,566	23%	54%	1,357,188	86%
HIV & STIs	45,642	383,719	437,945	14%	20%	632,895	69%
Malaria	58,865	67,775	226,614	234%	11%	262,011	86%
Maternal, Newborn, and Child Health	1,465	93,355	19,996	(79)%	1%	49,398	40%
Non-communicable diseases	-	809	183	(77)%	0%	-	0%
Nutrition	11	-	104	0%	0%	-	0%
Safe Abortion	14,294	38,201	88,878	133%	4%	90,136	99%
Tuberculosis	12,937	135,508	182,712	35%	9%	145,648	125%
WASH	81	8,369	16,363	96%	1%	13,180	124%

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Health Area**  
**Period: 12**  
**Year: 2017**

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>4,218,273</b>	<b>38,115,982</b>	<b>30,499,631</b>	<b>(20)%</b>		<b>29,529,513</b>	<b>103%</b>
<b>Family Planning</b>	<b>653,435</b>	<b>6,599,263</b>	<b>7,270,143</b>	<b>10%</b>	<b>100%</b>	<b>7,100,980</b>	<b>102 %</b>
West and Central Africa	220,631	2,738,708	2,655,826	(3)%	37 %	2,434,357	109%
East Africa	191,036	2,212,175	2,585,377	17%	36 %	2,436,560	106%
Southern Africa	146,281	659,923	814,507	23%	11 %	819,499	99%
Americas	4,557	39,884	49,867	25%	1 %	53,376	93%
Asia and Eastern Europe	90,930	948,572	1,164,566	23%	16 %	1,357,188	86%
<b>HIV &amp; STIs</b>	<b>1,226,761</b>	<b>11,664,983</b>	<b>11,046,615</b>	<b>(5)%</b>	<b>100%</b>	<b>11,438,404</b>	<b>97 %</b>
West and Central Africa	131,934	1,542,724	1,062,413	(31)%	10 %	1,434,900	74%
East Africa	248,227	3,613,556	2,840,680	(21)%	26 %	3,150,257	90%
Southern Africa	795,023	6,034,822	6,572,941	9%	60 %	6,106,101	108%
Americas	5,936	90,163	132,637	47%	1 %	114,251	116%
Asia and Eastern Europe	45,642	383,719	437,945	14%	4 %	632,895	69%
<b>Malaria</b>	<b>1,799,291</b>	<b>18,615,137</b>	<b>10,375,322</b>	<b>(44)%</b>	<b>100%</b>	<b>8,873,698</b>	<b>117 %</b>
West and Central Africa	1,085,581	15,565,001	6,599,183	(58)%	64 %	5,926,969	111%
East Africa	329,100	2,339,040	2,087,372	(11)%	20 %	1,760,498	119%
Southern Africa	323,406	643,322	1,459,816	127%	14 %	921,962	158%
Americas	2,338	-	2,338	0%	0 %	2,258	104%
Asia and Eastern Europe	58,865	67,775	226,614	234%	2 %	262,011	86%
<b>Maternal, Newborn, and Child Health</b>	<b>14,203</b>	<b>738,309</b>	<b>748,676</b>	<b>1%</b>	<b>100%</b>	<b>1,245,556</b>	<b>60 %</b>
West and Central Africa	5,160	148,628	184,940	24%	25 %	149,686	124%
East Africa	(1,349)	319,107	373,587	17%	50 %	866,929	43%
Southern Africa	8,927	165,099	159,854	(3)%	21 %	165,421	97%
Americas	-	12,121	10,301	(15)%	1 %	14,123	73%
Asia and Eastern Europe	1,465	93,355	19,996	(79)%	3 %	49,398	40%
<b>Non-communicable diseases</b>	<b>34</b>	<b>2,642</b>	<b>1,321</b>	<b>(50)%</b>	<b>100%</b>	<b>1,378</b>	<b>96 %</b>
West and Central Africa	4	683	513	(25)%	39 %	326	158%
East Africa	20	748	380	(49)%	29 %	894	42%
Southern Africa	10	401	239	(40)%	18 %	159	151%
Americas	-	-	7	0%	1 %	-	0%
Asia and Eastern Europe	-	809	183	(77)%	14 %	-	0%
<b>Nutrition</b>	<b>24</b>	<b>32,121</b>	<b>20,636</b>	<b>(36)%</b>	<b>100%</b>	<b>183</b>	<b>11,268 %</b>
West and Central Africa	-	-	-	0%	0 %	-	0%
East Africa	-	31,989	20,370	(36)%	99 %	-	0%
Southern Africa	-	-	-	0%	0 %	-	0%
Americas	13	132	162	23%	1 %	183	89%
Asia and Eastern Europe	11	-	104	0%	1 %	-	0%
<b>Safe Abortion</b>	<b>507,404</b>	<b>207,953</b>	<b>749,717</b>	<b>261%</b>	<b>100%</b>	<b>612,473</b>	<b>122 %</b>
West and Central Africa	177,230	122,137	273,235	124%	36 %	174,275	157%
East Africa	315,349	45,735	337,646	638%	45 %	344,144	98%
Southern Africa	416	1,744	49,318	2,728%	7 %	3,049	1,618%
Americas	114	137	640	369%	0 %	870	74%
Asia and Eastern Europe	14,294	38,201	88,878	133%	12 %	90,136	99%
<b>Tuberculosis</b>	<b>12,968</b>	<b>184,355</b>	<b>219,397</b>	<b>19%</b>	<b>100%</b>	<b>180,042</b>	<b>122 %</b>
West and Central Africa	-	14,311	-	(100)%	0 %	-	0%
East Africa	-	29	-	(100)%	0 %	-	0%
Southern Africa	31	289	277	(4)%	0 %	166	167%

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Health Area

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Americas	-	34,218	36,409	6%	17 %	34,228	106%
Asia and Eastern Europe	12,937	135,508	182,712	35%	83 %	145,648	125%
<b>WASH</b>	<b>4,154</b>	<b>71,219</b>	<b>67,803</b>	<b>(5)%</b>	<b>100%</b>	<b>76,798</b>	<b>88 %</b>
West and Central Africa	468	5,961	7,056	18%	10 %	4,364	162%
East Africa	1,908	29,007	18,903	(35)%	28 %	20,620	92%
Southern Africa	1,696	27,881	25,480	(9)%	38 %	38,634	66%
Asia and Eastern Europe	81	8,369	16,363	96%	24 %	13,180	124%

POPULATION SERVICES INTERNATIONAL  
 Monthly DALY Report by Country  
 Period: 12  
 Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>4,218,273</b>	<b>38,115,982</b>	<b>30,499,631</b>	<b>(20%)</b>		<b>29,529,513</b>	<b>103%</b>
<b>West and Central Africa</b>	<b>1,621,010</b>	<b>20,138,152</b>	<b>10,783,165</b>	<b>(46%)</b>		<b>10,124,875</b>	<b>107%</b>
<b>Benin</b>	<b>23,791</b>	<b>245,356</b>	<b>293,459</b>	<b>20 %</b>	100%	<b>252,456</b>	<b>116%</b>
Family Planning	20,510	170,564	243,174	43%	83%	185,959	131 %
HIV & STIs	1,376	17,633	19,860	13%	7%	21,795	91 %
Malaria	1	2,411	756	(69)%	0%	1,027	74 %
Maternal, Newborn, and Child Health	769	42,828	15,099	(65)%	5%	33,276	45 %
Non-communicable diseases	2	45	27	(39)%	0%	-	0 %
Safe Abortion	1,104	10,844	13,548	25%	5%	9,355	145 %
WASH	30	1,031	994	(4)%	0%	1,044	95 %
<b>Cameroon</b>	<b>35,128</b>	<b>467,975</b>	<b>351,017</b>	<b>(25)%</b>	100%	<b>343,441</b>	<b>102%</b>
Family Planning	16,942	233,946	196,185	(16)%	56%	200,367	98 %
HIV & STIs	15,820	161,184	84,946	(47)%	24%	59,219	143 %
Malaria	1,372	16,675	11,786	(29)%	3%	15,650	75 %
Maternal, Newborn, and Child Health	70	44,905	44,271	(1)%	13%	46,603	95 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	925	11,256	13,818	23%	4%	21,593	64 %
WASH	-	10	10	1%	0%	10	101 %
<b>Congo-Kinshasa</b>	<b>1,140,858</b>	<b>10,177,431</b>	<b>2,859,550</b>	<b>(72)%</b>	100%	<b>4,764,972</b>	<b>60%</b>
Family Planning	52,518	205,803	492,212	139%	17%	288,193	171 %
HIV & STIs	892	15,056	33,922	125%	1%	14,133	240 %
Malaria	1,083,975	9,952,344	2,266,817	(77)%	79%	4,452,382	51 %
Maternal, Newborn, and Child Health	3,082	1,645	65,800	3,900%	2%	10,012	657 %
WASH	390	2,583	800	(69)%	0%	252	317 %
<b>Cote d'Ivoire</b>	<b>7</b>	<b>2,297</b>	<b>2,068</b>	<b>(10)%</b>	100%	<b>1,263</b>	<b>164%</b>
Family Planning	-	1,039	919	(12)%	44%	537	171 %
HIV & STIs	7	1,259	1,150	(9)%	56%	726	158 %
<b>Ghana</b>	<b>7,807</b>	<b>4,019</b>	<b>167,533</b>	<b>4,068 %</b>	100%	<b>72,274</b>	<b>232%</b>
Family Planning	7,767	3,699	164,438	4,345%	98%	65,356	252 %
HIV & STIs	39	320	3,091	866%	2%	6,836	45 %
WASH	1	-	4	0%	0%	82	5 %
<b>Guinea</b>	<b>6,629</b>	<b>61,432</b>	<b>102,711</b>	<b>67 %</b>	100%	<b>146,993</b>	<b>70%</b>
Family Planning	5,287	22,211	59,495	168%	58%	117,224	51 %
HIV & STIs	1,341	1,697	15,124	791%	15%	29,768	51 %
Maternal, Newborn, and Child Health	-	22,978	25,030	9%	24%	-	0 %
Tuberculosis	-	14,311	-	(100)%	0%	-	0 %
WASH	-	235	3,062	1,204%	3%	-	0 %
<b>Liberia</b>	<b>376</b>	<b>12,361</b>	<b>8,136</b>	<b>(34)%</b>	100%	<b>9,880</b>	<b>82%</b>
Family Planning	128	8,430	2,795	(67)%	34%	3,417	82 %
HIV & STIs	231	3,880	5,028	30%	62%	6,271	80 %
WASH	17	51	314	514%	4%	193	163 %
<b>Mali</b>	<b>35,022</b>	<b>2,323,352</b>	<b>3,431,120</b>	<b>48 %</b>	100%	<b>1,673,132</b>	<b>205%</b>
Family Planning	34,137	220,924	235,059	6%	7%	224,782	105 %
HIV & STIs	-	1,068	-	(100)%	0%	570	0 %
Malaria	229	2,098,999	3,188,981	52%	93%	1,443,891	221 %
Non-communicable diseases	2	271	86	(68)%	0%	326	26 %
Safe Abortion	653	1,364	5,830	328%	0%	2,384	245 %
WASH	(1)	725	1,165	61%	0%	1,180	99 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Niger</b>	<b>3,933</b>	<b>8,497</b>	<b>39,317</b>	<b>363 %</b>	100%	<b>11,647</b>	<b>338%</b>
Family Planning	3,504	6,351	29,384	363%	75%	10,160	289 %
HIV & STIs	383	2,146	1,313	(39)%	3%	1,252	105 %
Safe Abortion	46	-	8,619	0%	22%	234	3,681 %
<b>Nigeria</b>	<b>367,388</b>	<b>6,786,514</b>	<b>3,492,723</b>	<b>(49)%</b>	100%	<b>2,755,660</b>	<b>127%</b>
Family Planning	79,767	1,847,524	1,220,340	(34)%	35%	1,309,753	93 %
HIV & STIs	111,844	1,313,188	875,982	(33)%	25%	1,240,068	71 %
Malaria	5	3,489,296	1,129,172	(68)%	32%	3,814	29,607 %
Maternal, Newborn, and Child Health	1,239	36,271	34,740	(4)%	1%	59,795	58 %
Non-communicable diseases	-	367	400	9%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	174,502	98,673	231,419	135%	7%	140,709	164 %
WASH	31	1,196	669	(44)%	0%	1,522	44 %
<b>Senegal</b>	<b>71</b>	<b>48,917</b>	<b>35,532</b>	<b>(27)%</b>	100%	<b>93,157</b>	<b>38%</b>
Family Planning	71	18,217	11,826	(35)%	33%	28,611	41 %
HIV & STIs	-	25,293	21,997	(13)%	62%	54,261	41 %
Malaria	-	5,275	1,670	(68)%	5%	10,205	16 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	-	131	39	(70)%	0%	81	48 %
<b>East Africa</b>	<b>1,084,291</b>	<b>8,591,386</b>	<b>8,264,313</b>	<b>(4)%</b>		<b>8,579,902</b>	<b>96%</b>
<b>Burundi</b>	<b>858</b>	<b>125,521</b>	<b>142,462</b>	<b>13 %</b>	100%	<b>162,466</b>	<b>88%</b>
Family Planning	578	27,117	27,686	2%	19%	28,897	96 %
HIV & STIs	273	43,431	46,339	7%	33%	36,855	126 %
Malaria	-	54,877	68,101	24%	48%	96,590	71 %
Safe Abortion	7	95	336	255%	0%	125	270 %
<b>Ethiopia</b>	<b>1,293</b>	<b>307,751</b>	<b>189,634</b>	<b>(38)%</b>	100%	<b>205,237</b>	<b>92%</b>
Family Planning	-	66,897	40,554	(39)%	21%	43,686	93 %
HIV & STIs	489	228,361	142,517	(38)%	75%	151,973	94 %
Tuberculosis	-	29	-	(100)%	0%	-	0 %
WASH	803	12,464	6,564	(47)%	3%	9,577	69 %
<b>Kenya</b>	<b>251,633</b>	<b>1,768,660</b>	<b>1,721,615</b>	<b>(3)%</b>	100%	<b>2,393,098</b>	<b>72%</b>
Family Planning	52,951	605,962	391,099	(35)%	23%	895,469	44 %
HIV & STIs	186,309	1,062,610	1,216,667	14%	71%	1,385,441	88 %
Malaria	9,977	73,769	72,574	(2)%	4%	80,480	90 %
Maternal, Newborn, and Child Health	1,686	20,665	34,766	68%	2%	26,033	134 %
Non-communicable diseases	4	347	101	(71)%	0%	93	109 %
WASH	706	5,306	6,407	21%	0%	5,584	115 %
<b>Malawi</b>	<b>26,516</b>	<b>868,620</b>	<b>1,121,108</b>	<b>29 %</b>	100%	<b>918,685</b>	<b>122%</b>
Family Planning	3,607	213,368	428,298	101%	38%	265,964	161 %
HIV & STIs	22,681	548,445	678,522	24%	61%	646,971	105 %
Malaria	82	99,558	13,138	(87)%	1%	4,573	287 %
Maternal, Newborn, and Child Health	-	6,241	-	(100)%	0%	-	0 %
WASH	146	1,007	1,150	14%	0%	1,178	98 %
<b>Rwanda</b>	<b>16,878</b>	<b>262,647</b>	<b>175,688</b>	<b>(33)%</b>	100%	<b>219,295</b>	<b>80%</b>
Family Planning	2,766	45,461	31,587	(31)%	18%	36,565	86 %
HIV & STIs	14,087	216,853	143,759	(34)%	82%	182,180	79 %
WASH	25	333	342	3%	0%	551	62 %
<b>Somaliland</b>	<b>3,153</b>	<b>32,538</b>	<b>32,006</b>	<b>(2)%</b>	100%	<b>32,618</b>	<b>98%</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 12**  
**Year: 2017**

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Family Planning	77	1,946	1,067	(45)%	3%	1,953	55 %
Maternal, Newborn, and Child Health	2,903	29,220	28,554	(2)%	89%	28,939	99 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	173	1,372	2,385	74%	7%	1,726	138 %
<b>South Sudan</b>	<b>153,835</b>	<b>2,231,477</b>	<b>2,002,731</b>	<b>(10)%</b>	100%	<b>2,218,619</b>	<b>90%</b>
Malaria	153,301	1,960,336	1,677,087	(14)%	84%	1,418,762	118 %
Maternal, Newborn, and Child Health	534	239,073	305,274	28%	15%	799,857	38 %
Nutrition	-	31,989	20,370	(36)%	1%	-	0 %
WASH	-	79	-	(100)%	0%	-	0 %
<b>Tanzania</b>	<b>220,089</b>	<b>1,870,996</b>	<b>1,501,975</b>	<b>(20)%</b>	100%	<b>1,346,068</b>	<b>112%</b>
Family Planning	43,697	685,583	746,365	9%	50%	613,291	122 %
HIV & STIs	1,201	1,034,905	470,925	(54)%	31%	590,393	80 %
Malaria	165,740	97,975	253,360	159%	17%	114,927	220 %
Maternal, Newborn, and Child Health	197	1,434	1,020	(29)%	0%	-	0 %
Non-communicable diseases	-	168	73	(57)%	0%	90	81 %
Safe Abortion	9,222	45,297	29,747	(34)%	2%	26,850	111 %
WASH	31	5,633	486	(91)%	0%	517	94 %
<b>Uganda</b>	<b>410,037</b>	<b>1,123,176</b>	<b>1,377,094</b>	<b>23 %</b>	100%	<b>1,083,816</b>	<b>127%</b>
Family Planning	87,360	565,841	918,722	62%	67%	550,735	167 %
HIV & STIs	23,186	478,950	141,951	(70)%	10%	156,444	91 %
Malaria	-	52,524	3,112	(94)%	0%	45,166	7 %
Maternal, Newborn, and Child Health	(6,669)	22,473	3,972	(82)%	0%	12,101	33 %
Non-communicable diseases	16	232	205	(12)%	0%	712	29 %
Safe Abortion	306,120	343	307,563	89,470%	22%	317,170	97 %
WASH	23	2,812	1,569	(44)%	0%	1,488	105 %
<b>Southern Africa</b>	<b>1,275,790</b>	<b>7,533,480</b>	<b>9,082,432</b>	<b>21%</b>		<b>8,054,990</b>	<b>113%</b>
<b>Angola</b>	<b>78,238</b>	<b>307,955</b>	<b>908,263</b>	<b>195 %</b>	100%	<b>534,115</b>	<b>170%</b>
Family Planning	3,912	22,340	29,289	31%	3%	37,672	78 %
HIV & STIs	2,299	25,895	14,520	(44)%	2%	19,464	75 %
Malaria	71,131	254,229	812,314	220%	89%	468,546	173 %
Safe Abortion	349	1,310	48,571	3,609%	5%	3,049	1,593 %
WASH	547	4,183	3,569	(15)%	0%	5,384	66 %
<b>Botswana</b>	<b>3,844</b>	<b>14,669</b>	<b>22,403</b>	<b>53 %</b>	100%	<b>16,170</b>	<b>139%</b>
Family Planning	269	1,027	1,569	53%	7%	1,133	139 %
HIV & STIs	3,575	13,642	20,834	53%	93%	15,038	139 %
<b>Lesotho</b>	<b>17,633</b>	<b>505,659</b>	<b>266,289</b>	<b>(47)%</b>	100%	<b>430,778</b>	<b>62%</b>
Family Planning	1,052	30,055	16,862	(44)%	6%	33,308	51 %
HIV & STIs	16,565	475,605	249,297	(48)%	94%	397,470	63 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	16	-	130	0%	0%	-	0 %
<b>Madagascar</b>	<b>286,759</b>	<b>818,680</b>	<b>1,135,980</b>	<b>39 %</b>	100%	<b>863,919</b>	<b>131%</b>
Family Planning	21,637	288,794	275,583	(5)%	24%	188,883	146 %
HIV & STIs	3,610	40,196	65,629	63%	6%	71,032	92 %
Malaria	252,270	310,881	624,345	101%	55%	418,610	149 %
Maternal, Newborn, and Child Health	8,927	165,099	159,854	(3)%	14%	165,421	97 %
Non-communicable diseases	1	4	31	700%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	67	434	747	72%	0%	-	0 %
WASH	248	13,273	9,792	(26)%	1%	19,974	49 %



POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Mozambique</b>	<b>100,374</b>	<b>263,687</b>	<b>576,005</b>	<b>118 %</b>	100%	<b>562,319</b>	<b>102%</b>
Family Planning	85,460	87,963	228,962	160%	40%	270,265	85 %
HIV & STIs	14,565	148,445	315,561	113%	55%	269,827	117 %
Malaria	6	20,571	23,157	13%	4%	13,281	174 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	343	6,708	8,325	24%	1%	8,947	93 %
<b>Namibia</b>	<b>-</b>	<b>26,511</b>	<b>3,442</b>	<b>(87)%</b>	100%	-	<b>-%</b>
Family Planning	-	2,107	275	(87)%	8%	-	0 %
HIV & STIs	-	24,389	3,167	(87)%	92%	-	0 %
Tuberculosis	-	14	-	(100)%	0%	-	0 %
<b>South Africa</b>	<b>526,951</b>	<b>2,625,678</b>	<b>2,719,954</b>	<b>4 %</b>	100%	<b>2,468,398</b>	<b>110%</b>
Family Planning	12,110	106,668	94,550	(11)%	3%	89,925	105 %
HIV & STIs	514,841	2,519,010	2,625,403	4%	97%	2,378,473	110 %
<b>Swaziland</b>	<b>92,916</b>	<b>655,839</b>	<b>772,009</b>	<b>18 %</b>	100%	<b>696,535</b>	<b>111%</b>
Family Planning	4,532	29,163	35,010	20%	5%	30,805	114 %
HIV & STIs	88,384	626,675	736,998	18%	95%	665,730	111 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Zambia</b>	<b>46,490</b>	<b>629,405</b>	<b>838,410</b>	<b>33 %</b>	100%	<b>752,675</b>	<b>111%</b>
Family Planning	14,122	10,044	88,947	786%	11%	117,895	75 %
HIV & STIs	31,809	616,347	746,448	21%	89%	631,328	118 %
WASH	558	3,014	3,015	0%	0%	3,451	87 %
<b>Zimbabwe</b>	<b>122,585</b>	<b>1,685,397</b>	<b>1,839,677</b>	<b>9 %</b>	100%	<b>1,730,081</b>	<b>106%</b>
Family Planning	3,187	81,761	43,460	(47)%	2%	49,613	88 %
HIV & STIs	119,375	1,544,619	1,795,083	16%	98%	1,657,739	108 %
Malaria	-	57,642	-	(100)%	0%	21,525	0 %
Non-communicable diseases	8	398	208	(48)%	0%	159	131 %
Tuberculosis	15	274	146	(47)%	0%	166	88 %
WASH	-	704	779	11%	0%	879	89 %
<b>Americas</b>	<b>12,958</b>	<b>176,655</b>	<b>232,360</b>	<b>32%</b>		<b>219,289</b>	<b>106%</b>
<b>Belize</b>	<b>-</b>	<b>47</b>	<b>-</b>	<b>(100)%</b>	0%	-	<b>-%</b>
Family Planning	-	1	-	(100)%	0%	-	0 %
HIV & STIs	-	46	-	(100)%	0%	-	0 %
<b>Caribbean</b>	<b>-</b>	<b>45</b>	<b>33</b>	<b>(27)%</b>	100%	-	<b>-%</b>
Family Planning	-	8	5	(30)%	17%	-	0 %
HIV & STIs	-	37	27	(26)%	83%	-	0 %
<b>Costa Rica</b>	<b>142</b>	<b>1,736</b>	<b>1,911</b>	<b>10 %</b>	100%	<b>1,607</b>	<b>119%</b>
Family Planning	9	115	126	10%	7%	106	119 %
HIV & STIs	133	1,621	1,785	10%	93%	1,501	119 %
<b>Dominican Republic</b>	<b>1,258</b>	<b>15,933</b>	<b>19,172</b>	<b>20 %</b>	100%	<b>15,810</b>	<b>121%</b>
Family Planning	273	3,493	4,233	21%	22%	3,483	122 %
HIV & STIs	985	12,440	14,938	20%	78%	12,327	121 %
<b>El Salvador</b>	<b>580</b>	<b>17,629</b>	<b>7,405</b>	<b>(58)%</b>	100%	<b>7,913</b>	<b>94%</b>
Family Planning	226	3,237	2,553	(21)%	34%	3,004	85 %
HIV & STIs	351	14,356	4,811	(66)%	65%	4,772	101 %
Maternal, Newborn, and Child Health	-	14	14	4%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	2	22	27	19%	0%	136	20 %
<b>Guatemala</b>	<b>4,484</b>	<b>35,468</b>	<b>42,619</b>	<b>20 %</b>	100%	<b>31,762</b>	<b>134%</b>
Family Planning	3,275	20,226	26,569	31%	62%	14,766	180 %
HIV & STIs	1,102	15,010	15,520	3%	36%	16,567	94 %
Maternal, Newborn, and Child Health	-	145	2	(99)%	0%	-	0 %
Safe Abortion	107	86	528	511%	1%	428	123 %
<b>Haiti</b>	<b>2,385</b>	<b>47,399</b>	<b>103,545</b>	<b>118 %</b>	100%	<b>94,734</b>	<b>109%</b>
Family Planning	47	154	4,734	2,974%	5%	17,271	27 %
HIV & STIs	-	2,742	49,774	1,715%	48%	26,854	185 %
Malaria	2,338	-	2,338	0%	2%	2,258	104 %
Maternal, Newborn, and Child Health	-	10,285	10,285	0%	10%	14,123	73 %
Non-communicable diseases	-	-	7	0%	0%	-	0 %
Tuberculosis	-	34,218	36,409	6%	35%	34,228	106 %
<b>Honduras</b>	<b>606</b>	<b>17,171</b>	<b>16,140</b>	<b>(6)%</b>	100%	<b>17,859</b>	<b>90%</b>
Family Planning	42	1,251	1,185	(5)%	7%	1,306	91 %
HIV & STIs	564	15,920	14,955	(6)%	93%	16,553	90 %
<b>Nicaragua</b>	<b>685</b>	<b>12,109</b>	<b>11,673</b>	<b>(4)%</b>	100%	<b>15,056</b>	<b>78%</b>
Family Planning	231	5,504	4,714	(14)%	40%	6,711	70 %
HIV & STIs	450	6,578	6,873	4%	59%	8,040	85 %
Safe Abortion	4	28	86	208%	1%	305	28 %
<b>Panama</b>	<b>196</b>	<b>8,041</b>	<b>6,528</b>	<b>(19)%</b>	100%	<b>7,586</b>	<b>86%</b>
Family Planning	22	840	864	3%	13%	1,008	86 %
HIV & STIs	173	5,524	5,664	3%	87%	6,578	86 %
Maternal, Newborn, and Child Health	-	1,678	-	(100)%	0%	-	0 %
<b>Paraguay</b>	<b>2,622</b>	<b>21,078</b>	<b>23,335</b>	<b>11 %</b>	100%	<b>26,963</b>	<b>87%</b>
Family Planning	431	5,057	4,883	(3)%	21%	5,721	85 %
HIV & STIs	2,177	15,889	18,290	15%	78%	21,059	87 %
Nutrition	13	132	162	23%	1%	183	89 %
<b>Asia and Eastern Europe</b>	<b>224,224</b>	<b>1,676,309</b>	<b>2,137,361</b>	<b>28%</b>		<b>2,550,456</b>	<b>84%</b>
<b>Cambodia</b>	<b>20,576</b>	<b>183,578</b>	<b>197,203</b>	<b>7 %</b>	100%	<b>194,931</b>	<b>101%</b>
Family Planning	9,493	86,023	95,161	11%	48%	90,297	105 %
HIV & STIs	8,421	67,972	73,608	8%	37%	77,864	95 %
Malaria	618	8,071	4,799	(41)%	2%	5,732	84 %
Maternal, Newborn, and Child Health	139	2,269	1,133	(50)%	1%	1,426	79 %
Safe Abortion	1,905	19,243	22,503	17%	11%	19,613	115 %
<b>India</b>	<b>17,459</b>	<b>179,545</b>	<b>172,363</b>	<b>(4)%</b>	100%	<b>338,455</b>	<b>51%</b>
Family Planning	17,386	118,200	139,555	18%	81%	276,022	51 %
HIV & STIs	-	34,337	(2)	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	5,558	(237)	(104)%	0%	-	0 %
Non-communicable diseases	-	803	182	(77)%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	-	6,748	(117)	(102)%	0%	-	0 %
Tuberculosis	-	5,598	16,691	198%	10%	49,533	34 %
WASH	72	8,300	16,289	96%	9%	12,899	126 %
<b>India LLC</b>	<b>37,217</b>	<b>138,234</b>	<b>411,425</b>	<b>198 %</b>	100%	<b>785,882</b>	<b>52%</b>
Family Planning	14,768	43,537	180,542	315%	44%	332,087	54 %
HIV & STIs	18,320	94,697	176,973	87%	43%	359,969	49 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Maternal, Newborn, and Child Health	135	-	6,116	0%	1%	37,493	16 %
Safe Abortion	3,994	-	47,794	0%	12%	56,332	85 %
<b>Kazakhstan</b>	<b>15</b>	<b>1,027</b>	<b>415</b>	<b>(60)%</b>	100%	<b>665</b>	<b>62%</b>
Family Planning	-	193	3	(98)%	1%	62	5 %
HIV & STIs	15	834	412	(51)%	99%	603	68 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Kyrgyzstan</b>	<b>34</b>	<b>506</b>	<b>639</b>	<b>26 %</b>	100%	<b>621</b>	<b>103%</b>
HIV & STIs	34	506	639	26%	100%	621	103 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Laos</b>	<b>4,202</b>	<b>19,996</b>	<b>24,052</b>	<b>20 %</b>	100%	<b>21,241</b>	<b>113%</b>
Family Planning	3,275	14,742	19,539	33%	81%	15,211	128 %
HIV & STIs	430	2,986	2,187	(27)%	9%	3,257	67 %
Malaria	105	-	105	0%	0%	-	0 %
Safe Abortion	392	2,170	2,146	(1)%	9%	2,709	79 %
Tuberculosis	-	98	75	(23)%	0%	65	117 %
<b>Myanmar</b>	<b>19,461</b>	<b>391,974</b>	<b>284,219</b>	<b>(27)%</b>	100%	<b>305,116</b>	<b>93%</b>
Family Planning	4,439	46,603	53,262	14%	19%	57,757	92 %
HIV & STIs	7,712	106,303	99,925	(6)%	35%	106,567	94 %
Malaria	264	58,918	29,751	(50)%	10%	37,680	79 %
Maternal, Newborn, and Child Health	1,191	85,331	12,859	(85)%	5%	9,975	129 %
Non-communicable diseases	-	6	-	(95)%	0%	-	0 %
Nutrition	11	-	104	0%	0%	-	0 %
Tuberculosis	5,843	94,776	88,297	(7)%	31%	93,110	95 %
WASH	-	36	20	(44)%	0%	27	76 %
<b>Nepal</b>	<b>3,584</b>	<b>41,046</b>	<b>33,942</b>	<b>(17)%</b>	100%	<b>30,235</b>	<b>112%</b>
Family Planning	2,629	32,501	24,568	(24)%	72%	17,486	141 %
HIV & STIs	-	94	1,183	1,164%	3%	1,267	93 %
Safe Abortion	955	8,444	8,191	(3)%	24%	11,481	71 %
WASH	-	7	-	(100)%	0%	-	0 %
<b>Pakistan</b>	<b>57,735</b>	<b>684,424</b>	<b>766,898</b>	<b>12 %</b>	100%	<b>591,047</b>	<b>130%</b>
Family Planning	38,923	605,883	650,795	7%	85%	566,770	115 %
HIV & STIs	4,671	41,889	30,093	(28)%	4%	24,276	124 %
Safe Abortion	7,048	1,596	8,361	424%	1%	-	0 %
Tuberculosis	7,093	35,037	77,648	122%	10%	-	0 %
WASH	-	19	-	(100)%	0%	-	0 %
<b>Papua New Guinea</b>	<b>57,874</b>	<b>3,444</b>	<b>194,652</b>	<b>5,552 %</b>	100%	<b>221,572</b>	<b>88%</b>
Family Planning	-	864	898	4%	0%	886	101 %
HIV & STIs	-	1,596	1,683	5%	1%	1,660	101 %
Malaria	57,874	786	191,945	24,324%	99%	218,518	88 %
Maternal, Newborn, and Child Health	-	197	125	(36)%	0%	504	25 %
WASH	-	2	1	(39)%	0%	4	33 %
<b>Tajikistan</b>	<b>3,470</b>	<b>151</b>	<b>22,655</b>	<b>14,858 %</b>	100%	<b>28,120</b>	<b>81%</b>
Family Planning	11	12	182	1,467%	1%	173	105 %
HIV & STIs	3,459	140	22,474	15,968%	99%	27,947	80 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Viet Nam</b>	<b>2,598</b>	<b>32,385</b>	<b>28,898</b>	<b>(11)%</b>	100%	<b>32,573</b>	<b>89%</b>
Family Planning	6	13	60	373%	0%	438	14 %
HIV & STIs	2,581	32,366	28,771	(11)%	100%	28,864	100 %

**POPULATION SERVICES INTERNATIONAL**

**Monthly DALY Report by Country**

Period: 12

Year: 2017

	DALY 12/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Malaria	3	-	13	0%	0%	81	17 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	2,940	0 %
WASH	9	6	53	781%	0%	250	21 %

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Acute Malnutrition Screening_CU</b>	203	166	1,377	-	-	-%	-	1,377	-
West and Central Africa	203	166	1,377	-	-	-%	-	1,377	-
<b>Antiretroviral Treatment</b>	-	-	-	-	-	-%	-	18,119	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	18,119	-
<b>Antiretroviral Treatment (Currentl</b>	16,043	40,990	460,107	128,032	12,235	3,661%	12,235	472,342	80,294
East Africa	2,135	4,156	40,208	6,986	5,564	623%	5,564	45,772	7,969
Southern Africa	8,981	9,593	103,911	76,596	5,010	1,974%	5,010	108,921	18,461
Americas	-	22,602	269,998	8,000	-	-%	-	269,998	45,829
Asia and Eastern Europe	4,927	4,638	45,990	36,450	1,661	2,669%	1,661	47,651	8,034
<b>Antiretroviral Treatment (Newly E</b>	628	1,521	19,872	2,100	7,226	175%	7,226	27,098	-
East Africa	156	268	3,161	-	901	251%	901	4,062	-
Southern Africa	284	624	9,493	-	5,283	80%	5,283	14,776	-
Americas	-	387	4,301	-	-	-%	-	4,301	-
Asia and Eastern Europe	188	242	2,917	2,100	1,042	180%	1,042	3,959	-
<b>Antiretroviral Treatment (Tablet)</b>	-	-	-	-	-	-%	-	97,980	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	97,980	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	382	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	382	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	359	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	359	-
<b>Basic Care Package</b>	-	-	400	-	52,637,120	(100)%	52,637,120	176,452,481	-
East Africa	-	-	400	-	52,637,120	(100)%	52,637,120	176,034,156	-
Southern Africa	-	-	-	-	-	-%	-	418,325	-
<b>CD4 Tests Provided to HIV+ Clie</b>	449	664	14,975	-	1,193	1,155%	1,193	16,168	-
West and Central Africa	22	53	1,017	-	297	242%	297	1,314	-
East Africa	-	-	485	-	-	-%	-	485	-
Southern Africa	312	558	13,087	-	778	1,582%	778	13,865	-
Americas	115	53	386	-	118	227%	118	504	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Cervical Cancer-HPV DNA and Re</b>	-	-	11	-	-	-%	-	11	3
Southern Africa	-	-	11	-	-	-%	-	11	3
<b>Cervical Cancer-HPV DNA and Re</b>	-	-	9	-	-	-%	-	9	2
Southern Africa	-	-	9	-	-	-%	-	9	2
<b>Cervical Cancer-Pap and Cryothe</b>	-	-	-	-	-	-%	-	35	-
Americas	-	-	-	-	-	-%	-	35	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	1	-	1	-%	1	2	-
Southern Africa	-	-	1	-	1	-%	1	2	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	-	-	7	(100)%	7	9	-
Southern Africa	-	-	-	-	7	(100)%	7	9	-
<b>Cervical Cancer-Pap Smear Scree</b>	20	72	715	-	6,309	(89)%	6,309	7,265	-
West and Central Africa	-	-	-	-	1,450	(100)%	1,450	1,450	-
East Africa	-	-	173	-	-	-%	-	173	-
Southern Africa	-	-	2	-	116	(98)%	116	118	-
Americas	20	72	236	-	-	-%	-	477	-
Asia and Eastern Europe	-	-	304	-	4,743	(94)%	4,743	5,047	-
<b>Cervical Cancer-VIA and Conizati</b>	1	7	168	185	10	1,580%	10	178	48
Southern Africa	1	7	168	185	10	1,580%	10	178	48
<b>Cervical Cancer-VIA and Cryothe</b>	106	649	4,410	3,542	9,025	(51)%	9,025	20,277	1,183
West and Central Africa	12	511	2,087	719	2,406	(13)%	2,406	5,102	513
East Africa	61	86	1,224	2,545	2,707	(55)%	2,707	6,728	380
Southern Africa	33	49	601	278	1,194	(50)%	1,194	4,288	169
Americas	-	3	78	-	-	-%	-	146	7
Asia and Eastern Europe	-	-	420	-	2,718	(85)%	2,718	4,013	115
<b>Cervical Cancer-VIA and Refer to</b>	-	4	117	-	65	80%	65	413	16
Southern Africa	-	4	38	-	17	124%	17	286	5
Asia and Eastern Europe	-	-	79	-	48	65%	48	127	11
<b>Cervical Cancer-VIA and Refer to</b>	-	-	69	200	402	(83)%	402	1,958	10

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	-	69	200	402	(83)%	402	1,958	10
<b>Cervical Cancer-VIA and Refer to</b>	-	-	435	102	479	(9)%	479	2,045	59
West and Central Africa	-	-	-	-	-	-%	-	546	-
East Africa	-	-	-	102	-	-%	-	19	-
Southern Africa	-	-	16	-	33	(52)%	33	615	2
Asia and Eastern Europe	-	-	419	-	446	(6)%	446	865	57
<b>Cervical Cancer-VIA/VILI Screenir</b>	15,511	28,430	238,312	-	443,880	(46)%	443,880	846,181	-
West and Central Africa	5,688	17,517	105,647	-	90,919	16%	90,919	242,120	-
East Africa	8,792	9,401	109,307	-	228,181	(52)%	228,181	426,418	-
Southern Africa	1,023	1,499	17,369	-	26,740	(35)%	26,740	68,850	-
Americas	1	7	360	-	-	-%	-	1,439	-
Asia and Eastern Europe	7	6	5,629	-	98,040	(94)%	98,040	107,354	-
<b>Chlorhexidine</b>	2,378	4,803	133,472	293,741	293,776	(55)%	293,776	487,173	12,209
West and Central Africa	1,600	3,000	102,406	200,000	46,000	123%	46,000	148,406	10,303
East Africa	507	595	6,361	40,000	6,682	(5)%	6,682	13,043	397
Southern Africa	271	1,208	24,705	53,741	241,094	(90)%	241,094	325,724	1,509
<b>Clean Delivery Kit</b>	2,064	3,284	46,836	15,000	58,792	(20)%	58,792	1,705,022	4,122
West and Central Africa	1,360	1,492	15,225	15,000	4,400	246%	4,400	240,335	1,928
East Africa	704	1,792	31,611	-	53,992	(41)%	53,992	466,554	2,194
Asia and Eastern Europe	-	-	-	-	400	(100)%	400	998,133	-
<b>Condom</b>	51,952,514	55,562,320	593,394,078	748,578,078	706,462,137	(16)%	706,462,137	20,941,719,664	5,768,389
West and Central Africa	9,050,966	9,449,540	124,423,911	163,145,833	166,460,451	(25)%	166,460,451	5,554,165,100	1,265,311
East Africa	4,434,934	14,903,530	119,525,724	147,400,070	168,952,588	(29)%	168,952,588	2,714,265,109	1,938,995
Southern Africa	9,287,634	9,733,847	91,270,147	99,975,773	100,081,646	(9)%	100,081,646	2,427,325,469	1,910,939
Americas	2,819,378	3,814,695	42,515,649	44,696,925	38,832,417	9%	38,832,417	1,191,620,037	96,844
Other Africa	-	-	-	-	-	-%	-	14,310,880	-
Asia and Eastern Europe	26,359,602	17,660,709	215,658,647	293,359,477	232,135,035	(7)%	232,135,035	9,040,033,069	556,299
<b>Condom Provided</b>	-	-	-	-	3,659,226	(100)%	3,659,226	18,930,351	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	55,399	(100)%	55,399	83,854	-
East Africa	-	-	-	-	2,231,548	(100)%	2,231,548	17,065,364	-
Southern Africa	-	-	-	-	842,352	(100)%	842,352	1,079,341	-
Americas	-	-	-	-	466,816	(100)%	466,816	616,702	-
Asia and Eastern Europe	-	-	-	-	63,111	(100)%	63,111	85,090	-
<b>Counseling &amp; Tx for Moderate Ac</b>	-	-	155,155	-	-	-%	-	155,155	-
West and Central Africa	-	-	8	-	-	-%	-	8	-
East Africa	-	-	155,147	-	-	-%	-	155,147	-
<b>Deworming Tablets</b>	-	-	-	-	-	-%	-	1,095,308	-
East Africa	-	-	-	-	-	-%	-	978,174	-
Southern Africa	-	-	-	-	-	-%	-	117,134	-
<b>Diarrhea Treatment Kit</b>	99,495	76,805	1,719,822	1,651,226	2,396,570	(28)%	2,396,570	19,071,025	113,321
West and Central Africa	59,086	45,091	1,202,560	1,012,000	1,301,535	(8)%	1,301,535	9,108,781	84,633
East Africa	14,810	19,873	188,408	188,671	176,147	7%	176,147	1,354,548	20,196
Southern Africa	18,551	7,096	251,650	318,195	479,996	(48)%	479,996	2,123,074	6,353
Americas	-	-	-	40,000	-	-%	-	-	-
Asia and Eastern Europe	7,048	4,744	77,204	92,360	438,892	(82)%	438,892	6,484,622	2,139
<b>Diarrhea Treatment Kit Provided</b>	1,474	2,096	24,289	-	24,604	(1)%	24,604	48,893	909
West and Central Africa	-	-	-	-	2,400	(100)%	2,400	2,400	-
East Africa	1,175	1,692	18,693	-	17,338	8%	17,338	36,031	752
Southern Africa	299	404	5,596	-	4,866	15%	4,866	10,462	157
<b>Early Infant Male Circumcision</b>	-	-	-	-	5	(100)%	5	4,886	-
Southern Africa	-	-	-	-	5	(100)%	5	4,886	-
<b>Emergency Contraception</b>	663,386	405,466	4,664,025	4,511,652	4,760,176	(2)%	4,760,176	41,539,257	33,254
West and Central Africa	166,041	154,332	1,834,004	2,055,000	1,808,411	1%	1,808,411	14,890,473	21,916
East Africa	2,872	1,182	126,615	154,000	73,906	71%	73,906	1,575,897	1,048
Southern Africa	(28)	64	57,634	181,900	208,155	(72)%	208,155	1,071,510	296
Americas	30,105	22,766	298,962	336,500	308,976	(3)%	308,976	4,162,509	413



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	464,396	227,122	2,346,810	1,784,252	2,360,728	(1)%	2,360,728	19,838,868	9,581
<b>Emergency Contraception Provid</b>	<b>672</b>	<b>713</b>	<b>11,779</b>	<b>2,170</b>	<b>11,214</b>	<b>5%</b>	<b>11,214</b>	<b>35,358</b>	<b>63</b>
West and Central Africa	34	33	335	-	201	67%	201	857	4
East Africa	231	105	1,720	2,000	246	599%	246	2,022	14
Southern Africa	50	75	1,026	170	1,660	(38)%	1,660	3,077	8
Americas	-	-	6	-	6	-%	6	94	-
Asia and Eastern Europe	357	500	8,692	-	9,101	(4)%	9,101	29,308	37
<b>Expanded Clean Delivery Kit</b>	<b>11,840</b>	<b>-</b>	<b>11,840</b>	<b>25,000</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>11,840</b>	<b>1,617</b>
East Africa	11,840	-	11,840	25,000	-	-%	-	11,840	1,617
<b>Expanded Clean Delivery Kit (+C</b>	<b>171</b>	<b>149</b>	<b>617</b>	<b>14,000</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>617</b>	<b>78</b>
East Africa	171	149	617	14,000	-	-%	-	617	78
<b>Family Planning Counseling</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>42,161</b>	<b>(100)%</b>	<b>42,161</b>	<b>42,190</b>	<b>-</b>
West and Central Africa	-	-	-	-	20,577	(100)%	20,577	20,606	-
East Africa	-	-	-	-	17,574	(100)%	17,574	17,574	-
Southern Africa	-	-	-	-	223	(100)%	223	223	-
Americas	-	-	-	-	3,787	(100)%	3,787	3,787	-
<b>Fecal Sludge Management (Hous</b>	<b>23</b>	<b>38</b>	<b>661</b>	<b>670</b>	<b>921</b>	<b>(28)%</b>	<b>921</b>	<b>1,582</b>	<b>-</b>
Asia and Eastern Europe	23	38	661	670	921	(28)%	921	1,582	-
<b>Fecal Sludge Management (Liters</b>	<b>1,310,000</b>	<b>130,000</b>	<b>4,125,200</b>	<b>1,571,000</b>	<b>3,021,000</b>	<b>37%</b>	<b>3,021,000</b>	<b>7,146,200</b>	<b>228</b>
Asia and Eastern Europe	1,310,000	130,000	4,125,200	1,571,000	3,021,000	37%	3,021,000	7,146,200	228
<b>Female Condom</b>	<b>246,829</b>	<b>130,256</b>	<b>1,835,060</b>	<b>1,538,252</b>	<b>6,171,177</b>	<b>(70)%</b>	<b>6,171,177</b>	<b>84,453,217</b>	<b>26,563</b>
West and Central Africa	168,180	67,886	645,416	224,568	2,318,144	(72)%	2,318,144	26,013,370	5,008
East Africa	840	4,053	391,746	140,000	1,099,340	(64)%	1,099,340	11,219,082	3,963
Southern Africa	69,892	40,953	663,604	1,020,724	2,644,759	(75)%	2,644,759	39,984,850	17,008
Americas	-	-	-	-	-	-%	-	3,751,762	-
Asia and Eastern Europe	7,917	17,364	134,294	152,960	108,934	23%	108,934	3,484,153	584
<b>Female Condom Provided</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>83,044</b>	<b>(100)%</b>	<b>83,044</b>	<b>112,394</b>	<b>-</b>
West and Central Africa	-	-	-	-	2,591	(100)%	2,591	3,027	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	-	-	-	-%	-	9,654	-
Southern Africa	-	-	-	-	80,452	(100)%	80,452	99,712	-
Americas	-	-	-	-	1	(100)%	1	1	-
<b>Fever Cases Attended</b>	<b>147,036</b>	<b>144,709</b>	<b>1,592,365</b>	<b>-</b>	<b>3,637,532</b>	<b>(56)%</b>	<b>3,637,532</b>	<b>5,229,897</b>	<b>-</b>
West and Central Africa	-	-	-	-	2,927,861	(100)%	2,927,861	2,927,861	-
East Africa	-	-	664	-	26,315	(97)%	26,315	26,979	-
Southern Africa	8,982	3,986	318,116	-	24,338	1,207%	24,338	342,454	-
Americas	1,352	1,304	36,368	-	1,187	2,964%	1,187	37,555	-
Asia and Eastern Europe	136,702	139,419	1,237,217	-	657,831	88%	657,831	1,895,048	-
<b>Fever Cases Tested with Microsc</b>	<b>6,111</b>	<b>5,728</b>	<b>120,747</b>	<b>-</b>	<b>261,944</b>	<b>(54)%</b>	<b>261,944</b>	<b>382,691</b>	<b>-</b>
West and Central Africa	-	-	-	-	247,772	(100)%	247,772	247,772	-
East Africa	-	-	121	-	7,353	(98)%	7,353	7,474	-
Southern Africa	580	175	5,050	-	1,885	168%	1,885	6,935	-
Americas	5,531	5,554	115,576	-	4,934	2,242%	4,934	120,510	-
<b>Fever Cases Tested with RDTs</b>	<b>177,500</b>	<b>171,237</b>	<b>2,069,325</b>	<b>-</b>	<b>3,355,756</b>	<b>(38)%</b>	<b>3,355,756</b>	<b>5,425,081</b>	<b>-</b>
West and Central Africa	14,482	-	14,482	-	2,634,426	(99)%	2,634,426	2,648,908	-
East Africa	-	-	543	-	18,608	(97)%	18,608	19,151	-
Southern Africa	7,337	3,276	294,643	-	20,935	1,307%	20,935	315,578	-
Americas	18,982	28,547	522,476	-	23,956	2,081%	23,956	546,432	-
Asia and Eastern Europe	136,699	139,414	1,237,181	-	657,831	88%	657,831	1,895,012	-
<b>Free Condom</b>	<b>26,009,685</b>	<b>19,903,826</b>	<b>205,169,400</b>	<b>210,301,145</b>	<b>220,640,510</b>	<b>(7)%</b>	<b>220,640,510</b>	<b>2,439,041,602</b>	<b>3,464,784</b>
West and Central Africa	9,266,000	2,711,090	48,790,044	62,124,626	32,825,359	49%	32,825,359	219,380,035	298,591
East Africa	6,640,104	9,445,611	66,077,570	57,032,717	85,946,047	(23)%	85,946,047	691,915,518	1,117,255
Southern Africa	10,069,281	7,658,227	87,501,654	78,425,768	93,108,576	(6)%	93,108,576	1,416,456,118	2,042,713
Americas	16,000	60,474	1,960,215	7,684,000	8,079,494	(76)%	8,079,494	63,971,727	3,327
Asia and Eastern Europe	18,300	28,424	839,917	5,034,034	681,034	23%	681,034	47,318,204	2,898
<b>Free Female Condom</b>	<b>208,867</b>	<b>143,047</b>	<b>2,606,844</b>	<b>4,018,234</b>	<b>1,354,037</b>	<b>93%</b>	<b>1,354,037</b>	<b>15,800,498</b>	<b>27,064</b>
West and Central Africa	15,000	30,867	992,544	1,564,945	431,422	130%	431,422	3,583,233	3,437

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	86,987	52,153	1,034,969	1,419,000	107,658	861%	107,658	3,825,699	11,648
Southern Africa	106,880	59,837	574,761	1,000,289	626,979	(8)%	626,979	7,956,413	11,974
Americas	-	-	-	-	167,978	(100)%	167,978	258,270	-
Asia and Eastern Europe	-	190	4,570	34,000	20,000	(77)%	20,000	176,883	5
<b>HAART (Mother and Baby)</b>	-	-	-	-	-	-%	-	256	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	256	-
<b>HAART (Mother Only)</b>	-	-	-	-	-	-%	-	239	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	239	-
<b>HIV Self-Testing Kit</b>	31,608	39,180	274,547	-	95,000	189%	95,000	369,547	-
East Africa	25,291	21,235	88,997	-	-	-%	-	88,997	-
Southern Africa	6,317	17,944	185,550	-	95,000	95%	95,000	280,550	-
<b>HIV Testing Services</b>	251,482	174,527	2,335,111	1,978,892	2,028,322	15%	2,028,322	21,087,361	108,800
West and Central Africa	7,733	7,275	112,346	65,753	201,781	(44)%	201,781	3,735,741	700
East Africa	26,282	33,983	411,597	332,377	450,690	(9)%	450,690	3,052,846	12,105
Southern Africa	199,991	100,729	1,443,294	1,299,724	950,683	52%	950,683	12,792,973	94,084
Americas	7,588	22,174	254,963	167,485	355,059	(28)%	355,059	848,530	1,739
Asia and Eastern Europe	9,888	10,367	112,911	113,553	70,109	61%	70,109	657,271	172
<b>Hypertension Diagnosis</b>	17,316	6,692	50,253	-	31,408	60%	31,408	81,661	-
East Africa	-	-	5,790	-	31,404	(82)%	31,404	37,194	-
Southern Africa	22	405	2,087	-	4	52,075%	4	2,091	-
Americas	-	1	2	-	-	-%	-	2	-
Asia and Eastern Europe	17,294	6,286	42,374	-	-	-%	-	42,374	-
<b>Hypertension Screening</b>	207,327	20,774	631,537	-	142,939	342%	142,939	774,476	-
East Africa	-	-	57,107	-	129,978	(56)%	129,978	187,085	-
Southern Africa	7,938	11,829	337,699	-	12,961	2,506%	12,961	350,660	-
Americas	1	1	3	-	-	-%	-	3	-
Asia and Eastern Europe	199,388	8,944	236,728	-	-	-%	-	236,728	-
<b>Hypertension_Controlled Conditio</b>	20,260	2,380	35,978	-	25,845	39%	25,845	61,823	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	3,495	-	25,842	(86)%	25,842	29,337	-
Southern Africa	5	3	63	-	3	2,000%	3	66	-
Americas	-	1	2	-	-	-%	-	2	-
Asia and Eastern Europe	20,255	2,376	32,418	-	-	-%	-	32,418	-
<b>Implant 3</b>	<b>(4,199)</b>	<b>(2,282)</b>	<b>82,087</b>	<b>356,915</b>	<b>153,491</b>	<b>(47)%</b>	<b>153,491</b>	<b>763,567</b>	<b>106,465</b>
West and Central Africa	(370)	72	14,874	7,550	9,011	65%	9,011	15,179	24,888
East Africa	(4,025)	(2,400)	58,860	331,101	143,202	(59)%	143,202	713,807	78,646
Southern Africa	(168)	(139)	(1,257)	6,814	(1,712)	-%	(1,712)	246	(1,254)
Americas	(1)	(6)	1,897	450	333	470%	333	2,529	1,909
Asia and Eastern Europe	365	191	7,713	11,000	2,657	190%	2,657	31,806	2,277
<b>Implant 3 Insertion</b>	<b>20,944</b>	<b>28,546</b>	<b>282,285</b>	<b>49,442</b>	<b>165,326</b>	<b>71%</b>	<b>165,326</b>	<b>609,091</b>	<b>483,233</b>
West and Central Africa	3,451	4,572	41,828	20,002	20,727	102%	20,727	73,703	88,917
East Africa	14,699	21,790	215,907	21,248	127,841	69%	127,841	459,753	374,694
Southern Africa	776	1,283	11,910	1,151	11,806	1%	11,806	50,489	13,737
Americas	36	38	560	311	797	(30)%	797	5,209	327
Asia and Eastern Europe	1,982	862	12,080	6,730	4,155	191%	4,155	19,937	5,558
<b>Implant 4</b>	<b>(1)</b>	<b>(1)</b>	<b>(8)</b>	<b>51</b>	<b>(452)</b>	<b>-%</b>	<b>(452)</b>	<b>24,679</b>	<b>(10)</b>
East Africa	-	-	-	-	(369)	-%	(369)	(369)	-
Southern Africa	(1)	(1)	(8)	51	(83)	-%	(83)	25,748	(10)
Asia and Eastern Europe	-	-	-	-	-	-%	-	(700)	-
<b>Implant 4 Insertion</b>	<b>12</b>	<b>1</b>	<b>43</b>	<b>169</b>	<b>1,789</b>	<b>(98)%</b>	<b>1,789</b>	<b>10,185</b>	<b>63</b>
West and Central Africa	11	-	18	-	-	-%	-	18	28
East Africa	-	-	-	-	1,460	(100)%	1,460	1,460	-
Southern Africa	1	1	25	169	329	(92)%	329	3,365	35
Asia and Eastern Europe	-	-	-	-	-	-%	-	5,342	-
<b>Implant 5</b>	<b>21,324</b>	<b>7,224</b>	<b>98,163</b>	<b>268,613</b>	<b>113,559</b>	<b>(14)%</b>	<b>113,559</b>	<b>559,613</b>	<b>240,009</b>
West and Central Africa	15,688	7,982	80,643	84,157	29,265	176%	29,265	269,819	200,676
East Africa	5,556	(1,087)	18,187	180,121	63,837	(72)%	63,837	164,105	44,645

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	467	(170)	(4,121)	527	(485)	-%	(485)	43,362	(7,984)
Americas	(886)	39	(1,420)	558	(333)	-%	(333)	12,012	(898)
Asia and Eastern Europe	499	461	4,874	3,250	21,275	(77)%	21,275	70,315	3,570
<b>Implant 5 Insertion</b>	<b>22,284</b>	<b>35,300</b>	<b>333,010</b>	<b>147,439</b>	<b>251,846</b>	<b>32%</b>	<b>251,846</b>	<b>1,613,747</b>	<b>847,543</b>
West and Central Africa	10,318	12,205	134,846	41,399	106,632	26%	106,632	645,425	398,154
East Africa	6,859	16,562	138,279	38,768	104,800	32%	104,800	579,229	319,436
Southern Africa	3,259	5,390	47,109	62,375	32,406	45%	32,406	321,887	123,057
Americas	1,586	883	9,220	2,372	4,862	90%	4,862	35,605	4,415
Asia and Eastern Europe	262	260	3,556	2,525	3,146	13%	3,146	31,601	2,481
<b>Infant Fortified Food</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>91,859</b>	<b>-</b>
Asia and Eastern Europe	-	-	-	-	-	-%	-	91,859	-
<b>Injectable 1</b>	<b>6,570</b>	<b>10,271</b>	<b>115,687</b>	<b>133,742</b>	<b>116,015</b>	<b>-%</b>	<b>116,015</b>	<b>3,529,290</b>	<b>1,685</b>
West and Central Africa	-	-	-	-	-	-%	-	224,928	-
Americas	(154)	2,978	30,936	54,269	30,791	-%	30,791	371,663	223
Asia and Eastern Europe	6,724	7,293	84,751	79,473	85,224	(1)%	85,224	2,932,699	1,462
<b>Injectable 1 Provided</b>	<b>4,222</b>	<b>5,334</b>	<b>66,002</b>	<b>142</b>	<b>41,833</b>	<b>58%</b>	<b>41,833</b>	<b>138,570</b>	<b>941</b>
Southern Africa	27	99	1,095	100	135	711%	135	1,230	40
Americas	1,919	2,925	30,658	42	11,222	173%	11,222	47,935	245
Asia and Eastern Europe	2,276	2,310	34,249	-	30,476	12%	30,476	89,405	656
<b>Injectable 2</b>	<b>55,942</b>	<b>98,622</b>	<b>1,259,785</b>	<b>1,270,556</b>	<b>1,838,773</b>	<b>(31)%</b>	<b>1,838,773</b>	<b>23,099,326</b>	<b>106,141</b>
West and Central Africa	50,551	79,943	982,983	1,045,150	1,538,928	(36)%	1,538,928	16,146,742	96,593
Americas	-	-	-	-	(7)	-%	(7)	22	-
Asia and Eastern Europe	5,391	18,680	276,802	225,406	299,852	(8)%	299,852	6,952,562	9,548
<b>Injectable 2 Provided</b>	<b>3,450</b>	<b>4,952</b>	<b>52,361</b>	<b>538</b>	<b>40,856</b>	<b>28%</b>	<b>40,856</b>	<b>124,294</b>	<b>2,752</b>
West and Central Africa	856	1,119	12,469	-	10,433	20%	10,433	22,902	878
Southern Africa	888	1,654	10,962	538	686	1,498%	686	11,648	926
Americas	377	779	7,192	-	6,869	5%	6,869	21,875	115
Asia and Eastern Europe	1,329	1,400	21,738	-	22,868	(5)%	22,868	67,869	833

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Injectable 3</b>	440,294	520,397	8,728,369	7,199,351	6,510,929	34%	6,510,929	88,158,502	724,575
West and Central Africa	80,794	146,061	3,118,113	2,252,284	1,814,801	72%	1,814,801	28,267,609	314,634
East Africa	60,728	101,879	2,258,231	1,894,283	857,441	163%	857,441	15,478,745	228,617
Southern Africa	174,115	165,756	1,777,834	1,138,166	2,240,708	(21)%	2,240,708	19,941,590	125,274
Americas	-	(1)	(2)	57,500	(414)	-%	(414)	3,366,884	-
Asia and Eastern Europe	124,657	106,702	1,574,193	1,857,118	1,598,393	(2)%	1,598,393	21,103,674	56,049
<b>Injectable 3 Provided</b>	61,315	73,723	969,162	386,273	365,694	165%	365,694	1,565,043	88,552
West and Central Africa	5,786	3,813	56,083	27,082	16,028	250%	16,028	85,542	8,114
East Africa	15,006	18,101	200,670	155,758	62,588	221%	62,588	295,426	20,725
Southern Africa	28,672	35,597	351,408	193,875	210,309	67%	210,309	696,641	42,063
Americas	3,996	7,007	70,829	58	37,200	90%	37,200	136,622	1,713
Asia and Eastern Europe	7,855	9,206	290,172	9,500	39,569	633%	39,569	350,812	15,937
<b>IPtP2</b>	413	10,191	52,192	1,009,317	177,461	(71)%	177,461	258,647	3,021
West and Central Africa	-	-	54	836,961	-	-%	-	54	3
East Africa	360	722	7,152	-	19,006	(62)%	19,006	55,152	353
Southern Africa	53	9,468	44,986	172,356	158,455	(72)%	158,455	203,441	2,665
<b>Iron Folic Acid Tablet</b>	540	5,420	39,960	-	9,088	340%	9,088	48,283,018	-
West and Central Africa	540	5,420	39,960	-	14,500	176%	14,500	54,460	-
Asia and Eastern Europe	-	-	-	-	(5,412)	-%	(5,412)	48,228,558	-
<b>IRS (# of household)</b>	-	-	-	721,863	-	-%	-	-	-
Southern Africa	-	-	-	721,863	-	-%	-	-	-
<b>ITN</b>	-	-	-	-	-	-%	-	19,397,605	-
West and Central Africa	-	-	-	-	-	-%	-	891,146	-
East Africa	-	-	-	-	-	-%	-	17,134,604	-
Southern Africa	-	-	-	-	-	-%	-	1,341,567	-
Americas	-	-	-	-	-	-%	-	30,288	-
<b>IUD 10</b>	39,699	6,566	228,293	249,325	275,556	(17)%	275,556	2,644,505	481,349
West and Central Africa	2,709	4,787	56,534	95,321	112,075	(50)%	112,075	1,625,670	180,859

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	11,424	(5,076)	15,830	(17,071)	(6,010)	-%	(6,010)	261,767	60,097
Southern Africa	20,543	(498)	21,014	14,334	3,605	483%	3,605	46,883	71,165
Americas	117	535	3,866	2,183	4,625	(16)%	4,625	207,066	2,138
Asia and Eastern Europe	4,906	6,817	131,049	154,558	161,261	(19)%	161,261	503,119	167,089
<b>IID 10 Insertion</b>	<b>44,291</b>	<b>51,818</b>	<b>582,271</b>	<b>411,678</b>	<b>404,855</b>	<b>44%</b>	<b>404,855</b>	<b>2,634,391</b>	<b>1,572,914</b>
West and Central Africa	12,271	12,842	132,124	57,282	117,595	12%	117,595	673,692	516,164
East Africa	19,282	28,491	266,445	242,836	195,352	36%	195,352	1,054,550	805,162
Southern Africa	3,609	3,253	31,791	48,331	25,159	26%	25,159	292,236	85,662
Americas	1,269	1,691	19,655	25,173	18,956	4%	18,956	186,911	10,870
Asia and Eastern Europe	7,860	5,541	132,256	38,056	47,793	177%	47,793	427,002	155,056
<b>IID 5</b>	<b>5,874</b>	<b>8,413</b>	<b>151,902</b>	<b>399,277</b>	<b>35,316</b>	<b>330%</b>	<b>35,316</b>	<b>4,283,293</b>	<b>122,085</b>
West and Central Africa	-	-	-	-	-	-%	-	3,726	-
East Africa	(18)	(24)	(243)	-	477	(151)%	477	13,881	(542)
Southern Africa	-	-	-	-	-	-%	-	937	-
Americas	50	17	310	50	587	(47)%	587	897	105
Asia and Eastern Europe	5,842	8,419	151,835	399,227	34,252	343%	34,252	4,263,852	122,521
<b>IID 5 Insertion</b>	<b>13,146</b>	<b>13,133</b>	<b>174,412</b>	<b>950</b>	<b>203,272</b>	<b>(14)%</b>	<b>203,272</b>	<b>1,040,405</b>	<b>176,844</b>
West and Central Africa	-	-	-	-	-	-%	-	45	-
East Africa	18	24	485	-	691	(30)%	691	28,228	1,202
Southern Africa	-	-	8	150	241	(97)%	241	3,170	20
Americas	5	2	12	800	154	(92)%	154	166	4
Asia and Eastern Europe	13,123	13,107	173,907	-	202,186	(14)%	202,186	1,008,796	175,618
<b>IUS 5</b>	<b>(4)</b>	<b>161</b>	<b>954</b>	<b>3,500</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>954</b>	<b>1,964</b>
Southern Africa	(4)	161	954	-	-	-%	-	954	1,964
Asia and Eastern Europe	-	-	-	3,500	-	-%	-	-	-
<b>IUS 5 Insertion</b>	<b>188</b>	<b>131</b>	<b>993</b>	<b>500</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>993</b>	<b>2,675</b>
West and Central Africa	119	69	626	-	-	-%	-	626	1,981
Southern Africa	68	62	366	500	-	-%	-	366	694

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	1	-	1	-	-	-%	-	1	-
<b>LifeStraw</b>	-	-	-	-	-	-%	-	15,965	-
West and Central Africa	-	-	-	-	-	-%	-	645	-
East Africa	-	-	-	-	-	-%	-	15,320	-
<b>LLIN</b>	7,955,511	1,899,141	24,977,050	25,051,409	42,829,969	(42)%	42,829,969	327,530,514	4,554,975
West and Central Africa	2,323,552	648,330	6,789,265	12,347,682	30,675,129	(78)%	30,675,129	147,461,598	2,584,036
East Africa	4,393,209	925,841	11,224,693	7,978,360	9,344,931	20%	9,344,931	98,981,897	1,107,218
Southern Africa	557,810	324,827	6,266,352	4,334,567	2,787,629	125%	2,787,629	71,195,522	860,159
Americas	680,940	-	680,940	375,000	-	-%	-	4,077,475	2,338
Other Africa	-	-	-	-	-	-%	-	22,408	-
Asia and Eastern Europe	-	143	15,800	15,800	22,280	(29)%	22,280	5,791,614	1,225
<b>LLIN (Hammock net)</b>	45	-	45	550	-	-%	-	45	-
Asia and Eastern Europe	45	-	45	550	-	-%	-	45	-
<b>Lubricant</b>	916,548	655,334	10,643,756	-	3,223,877	230%	3,223,877	72,156,795	-
West and Central Africa	481,957	246,137	6,122,064	-	349,026	1,654%	349,026	8,478,026	-
East Africa	15,600	93,873	1,006,747	-	538,215	87%	538,215	2,504,459	-
Southern Africa	228,525	163,921	1,551,218	-	621,962	149%	621,962	5,866,600	-
Americas	138,728	80,827	1,124,334	-	1,002,585	12%	1,002,585	7,555,807	-
Asia and Eastern Europe	51,738	70,576	839,393	-	712,089	18%	712,089	47,751,903	-
<b>Malaria PPT (ACT)</b>	1,940,159	931,837	15,274,634	9,875,035	17,642,023	(13)%	17,642,023	127,588,741	5,057,421
West and Central Africa	791,713	313,908	9,078,596	4,289,752	12,109,484	(25)%	12,109,484	84,857,543	3,260,492
East Africa	21,169	189,901	3,184,246	3,117,784	4,074,406	(22)%	4,074,406	27,700,471	979,783
Southern Africa	877,351	229,790	1,985,703	1,237,169	991,622	100%	991,622	8,904,023	596,992
Asia and Eastern Europe	249,926	198,238	1,026,089	1,230,330	466,511	120%	466,511	6,126,704	220,154
<b>Malaria PPT (Non-ACT)</b>	(180)	87	1,261	11,344	3,078	(59)%	3,078	13,896,329	176
West and Central Africa	-	-	-	-	-	-%	-	5,009,188	-
Southern Africa	-	-	-	-	-	-%	-	8,462,175	-
Americas	-	-	-	11,000	-	-%	-	318,740	-



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	(180)	87	1,261	344	3,078	(59)%	3,078	106,226	176
<b>Malaria RDK</b>	<b>584,125</b>	<b>905,310</b>	<b>9,167,497</b>	<b>12,669,578</b>	<b>12,864,534</b>	<b>(29)%</b>	<b>12,864,534</b>	<b>47,266,978</b>	<b>-</b>
West and Central Africa	345,264	201,998	2,598,445	7,528,315	8,902,668	(71)%	8,902,668	19,538,556	-
East Africa	20,000	186,092	1,812,525	1,881,088	1,596,819	14%	1,596,819	6,007,443	-
Southern Africa	150	4,075	2,065,676	1,873,659	1,133,756	82%	1,133,756	10,120,801	-
Americas	-	-	-	-	-	-%	-	190	-
Asia and Eastern Europe	218,711	513,145	2,690,851	1,386,516	1,231,291	119%	1,231,291	11,599,988	-
<b>Male Circumcision (HIV-Positive)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,526</b>	<b>(100)%</b>	<b>3,526</b>	<b>10,836</b>	<b>-</b>
East Africa	-	-	-	-	287	(100)%	287	614	-
Southern Africa	-	-	-	-	3,239	(100)%	3,239	10,222	-
<b>Manual Vacuum Aspiration for PA</b>	<b>4,127</b>	<b>3,640</b>	<b>42,021</b>	<b>2,994</b>	<b>46,635</b>	<b>(10)%</b>	<b>46,635</b>	<b>88,727</b>	<b>4,422</b>
West and Central Africa	473	252	3,532	1,909	7,369	(52)%	7,369	10,972	1,802
East Africa	28	140	1,824	250	1,253	46%	1,253	3,077	358
Southern Africa	193	252	2,223	55	1,457	53%	1,457	3,680	665
Americas	409	251	5,793	780	5,421	7%	5,421	11,214	129
Asia and Eastern Europe	3,024	2,745	28,649	-	31,135	(8)%	31,135	59,784	1,469
<b>Manual Vacuum Aspiration for SA</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>3,249</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	-	-
East Africa	-	-	-	-	-	-%	-	-	-
Southern Africa	-	-	-	-	-	-%	-	-	-
Americas	-	-	-	-	-	-%	-	-	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	3,249	-
<b>Medical Abortion</b>	<b>82,317</b>	<b>95,128</b>	<b>874,342</b>	<b>979,436</b>	<b>390,819</b>	<b>124%</b>	<b>390,819</b>	<b>3,816,901</b>	<b>81,035</b>
West and Central Africa	(32)	-	(60)	-	(105)	-%	(105)	(165)	(22)
East Africa	7,648	1,112	11,011	25,000	-	-%	-	11,011	3,368
Southern Africa	-	-	-	-	-	-%	-	10,451	-
Asia and Eastern Europe	74,701	94,016	863,391	954,436	390,924	121%	390,924	3,795,604	77,690
<b>Medical Abortion Provided</b>	<b>815</b>	<b>825</b>	<b>8,676</b>	<b>-</b>	<b>105</b>	<b>8,163%</b>	<b>105</b>	<b>8,781</b>	<b>927</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	57	-	85	-	105	(19)%	105	190	35
East Africa	40	110	621	-	-	-%	-	621	211
Asia and Eastern Europe	718	716	7,970	-	-	-%	-	7,970	681
<b>Micronutrient Powder</b>	<b>105,120</b>	<b>1,173,201</b>	<b>14,257,920</b>	<b>6,672,570</b>	<b>4,607,780</b>	<b>209%</b>	<b>4,607,780</b>	<b>39,796,480</b>	<b>-</b>
West and Central Africa	75,630	134,243	1,302,620	1,713,790	85,400	1,425%	85,400	1,388,020	-
East Africa	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-
Southern Africa	29,490	121,223	5,553,590	4,858,780	4,024,990	38%	4,024,990	17,348,900	-
Americas	-	-	-	-	395,910	(100)%	395,910	3,365,323	-
Asia and Eastern Europe	-	917,734	7,401,710	-	97,980	7,454%	97,980	16,456,182	-
<b>Misoprostol for PAC (Oral)</b>	<b>1,057,828</b>	<b>125,712</b>	<b>2,312,171</b>	<b>1,931,906</b>	<b>2,011,632</b>	<b>15%</b>	<b>2,011,632</b>	<b>8,272,852</b>	<b>298,253</b>
West and Central Africa	764,371	48,841	1,314,021	906,686	626,258	110%	626,258	2,965,994	266,995
East Africa	257,513	61,607	824,353	750,300	1,265,369	(35)%	1,265,369	4,852,146	29,423
Southern Africa	(957)	(1,078)	(8,193)	-	(6,537)	-%	(6,537)	(14,730)	(735)
Americas	14,331	8,008	58,420	118,920	2,042	2,761%	2,042	75,972	425
Asia and Eastern Europe	22,570	8,333	123,570	156,000	124,500	(1)%	124,500	393,470	2,146
<b>Misoprostol for PAC (oral) Provid</b>	<b>4,278</b>	<b>4,044</b>	<b>47,223</b>	<b>10,720</b>	<b>9,129</b>	<b>417%</b>	<b>9,129</b>	<b>56,352</b>	<b>5,716</b>
West and Central Africa	2,631	2,159	24,039	10,120	2,427	890%	2,427	26,466	4,425
East Africa	99	308	3,855	-	129	2,888%	129	3,984	387
Southern Africa	957	1,078	8,193	-	6,537	25%	6,537	14,730	817
Americas	591	499	11,136	600	36	30,833%	36	11,172	86
<b>Misoprostol for PAC (Sublingual)</b>	<b>2,734,838</b>	<b>2,254</b>	<b>2,974,460</b>	<b>2,495,200</b>	<b>6,156</b>	<b>48,218%</b>	<b>6,156</b>	<b>2,980,616</b>	<b>359,339</b>
East Africa	2,434,306	61	2,434,732	2,480,200	156	1,560,626%	156	2,434,888	303,875
Southern Africa	1,732	2,193	240,928	15,000	6,000	3,915%	6,000	246,928	48,571
Asia and Eastern Europe	298,800	-	298,800	-	-	-%	-	298,800	6,893
<b>Misoprostol for PAC (sublingual)</b>	<b>2</b>	<b>7</b>	<b>80</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>80</b>	<b>24</b>
East Africa	2	7	80	-	-	-%	-	80	24
<b>Misoprostol for PPH</b>	<b>(2,353,240)</b>	<b>201,293</b>	<b>160,280</b>	<b>330,000</b>	<b>1,714,080</b>	<b>(91)%</b>	<b>1,714,080</b>	<b>6,386,138</b>	<b>525</b>
West and Central Africa	-	-	-	300,000	-	-%	-	373,010	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	(2,353,240)	201,293	159,400	30,000	1,634,400	(90)%	1,634,400	5,122,139	523
Southern Africa	-	-	-	-	-	-%	-	684,608	-
Americas	-	-	880	-	79,680	(99)%	79,680	184,166	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	22,215	-
<b>Multivitamin</b>	<b>222,750</b>	<b>220,187</b>	<b>2,628,610</b>	<b>2,476,080</b>	<b>1,789,770</b>	<b>47%</b>	<b>1,789,770</b>	<b>95,930,699</b>	<b>267</b>
West and Central Africa	-	-	-	-	-	-%	-	15,761,378	-
Southern Africa	-	-	-	-	-	-%	-	12,270,645	-
Americas	177,660	160,530	2,195,100	2,476,080	1,789,770	23%	1,789,770	53,955,121	162
Asia and Eastern Europe	45,090	59,657	433,510	-	-	-%	-	13,943,555	104
<b>Naloxone</b>	<b>600</b>	<b>282</b>	<b>3,511</b>	<b>5,892</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>65,681</b>	<b>4,790</b>
Asia and Eastern Europe	600	282	3,511	5,892	-	-%	-	65,681	4,790
<b>Needle &amp; Syringe</b>	<b>1,011,864</b>	<b>619,873</b>	<b>6,912,895</b>	<b>6,082,749</b>	<b>4,903,605</b>	<b>41%</b>	<b>4,903,605</b>	<b>26,550,543</b>	<b>57,424</b>
Americas	-	-	-	-	-	-%	-	1,540,000	-
Asia and Eastern Europe	1,011,864	619,873	6,912,895	6,082,749	4,903,605	41%	4,903,605	25,010,543	57,424
<b>NVP</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>11,442</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	235	-
Southern Africa	-	-	-	-	-	-%	-	11,057	-
Americas	-	-	-	-	-	-%	-	150	-
<b>OCs</b>	<b>3,153,539</b>	<b>2,356,879</b>	<b>33,046,062</b>	<b>38,762,595</b>	<b>30,011,035</b>	<b>10%</b>	<b>30,011,035</b>	<b>608,848,955</b>	<b>620,385</b>
West and Central Africa	434,562	501,891	8,042,488	11,612,236	9,528,389	(16)%	9,528,389	167,439,970	262,878
East Africa	965,201	301,676	6,590,767	6,170,698	7,878,628	(16)%	7,878,628	76,937,258	168,206
Southern Africa	233,055	286,046	3,473,450	2,721,504	2,583,428	34%	2,583,428	72,145,632	67,341
Americas	53,679	60,993	800,182	1,100,620	901,873	(11)%	901,873	35,652,614	3,747
Asia and Eastern Europe	1,467,042	1,206,273	14,139,175	17,157,537	9,118,717	55%	9,118,717	256,673,481	118,212
<b>OCs Provided</b>	<b>51,296</b>	<b>66,994</b>	<b>1,215,930</b>	<b>457,682</b>	<b>764,724</b>	<b>59%</b>	<b>764,724</b>	<b>2,590,399</b>	<b>29,209</b>
West and Central Africa	6,435	8,002	116,994	15,000	28,690	308%	28,690	170,121	4,807
East Africa	4,812	5,765	72,500	39,344	58,379	24%	58,379	160,757	2,191
Southern Africa	28,773	38,407	431,442	379,864	573,214	(25)%	573,214	1,484,047	13,492

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	914	2,689	27,077	40	12,463	117%	12,463	57,197	181
Asia and Eastern Europe	10,362	12,129	567,917	23,434	91,978	517%	91,978	718,277	8,538
<b>ORS</b>	<b>52,525</b>	<b>309,042</b>	<b>2,441,964</b>	<b>3,789,196</b>	<b>1,692,324</b>	<b>44%</b>	<b>1,692,324</b>	<b>437,027,112</b>	<b>76,081</b>
West and Central Africa	-	-	500,903	1,965	70,974	606%	70,974	64,412,787	19,524
East Africa	-	232,082	873,533	1,086,611	752,366	16%	752,366	24,887,396	28,474
Southern Africa	-	-	-	-	-	-%	-	1,999,000	-
Americas	-	-	300,000	330,000	300,000	-%	300,000	10,047,338	10,285
Other Africa	-	-	-	-	-	-%	-	6,127,779	-
Asia and Eastern Europe	52,525	76,960	767,528	2,370,620	568,984	35%	568,984	329,552,812	17,798
<b>ORS Provided</b>	<b>348</b>	<b>443</b>	<b>124,926</b>	<b>-</b>	<b>5,546</b>	<b>2,153%</b>	<b>5,546</b>	<b>130,472</b>	<b>4,485</b>
East Africa	348	443	124,926	-	5,546	2,153%	5,546	130,472	4,485
<b>Pneumonia PPT</b>	<b>24,838</b>	<b>85,177</b>	<b>692,057</b>	<b>1,390,257</b>	<b>827,943</b>	<b>(16)%</b>	<b>827,943</b>	<b>6,356,023</b>	<b>386,462</b>
West and Central Africa	-	6,267	56,930	60,000	57,518	(1)%	57,518	849,845	39,000
East Africa	1,858	55,383	221,387	910,330	266,190	(17)%	266,190	2,371,094	195,628
Southern Africa	22,980	23,527	413,740	419,927	376,369	10%	376,369	1,600,838	151,835
Asia and Eastern Europe	-	-	-	-	127,866	(100)%	127,866	1,534,246	-
<b>Pneumonia PPT Provided</b>	<b>1,082</b>	<b>1,573</b>	<b>101,564</b>	<b>-</b>	<b>22,354</b>	<b>354%</b>	<b>22,354</b>	<b>123,918</b>	<b>90,148</b>
West and Central Africa	-	-	-	-	2,500	(100)%	2,500	2,500	-
East Africa	1,082	1,573	101,564	-	19,854	412%	19,854	121,418	90,148
<b>Positive RDTs</b>	<b>20,932</b>	<b>7,407</b>	<b>186,025</b>	<b>-</b>	<b>2,068,034</b>	<b>(91)%</b>	<b>2,068,034</b>	<b>2,254,059</b>	<b>-</b>
West and Central Africa	13,690	-	13,690	-	2,047,931	(99)%	2,047,931	2,061,621	-
East Africa	-	-	110	-	3,656	(97)%	3,656	3,766	-
Southern Africa	911	468	102,632	-	2,177	4,614%	2,177	104,809	-
Americas	1,226	1,251	30,261	-	1,069	2,731%	1,069	31,330	-
Asia and Eastern Europe	5,105	5,688	39,332	-	13,201	198%	13,201	52,533	-
<b>Positive RDTs Given First Line Tr</b>	<b>18,349</b>	<b>5,397</b>	<b>50,266</b>	<b>-</b>	<b>2,062,102</b>	<b>(98)%</b>	<b>2,062,102</b>	<b>2,112,368</b>	<b>-</b>
West and Central Africa	13,515	-	13,515	-	2,047,743	(99)%	2,047,743	2,061,258	-
East Africa	-	-	110	-	3,489	(97)%	3,489	3,599	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	4,834	5,397	36,641	-	10,870	237%	10,870	47,511	-
<b>Pregnancy Test</b>	-	-	-	-	-	-%	-	930,449	-
West and Central Africa	-	-	-	-	-	-%	-	5,685	-
Americas	-	-	-	-	-	-%	-	129,873	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	794,891	-
<b>PrEP</b>	50	264	2,713	19,960	403	573%	403	3,116	88
Southern Africa	50	264	2,713	19,960	403	573%	403	3,116	88
<b>PUR</b>	5,710,927	6,268,825	82,280,174	54,971,647	73,371,542	12%	73,371,542	569,378,963	3,161
West and Central Africa	568,560	120,800	2,247,366	4,792,000	5,988,604	(62)%	5,988,604	46,107,011	206
East Africa	5,135,820	6,134,896	79,186,077	49,069,647	65,302,222	21%	65,302,222	438,233,147	2,935
Southern Africa	-	-	-	-	-	-%	-	4,694,784	-
Americas	-	-	-	-	-	-%	-	21,231,358	-
Asia and Eastern Europe	6,547	13,129	846,731	1,110,000	2,080,716	(59)%	2,080,716	59,112,663	20
<b>QAACts Provided after Confirma</b>	4,971	5,005	33,075	10,513	2,046,155	(98)%	2,046,155	2,079,230	4,719
West and Central Africa	-	-	-	-	2,034,979	(100)%	2,034,979	2,034,979	-
East Africa	-	-	110	-	3,815	(97)%	3,815	3,925	18
Asia and Eastern Europe	4,971	5,005	32,965	10,513	7,361	348%	7,361	40,326	4,701
<b>Referral to Advanced Cervical Cai</b>	1	5	57	85	142	(60)%	142	400	-
Southern Africa	1	5	57	85	142	(60)%	142	400	-
<b>Referral to CD4/Clinical Staging</b>	-	-	-	11,794	10,820	(100)%	10,820	34,138	-
West and Central Africa	-	-	-	553	-	-%	-	18	-
East Africa	-	-	-	2,043	2,210	(100)%	2,210	3,364	-
Southern Africa	-	-	-	9,198	8,610	(100)%	8,610	30,613	-
Americas	-	-	-	-	-	-%	-	143	-
<b>Referral to Clinical Staging</b>	-	-	-	-	2,986	(100)%	2,986	18,909	-
East Africa	-	-	-	-	107	(100)%	107	1,893	-
Southern Africa	-	-	-	-	2,879	(100)%	2,879	17,016	-
<b>Referral to Diabetes Management</b>	-	-	1	-	-	-%	-	1	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	-	1	-	-	-%	-	1	-
<b>Referral to Early Infant Male Circu</b>	-	-	-	-	36	(100)%	36	94	-
Southern Africa	-	-	-	-	36	(100)%	36	94	-
<b>Referral to Emergency Contracep</b>	-	26	82	-	43	91%	43	218	-
East Africa	-	-	5	-	37	(86)%	37	133	-
Southern Africa	-	-	1	-	6	(83)%	6	9	-
Asia and Eastern Europe	-	25	76	-	-	-%	-	76	-
<b>Referral to HIV Testing Services</b>	2,486	5,117	44,435	183,580	36,096	23%	36,096	285,731	1,316
West and Central Africa	601	-	601	60,035	5,682	(89)%	5,682	66,706	2
East Africa	393	774	14,448	113,410	12,052	20%	12,052	132,493	38
Southern Africa	1,491	4,334	24,157	7,200	7,911	205%	7,911	50,840	1,268
Americas	-	-	-	-	27	(100)%	27	577	-
Asia and Eastern Europe	1	9	5,229	2,935	10,424	(50)%	10,424	35,115	8
<b>Referral to Hypertension Manage</b>	22	19	536	50	27	1,885%	27	563	-
Southern Africa	22	19	536	50	27	1,885%	27	563	-
<b>Referral to Implant 3 Insertion</b>	2	2	31	8,500	1,223	(97)%	1,223	16,114	22
West and Central Africa	-	-	-	-	-	-%	-	4,343	-
East Africa	-	-	19	8,500	586	(97)%	586	7,940	15
Southern Africa	2	2	12	-	1	1,100%	1	1,519	7
Americas	-	-	-	-	-	-%	-	974	-
Asia and Eastern Europe	-	-	-	-	636	(100)%	636	1,338	-
<b>Referral to Implant 5 Insertion</b>	8	21	284	1,520	1,831	(84)%	1,831	19,506	170
West and Central Africa	-	-	49	-	-	-%	-	12,990	63
East Africa	-	-	23	1,500	1,717	(99)%	1,717	3,702	26
Southern Africa	1	4	18	20	-	-%	-	1,766	14
Americas	-	-	-	-	-	-%	-	260	-
Asia and Eastern Europe	7	17	194	-	114	70%	114	788	68
<b>Referral to Implant Insertion (dura</b>	-	-	-	-	-	-%	-	89	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	-	-	-	-	-	-%	-	89	-
<b>Referral to Injectable (duration un</b>	-	-	-	-	-	-%	-	773	-
Southern Africa	-	-	-	-	-	-%	-	110	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	663	-
<b>Referral to Injectable 1</b>	8	60	332	100	32	938%	32	364	6
Southern Africa	8	60	332	100	32	938%	32	364	6
<b>Referral to Injectable 2</b>	-	18	55	200	-	-%	-	56	2
Southern Africa	-	18	55	200	-	-%	-	56	2
<b>Referral to Injectable 3</b>	93	206	1,174	15,848	13,305	(91)%	13,305	23,002	57
West and Central Africa	-	-	49	-	-	-%	-	49	3
East Africa	-	-	39	10,000	12,012	(100)%	12,012	13,715	2
Southern Africa	81	183	927	370	45	1,960%	45	1,704	50
Asia and Eastern Europe	12	23	159	5,478	1,248	(87)%	1,248	7,534	3
<b>Referral to IUD 10 Insertion</b>	59	46	905	67,034	2,382	(62)%	2,382	132,529	809
West and Central Africa	-	-	348	-	22	1,482%	22	21,151	550
East Africa	-	-	-	11,200	343	(100)%	343	24,155	-
Southern Africa	2	2	40	-	7	471%	7	14,762	37
Americas	-	-	-	-	-	-%	-	52,430	-
Asia and Eastern Europe	57	45	517	55,834	2,010	(74)%	2,010	20,031	222
<b>Referral to IUD 5 Insertion</b>	-	-	-	30	9	(100)%	9	498	-
East Africa	-	-	-	-	9	(100)%	9	49	-
Southern Africa	-	-	-	30	-	-%	-	9	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	440	-
<b>Referral to IUD Insertion (durati</b>	-	-	5	-	2	150%	2	16	3
East Africa	-	-	-	-	-	-%	-	9	-
Southern Africa	-	-	5	-	2	150%	2	7	3
<b>Referral to IUS 3 Insertion</b>	-	-	26	-	-	-%	-	26	13
Southern Africa	-	-	26	-	-	-%	-	26	13

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Referral to Linkage to HIV Care</b>	1,811	1,761	22,007	17,241	4,072	440%	4,072	26,079	13,418
West and Central Africa	-	-	-	460	281	(100)%	281	281	-
East Africa	313	376	2,800	-	-	-%	-	2,800	1,423
Southern Africa	1,071	1,289	17,034	15,609	2,624	549%	2,624	19,658	10,139
Americas	314	-	314	-	333	(6)%	333	647	179
Asia and Eastern Europe	113	97	1,859	1,172	834	123%	834	2,693	1,676
<b>Referral to Manual Vacuum Aspir:</b>	-	-	-	-	46	(100)%	46	46	-
Asia and Eastern Europe	-	-	-	-	46	(100)%	46	46	-
<b>Referral to Medication Abortion</b>	-	-	-	-	24	(100)%	24	24	-
Asia and Eastern Europe	-	-	-	-	24	(100)%	24	24	-
<b>Referral to OCs</b>	67	194	1,053	1,830	3,408	(69)%	3,408	9,616	14
West and Central Africa	-	-	11	-	-	-%	-	11	-
East Africa	-	-	7	1,500	2,049	(100)%	2,049	2,725	-
Southern Africa	52	189	942	330	79	1,092%	79	1,868	14
Asia and Eastern Europe	15	4	93	-	1,280	(93)%	1,280	5,012	-
<b>Referral to Opioid Treatment</b>	7	13	201	-	136	48%	136	337	-
Asia and Eastern Europe	7	13	201	-	136	48%	136	337	-
<b>Referral to PAC Service (unknowr</b>	-	-	-	-	488	(100)%	488	488	-
Asia and Eastern Europe	-	-	-	-	488	(100)%	488	488	-
<b>Referral to Pre-Exposure Prophyl:</b>	-	36	230	-	-	-%	-	230	4
Southern Africa	-	36	230	-	-	-%	-	230	4
<b>Referral to STI Diagnosis (lab con</b>	-	-	332	-	-	-%	-	332	-
East Africa	-	-	332	-	-	-%	-	332	-
<b>Referral to STI Screening (syndro</b>	381	538	14,404	338	8	179,950%	8	14,412	-
East Africa	372	532	14,307	-	-	-%	-	14,307	-
Southern Africa	9	6	97	338	8	1,113%	8	105	-
<b>Referral to STI Treatment (unknov</b>	1	3	56	142,281	957	(94)%	957	8,893	-
East Africa	-	-	1	142,281	5	(80)%	5	916	-



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	1	3	55	-	952	(94)%	952	5,647	-
Americas	-	-	-	-	-	-%	-	4	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,326	-
<b>Referral to TB Diagnosis</b>	<b>7</b>	<b>252</b>	<b>3,642</b>	<b>19,794</b>	<b>1,446</b>	<b>152%</b>	<b>1,446</b>	<b>30,952</b>	<b>-</b>
East Africa	-	71	628	-	-	-%	-	8,326	-
Southern Africa	7	25	252	6,750	11	2,191%	11	7,715	-
Asia and Eastern Europe	-	156	2,762	13,044	1,435	92%	1,435	14,911	-
<b>Referral to TB DOTS (completion)</b>	<b>-</b>	<b>129</b>	<b>1,105</b>	<b>9,502</b>	<b>773</b>	<b>43%</b>	<b>773</b>	<b>2,162</b>	<b>1,583</b>
Southern Africa	-	-	1	-	2	(50)%	2	17	1
Asia and Eastern Europe	-	129	1,104	9,502	771	43%	771	2,145	1,582
<b>Referral to TB DOTS (completion)</b>	<b>22</b>	<b>143</b>	<b>2,477</b>	<b>7,096</b>	<b>1,778</b>	<b>39%</b>	<b>1,778</b>	<b>7,996</b>	<b>3,481</b>
East Africa	-	-	-	-	26	(100)%	26	1,617	-
Southern Africa	22	14	244	300	484	(50)%	484	2,697	135
Asia and Eastern Europe	-	128	2,233	6,796	1,268	76%	1,268	3,682	3,346
<b>Referral to TB Screening</b>	<b>559</b>	<b>5,248</b>	<b>79,597</b>	<b>12,177</b>	<b>35,695</b>	<b>123%</b>	<b>35,695</b>	<b>115,292</b>	<b>-</b>
East Africa	372	817	13,484	-	-	-%	-	13,484	-
Southern Africa	163	2,139	15,631	-	434	3,502%	434	16,065	-
Asia and Eastern Europe	24	2,292	50,482	12,177	35,261	43%	35,261	85,743	-
<b>Referral to Treatment for Cerviciti</b>	<b>4</b>	<b>3</b>	<b>46</b>	<b>-</b>	<b>4</b>	<b>1,050%</b>	<b>4</b>	<b>72</b>	<b>2</b>
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	4	3	46	-	4	1,050%	4	69	2
<b>Referral to Treatment for Genital I</b>	<b>-</b>	<b>-</b>	<b>3</b>	<b>5</b>	<b>3</b>	<b>-%</b>	<b>3</b>	<b>9</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	-	-	3	5	3	-%	3	6	-
<b>Referral to Treatment for Inguinal</b>	<b>-</b>	<b>-</b>	<b>29</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>134</b>	<b>-</b>
East Africa	-	-	29	-	-	-%	-	134	-
<b>Referral to Treatment for Lower A</b>	<b>-</b>	<b>2</b>	<b>40</b>	<b>-</b>	<b>13</b>	<b>208%</b>	<b>13</b>	<b>136</b>	<b>-</b>
East Africa	-	2	36	-	5	620%	5	109	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	-	4	-	8	(50)%	8	27	-
<b>Referral to Treatment for Urethral</b>	<b>5</b>	<b>9</b>	<b>135</b>	<b>-</b>	<b>32</b>	<b>322%</b>	<b>32</b>	<b>2,606</b>	<b>1</b>
East Africa	4	8	131	-	-	-%	-	2,546	1
Southern Africa	1	1	4	-	32	(88)%	32	60	-
<b>Referral to Treatment for Vaginitis</b>	<b>-</b>	<b>10</b>	<b>197</b>	<b>5</b>	<b>143</b>	<b>38%</b>	<b>143</b>	<b>7,247</b>	<b>2</b>
East Africa	-	10	197	-	136	45%	136	7,235	2
Southern Africa	-	-	-	5	7	(100)%	7	12	-
<b>Referral to Tubal Ligation</b>	<b>-</b>	<b>-</b>	<b>1</b>	<b>-</b>	<b>3</b>	<b>(67)%</b>	<b>3</b>	<b>65</b>	<b>2</b>
East Africa	-	-	-	-	3	(100)%	3	3	-
Southern Africa	-	-	1	-	-	-%	-	1	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	61	-
<b>Referral to Tx for Nonherpetic Gei</b>	<b>-</b>	<b>-</b>	<b>65</b>	<b>-</b>	<b>35</b>	<b>86%</b>	<b>35</b>	<b>1,074</b>	<b>7</b>
East Africa	-	-	40	-	22	82%	22	1,027	3
Southern Africa	-	-	25	-	13	92%	13	47	4
<b>Referral to Tx for Urethral Discha</b>	<b>2</b>	<b>1</b>	<b>102</b>	<b>-</b>	<b>222</b>	<b>(54)%</b>	<b>222</b>	<b>2,422</b>	<b>9</b>
East Africa	-	1	2	-	66	(97)%	66	1,923	-
Southern Africa	2	-	100	-	156	(36)%	156	499	9
<b>Referral to Vasectomy</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>2</b>	<b>-</b>
Southern Africa	-	-	-	3	-	-%	-	2	-
<b>Referral to Voluntary Medical Mal</b>	<b>64</b>	<b>14</b>	<b>462</b>	<b>2,249</b>	<b>3,891</b>	<b>(88)%</b>	<b>3,891</b>	<b>20,588</b>	<b>2,004</b>
East Africa	-	-	-	-	42	(100)%	42	42	-
Southern Africa	64	14	462	2,249	3,849	(88)%	3,849	20,546	2,004
<b>Retreatment</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>46,984,114</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	1,638,283	-
East Africa	-	-	-	-	-	-%	-	40,242,797	-
Southern Africa	-	-	-	-	-	-%	-	543,345	-
Americas	-	-	-	-	-	-%	-	111,568	-
Other Africa	-	-	-	-	-	-%	-	26,407	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	-	-	-	-	-	-%	-	4,421,714	-
<b>Retreatment IconMaxx</b>	-	-	-	-	-	-%	-	4,873,846	-
East Africa	-	-	-	-	-	-%	-	2,297,300	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,576,546	-
<b>Retreatment KO123</b>	-	-	-	-	-	-%	-	9,124,110	-
West and Central Africa	-	-	-	-	-	-%	-	4,082	-
East Africa	-	-	-	-	-	-%	-	8,813,436	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	306,592	-
<b>Retreatment KO123 net</b>	-	-	-	-	-	-%	-	10,259,477	-
East Africa	-	-	-	-	-	-%	-	10,259,477	-
<b>Safe Injection Kit</b>	-	-	-	-	-	-%	-	5	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	5	-
<b>Safe Water Solution</b>	663,405	516,719	7,799,249	10,138,837	9,075,837	(14)%	9,075,837	157,854,858	36,977
West and Central Africa	8,184	11,112	771,875	200,000	160,999	379%	160,999	13,298,626	4,037
East Africa	421,345	261,099	3,337,393	4,239,239	4,616,248	(28)%	4,616,248	64,106,730	11,799
Southern Africa	233,876	244,509	3,689,981	5,699,598	4,291,617	(14)%	4,291,617	73,821,017	21,140
Americas	-	-	-	-	-	-%	-	449,298	-
Asia and Eastern Europe	-	-	-	-	6,973	(100)%	6,973	6,179,187	-
<b>SD NVP w/o Baby ARV Prophylax</b>	-	-	-	-	-	-%	-	271	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	271	-
<b>SD NVP with Baby ARV Prophyla:</b>	-	-	-	-	-	-%	-	235	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	235	-
<b>SDM (Cycle Beads)</b>	10,156	489	42,577	35,563	31,571	35%	31,571	620,951	41,634
West and Central Africa	2,341	375	14,541	18,256	20,227	(28)%	20,227	373,563	18,139
East Africa	-	-	-	-	5	(100)%	5	8,591	-
Southern Africa	7,815	114	28,036	17,307	11,341	147%	11,341	236,303	23,495
Americas	-	-	-	-	(2)	-%	(2)	(2)	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,496	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>SDM (Cycle Beads) Provided</b>	24	157	5,267	-	5,027	5%	5,027	12,056	6,201
West and Central Africa	2	90	3,465	-	2,812	23%	2,812	7,149	4,852
East Africa	-	-	-	-	-	-%	-	134	-
Southern Africa	22	66	1,789	-	2,176	(18)%	2,176	4,654	1,346
Americas	-	-	13	-	39	(67)%	39	119	3
<b>Seasonal Malaria Chemopreventi</b>	-	-	2,411,009	-	-	-%	-	2,411,009	754,652
West and Central Africa	-	-	2,411,009	-	-	-%	-	2,411,009	754,652
<b>Skilled Birth Attendance</b>	1,324	3,346	47,213	16,237	28,307	67%	28,307	109,796	25,180
West and Central Africa	-	-	17,175	-	-	-%	-	17,175	-
East Africa	1,324	3,346	30,038	16,237	28,307	6%	28,307	92,621	25,180
<b>STI Kit</b>	-	-	-	-	-	-%	-	691,263	-
West and Central Africa	-	-	-	-	-	-%	-	1,796	-
East Africa	-	-	-	-	-	-%	-	438,695	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	250,772	-
<b>STI Kit (Non-Ulcerative)</b>	760	347	5,640	9,311	62,276	(91)%	62,276	4,011,513	342
West and Central Africa	-	-	-	-	-	-%	-	7,704	-
East Africa	760	347	5,640	9,070	18,139	(69)%	18,139	855,582	342
Southern Africa	-	-	-	241	749	(100)%	749	2,057,518	-
Asia and Eastern Europe	-	-	-	-	43,388	(100)%	43,388	1,090,709	-
<b>STI Kit (Ulcerative)</b>	-	3	700	1,305	7,171	(90)%	7,171	1,854,154	134
West and Central Africa	-	-	-	-	-	-%	-	480	-
East Africa	-	3	700	1,121	3,373	(79)%	3,373	72,228	134
Southern Africa	-	-	-	184	119	(100)%	119	1,720,973	-
Asia and Eastern Europe	-	-	-	-	3,679	(100)%	3,679	60,473	-
<b>STI Screening</b>	19,172	37,433	430,622	3,000	443,197	(3)%	443,197	1,032,081	-
West and Central Africa	316	410	5,825	-	19,906	(71)%	19,906	29,423	-
East Africa	10,650	12,268	122,608	3,000	153,790	(20)%	153,790	413,436	-
Southern Africa	5,266	7,169	82,694	-	47,096	76%	47,096	144,046	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	10	14,794	185,852	-	222,184	(16)%	222,184	410,729	-
Asia and Eastern Europe	2,930	2,792	33,643	-	221	15,123%	221	34,447	-
<b>TB Diagnosis</b>	<b>3,828</b>	<b>5,572</b>	<b>73,962</b>	<b>-</b>	<b>62,507</b>	<b>18%</b>	<b>62,507</b>	<b>161,166</b>	<b>-</b>
West and Central Africa	-	-	-	-	10,219	(100)%	10,219	10,219	-
East Africa	-	-	-	-	-	-%	-	615	-
Southern Africa	27	35	459	-	336	37%	336	1,194	-
Americas	-	-	9,484	-	11,406	(17)%	11,406	20,890	-
Asia and Eastern Europe	3,801	5,536	64,019	-	40,546	58%	40,546	128,248	-
<b>TB DOTS</b>	<b>2,496</b>	<b>3,168</b>	<b>45,393</b>	<b>32,517</b>	<b>39,561</b>	<b>15%</b>	<b>39,561</b>	<b>323,228</b>	<b>214,334</b>
West and Central Africa	-	-	-	-	5,763	(100)%	5,763	5,763	-
Southern Africa	4	1	24	-	11	118%	11	66	141
Americas	-	-	10,637	10,000	9,997	6%	9,997	20,634	36,409
Asia and Eastern Europe	2,492	3,167	34,732	22,517	23,790	46%	23,790	296,765	177,784
<b>TB Screening</b>	<b>40,297</b>	<b>51,266</b>	<b>623,288</b>	<b>-</b>	<b>556,967</b>	<b>12%</b>	<b>556,967</b>	<b>1,701,349</b>	<b>-</b>
West and Central Africa	-	-	-	-	7,139	(100)%	7,139	7,139	-
East Africa	9,794	11,484	109,508	-	143,594	(24)%	143,594	461,117	-
Southern Africa	19,172	24,747	305,263	-	284,453	7%	284,453	838,067	-
Americas	-	-	11,507	-	12,026	(4)%	12,026	23,533	-
Asia and Eastern Europe	11,331	15,034	197,010	-	109,755	79%	109,755	371,493	-
<b>Toilets Constructed</b>	<b>-</b>	<b>36</b>	<b>16,479</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>16,479</b>	<b>-</b>
West and Central Africa	-	36	3,677	-	-	-%	-	3,677	-
Asia and Eastern Europe	-	-	12,802	-	-	-%	-	12,802	-
<b>Toilets Sold</b>	<b>311</b>	<b>243</b>	<b>128,169</b>	<b>108,137</b>	<b>75,880</b>	<b>69%</b>	<b>75,880</b>	<b>204,049</b>	<b>17,098</b>
West and Central Africa	-	36	3,672	3,000	2,598	41%	2,598	6,270	984
Asia and Eastern Europe	311	207	124,497	105,137	73,282	70%	73,282	197,779	16,114
<b>Treatment for Cervicitis</b>	<b>5</b>	<b>9</b>	<b>298</b>	<b>120</b>	<b>20</b>	<b>1,390%</b>	<b>20</b>	<b>318</b>	<b>25</b>
East Africa	-	1	13	-	-	-%	-	13	-
Southern Africa	2	4	270	120	20	1,250%	20	290	25

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	3	4	15	-	-	-%	-	15	-
<b>Treatment for Genital Herpes</b>	<b>1</b>	<b>10</b>	<b>94</b>	<b>312</b>	<b>7</b>	<b>1,243%</b>	<b>7</b>	<b>101</b>	<b>3</b>
East Africa	-	6	39	300	2	1,850%	2	41	1
Southern Africa	1	2	47	12	5	840%	5	52	2
Americas	-	3	8	-	-	-%	-	8	-
<b>Treatment for Inguinal Bubo</b>	<b>2</b>	<b>12</b>	<b>123</b>	<b>-</b>	<b>8</b>	<b>1,438%</b>	<b>8</b>	<b>131</b>	<b>-</b>
East Africa	1	6	34	-	-	-%	-	34	-
Southern Africa	1	6	89	-	8	1,013%	8	97	-
<b>Treatment for Lower Abdominal P</b>	<b>101</b>	<b>120</b>	<b>1,700</b>	<b>430</b>	<b>106</b>	<b>1,504%</b>	<b>106</b>	<b>1,806</b>	<b>-</b>
East Africa	34	32	433	400	4	10,725%	4	437	-
Southern Africa	67	88	1,267	30	102	1,142%	102	1,369	-
<b>Treatment for Nonherpetic Genita</b>	<b>146</b>	<b>569</b>	<b>8,316</b>	<b>450</b>	<b>1,466</b>	<b>467%</b>	<b>1,466</b>	<b>9,782</b>	<b>1,384</b>
East Africa	45	66	803	300	14	5,636%	14	817	120
Southern Africa	101	135	2,084	150	162	1,186%	162	2,246	359
Americas	-	369	5,429	-	1,290	321%	1,290	6,719	905
<b>Treatment for Pre-Eclampsia (witt</b>	<b>2</b>	<b>10</b>	<b>93</b>	<b>39</b>	<b>28</b>	<b>232%</b>	<b>28</b>	<b>121</b>	<b>63</b>
East Africa	2	10	93	39	28	232%	28	121	63
<b>Treatment for Severe Acute Malnu</b>	<b>-</b>	<b>-</b>	<b>16,206</b>	<b>-</b>	<b>25,444</b>	<b>(36)%</b>	<b>25,444</b>	<b>41,650</b>	<b>20,370</b>
West and Central Africa	-	-	4	-	-	-%	-	4	-
East Africa	-	-	16,202	-	25,444	(36)%	25,444	41,646	20,370
<b>Treatment for Urethral Discharge</b>	<b>531</b>	<b>688</b>	<b>8,858</b>	<b>772</b>	<b>698</b>	<b>1,169%</b>	<b>698</b>	<b>9,556</b>	<b>113</b>
West and Central Africa	-	-	-	-	116	(100)%	116	116	-
East Africa	113	116	1,348	700	1	134,700%	1	1,349	16
Southern Africa	418	572	7,510	72	581	1,193%	581	8,091	97
<b>Treatment for Urethral Discharge</b>	<b>143</b>	<b>157</b>	<b>2,270</b>	<b>1,240</b>	<b>224</b>	<b>913%</b>	<b>224</b>	<b>2,494</b>	<b>205</b>
West and Central Africa	-	-	-	-	138	(100)%	138	138	-
East Africa	125	118	1,395	900	2	69,650%	2	1,397	45
Southern Africa	18	37	868	340	84	933%	84	952	160

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	-	2	7	-	-	-%	-	7	-
<b>Treatment for Vaginitis</b>	416	552	8,098	5	671	1,107%	671	8,769	228
East Africa	53	85	1,057	-	67	1,478%	67	1,124	22
Southern Africa	360	467	7,038	5	604	1,065%	604	7,642	206
Americas	3	-	3	-	-	-%	-	3	-
<b>Tubal Ligation</b>	5,039	4,153	49,127	72,802	24,786	98%	24,786	304,049	201,082
West and Central Africa	-	-	12	-	-	-%	-	12	86
East Africa	-	1,838	14,190	5,500	4,523	214%	4,523	19,252	83,423
Southern Africa	9	25	245	-	-	-%	-	245	1,343
Americas	1,269	442	4,899	-	1,982	147%	1,982	15,509	7,670
Asia and Eastern Europe	3,761	1,848	29,781	67,302	18,281	63%	18,281	269,031	108,559
<b>Type 2 Diabetes Diagnosis</b>	-	461	1,431	-	-	-%	-	1,431	-
Southern Africa	-	461	1,431	-	-	-%	-	1,431	-
<b>Type 2 Diabetes Screening</b>	885	1,493	9,881	-	-	-%	-	9,881	-
Southern Africa	885	1,492	9,879	-	-	-%	-	9,879	-
Americas	-	1	2	-	-	-%	-	2	-
<b>Type 2 Diabetes_ Controlled Cond</b>	-	-	6	-	-	-%	-	6	-
Southern Africa	-	-	6	-	-	-%	-	6	-
<b>Vasectomy</b>	136	109	2,147	2,112	1,886	14%	1,886	4,292	7,479
West and Central Africa	-	-	1	-	-	-%	-	1	7
East Africa	-	-	7	-	2	250%	2	11	43
Southern Africa	-	-	29	-	-	-%	-	29	188
Americas	48	44	312	-	14	2,129%	14	583	497
Asia and Eastern Europe	88	65	1,798	2,112	1,870	(4)%	1,870	3,668	6,743
<b>Vivax Treatment after Confirmato</b>	209	189	2,175	3,443	3,796	(43)%	3,796	5,971	358
Asia and Eastern Europe	209	189	2,175	3,443	3,796	(43)%	3,796	5,971	358
<b>Voluntary Medical Male Circumcis</b>	52,581	25,869	422,966	385,679	279,911	51%	279,911	2,067,899	2,858,574
East Africa	1,578	3,387	40,038	68,253	30,631	31%	30,631	132,034	144,322

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	51,003	22,482	382,928	317,426	249,280	54%	249,280	1,935,865	2,714,252
<b>Water Treatment Tablets</b>	<b>4,473,000</b>	<b>4,106,520</b>	<b>55,658,823</b>	<b>62,058,922</b>	<b>92,147,698</b>	<b>(40)%</b>	<b>92,147,698</b>	<b>780,079,734</b>	<b>10,339</b>
West and Central Africa	2,073,060	2,012,506	12,549,741	14,097,521	23,980,058	(48)%	23,980,058	182,513,342	1,829
East Africa	845,840	990,027	24,482,710	23,405,999	47,341,850	(48)%	47,341,850	397,471,822	4,169
Southern Africa	1,554,100	1,103,553	18,610,072	24,505,402	20,557,660	(9)%	20,557,660	184,511,580	4,340
Americas	-	-	-	-	-	-%	-	4,918,000	-
Asia and Eastern Europe	-	433	16,300	50,000	268,130	(94)%	268,130	10,664,990	1
<b>Woman Condom</b>	<b>4,296</b>	<b>2,640</b>	<b>32,232</b>	<b>81,624</b>	<b>9,600</b>	<b>236%</b>	<b>9,600</b>	<b>41,832</b>	<b>602</b>
Southern Africa	4,296	2,640	32,232	81,624	9,600	236%	9,600	41,832	602
<b>Zika Prevention Kit</b>	<b>21</b>	<b>280</b>	<b>966</b>	<b>-</b>	<b>112,890</b>	<b>(99)%</b>	<b>112,890</b>	<b>113,856</b>	<b>14</b>
Americas	21	280	966	-	112,890	(99)%	112,890	113,856	14
<b>Zinc</b>	<b>-</b>	<b>95,840</b>	<b>2,556,522</b>	<b>356,167</b>	<b>98,094</b>	<b>2,506%</b>	<b>98,094</b>	<b>6,696,563</b>	<b>33,061</b>
West and Central Africa	-	45,310	2,232,085	34,685	42,892	5,104%	42,892	2,866,829	29,552
East Africa	-	50,530	315,947	312,992	53,910	486%	53,910	2,395,083	3,450
Asia and Eastern Europe	-	-	8,490	8,490	1,292	557%	1,292	1,434,651	58
<b>Zinc Provided</b>	<b>-</b>	<b>-</b>	<b>33,075</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>33,075</b>	<b>401</b>
East Africa	-	-	33,075	-	-	-%	-	33,075	401





# West & Central Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	26,543	-	-	-	4,910,842	5,024	1,178,400	79,241	1,625	457	-	86,390
Benin	489	-	-	-	483,542	385	144,420	9	187	-	-	441
Cameroon	2,007	-	-	-	370,139	365	99,091	141	61	457	-	908
Congo-Kinshasa	769	-	-	-	816,100	896	207,252	27,606	751	-	-	28,357
Cote d'Ivoire	29	-	-	-	3,543	2	504	-	-	-	-	-
Ghana	76	-	-	-	595,776	305	134,084	-	-	-	-	-
Guinea	381	-	-	-	179,990	123	25,735	-	329	-	-	329
Liberia	107	-	-	-	10,946	8	1,562	-	4	-	-	4
Mali	-	-	-	-	259,727	347	88,075	38,286	24	-	-	38,414
Niger	32	-	-	-	36,095	39	11,197	-	-	-	-	155
Nigeria	22,065	-	-	-	2,107,259	2,538	458,131	13,178	268	-	-	17,760
Senegal	587	-	-	-	47,724	17	8,348	21	1	-	-	21

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>									<b>1,062,413</b>	<b>9,720,752</b>	<b>10,783,165</b>
Acute Malnutrition Screen	203	166	1,377	-	-	-%	-	1,377	-	-	-
CD4 Tests Provided to HIV	22	53	1,017	-	297	242%	297	1,314	-	-	-
Cervical Cancer-Pap Sme:	-	-	-	-	1,450	(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and C	12	511	2,087	719	2,406	(13)%	2,406	5,102	-	513	513
Cervical Cancer-VIA/VILI §	5,688	17,517	105,647	-	90,919	16%	90,919	232,766	-	-	-
Chlorhexidine	1,600	3,000	102,406	200,000	46,000	123%	46,000	148,406	-	10,303	10,303
Clean Delivery Kit	1,360	1,492	15,225	15,000	4,400	246%	4,400	58,975	-	1,928	1,928
Condom	9,050,966	9,449,540	124,423,911	163,145,833	166,491,204	(25)%	166,491,204	3,979,130,343	898,344	366,967	1,265,311
Condom Provided	-	-	-	-	55,399	(100)%	55,399	83,854	-	-	-
Counseling & Tx for Mode	-	-	8	-	-	-%	-	8	-	-	-
Diarrhea Treatment Kit	59,086	45,091	1,202,560	1,012,000	1,303,935	(8)%	1,303,935	8,295,098	-	84,633	84,633
Diarrhea Treatment Kit Pri	-	-	-	-	2,400	(100)%	2,400	2,400	-	-	-
Emergency Contraception	166,041	154,332	1,834,004	2,055,000	1,808,411	1%	1,808,411	13,888,550	-	21,916	21,916
Emergency Contraception	34	33	335	-	201	67%	201	857	-	4	4
Family Planning Counseli	-	-	-	-	20,577	(100)%	20,577	20,606	-	-	-
Female Condom	168,180	67,886	645,416	224,568	2,318,459	(72)%	2,318,459	22,830,087	3,770	1,238	5,008
Female Condom Provided	-	-	-	-	2,591	(100)%	2,591	3,027	-	-	-
Fever Cases Attended	-	-	-	-	2,927,861	(100)%	2,927,861	2,927,861	-	-	-
Fever Cases Tested with I	-	-	-	-	247,772	(100)%	247,772	247,772	-	-	-
Fever Cases Tested with F	14,482	-	14,482	-	2,634,426	(99)%	2,634,426	2,648,908	-	-	-
Free Condom	9,266,000	2,711,090	48,790,044	62,124,626	32,825,359	49%	32,825,359	187,068,172	158,303	140,288	298,591

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	15,000	30,867	992,544	1,564,945	431,422	130%	431,422	2,768,430	1,295	2,142	3,437
HIV Testing Services	7,733	7,275	112,346	65,753	201,781	(44)%	201,781	3,110,739	700	-	700
Implant 3	(370)	72	14,874	7,550	9,211	61%	9,211	23,797	-	24,888	24,888
Implant 3 Insertion	3,451	4,572	41,828	20,002	20,727	102%	20,727	66,041	-	88,917	88,917
Implant 4 Insertion	11	-	18	-	-	-%	-	18	-	28	28
Implant 5	15,688	7,982	80,643	84,157	32,153	151%	32,153	341,666	-	200,676	200,676
Implant 5 Insertion	10,318	12,205	134,846	41,399	106,632	26%	106,632	581,827	-	398,154	398,154
Injectable 2	50,551	79,943	982,983	1,045,150	1,538,928	(36)%	1,538,928	16,146,742	-	96,593	96,593
Injectable 2 Provided	856	1,119	12,469	-	10,433	20%	10,433	22,902	-	878	878
Injectable 3	80,794	146,061	3,118,113	2,252,284	1,815,961	72%	1,815,961	25,861,377	-	314,634	314,634
Injectable 3 Provided	5,786	3,813	56,083	27,082	16,028	250%	16,028	85,542	-	8,114	8,114
IPTp2	-	-	54	836,961	-	-%	-	54	-	3	3
Iron Folic Acid Tablet	540	5,420	39,960	-	14,500	176%	14,500	54,460	-	-	-
IUD 10	2,709	4,787	56,534	95,321	115,968	(51)%	115,968	1,714,041	-	180,859	180,859
IUD 10 Insertion	12,271	12,842	132,124	57,282	117,595	12%	117,595	659,452	-	516,164	516,164
IUS 5 Insertion	119	69	626	-	-	-%	-	626	-	1,981	1,981
LLIN	2,323,552	648,330	6,789,265	12,347,682	30,675,129	(78)%	30,675,129	112,898,972	-	2,584,036	2,584,036
Lubricant	481,957	246,137	6,122,064	-	349,026	1,654%	349,026	8,002,215	-	-	-
Malaria PPT (ACT)	791,713	313,908	9,078,596	4,289,752	14,144,463	(36)%	14,144,463	64,538,497	-	3,260,492	3,260,492
Malaria RDK	345,264	201,998	2,598,445	7,528,315	8,902,668	(71)%	8,902,668	17,768,031	-	-	-
Manual Vacuum Aspiratio	473	252	3,532	1,909	7,369	(52)%	7,369	10,972	-	1,802	1,802
Medical Abortion	(32)	-	(60)	-	-	-%	-	(60)	-	(22)	(22)

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion Provider	57	-	85	-	105	(19)%	105	190	-	35	35
Micronutrient Powder	75,630	134,243	1,302,620	1,713,790	85,400	1,425%	85,400	1,388,020	-	-	-
Misoprostol for PAC (Oral	764,371	48,841	1,314,021	906,686	626,258	110%	626,258	2,965,994	-	266,995	266,995
Misoprostol for PAC (oral)	2,631	2,159	24,039	10,120	2,427	890%	2,427	26,466	-	4,425	4,425
Misoprostol for PPH	-	-	-	300,000	-	-%	-	349,630	-	-	-
OCs	434,562	501,891	8,042,488	11,612,236	9,528,389	(16)%	9,528,389	70,560,277	-	262,878	262,878
OCs Provided	6,435	8,002	116,994	15,000	28,690	308%	28,690	170,121	-	4,807	4,807
ORS	-	-	500,903	1,965	70,974	606%	70,974	4,059,917	-	19,524	19,524
Pneumonia PPT	-	6,267	56,930	60,000	60,018	(5)%	60,018	447,108	-	39,000	39,000
Pneumonia PPT Provided	-	-	-	-	2,500	(100)%	2,500	2,500	-	-	-
Positive RDTs	13,690	-	13,690	-	2,047,931	(99)%	2,047,931	2,061,621	-	-	-
Positive RDTs Given First	13,515	-	13,515	-	2,047,743	(99)%	2,047,743	2,061,258	-	-	-
PUR	568,560	120,800	2,247,366	4,792,000	5,988,604	(62)%	5,988,604	21,116,132	-	206	206
QAACs Provided after Ct	-	-	-	-	2,034,979	(100)%	2,034,979	2,034,979	-	-	-
Referral to CD4/Clinical St	-	-	-	553	-	-%	-	18	-	-	-
Referral to HIV Testing Se	601	-	601	60,035	5,682	(89)%	5,682	8,072	2	-	2
Referral to Implant 5 Inser	-	-	49	-	-	-%	-	3,581	-	63	63
Referral to Injectable 3	-	-	49	-	-	-%	-	49	-	3	3
Referral to IUD 10 Insertio	-	-	348	-	22	1,482%	22	6,046	-	550	550
Referral to Linkage to HIV	-	-	-	460	281	(100)%	281	281	-	-	-
Referral to OCs	-	-	11	-	-	-%	-	11	-	-	-
Safe Water Solution	8,184	11,112	771,875	200,000	160,999	379%	160,999	12,890,659	-	4,037	4,037

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>SDM (Cycle Beads)</b>	<b>2,341</b>	<b>375</b>	<b>14,541</b>	<b>18,256</b>	<b>20,227</b>	<b>(28)%</b>	<b>20,227</b>	<b>330,814</b>	-	<b>18,139</b>	<b>18,139</b>
<b>SDM (Cycle Beads) Provic</b>	<b>2</b>	<b>90</b>	<b>3,465</b>	-	<b>2,812</b>	<b>23%</b>	<b>2,812</b>	<b>7,149</b>	-	<b>4,852</b>	<b>4,852</b>
<b>Seasonal Malaria Chemop</b>	-	-	<b>2,411,009</b>	-	-	<b>-%</b>	-	<b>2,411,009</b>	-	<b>754,652</b>	<b>754,652</b>
<b>Skilled Birth Attendance</b>	-	-	<b>17,175</b>	-	-	<b>-%</b>	-	<b>17,175</b>	-	-	-
<b>STI Screening</b>	<b>316</b>	<b>410</b>	<b>5,825</b>	-	<b>19,906</b>	<b>(71)%</b>	<b>19,906</b>	<b>29,423</b>	-	-	-
<b>TB Diagnosis</b>	-	-	-	-	<b>10,219</b>	<b>(100)%</b>	<b>10,219</b>	<b>10,219</b>	-	-	-
<b>TB DOTS</b>	-	-	-	-	<b>5,763</b>	<b>(100)%</b>	<b>5,763</b>	<b>5,763</b>	-	-	-
<b>TB Screening</b>	-	-	-	-	<b>7,139</b>	<b>(100)%</b>	<b>7,139</b>	<b>7,139</b>	-	-	-
<b>Toilets Constructed</b>	-	<b>36</b>	<b>3,677</b>	-	-	<b>-%</b>	-	<b>3,677</b>	-	-	-
<b>Toilets Sold</b>	-	<b>36</b>	<b>3,672</b>	<b>3,000</b>	<b>2,598</b>	<b>41%</b>	<b>2,598</b>	<b>6,270</b>	-	<b>984</b>	<b>984</b>
<b>Treatment for Severe Acu</b>	-	-	<b>4</b>	-	-	<b>-%</b>	-	<b>4</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	<b>116</b>	<b>(100)%</b>	<b>116</b>	<b>116</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	<b>138</b>	<b>(100)%</b>	<b>138</b>	<b>138</b>	-	-	-
<b>Tubal Ligation</b>	-	-	<b>12</b>	-	-	<b>-%</b>	-	<b>12</b>	-	<b>86</b>	<b>86</b>
<b>Vasectomy</b>	-	-	<b>1</b>	-	-	<b>-%</b>	-	<b>1</b>	-	<b>7</b>	<b>7</b>
<b>Water Treatment Tablets</b>	<b>2,073,060</b>	<b>2,012,506</b>	<b>12,549,741</b>	<b>14,097,521</b>	<b>23,980,058</b>	<b>(48)%</b>	<b>23,980,058</b>	<b>173,584,892</b>	-	<b>1,829</b>	<b>1,829</b>
<b>Zinc</b>	-	<b>45,310</b>	<b>2,232,085</b>	<b>34,685</b>	<b>42,892</b>	<b>5,104%</b>	<b>42,892</b>	<b>2,487,039</b>	-	<b>29,552</b>	<b>29,552</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>										<b>1,062,413</b>	<b>9,720,752</b>	<b>10,783,165</b>
<b>Benin</b>										<b>19,860</b>	<b>273,599</b>	<b>293,459</b>
Cervical Cancer-VIA and Cryotherapy	7	11	95	-	155		(39)%	155	326	-	27	27
Cervical Cancer-VIA and Cryotherapy	7	11	95	-	155	2/13	(39)%	155	326	-	27	27
Cervical Cancer-VIA/VILI Screening	4,021	6,052	46,271	-	41,466		12%	41,466	100,883	-	-	-
Cervical Cancer-VIA/VILI Screening	4,021	6,052	46,271	-	41,466		12%	41,466	100,883	-	-	-
Condom	559,700	711,293	6,678,634	9,000,000	6,861,921		(3)%	6,861,921	72,015,450	16,031	13,481	29,512
PSI Condom Distributed Provided	-	-	-	-	(28,048)		-%	(28,048)	(49,532)	-	-	-
Kool	81,676	192,665	1,765,516	2,000,000	1,872,356	2/10	(6)%	1,872,356	16,627,203	4,238	3,564	7,801
Prudence Plus	478,024	518,627	4,913,118	7,000,000	5,017,613	1/08	(2)%	5,017,613	55,437,779	11,793	9,917	21,710
Condom Provided	-	-	-	-	28,116		(100)%	28,116	49,600	-	-	-
PSI Condom Provided	-	-	-	-	28,048		(100)%	28,048	49,532	-	-	-
Non-PSI Condom Provided	-	-	-	-	68		(100)%	68	68	-	-	-
Diarrhea Treatment Kit	8,092	9,391	158,815	350,000	450,468		(65)%	450,468	2,956,178	-	15,099	15,099
Orasel Zinc DTK	8,092	9,391	158,815	350,000	450,468	4/08	(65)%	450,468	2,956,178	-	15,099	15,099
Family Planning Counseling	-	-	-	-	19,918		(100)%	19,918	19,918	-	-	-
Family Planning Counseling	-	-	-	-	19,918		(100)%	19,918	19,918	-	-	-
Female Condom	10	2,162	56,683	5,000	21,399		165%	21,399	161,661	136	88	224
Cupid	10	2	13,932	-	5,698	3/14	145%	5,698	23,661	33	22	55
Femidom	-	2,160	42,751	5,000	15,701	6/08	172%	15,701	138,000	103	66	169
Free Condom	-	369,761	1,357,528	-	247,097		449%	247,097	2,253,479	3,259	2,740	5,999
No Logo	-	369,761	1,357,528	-	247,097	1/12	449%	247,097	2,253,479	3,259	2,740	5,999
HIV Testing Services	6,200	5,637	82,146	34,058	83,163		(1)%	83,163	585,393	435	-	435
VCT Concordant Couple (HIV-Negative)	-	-	-	-	30	1/10	(100)%	30	8,527	-	-	-
VCT Individual (HIV-Negative)	6,158	5,589	81,325	34,058	82,139	1/10	(1)%	82,139	570,323	430	-	430

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	42	48	821	-	994	1/10	(17)%	994	6,543	4	-	4
Implant 5	1,938	6,397	28,350	20,501	437		6387%	437	55,693	-	55,591	55,591
PSI Implant 5 Distributed Inserted (	(764)	(930)	(8,663)	(19,499)	(31,168)		-%	(31,168)	(123,884)	-	(16,987)	(16,987)
Implant 5 (insertion)	2,702	7,327	37,013	-	31,605	12/09	17%	31,605	92,371	-	72,578	72,578
Jadelle	-	-	-	40,000	-	9/09	-%	-	87,206	-	-	-
Implant 5 Insertion	3,362	5,567	38,276	19,499	31,849		20%	31,849	154,178	-	83,394	83,394
PSI Implant 5 Inserted	764	930	8,663	19,499	31,168		(72)%	31,168	123,884	-	18,875	18,875
Non-PSI Implant 5 Inserted	2,598	4,637	29,613	-	681		4,248%	681	30,294	-	64,519	64,519
Injectable 2	3,051	4,043	48,677	45,150	30,602		59%	30,602	239,742	-	3,086	3,086
PSI Injectable 2 Distributed Provide	(374)	(574)	(6,514)	-	(9,797)		-%	(9,797)	(16,311)	-	(413)	(413)
Noristerat	3,425	4,617	55,191	45,150	40,399	1/12	37%	40,399	256,053	-	3,499	3,499
Injectable 2 Provided	856	1,119	12,469	-	10,433		20%	10,433	22,902	-	878	878
PSI Injectable 2 Provided	374	574	6,514	-	9,797		(34)%	9,797	16,311	-	459	459
Non-PSI Injectable 2 Provided	482	545	5,955	-	636		836%	636	6,591	-	420	420
Injectable 3	-	-	-	-	(1,160)		0%	(1,160)	(6,968)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(1,160)		-%	(1,160)	(6,968)	-	-	-
Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
PSI Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
IUD 10	893	2,623	9,332	13,000	9,115		2%	9,115	51,728	-	22,623	22,623
PSI IUD 10 Distributed Inserted (1)	(1,336)	(1,476)	(14,097)	(16,000)	(19,392)		-%	(19,392)	(92,156)	-	(34,174)	(34,174)
IUD (insertion)	1,279	2,231	11,601	-	-	12/09	-%	-	12,311	-	28,123	28,123
IUD Copper-T TCU 380A	950	1,869	11,828	29,000	28,507	9/09	(59)%	28,507	131,573	-	28,673	28,673
IUD 10 Insertion	2,037	2,382	20,037	16,000	19,549		2%	19,549	98,265	-	53,971	53,971
PSI IUD 10 Inserted	1,336	1,476	14,097	16,000	19,392		(27)%	19,392	92,156	-	37,971	37,971
Non-PSI IUD 10 Inserted	701	906	5,940	-	157		3,683%	157	6,109	-	16,000	16,000

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>LLIN</b>	<b>5</b>	<b>747</b>	<b>5,743</b>	<b>7,800</b>	<b>18,304</b>		<b>(69)%</b>	<b>18,304</b>	<b>752,434</b>	-	<b>756</b>	<b>756</b>
Moustiquaires Peace Corps	-	-	-	-	10,000	3/13	(100)%	10,000	20,000	-	-	-
Super Moustiquaire Longue Durée	-	581	4,866	7,800	6,209	5/06	(22)%	6,209	725,793	-	641	641
SuperMoustiquaire (blanche 1 place	5	161	846	-	1,404	9/15	(40)%	1,404	3,640	-	111	111
SuperMoustiquaire (blanche 3 place	-	5	31	-	691	9/15	(96)%	691	3,001	-	4	4
<b>Lubricant</b>	-	<b>52,405</b>	<b>369,168</b>	-	<b>106,260</b>		<b>247%</b>	<b>106,260</b>	<b>475,428</b>	-	-	-
Gel Lubricant 5 mL	-	52,405	369,168	-	106,260	12/16	247%	106,260	475,428	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	-	-	<b>478</b>	-	<b>689</b>		<b>(31)%</b>	<b>689</b>	<b>1,167</b>	-	<b>149</b>	<b>149</b>
MVA for PAC	-	-	478	-	689	10/16	(31)%	689	1,167	-	149	149
<b>Medical Abortion</b>	-	-	-	-	<b>(105)</b>		<b>0%</b>	<b>(105)</b>	<b>(105)</b>	-	-	-
PSI Medical Abortion Distributed Pr	-	-	-	-	(105)		-%	(105)	(105)	-	-	-
<b>Medical Abortion Provided</b>	-	-	-	-	<b>105</b>		<b>(100)%</b>	<b>105</b>	<b>105</b>	-	-	-
PSI Medical Abortion Provided	-	-	-	-	105		(100)%	105	105	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>11,800</b>	<b>12,780</b>	<b>142,420</b>	<b>100,000</b>	<b>113,461</b>		<b>26%</b>	<b>113,461</b>	<b>425,769</b>	-	<b>13,323</b>	<b>13,323</b>
PSI Misoprostol for PAC Oral Dist F	-	-	(720)	-	(111)		-%	(111)	(831)	-	(67)	(67)
Misoprostol for PAC (oral)	11,800	12,780	143,140	100,000	113,572	1/13	26%	113,572	426,600	-	13,390	13,390
<b>Misoprostol for PAC (oral) Provided</b>	-	-	<b>726</b>	-	<b>111</b>		<b>554%</b>	<b>111</b>	<b>837</b>	-	<b>75</b>	<b>75</b>
PSI Misoprostol for PAC (oral) Prov	-	-	720	-	111		549%	111	831	-	75	75
Non-PSI Misoprostol for PAC (oral) I	-	-	6	-	-		-%	-	6	-	1	1
<b>OCs</b>	<b>10,492</b>	<b>20,292</b>	<b>225,851</b>	<b>208,635</b>	<b>209,829</b>		<b>8%</b>	<b>209,829</b>	<b>1,081,936</b>	-	<b>5,816</b>	<b>5,816</b>
PSI OCs Distributed Provided	(209)	(247)	(3,166)	-	(3,299)		-%	(3,299)	(25,120)	-	(82)	(82)
Laafia Pilule	10,701	20,539	229,017	208,635	213,125	6/12	7%	213,125	1,107,053	-	5,897	5,897
Microgynon	-	-	-	-	3	9/15	(100)%	3	3	-	-	-
<b>OCs Provided</b>	<b>365</b>	<b>399</b>	<b>4,507</b>	-	<b>3,373</b>		<b>34%</b>	<b>3,373</b>	<b>26,535</b>	-	<b>129</b>	<b>129</b>
PSI OCs Provided	209	247	3,166	-	3,299		(4)%	3,299	25,120	-	91	91

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI OCs Provided	156	152	1,341	-	74		1,712%	74	1,415	-	38	38
SDM (Cycle Beads)	74	203	1,429	2,500	3,196		(55)%	3,196	35,802	-	1,289	1,289
PSI SDM (Cycle Beads) Distributed	(2)	(4)	(78)	-	(48)		-%	(48)	(156)	-	(70)	(70)
CycleBeads	76	207	1,507	2,500	3,244	12/04	(54)%	3,244	35,958	-	1,359	1,359
SDM (Cycle Beads) Provided	2	7	89	-	48		85%	48	167	-	89	89
PSI SDM (Cycle Beads) Provided	2	4	78	-	48		63%	48	156	-	78	78
Non-PSI SDM (Cycle Beads) Provid	-	3	11	-	-		-%	-	11	-	11	11
Skilled Birth Attendance	-	-	17,175	-	-		0%	-	17,175	-	-	-
Skilled Birth Attendance	-	-	17,175	-	-		-%	-	17,175	-	-	-
STI Screening	315	336	5,326	-	6,499		(18)%	6,499	15,517	-	-	-
STI Screening	315	336	5,326	-	6,499		(18)%	6,499	15,517	-	-	-
Toilets Constructed	-	-	5	-	-		0%	-	5	-	-	-
Toilet Type 1	-	-	5	-	-		-%	-	5	-	-	-
Treatment for Urethral Discharge (Mer	-	-	-	-	116		(100)%	116	116	-	-	-
Treatment for Urethral Discharge (M	-	-	-	-	116		(100)%	116	116	-	-	-
Treatment for Urethral Discharge (Wor	-	-	-	-	138		(100)%	138	138	-	-	-
Treatment for Urethral Discharge (W	-	-	-	-	138		(100)%	138	138	-	-	-
Water Treatment Tablets	214,800	984,600	7,197,000	7,560,000	7,464,550		(4)%	7,464,550	65,768,470	-	994	994
Aquatab	214,800	984,600	7,197,000	7,560,000	7,464,550	1/08	(4)%	7,464,550	65,768,470	-	994	994
<b>Cameroon</b>										84,946	266,070	351,017
CD4 Tests Provided to HIV+ Clients	-	-	295	-	297		(1)%	297	592	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	295	-	297		(1)%	297	592	-	-	-
Condom	2,034,726	1,438,073	11,374,019	8,250,000	20,438,811		(44)%	20,438,811	194,800,349	80,493	27,052	107,545
Lovers Plus	-	-	(139,356)	-	2,169,288	1/15	(106)%	2,169,288	3,230,280	(986)	(331)	(1,318)
Préservatif Masculin Aromatisé UNF	-	-	1,930	50,000	144	12/15	1,240%	144	2,074	14	5	18

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Préservatif Masculin UNFPA	-	-	59,824	1,200,000	61,016	12/15	(2)%	61,016	120,840	423	142	566
Prudence Plus	-	-	(2,160)	-	2,718	8/06	(179)%	2,718	141,672,845	(15)	(5)	(20)
Prudence Plus Nouveau	2,034,726	1,438,073	11,453,781	7,000,000	18,205,645	1/15	(37)%	18,205,645	49,774,310	81,058	27,241	108,299
Diarrhea Treatment Kit	1,210	4,508	83,757	87,000	16,065		421%	16,065	745,619	-	4,820	4,820
PSI Diarrhea Treatment Kit Distribu	-	-	-	-	(2,400)		-%	(2,400)	(2,400)	-	-	-
Orasel Zinc	1,210	4,508	83,757	87,000	18,465	10/09	354%	18,465	748,019	-	4,820	4,820
Diarrhea Treatment Kit Provided	-	-	-	-	2,400		(100)%	2,400	2,400	-	-	-
PSI Diarrhea Treatment Kit Provide	-	-	-	-	2,400		(100)%	2,400	2,400	-	-	-
Emergency Contraception	1,593	1,822	23,927	15,000	10,842		121%	10,842	34,769	-	214	214
PSI Emergency Contraception Distr	(34)	(26)	(145)	-	(65)		-%	(65)	(210)	-	(1)	(1)
Norlevo	1,627	1,848	24,072	15,000	10,907	11/15	121%	10,907	34,979	-	216	216
Emergency Contraception Provided	34	27	150	-	65		131%	65	215	-	1	1
PSI Emergency Contraception Prov	34	26	145	-	65		123%	65	210	-	1	1
Non-PSI Emergency Contraception I	-	1	5	-	-		-%	-	5	-	-	-
Female Condom	168,170	64,524	425,708	19,568	1,531,414		(72)%	1,531,414	8,413,154	3,013	779	3,792
Préservatif Féminin CUPID	163,890	62,313	353,025	10,000	488,548	7/14	(28)%	488,548	964,695	2,498	646	3,144
Préservatif Féminins UNFPA	4,200	1,844	19,503	-	504,712	3/15	(96)%	504,712	804,119	138	36	174
Protectiv	-	-	-	6,437	-	11/02	-%	-	4,184,561	-	-	-
Protectiv Plus	-	-	1,000	-	19,116	4/14	(95)%	19,116	958,157	7	2	9
Securite Plus Female Condom	80	367	52,180	3,131	519,038	11/13	(90)%	519,038	1,501,622	369	95	465
Fever Cases Attended	-	-	-	-	12,764		(100)%	12,764	12,764	-	-	-
Fever Cases Attended	-	-	-	-	12,764		(100)%	12,764	12,764	-	-	-
Fever Cases Tested with RDTs	14,482	-	14,482	-	13,416		8%	13,416	27,898	-	-	-
Fever Cases Tested with RDTs	14,482	-	14,482	-	13,416		8%	13,416	27,898	-	-	-
Free Condom	31,800	43,253	192,485	-	735,220		(74)%	735,220	927,705	1,362	458	1,820

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Generic MC	31,800	43,253	192,485	-	735,220	11/16	(74)%	735,220	927,705	1,362	458	1,820
Free Female Condom	-	200	2,100	-	1,000		110%	1,000	3,100	15	4	19
Generic FC	-	200	2,100	-	1,000	1/08	110%	1,000	3,100	15	4	19
HIV Testing Services	226	67	2,717	10,035	11,896		(77)%	11,896	61,216	63	-	63
VCT Individual (HIV-Negative)	221	66	2,299	9,523	11,335	1/10	(80)%	11,335	57,518	54	-	54
VCT Individual (HIV-Positive)	5	1	418	512	561	1/10	(25)%	561	3,698	10	-	10
Implant 3	(370)	(135)	9,865	6,612	9,165		8%	9,165	19,030	-	15,480	15,480
PSI Implant 3 Distributed Inserted (	(916)	(1,092)	(8,563)	(8,388)	(4,594)	3/16	-%	(4,594)	(13,157)	-	(13,437)	(13,437)
Implanon NXT	546	957	18,428	15,000	13,759	12/15	34%	13,759	32,187	-	28,917	28,917
Implant 3 Insertion	916	1,092	8,566	8,388	4,594		86%	4,594	13,160	-	14,935	14,935
PSI Implant 3 Inserted	916	1,092	8,563	8,388	4,594	3/16	86%	4,594	13,157	-	14,930	14,930
Non-PSI Implant 3 Inserted	-	-	3	-	-		-%	-	3	-	5	5
Implant 5	44	139	3,116	5,000	8,625		(64)%	8,625	4,358	-	7,184	7,184
PSI Implant 5 Distributed Inserted (	(527)	(524)	(5,325)	-	(3,134)		-%	(3,134)	(29,508)	-	(12,276)	(12,276)
Jadelle UNFPA	571	663	8,441	5,000	11,759	3/15	(28)%	11,759	33,866	-	19,460	19,460
Implant 5 Insertion	573	599	5,744	-	3,170		81%	3,170	30,669	-	14,714	14,714
PSI Implant 5 Inserted	527	524	5,325	-	3,134		70%	3,134	29,508	-	13,640	13,640
Non-PSI Implant 5 Inserted	46	75	419	-	36		1,064%	36	1,161	-	1,073	1,073
Injectable 3	(955)	16,010	78,267	172,568	52,057		50%	52,057	178,344	-	8,770	8,770
PSI Injectable 3 Distributed Provide (	3,051)	(1,647)	(22,557)	(26,082)	(4,794)		-%	(4,794)	(27,351)	-	(2,528)	(2,528)
Depo-Provera UNFPA	-	14,808	61,544	37,650	42,529	3/15	45%	42,529	152,093	-	6,896	6,896
Equilibre	2,096	2,848	39,280	161,000	14,322	5/16	174%	14,322	53,602	-	4,402	4,402
Injectable 3 Provided	3,092	1,708	23,032	26,082	4,794		380%	4,794	27,826	-	2,868	2,868
PSI Injectable 3 Provided	3,051	1,647	22,557	26,082	4,794		371%	4,794	27,351	-	2,809	2,809
Non-PSI Injectable 3 Provided	41	61	475	-	-		-%	-	475	-	59	59

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	1,816	1,819	20,867	21,118	29,990		(30)%	29,990	100,634	-	59,382	59,382
PSI IUD 10 Distributed Inserted (1)	(994)	(1,106)	(11,722)	(17,882)	(11,279)		-%	(11,279)	(68,031)	-	(33,358)	(33,358)
DIU UNFPA	-	13	1,290	-	17,643	3/15	(93)%	17,643	22,733	-	3,671	3,671
IUD	2,100	2,480	24,765	-	12,250	9/09	102%	12,250	128,022	-	70,475	70,475
IUD Copper T 380A	710	432	6,534	39,000	11,376	2/16	(43)%	11,376	17,910	-	18,594	18,594
IUD 10 Insertion	1,084	1,240	12,321	17,882	11,303		9%	11,303	69,260	-	38,958	38,958
PSI IUD 10 Inserted	994	1,106	11,722	17,882	11,279		4%	11,279	68,031	-	37,064	37,064
Non-PSI IUD 10 Inserted	90	133	599	-	24		2,396%	24	1,229	-	1,894	1,894
LLIN	6,275	2,220	25,283	40,000	39,178		(35)%	39,178	8,000,406	-	5,526	5,526
Super Moustiquaire	6,271	2,220	25,239	40,000	39,178	1/09	(36)%	39,178	8,000,362	-	5,516	5,516
Super Moustiquaire Interceptor	4	-	44	-	-	10/15	-%	-	44	-	10	10
Lubricant	270	521	8,163	-	11,891		(31)%	11,891	20,374	-	-	-
Lubricant 60 mL bottle	270	188	1,913	-	7,266	12/15	(74)%	7,266	9,499	-	-	-
Water-based Lubricant, 4 mL sachet	-	333	6,250	-	4,625	12/16	35%	4,625	10,875	-	-	-
Malaria PPT (ACT)	-	3,669	22,659	25,000	29,363		(23)%	29,363	94,221	-	6,260	6,260
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablet	-	500	1,500	1,000	5,100	2/15	(71)%	5,100	6,600	-	414	414
ACT 2 (ASAQ 50 / 135.5 mg, 3 table	-	1,608	11,382	15,000	15,000	2/15	(24)%	15,000	56,456	-	3,145	3,145
ACT 3 (ASAQ 100 / 270 mg, 3 table	-	733	4,572	4,500	4,493	2/15	2%	4,493	15,565	-	1,263	1,263
ACT 4 (ASAQ 100 / 270 mg, 6 table	-	827	5,205	4,500	4,770	2/15	9%	4,770	15,600	-	1,438	1,438
Malaria RDK	-	3,048	25,000	25,000	25,569		(2)%	25,569	200,277	-	-	-
Malaria Ag Pf/Pan_PA	-	3,048	25,000	25,000	25,569	12/12	(2)%	25,569	200,277	-	-	-
Manual Vacuum Aspiration for PAC	130	-	327	314	-		0%	-	327	-	113	113
MVA for PAC	130	-	327	314	-		-%	-	327	-	113	113
Medical Abortion	(32)	-	(60)	-	-		0%	-	(60)	-	(22)	(22)
PSI Medical Abortion Distributed Pr	(32)	-	(60)	-	-		-%	-	(60)	-	(22)	(22)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion Provided	57	-	85	-	-		0%	-	85	-	35	35
PSI Medical Abortion Provided	32	-	60	-	-		-%	-	60	-	25	25
Non-PSI Medical Abortion Provided	25	-	25	-	-		-%	-	25	-	10	10
Micronutrient Powder	75,630	134,243	1,302,620	1,713,790	85,400		1425%	85,400	1,388,020	-	-	-
Super Bebe	75,630	134,243	1,302,620	1,713,790	85,400	9/16	1,425%	85,400	1,388,020	-	-	-
Misoprostol for PAC (Oral)	8,191	11,707	131,821	205,380	107,297		23%	107,297	499,995	-	13,633	13,633
PSI Misoprostol for PAC Oral Dist F	(189)	-	(519)	(2,120)	(1,383)		-%	(1,383)	(1,902)	-	(54)	(54)
Misoprostol for PAC (oral)	8,380	11,707	132,340	207,500	108,680	1/13	22%	108,680	501,897	-	13,687	13,687
Misoprostol for PAC (oral) Provided	189	-	519	2,120	1,383		(62)%	1,383	1,902	-	60	60
PSI Misoprostol for PAC (oral) Prov	189	-	519	2,120	1,383		(62)%	1,383	1,902	-	60	60
OCs	6,049	5,384	137,356	159,000	88,610		55%	88,610	668,067	-	4,168	4,168
PSI OCs Distributed Provided	(1,821)	(1,947)	(17,734)	-	(2,500)		-%	(2,500)	(20,234)	-	(538)	(538)
Microgynon Ed Fe	-	440	23,069	15,000	67,958	7/14	(66)%	67,958	458,192	-	700	700
Novelle Duo	7,870	6,892	132,021	144,000	23,152	1/08	470%	23,152	230,109	-	4,006	4,006
OCs Provided	1,839	1,972	17,862	-	2,567		596%	2,567	20,429	-	602	602
PSI OCs Provided	1,821	1,947	17,734	-	2,500		609%	2,500	20,234	-	598	598
Non-PSI OCs Provided	18	24	128	-	67		91%	67	195	-	4	4
ORS	-	-	450	1,965	70,974		(99)%	70,974	3,559,464	-	13	13
Orasel	-	-	450	1,965	70,974	9/98	(99)%	70,974	3,559,464	-	13	13
Pneumonia PPT	-	6,267	56,930	60,000	57,518		(1)%	57,518	444,608	-	39,000	39,000
PSI Pneumonia PPT Distributed Pr	-	-	-	-	(2,500)		-%	(2,500)	(2,500)	-	-	-
Amoxicillin 500mg x 15's -- Children	-	5,867	55,730	2,400	57,600	1/13	(3)%	57,600	297,392	-	38,177	38,177
Amoxicillin 500mg x 7's - Children 2-	-	400	1,200	57,600	2,418	1/13	(50)%	2,418	149,716	-	822	822
Pneumonia PPT Provided	-	-	-	-	2,500		(100)%	2,500	2,500	-	-	-
PSI Pneumonia PPT Provided	-	-	-	-	2,500		(100)%	2,500	2,500	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Positive RDTs	13,690	-	13,690	-	12,952		6%	12,952	26,642	-	-	-
Positive RDTs	13,690	-	13,690	-	12,952		6%	12,952	26,642	-	-	-
Positive RDTs Given First Line Treatm	13,515	-	13,515	-	12,764		6%	12,764	26,279	-	-	-
Positive RDTs Given First Line Trea	13,515	-	13,515	-	12,764		6%	12,764	26,279	-	-	-
Referral to HIV Testing Services	-	-	-	10,035	281		(100)%	281	1,285	-	-	-
Referral to HIV Testing & Counselinç	-	-	-	10,035	281	12/13	(100)%	281	1,285	-	-	-
Referral to Implant 5 Insertion	-	-	49	-	-		0%	-	3,581	-	63	63
Referral to Implant 5 Insertion	-	-	49	-	-	12/14	-%	-	3,581	-	63	63
Referral to Injectable 3	-	-	49	-	-		0%	-	49	-	3	3
Referral to Injectable 3	-	-	49	-	-		-%	-	49	-	3	3
Referral to IUD 10 Insertion	-	-	348	-	-		0%	-	6,024	-	550	550
Referral to IUD 10 Insertion	-	-	348	-	-	12/14	-%	-	6,024	-	550	550
Referral to Linkage to HIV Care	-	-	-	460	281		(100)%	281	281	-	-	-
Referral to Linkage to HIV Care	-	-	-	460	281		(100)%	281	281	-	-	-
Referral to OCs	-	-	11	-	-		0%	-	11	-	-	-
Referral to OCs	-	-	11	-	-		-%	-	11	-	-	-
Water Treatment Tablets	400	361	77,253	76,791	76,459		1%	76,459	153,712	-	10	10
Aquatabs 67 mg (20 L)	400	361	77,253	76,791	76,459	12/15	1%	76,459	153,712	-	10	10
Zinc	-	2,643	34,685	34,685	42,892		(19)%	42,892	289,639	-	439	439
Zinc	-	2,643	34,685	34,685	42,892	7/09	(19)%	42,892	289,639	-	439	439
<b>Congo-Kinshasa</b>										33,922	2,825,628	2,859,550
Condom	596,600	159,743	13,341,338	9,000,000	5,295,269		152%	5,295,269	502,855,338	17,996	37,972	55,968
PSI Condom Distributed Provided	-	-	-	-	(2,705)		-%	(2,705)	(6,043)	-	-	-
Prudence	318,032	60,236	1,038,311	9,000,000	4,679,032	11/87	(78)%	4,679,032	473,980,983	1,401	2,955	4,356
Prudence Sensuel	278,568	99,507	12,303,027	-	618,942	12/12	1,888%	618,942	28,880,398	16,595	35,017	51,612

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Condom Provided	-	-	-	-	17,042		(100)%	17,042	23,943	-	-	-
PSI Condom Provided	-	-	-	-	2,705		(100)%	2,705	6,043	-	-	-
Non-PSI Condom Provided	-	-	-	-	14,337		(100)%	14,337	17,900	-	-	-
Diarrhea Treatment Kit	38,484	18,425	214,428	125,000	20,537		944%	20,537	631,630	-	17,175	17,175
ORA-ZINC	38,484	18,425	214,428	125,000	20,537	11/13	944%	20,537	631,630	-	17,175	17,175
Emergency Contraception	1,440	639	29,079	40,000	7,209		303%	7,209	56,112	-	312	312
PSI Emergency Contraception Distr	-	(1)	(80)	-	(67)		-%	(67)	(399)	-	(1)	(1)
Norlevo	1,440	640	29,159	40,000	7,276	10/14	301%	7,276	56,511	-	313	313
Emergency Contraception Provided	-	5	185	-	136		36%	136	642	-	2	2
PSI Emergency Contraception Prov	-	1	80	-	67		19%	67	399	-	1	1
Non-PSI Emergency Contraception I	-	4	105	-	69		52%	69	243	-	1	1
Female Condom	-	-	107,875	-	309,955		(65)%	309,955	7,739,170	146	236	382
PSI Female Condom Distributed Pr	-	-	-	-	(315)		-%	(315)	(374)	-	-	-
Prudence Femme	-	-	107,875	-	310,270	8/04	(65)%	310,270	7,739,544	146	236	382
Female Condom Provided	-	-	-	-	2,591		(100)%	2,591	3,027	-	-	-
PSI Female Condom Provided	-	-	-	-	315		(100)%	315	374	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	2,276		(100)%	2,276	2,653	-	-	-
Fever Cases Attended	-	-	-	-	2,915,097		(100)%	2,915,097	2,915,097	-	-	-
Fever Cases Attended	-	-	-	-	2,915,097		(100)%	2,915,097	2,915,097	-	-	-
Fever Cases Tested with Microscopy	-	-	-	-	247,772		(100)%	247,772	247,772	-	-	-
Fever Cases Tested with Microscop	-	-	-	-	247,772		(100)%	247,772	247,772	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	2,621,010		(100)%	2,621,010	2,621,010	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	2,621,010		(100)%	2,621,010	2,621,010	-	-	-
Free Condom	60,000	723,003	10,926,990	859,750	5,115,000		114%	5,115,000	43,696,875	14,739	31,100	45,839
Generic MC	60,000	723,003	10,926,990	859,750	5,115,000	3/09	114%	5,115,000	43,696,875	14,739	31,100	45,839

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	5,000	21,333	772,157	617,960	420,000		84%	420,000	2,495,757	1,042	1,691	2,732
Generic FC	5,000	21,333	772,157	617,960	420,000	3/09	84%	420,000	2,495,757	1,042	1,691	2,732
Implant 3	-	208	5,013	938	(154)		0%	(154)	4,571	-	9,412	9,412
PSI Implant 3 Distributed Inserted (	-	-	(21)	-	(14,530)		-%	(14,530)	(14,839)	-	(39)	(39)
Implanon	-	208	5,034	938	14,376	6/16	(65)%	14,376	19,410	-	9,452	9,452
Implant 3 Insertion	-	-	14,530	-	14,530		0%	14,530	29,348	-	30,313	30,313
PSI Implant 3 Inserted	-	-	21	-	14,530		(100)%	14,530	14,839	-	44	44
Non-PSI Implant 3 Inserted	-	-	14,509	-	-		-%	-	14,509	-	30,269	30,269
Implant 5	13,706	1,398	42,545	46,656	3,351		1170%	3,351	55,891	-	117,347	117,347
PSI Implant 5 Distributed Inserted (	-	(230)	(21,278)	-	(18,068)		-%	(18,068)	(92,994)	-	(58,689)	(58,689)
Jadelle	13,706	1,628	63,823	46,656	21,419	9/09	198%	21,419	148,885	-	176,036	176,036
Implant 5 Insertion	-	259	33,653	-	19,994		68%	19,994	111,041	-	103,135	103,135
PSI Implant 5 Inserted	-	230	21,278	-	18,068		18%	18,068	92,994	-	65,210	65,210
Non-PSI Implant 5 Inserted	-	29	12,375	-	1,926		543%	1,926	18,047	-	37,925	37,925
Injectable 3	46,399	34,246	468,934	422,467	126,833		270%	126,833	2,285,129	-	62,884	62,884
PSI Injectable 3 Distributed Provide	-	(359)	(11,250)	-	(7,886)		-%	(7,886)	(25,250)	-	(1,509)	(1,509)
Confiance Depo-Provera	37,399	26,093	316,257	272,467	129,721	9/03	144%	129,721	2,141,452	-	42,410	42,410
Sayana Press	9,000	8,511	163,927	150,000	4,998	10/15	3,180%	4,998	168,927	-	21,982	21,982
Injectable 3 Provided	-	378	12,208	-	8,514		43%	8,514	27,066	-	1,819	1,819
PSI Injectable 3 Provided	-	359	11,250	-	7,886		43%	7,886	25,250	-	1,676	1,676
Non-PSI Injectable 3 Provided	-	20	958	-	628		53%	628	1,816	-	143	143
IPTp2	-	-	-	836,961	-		0%	-	-	-	-	-
IPTp2	-	-	-	836,961	-		-%	-	-	-	-	-
IUD 10	-	39	4,810	5,203	2,590		86%	2,590	33,066	-	16,373	16,373
PSI IUD 10 Distributed Inserted (1)	-	(33)	(1,550)	-	(2,334)		-%	(2,334)	(10,310)	-	(5,276)	(5,276)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Confiance	-	72	6,360	5,203	4,924	9/03	29%	4,924	43,376	-	21,649	21,649
IUD 10 Insertion	-	34	3,494	-	2,538		38%	2,538	12,618	-	13,215	13,215
PSI IUD 10 Inserted	-	33	1,550	-	2,334		(34)%	2,334	10,310	-	5,862	5,862
Non-PSI IUD 10 Inserted	-	1	1,944	-	204		853%	204	2,308	-	7,353	7,353
<b>LLIN</b>	<b>2,316,669</b>	<b>8,588</b>	<b>2,665,167</b>	<b>8,769,882</b>	<b>22,968,572</b>		<b>(88)%</b>	<b>22,968,572</b>	<b>69,790,981</b>	-	<b>973,872</b>	<b>973,872</b>
Dawa Plus Large Rectangular Mos	36,216	-	36,216	8,037,600	7,782,222	11/15	(100)%	7,782,222	8,702,684	-	13,234	13,234
Dawa Plus Rectangular Mosquito Net	80,141	-	980,141	-	11,733,728	11/15	(92)%	11,733,728	14,720,688	-	358,151	358,151
Olyset 160X180X150 cm	-	-	-	-	13,803	7/14	(100)%	13,803	3,680,169	-	-	-
PermaNet	4,854	8,588	353,352	-	1,662,210	9/06	(79)%	1,662,210	37,607,080	-	129,117	129,117
Yorkool Rectangular Mosquito Net	295,458	-	1,295,458	732,282	1,776,609	11/15	(27)%	1,776,609	5,080,360	-	473,370	473,370
Lubricant	-	6,200	83,999	-	-		0%	-	103,399	-	-	-
Personal Lubricant 4.5 g	-	6,200	83,999	-	-	7/13	-%	-	103,399	-	-	-
Malaria PPT (ACT)	791,713	310,239	4,311,041	3,944,752	2,805,565		54%	2,805,565	15,613,296	-	1,292,945	1,292,945
PSI QAACTs Distributed Provided ε	-	-	-	-	(2,034,979)		-%	(2,034,979)	(2,034,979)	-	-	-
ACT 1 (2 to 11 months)	133,484	43,436	496,983	3,944,752	445,352	4/11	12%	445,352	1,672,289	-	149,053	149,053
ACT 2 (1 to 5 years)	189,568	92,257	1,132,482	-	1,210,730	4/11	(6)%	1,210,730	5,571,096	-	339,648	339,648
ACT 3 (6 to 13 years)	222,957	74,530	1,156,735	-	1,268,434	12/13	(9)%	1,268,434	4,605,827	-	346,922	346,922
ACT 4 (over 13 years)	245,704	100,016	1,524,841	-	1,916,028	12/13	(20)%	1,916,028	5,799,063	-	457,322	457,322
Malaria RDK	345,264	198,950	2,265,339	7,503,315	3,773,657		(40)%	3,773,657	10,824,883	-	-	-
SD Bioline	345,264	198,950	2,265,339	7,503,315	3,773,657	12/13	(40)%	3,773,657	10,824,883	-	-	-
OCs	102,421	127,669	1,246,999	1,273,200	739,882		69%	739,882	5,604,652	-	45,278	45,278
PSI OCs Distributed Provided	-	(646)	(32,037)	-	(9,528)		-%	(9,528)	(46,785)	-	(1,163)	(1,163)
Combination 3	102,421	124,167	1,145,398	1,102,500	749,410	11/11	53%	749,410	5,517,799	-	41,589	41,589
Microgynon	-	3,324	13,162	-	-	8/16	-%	-	13,162	-	478	478

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Microlut	-	823	120,476	170,700	-	2/17	-%	-	120,476	-	4,374	4,374
OCs Provided	-	675	34,051	-	10,744		217%	10,744	50,335	-	1,374	1,374
PSI OCs Provided	-	646	32,037	-	9,528		236%	9,528	46,785	-	1,293	1,293
Non-PSI OCs Provided	-	29	2,014	-	1,216		66%	1,216	3,550	-	81	81
ORS	-	-	500,453	-	-		0%	-	500,453	-	19,511	19,511
ORS	-	-	500,453	-	-	10/16	-%	-	500,453	-	19,511	19,511
Positive RDTs	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
Positive RDTs	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Treatm	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Trea	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
PUR	566,640	119,920	2,156,880	1,292,000	929,884		132%	929,884	5,341,961	-	198	198
P&G Purifiant	-	-	-	-	26,204	12/13	(100)%	26,204	907,200	-	-	-
P&G Purifiant Water	566,640	119,920	2,156,880	1,292,000	903,680	3/14	139%	903,680	4,434,761	-	198	198
QAACts Provided after Confirmatory I	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
PSI QAACts Provided after Confirm	-	-	-	-	2,034,979		(100)%	2,034,979	2,034,979	-	-	-
SDM (Cycle Beads)	2,267	39	11,806	5,756	4,731		150%	4,731	93,565	-	14,990	14,990
PSI SDM (Cycle Beads) Distributed	-	(68)	(2,940)	-	(2,561)		-%	(2,561)	(6,292)	-	(3,733)	(3,733)
CycleBeads	2,267	106	14,746	5,756	7,292	9/04	102%	7,292	99,857	-	18,722	18,722
SDM (Cycle Beads) Provided	-	83	3,374	-	2,763		22%	2,763	6,972	-	4,760	4,760
PSI SDM (Cycle Beads) Provided	-	68	2,940	-	2,561		15%	2,561	6,292	-	4,148	4,148
Non-PSI SDM (Cycle Beads) Provid	-	16	434	-	202		115%	202	680	-	612	612
Water Treatment Tablets	1,840,160	462,112	3,270,438	725,000	13,584,989		(76)%	13,584,989	56,820,974	-	601	601
Aquatab	1,840,160	462,112	3,270,438	725,000	13,584,989	7/08	(76)%	13,584,989	56,820,974	-	601	601
Zinc	-	42,667	2,197,400	-	-		0%	-	2,197,400	-	29,114	29,114
Zinc Sulfate 20 mg	-	42,667	2,197,400	-	-	10/16	-%	-	2,197,400	-	29,114	29,114

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Cote d'Ivoire</b>										<b>1,150</b>	<b>919</b>	<b>2,068</b>
CD4 Tests Provided to HIV+ Clients	22	53	722	-	-		0%	-	722	-	-	-
CD4 Tests Provided to HIV+ Clients	22	53	722	-	-		-%	-	722	-	-	-
Free Condom	-	8,000	413,526	238,320	469,778		(12)%	469,778	5,227,277	999	899	1,898
Free Distribution	-	8,000	413,526	238,320	469,778	1/08	(12)%	469,778	5,227,277	999	899	1,898
Free Female Condom	-	-	11,627	11,000	10,272		13%	10,272	62,763	28	19	48
Female Condom Free	-	-	11,627	11,000	10,272	8/12	13%	10,272	62,763	28	19	48
HIV Testing Services	1,040	927	17,095	17,260	11,043		55%	11,043	113,203	122	-	122
VCT Individual (HIV-Negative)	974	874	16,094	16,569	10,827	1/10	49%	10,827	107,794	115	-	115
VCT Individual (HIV-Positive)	66	53	1,001	691	216	1/10	363%	216	5,409	7	-	7
Lubricant	-	-	14,884	-	28,568		(48)%	28,568	72,531	-	-	-
Gel Lubricant 4.5 g	-	-	14,884	-	28,568	9/12	(48)%	28,568	72,531	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		0%	-	18	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		-%	-	18	-	-	-
Referral to HIV Testing Services	-	-	-	-	5,401		(100)%	5,401	6,185	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	5,401		(100)%	5,401	6,185	-	-	-
<b>Ghana</b>										<b>3,091</b>	<b>164,443</b>	<b>167,533</b>
Condom	8,860	-	710,956	1,572,430	73,612		866%	73,612	784,568	3,091	1,041	4,132
Protector	8,860	-	710,956	1,572,430	73,612		866%	73,612	784,568	3,091	1,041	4,132
Injectable 3	26,950	40,718	1,759,791	427,249	4,771		36785%	4,771	1,764,562	-	121,397	121,397
Famplan	26,950	40,718	1,759,791	427,249	4,771		36,785%	4,771	1,764,562	-	121,397	121,397
OCs	315,600	204,220	2,248,560	1,797,801	174,665		1187%	174,665	2,423,225	-	42,000	42,000
Secure	315,600	204,220	2,248,560	1,797,801	174,665		1,187%	174,665	2,423,225	-	42,000	42,000
Water Treatment Tablets	20,900	24,167	93,400	1,761,730	-		0%	-	93,400	-	4	4
Aquatabs 67 mg (20 L)	20,900	24,167	93,400	1,761,730	-	7/17	-%	-	93,400	-	4	4

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Guinea</b>										<b>15,124</b>	<b>87,587</b>	<b>102,711</b>
Condom	-	-	-	-	<b>1,562,745</b>		<b>(100)%</b>	<b>1,562,745</b>	<b>48,130,314</b>	-	-	-
Prudence Plus	-	-	-	-	<b>1,562,745</b>	1/08	(100)%	<b>1,562,745</b>	<b>48,130,314</b>	-	-	-
Diarrhea Treatment Kit	-	-	<b>464,760</b>	-	<b>426,665</b>		<b>9%</b>	<b>426,665</b>	<b>2,746,946</b>	-	<b>25,030</b>	<b>25,030</b>
Orasel Zinc DTK	-	-	<b>464,760</b>	-	<b>426,665</b>	9/12	9%	<b>426,665</b>	<b>2,746,946</b>	-	<b>25,030</b>	<b>25,030</b>
Free Condom	<b>1,908,000</b>	<b>1,470,903</b>	<b>21,413,106</b>	<b>42,136,556</b>	<b>864,000</b>		<b>2378%</b>	<b>864,000</b>	<b>22,277,106</b>	<b>14,973</b>	<b>59,101</b>	<b>74,074</b>
Condom Combo	-	<b>(297)</b>	<b>145,286</b>	<b>1,086,696</b>	-	11/16	-%	-	<b>145,286</b>	<b>102</b>	<b>401</b>	<b>503</b>
Generic Condom	<b>1,908,000</b>	<b>1,471,200</b>	<b>21,267,820</b>	<b>41,049,860</b>	<b>864,000</b>	11/16	2,362%	<b>864,000</b>	<b>22,131,820</b>	<b>14,871</b>	<b>58,700</b>	<b>73,571</b>
Free Female Condom	<b>10,000</b>	<b>2,333</b>	<b>185,660</b>	<b>435,985</b>	-		<b>0%</b>	-	<b>185,660</b>	<b>130</b>	<b>394</b>	<b>524</b>
Condom Feminin	<b>10,000</b>	<b>2,333</b>	<b>185,660</b>	<b>435,985</b>	-	5/16	-%	-	<b>185,660</b>	<b>130</b>	<b>394</b>	<b>524</b>
HIV Testing Services	-	<b>359</b>	<b>2,478</b>	-	-		<b>0%</b>	-	<b>327,640</b>	<b>21</b>	-	<b>21</b>
VCT Individual (HIV-Negative)	-	<b>327</b>	<b>2,299</b>	-	-	12/09	-%	-	<b>312,316</b>	<b>20</b>	-	<b>20</b>
VCT Individual (HIV-Positive)	-	<b>32</b>	<b>179</b>	-	-	12/09	-%	-	<b>15,324</b>	<b>2</b>	-	<b>2</b>
Injectable 3	-	-	-	-	<b>60,259</b>		<b>(100)%</b>	<b>60,259</b>	<b>1,438,474</b>	-	-	-
Equilibre	-	-	-	-	<b>60,259</b>	9/07	(100)%	<b>60,259</b>	<b>1,438,474</b>	-	-	-
Lubricant	<b>464,000</b>	<b>128,000</b>	<b>5,397,223</b>	-	-		<b>0%</b>	-	<b>5,397,223</b>	-	-	-
Vanilla Scented Lubricant Sachet,	<b>464,000</b>	<b>128,000</b>	<b>5,397,223</b>	-	-	10/16	-%	-	<b>5,397,223</b>	-	-	-
OCs	-	-	-	-	<b>218,035</b>		<b>(100)%</b>	<b>218,035</b>	<b>6,447,369</b>	-	-	-
Planyl	-	-	-	-	<b>218,035</b>	12/95	(100)%	<b>218,035</b>	<b>6,447,369</b>	-	-	-
Safe Water Solution	-	-	<b>608,310</b>	-	<b>46,632</b>		<b>1204%</b>	<b>46,632</b>	<b>3,994,084</b>	-	<b>3,062</b>	<b>3,062</b>
Sur Eau	-	-	<b>608,310</b>	-	<b>46,632</b>	7/06	1,204%	<b>46,632</b>	<b>3,994,084</b>	-	<b>3,062</b>	<b>3,062</b>
STI Screening	-	<b>74</b>	<b>498</b>	-	-		<b>0%</b>	-	<b>498</b>	-	-	-
STI Screening	-	<b>74</b>	<b>498</b>	-	-		-%	-	<b>498</b>	-	-	-
TB Diagnosis	-	-	-	-	<b>10,219</b>		<b>(100)%</b>	<b>10,219</b>	<b>10,219</b>	-	-	-
TB Diagnosis	-	-	-	-	<b>10,219</b>		(100)%	<b>10,219</b>	<b>10,219</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB DOTS	-	-	-	-	5,763		(100)%	5,763	5,763	-	-	-
TB DOTS	-	-	-	-	5,763		(100)%	5,763	5,763	-	-	-
TB Screening	-	-	-	-	7,139		(100)%	7,139	7,139	-	-	-
TB Screening	-	-	-	-	7,139		(100)%	7,139	7,139	-	-	-
<b>Liberia</b>										5,028	3,109	8,136
Condom	59,904	133,760	1,143,360	1,100,000	1,014,608		13%	1,014,608	5,453,986	4,372	2,442	6,814
STAR	59,904	133,760	1,143,360	1,100,000	1,014,608	7/09	13%	1,014,608	5,453,986	4,372	2,442	6,814
Free Condom	-	43,147	149,141	500,000	-		0%	-	196,349	570	318	889
Free Condom	-	-	-	500,000	-	11/13	-%	-	47,208	-	-	-
Generic Condom	-	43,147	149,141	-	-	5/17	-%	-	149,141	570	318	889
Free Female Condom	-	7,000	21,000	-	-		0%	-	21,000	80	34	115
Generic Female Condom	-	7,000	21,000	-	-	5/17	-%	-	21,000	80	34	115
HIV Testing Services	-	23	451	-	-		0%	-	2,256	3	-	3
VCT Individual (HIV-Negative)	-	20	392	-	-	5/14	-%	-	2,179	2	-	2
VCT Individual (HIV-Positive)	-	4	59	-	-	5/14	-%	-	77	-	-	-
Implant 5	-	-	-	-	3,030		(100)%	3,030	4,745	-	-	-
Jadelle	-	-	-	-	3,030	11/13	(100)%	3,030	4,745	-	-	-
Lubricant	-	53,480	170,141	-	-		0%	-	170,141	-	-	-
Lube Sachet Free	-	53,480	170,141	-	-	5/17	-%	-	170,141	-	-	-
Referral to HIV Testing Services	601	-	601	50,000	-		0%	-	602	2	-	2
Referral to HIV Testing & Counseling	601	-	601	50,000	-	12/13	-%	-	602	2	-	2
Safe Water Solution	4,488	4,832	81,551	50,000	13,272		514%	13,272	734,889	-	314	314
WaterGuard	4,488	4,832	81,551	50,000	13,272	7/09	514%	13,272	734,889	-	314	314
STI Screening	1	-	1	-	-		0%	-	1	-	-	-
STI Screening	1	-	1	-	-		-%	-	1	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Mali</b>										-	<b>3,431,120</b>	<b>3,431,120</b>
Cervical Cancer-VIA and Cryotherapy	5	10	189	719	599		(68)%	599	918	-	86	86
Cervical Cancer-VIA and Cryotherapy	5	10	189	719	599	12/13	(68)%	599	918	-	86	86
Cervical Cancer-VIA/VILI Screening	1,667	3,171	28,220	-	23,345		21%	23,345	58,090	-	-	-
Cervical Cancer-VIA/VILI Screening	1,667	3,171	28,220	-	23,345		21%	23,345	58,090	-	-	-
Condom Provided	-	-	-	-	18		(100)%	18	88	-	-	-
Non-PSI Condom Provided	-	-	-	-	18		(100)%	18	88	-	-	-
Family Planning Counseling	-	-	-	-	659		(100)%	659	688	-	-	-
Family Planning Counseling	-	-	-	-	659		(100)%	659	688	-	-	-
Free Condom	-	-	-	110,000	204,200		(100)%	204,200	916,360	-	-	-
Protector Free	-	-	-	110,000	-	1/08	-%	-	72,000	-	-	-
Protector Plus Free	-	-	-	-	204,200	4/14	(100)%	204,200	844,360	-	-	-
Free Female Condom	-	-	-	-	150		(100)%	150	150	-	-	-
Protectiv Free	-	-	-	-	150	1/08	(100)%	150	150	-	-	-
HIV Testing Services	-	-	-	-	4,351		(100)%	4,351	128,136	-	-	-
VCT Concordant Couple (HIV-Negative)	-	-	-	-	6	1/10	(100)%	6	611	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	4,230	1/10	(100)%	4,230	124,942	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	115	1/10	(100)%	115	2,583	-	-	-
Implant 3	-	-	-	-	-		0%	-	(3,198)	-	-	-
PSI Implant 3 Distributed Inserted ('	-	-	-	-	(200)		-%	(200)	(3,398)	-	-	-
Implanon NXT	-	-	-	-	200	2/16	(100)%	200	200	-	-	-
Implant 3 Insertion	2,146	2,930	13,367	10,000	796		1579%	796	17,361	-	31,370	31,370
PSI Implant 3 Inserted	-	-	-	-	200		(100)%	200	3,398	-	-	-
Non-PSI Implant 3 Inserted	2,146	2,930	13,367	10,000	596		2,143%	596	13,963	-	31,370	31,370
Implant 5	-	-	-	-	(30)		0%	(30)	(1,060)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Distributed Inserted (	-	-	-	-	(2,340)		-%	(2,340)	(108,214)	-	-	-
Jadelle	-	-	-	-	2,310	7/09	(100)%	2,310	107,154	-	-	-
<b>Implant 5 Insertion</b>	<b>4,438</b>	<b>3,393</b>	<b>29,334</b>	<b>21,000</b>	<b>28,286</b>		<b>4%</b>	<b>28,286</b>	<b>174,516</b>	-	<b>101,306</b>	<b>101,306</b>
PSI Implant 5 Inserted	-	-	-	-	2,340		(100)%	2,340	108,214	-	-	-
Non-PSI Implant 5 Inserted	4,438	3,393	29,334	21,000	25,946		13%	25,946	66,302	-	101,306	101,306
<b>Injectable 3</b>	-	-	-	-	<b>95,040</b>		<b>(100)%</b>	<b>95,040</b>	<b>4,053,900</b>	-	-	-
Confiance Injectable	-	-	-	-	95,040	5/03	(100)%	95,040	4,053,900	-	-	-
<b>Injectable 3 Provided</b>	<b>96</b>	<b>68</b>	<b>789</b>	-	<b>739</b>		<b>7%</b>	<b>739</b>	<b>2,807</b>	-	<b>132</b>	<b>132</b>
Non-PSI Injectable 3 Provided	96	68	789	-	739		7%	739	2,807	-	132	132
<b>IUD 10</b>	-	<b>167</b>	<b>1,320</b>	<b>6,000</b>	<b>1,783</b>		<b>(26)%</b>	<b>1,783</b>	<b>(48,083)</b>	-	<b>5,077</b>	<b>5,077</b>
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(2,650)		-%	(2,650)	(67,117)	-	-	-
IUD Copper T 380A	-	167	1,320	6,000	4,433	12/13	(70)%	4,433	19,034	-	5,077	5,077
<b>IUD 10 Insertion</b>	<b>3,219</b>	<b>2,417</b>	<b>21,076</b>	<b>23,000</b>	<b>21,400</b>		<b>(2)%</b>	<b>21,400</b>	<b>107,066</b>	-	<b>90,063</b>	<b>90,063</b>
PSI IUD 10 Inserted	-	-	-	-	2,650		(100)%	2,650	67,117	-	-	-
Non-PSI IUD 10 Inserted	3,219	2,417	21,076	23,000	18,750		12%	18,750	39,949	-	90,063	90,063
<b>LLIN</b>	<b>578</b>	<b>623,628</b>	<b>4,028,501</b>	<b>3,210,000</b>	<b>2,275,809</b>		<b>77%</b>	<b>2,275,809</b>	<b>14,626,371</b>	-	<b>1,599,248</b>	<b>1,599,248</b>
MILD - (G)	578	223,788	2,325,627	3,210,000	549,100	10/14	324%	549,100	7,512,446	-	923,235	923,235
MILD - (O)	-	263,166	789,498	-	336,140	9/16	135%	336,140	1,125,638	-	313,418	313,418
MILD - (U)	-	136,673	913,376	-	1,390,569	12/14	(34)%	1,390,569	5,988,287	-	362,595	362,595
<b>Lubricant</b>	-	-	-	-	<b>19</b>		<b>(100)%</b>	<b>19</b>	<b>19</b>	-	-	-
Lubricant	-	-	-	-	19		(100)%	19	19	-	-	-
<b>Malaria PPT (ACT)</b>	-	-	<b>1,575,859</b>	<b>320,000</b>	<b>2,256,073</b>		<b>(30)%</b>	<b>2,256,073</b>	<b>7,318,433</b>	-	<b>835,081</b>	<b>835,081</b>
Coartem 12 tabs	-	-	96,000	96,000	464,105	5/10	(79)%	464,105	1,556,315	-	50,872	50,872
Coartem 24 tabs	-	-	1,255,849	-	1,005,793	10/14	25%	1,005,793	3,132,108	-	665,501	665,501
Coartem 6 tabs	-	-	224,010	224,000	786,175	5/10	(72)%	786,175	2,630,010	-	118,708	118,708

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Manual Vacuum Aspiration for PAC	343	252	2,727	1,555	1,384		97%	1,384	4,182	-	1,540	1,540
MVA for PAC	343	252	2,727	1,555	1,384	7/15	97%	1,384	4,182	-	1,540	1,540
Misoprostol for PAC (Oral)	-	-	-	-	2,400		(100)%	2,400	2,400	-	-	-
Misoprostol for PAC (oral)	-	-	-	-	2,400	9/16	(100)%	2,400	2,400	-	-	-
Misoprostol for PAC (oral) Provided	2,442	2,159	22,794	8,000	933		2343%	933	23,727	-	4,290	4,290
Non-PSI Misoprostol for PAC (oral) I	2,442	2,159	22,794	8,000	933		2,343%	933	23,727	-	4,290	4,290
OCs	-	-	173,600	173,600	197,680		(12)%	197,680	14,158,129	-	7,077	7,077
Pilplan	-	-	173,600	173,600	197,680	5/03	(12)%	197,680	14,158,129	-	7,077	7,077
OCs Provided	56	77	684	-	262		161%	262	1,188	-	31	31
Non-PSI OCs Provided	56	77	684	-	262		161%	262	1,188	-	31	31
SDM (Cycle Beads) Provided	-	-	2	-	1		100%	1	10	-	3	3
Non-PSI SDM (Cycle Beads) Provid	-	-	2	-	1		100%	1	10	-	3	3
Seasonal Malaria Chemoprevention	-	-	2,411,009	-	-		0%	-	2,411,009	-	754,652	754,652
SMC for Children ages 12-59 month	-	-	1,971,592	-	-		-%	-	1,971,592	-	617,113	617,113
SMC for Infants ages 3-11 months	-	-	439,417	-	-	3/17	-%	-	439,417	-	137,539	137,539
Toilets Constructed	-	36	3,672	-	-		0%	-	3,672	-	-	-
Toilet Type 1	-	36	3,672	-	-	10/16	-%	-	3,672	-	-	-
Toilets Sold	-	36	3,672	3,000	2,598		41%	2,598	6,270	-	984	984
Toilet Type 1, Direct Sales	-	36	3,672	3,000	2,598	12/16	41%	2,598	6,270	-	984	984
Water Treatment Tablets	(3,200)	350,933	1,116,800	2,324,000	176,000		535%	176,000	43,262,070	-	181	181
Aquatab	(3,200)	350,933	1,116,800	2,324,000	176,000	2/09	535%	176,000	43,262,070	-	181	181
<b>Niger</b>										1,313	38,003	39,317
Condom Provided	-	-	-	-	10,223		(100)%	10,223	10,223	-	-	-
Non-PSI Condom Provided	-	-	-	-	10,223		(100)%	10,223	10,223	-	-	-
Free Condom	87,800	48,000	289,400	280,000	465,120		(38)%	465,120	754,520	1,258	911	2,169

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Generic Condom	87,800	48,000	289,400	280,000	465,120	6/16	(38)%	465,120	754,520	1,258	911	2,169
HIV Testing Services	198	192	6,870	4,400	9,319		(26)%	9,319	16,189	55	-	55
VCT Concordant Couple (HIV-Nega	-	-	-	-	127		(100)%	127	127	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	6		(100)%	6	6	-	-	-
VCT Individual (HIV-Negative)	197	190	6,807	4,385	8,639		(21)%	8,639	15,446	55	-	55
VCT Individual (HIV-Positive)	1	2	63	15	547		(88)%	547	610	1	-	1
Implant 3 Insertion	377	543	5,294	1,614	807		556%	807	6,101	-	12,211	12,211
Non-PSI Implant 3 Inserted	377	543	5,294	1,614	807		556%	807	6,101	-	12,211	12,211
Implant 5 Insertion	81	114	1,207	900	430		181%	430	1,637	-	4,090	4,090
Non-PSI Implant 5 Inserted	81	114	1,207	900	430		181%	430	1,637	-	4,090	4,090
Injectable 3 Provided	2,584	1,651	19,953	1,000	821		2330%	821	20,774	-	3,287	3,287
Non-PSI Injectable 3 Provided	2,584	1,651	19,953	1,000	821		2,330%	821	20,774	-	3,287	3,287
IUD 10	-	-	100	-	-		0%	-	100	-	376	376
Generic IUD 10	-	-	100	-	-	6/17	-%	-	100	-	376	376
IUD 10 Insertion	352	145	1,396	400	198		605%	198	1,594	-	5,839	5,839
Non-PSI IUD 10 Inserted	352	145	1,396	400	198		605%	198	1,594	-	5,839	5,839
Manual Vacuum Aspiration for PAC	-	-	-	40	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	40	-	1/16	-%	-	-	-	-	-
Misoprostol for PAC (Oral)	280	555	52,980	1,306	-		0%	-	52,980	-	8,619	8,619
Misoprostol for PAC (oral)	280	555	52,980	1,306	-		-%	-	52,980	-	8,619	8,619
OCs Provided	4,175	4,879	59,884	15,000	11,744		410%	11,744	71,628	-	2,671	2,671
Non-PSI OCs Provided	4,175	4,879	59,884	15,000	11,744		410%	11,744	71,628	-	2,671	2,671
Referral to IUD 10 Insertion	-	-	-	-	22		(100)%	22	22	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	22		(100)%	22	22	-	-	-
<b>Nigeria</b>										875,982	2,616,740	3,492,723

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-Pap Smear Screening	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	490	1,803	-	1,652		9%	1,652	3,858	-	400	400
Cervical Cancer-VIA and Cryotheraç	-	490	1,803	-	1,652	3/16	9%	1,652	3,858	-	400	400
Cervical Cancer-VIA/VILI Screening	-	8,294	31,156	-	26,108		19%	26,108	73,793	-	-	-
Cervical Cancer-VIA/VILI Screening	-	8,294	31,156	-	26,108		19%	26,108	73,793	-	-	-
Chlorhexidine	1,600	3,000	102,406	200,000	46,000		123%	46,000	148,406	-	10,303	10,303
Chlorxy-G Gel 25 gm tube	1,600	3,000	102,406	200,000	46,000	11/16	123%	46,000	148,406	-	10,303	10,303
Clean Delivery Kit	1,360	1,492	15,225	15,000	4,400		246%	4,400	58,975	-	1,928	1,928
Clean Delivery Kit	1,360	1,492	15,225	15,000	4,400	9/10	246%	4,400	58,975	-	1,928	1,928
Condom	5,791,176	6,392,328	87,477,082	125,100,000	126,960,705		(31)%	126,960,705	3,128,122,788	754,364	278,725	1,033,089
Gold Circle	5,423,328	6,069,984	83,426,848	120,000,000	122,269,932	3/90	(32)%	122,269,932	3,110,102,484	719,437	265,820	985,257
Gold Circle Flex	345,816	294,264	3,638,754	4,500,000	4,119,660	5/14	(12)%	4,119,660	10,813,986	31,379	11,594	42,973
Lifestyle - Flavours	5,184	6,912	105,624	120,000	160,281	10/06	(34)%	160,281	1,704,774	911	337	1,247
Lifestyle - Original Small Cartons	-	2,592	54,432	120,000	102,384	10/06	(47)%	102,384	1,544,052	469	173	643
Lifestyle - Ribbed	7,128	9,936	128,952	180,000	153,576	10/06	(16)%	153,576	1,992,261	1,112	411	1,523
Lifestyle - Ultra Thin	9,720	8,640	122,472	180,000	154,872	10/06	(21)%	154,872	1,965,231	1,056	390	1,446
Diarrhea Treatment Kit	11,300	12,767	280,800	450,000	387,800		(28)%	387,800	1,212,325	-	22,509	22,509
Pediatric Zinc Sulphate Tabs/ORS C11,300		12,767	280,800	450,000	387,800	2/14	(28)%	387,800	1,212,325	-	22,509	22,509
Emergency Contraception	163,008	151,872	1,780,998	2,000,000	1,790,360		(1)%	1,790,360	13,797,669	-	21,389	21,389
Postinor II	163,008	151,872	1,780,998	2,000,000	1,790,360	4/99	(1)%	1,790,360	13,797,669	-	21,389	21,389
Female Condom	-	1,200	55,150	200,000	455,376		(88)%	455,376	6,515,728	476	135	611
Female Condom	-	1,200	55,150	200,000	455,376	7/09	(88)%	455,376	6,515,728	476	135	611
Free Condom	7,178,400	5,023	14,047,868	18,000,000	24,724,944		(43)%	24,724,944	110,818,501	121,143	44,760	165,903
Condom Sample	-	5,023	1,167,068	-	10,821,744	12/05	(89)%	10,821,744	84,034,501	10,064	3,719	13,783

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
GF HIV Condom	<b>7,178,400</b>	-	<b>12,880,800</b>	<b>18,000,000</b>	<b>13,903,200</b>	1/16	(7)%	<b>13,903,200</b>	<b>26,784,000</b>	<b>111,078</b>	<b>41,042</b>	<b>152,120</b>
Free Female Condom	-	-	-	<b>500,000</b>	-		<b>0%</b>	-	-	-	-	-
Free Female Condoms	-	-	-	<b>500,000</b>	-		-%	-	-	-	-	-
HIV Testing Services	-	-	-	-	<b>82,009</b>		<b>(100)%</b>	<b>82,009</b>	<b>1,876,117</b>	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	<b>78,516</b>	12/09	(100)%	<b>78,516</b>	<b>1,738,272</b>	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	<b>3,493</b>	12/09	(100)%	<b>3,493</b>	<b>137,845</b>	-	-	-
Implant 5	-	<b>50</b>	<b>6,640</b>	<b>12,000</b>	<b>13,852</b>		<b>(52)%</b>	<b>13,852</b>	<b>95,003</b>	-	<b>20,567</b>	<b>20,567</b>
PSI Implant 5 Distributed Inserted (	-	-	-	-	<b>(548)</b>		-%	<b>(548)</b>	<b>(18,830)</b>	-	-	-
Jadelle	-	<b>50</b>	<b>6,640</b>	<b>12,000</b>	<b>14,400</b>	9/07	(54)%	<b>14,400</b>	<b>113,833</b>	-	<b>20,567</b>	<b>20,567</b>
Implant 5 Insertion	<b>1,857</b>	<b>2,261</b>	<b>26,545</b>	-	<b>22,903</b>		<b>16%</b>	<b>22,903</b>	<b>109,699</b>	-	<b>91,358</b>	<b>91,358</b>
PSI Implant 5 Inserted	-	-	-	-	<b>548</b>		(100)%	<b>548</b>	<b>18,830</b>	-	-	-
Non-PSI Implant 5 Inserted	<b>1,857</b>	<b>2,261</b>	<b>26,545</b>	-	<b>22,355</b>	3/16	19%	<b>22,355</b>	<b>90,869</b>	-	<b>91,358</b>	<b>91,358</b>
Injectable 2	<b>47,500</b>	<b>75,900</b>	<b>934,306</b>	<b>1,000,000</b>	<b>1,508,326</b>		<b>(38)%</b>	<b>1,508,326</b>	<b>15,907,000</b>	-	<b>93,507</b>	<b>93,507</b>
Noristerat	<b>47,500</b>	<b>75,900</b>	<b>934,306</b>	<b>1,000,000</b>	<b>1,508,326</b>	12/95	(38)%	<b>1,508,326</b>	<b>15,907,000</b>	-	<b>93,507</b>	<b>93,507</b>
Injectable 3	<b>8,400</b>	<b>54,533</b>	<b>808,506</b>	<b>1,200,000</b>	<b>1,476,701</b>		<b>(45)%</b>	<b>1,476,701</b>	<b>16,095,747</b>	-	<b>121,375</b>	<b>121,375</b>
Depo-Provera	<b>8,400</b>	<b>54,533</b>	<b>808,506</b>	<b>1,200,000</b>	<b>1,476,701</b>	12/95	(45)%	<b>1,476,701</b>	<b>16,095,747</b>	-	<b>121,375</b>	<b>121,375</b>
Iron Folic Acid Tablet	<b>540</b>	<b>5,420</b>	<b>39,960</b>	-	<b>14,500</b>		<b>176%</b>	<b>14,500</b>	<b>54,460</b>	-	-	-
Folic Acid 5 mg	<b>540</b>	<b>5,420</b>	<b>39,960</b>	-	<b>14,500</b>	11/16	176%	<b>14,500</b>	<b>54,460</b>	-	-	-
IUD 10	-	<b>140</b>	<b>20,106</b>	<b>50,000</b>	<b>68,597</b>		<b>(71)%</b>	<b>68,597</b>	<b>1,413,903</b>	-	<b>77,030</b>	<b>77,030</b>
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	<b>(1,243)</b>		-%	<b>(1,243)</b>	<b>(95,577)</b>	-	-	-
Copper T 380	-	-	-	<b>50,000</b>	-	9/12	-%	-	<b>21,250</b>	-	-	-
IUD	-	<b>140</b>	<b>20,106</b>	-	<b>69,840</b>	5/93	(71)%	<b>69,840</b>	<b>1,488,230</b>	-	<b>77,030</b>	<b>77,030</b>
IUD 10 Insertion	<b>5,568</b>	<b>6,622</b>	<b>73,780</b>	-	<b>62,607</b>		<b>18%</b>	<b>62,607</b>	<b>370,629</b>	-	<b>314,073</b>	<b>314,073</b>
PSI IUD 10 Inserted	-	-	-	-	<b>1,243</b>		(100)%	<b>1,243</b>	<b>95,577</b>	-	-	-
Non-PSI IUD 10 Inserted	<b>5,568</b>	<b>6,622</b>	<b>73,780</b>	-	<b>61,364</b>	3/16	20%	<b>61,364</b>	<b>275,052</b>	-	<b>314,073</b>	<b>314,073</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUS 5 Insertion	119	69	626	-	-		0%	-	626	-	1,981	1,981
Non-PSI IUS 5 Inserted	119	69	626	-	-		-%	-	626	-	1,981	1,981
LLIN	25	57	15,555	20,000	5,218,177		(100)%	5,218,177	19,014,033	-	2,966	2,966
GF Rectangular Net	-	-	-	-	5,204,770	11/13	(100)%	5,204,770	16,582,137	-	-	-
PermaNet	-	33	2,455	20,000	3,795	11/04	(35)%	3,795	2,157,576	-	468	468
Permanet Rectangular (220 x210x 1	-	15	12,900	-	8,662	1/16	49%	8,662	21,562	-	2,460	2,460
PermaNet Student	25	8	200	-	950	9/06	(79)%	950	252,758	-	38	38
Lubricant	17,687	5,530	78,486	-	202,288		(61)%	202,288	1,763,100	-	-	-
Lubrica	4,375	5,530	64,860	-	118,895	12/03	(45)%	118,895	1,666,081	-	-	-
Lubricant 30 ml Sachet	13,312	-	13,626	-	83,393	1/16	(84)%	83,393	97,019	-	-	-
Malaria PPT (ACT)	-	-	3,169,037	-	7,018,483		(55)%	7,018,483	39,477,568	-	1,126,206	1,126,206
ACT 1 (Lumartem 6's)	-	-	43,926	-	8,280	1/16	431%	8,280	52,206	-	15,610	15,610
ACT 1 (Yellow)	-	-	340,611	-	2,202,000	9/12	(85)%	2,202,000	10,039,498	-	121,046	121,046
ACT 2 (Blue)	-	-	723,186	-	1,853,860	9/12	(61)%	1,853,860	10,038,150	-	257,004	257,004
ACT 2 (Lumartem 12's)	-	-	183,606	-	142,920	1/16	28%	142,920	326,526	-	65,250	65,250
ACT 3 (Lumartem 18's)	-	-	45,360	-	3,600	1/16	1,160%	3,600	48,960	-	16,120	16,120
ACT 3 (Orange)	-	-	627,126	-	556,560	9/12	13%	556,560	7,189,124	-	222,867	222,867
ACT 4 (Green)	-	-	1,024,136	-	2,156,943	9/12	(53)%	2,156,943	11,507,698	-	363,955	363,955
ACT 4 (Lumartem 24's)	-	-	181,086	-	94,320	1/16	92%	94,320	275,406	-	64,354	64,354
Malaria RDK	-	-	308,106	-	5,103,442		(94)%	5,103,442	6,742,871	-	-	-
GF Malaria Test Kit (Access Bio by 2	-	-	37,800	-	4,882,275	1/16	(99)%	4,882,275	4,920,075	-	-	-
Rapid Diagnostic Test (RDT) Kit	-	-	270,306	-	221,167	9/10	22%	221,167	1,822,796	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	5,296		(100)%	5,296	5,296	-	-	-
MVA for PAC	-	-	-	-	5,296	11/16	(100)%	5,296	5,296	-	-	-
Misoprostol for PAC (Oral)	744,100	23,800	986,800	600,000	403,100		145%	403,100	1,984,850	-	231,419	231,419

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol for PAC (oral)	744,100	23,800	986,800	600,000	403,100	3/15	145%	403,100	1,984,850	-	231,419	231,419
Misoprostol for PPH	-	-	-	300,000	-		0%	-	349,630	-	-	-
Misoprostol	-	-	-	300,000	-	7/11	-%	-	349,630	-	-	-
OCs	-	116,100	3,775,956	7,500,000	7,389,890		(49)%	7,389,890	37,639,148	-	153,487	153,487
Combination 3	-	116,100	3,775,956	7,500,000	7,389,890	10/11	(49)%	7,389,890	37,639,148	-	153,487	153,487
PUR	1,920	880	90,486	3,500,000	5,058,720		(98)%	5,058,720	15,774,171	-	7	7
PuR	1,920	880	90,486	3,500,000	5,058,720	1/08	(98)%	5,058,720	15,774,171	-	7	7
Safe Water Solution	3,696	6,280	82,014	150,000	101,095		(19)%	101,095	8,161,686	-	662	662
WaterGuard	-	-	25,680	-	101,095	11/04	(75)%	101,095	8,105,352	-	198	198
WaterGuard Plus (1000L)	3,696	6,280	56,334	150,000	-	4/17	-%	-	56,334	-	463	463
SDM (Cycle Beads)	-	133	1,306	10,000	12,300		(89)%	12,300	201,447	-	1,860	1,860
CycleBeads	-	133	1,306	10,000	12,300	7/06	(89)%	12,300	201,447	-	1,860	1,860
STI Screening	-	-	-	-	13,407		(100)%	13,407	13,407	-	-	-
STI Screening	-	-	-	-	13,407		(100)%	13,407	13,407	-	-	-
Tubal Ligation	-	-	12	-	-		0%	-	12	-	86	86
Tubal Ligation	-	-	12	-	-		-%	-	12	-	86	86
Vasectomy	-	-	1	-	-		0%	-	1	-	7	7
Vasectomy	-	-	1	-	-		-%	-	1	-	7	7
<b>Senegal</b>										21,997	13,535	35,532
Acute Malnutrition Screening_CU5	203	166	1,377	-	-		0%	-	1,377	-	-	-
Acute Malnutrition Screening_CU5	203	166	1,377	-	-		-%	-	1,377	-	-	-
Condom	-	614,343	3,698,522	9,123,403	4,252,780		(13)%	4,252,780	26,911,975	21,997	6,256	28,252
Fagaru	-	223,583	1,164,334	1,876,597	1,443,536	11/12	(19)%	1,443,536	9,067,350	6,925	1,969	8,894
Protec	-	-	-	3,623,403	-	11/12	-%	-	1,160,433	-	-	-
Protec Fraise	-	92,100	515,456	655,380	524,304	1/13	(2)%	524,304	3,333,316	3,066	872	3,937

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Protec Naturel	-	298,660	2,018,732	2,742,231	2,108,540	1/13	(4)%	2,108,540	12,595,584	12,006	3,414	15,421
Protec Vanille	-	-	-	225,792	176,400	1/13	(100)%	176,400	755,292	-	-	-
Counseling & Tx for Moderate Acute M	-	-	8	-	-		0%	-	8	-	-	-
Counseling & Tx for Moderate Acute	-	-	8	-	-		-%	-	8	-	-	-
HIV Testing Services	69	70	589	-	-		0%	-	589	1	-	1
VCT Individual (HIV-Negative)	69	67	575	-	-		-%	-	575	-	-	-
VCT Individual (HIV-Positive)	-	3	14	-	-		-%	-	14	-	-	-
Implant 3	-	(1)	(4)	-	-		0%	-	(4)	-	(4)	(4)
PSI Implant 3 Distributed Inserted (	-	(1)	(4)	-	-		-%	-	(4)	-	(4)	(4)
Implant 3 Insertion	12	7	71	-	-		0%	-	71	-	88	88
PSI Implant 3 Inserted	-	1	4	-	-		-%	-	4	-	5	5
Non-PSI Implant 3 Inserted	12	6	67	-	-		-%	-	67	-	83	83
Implant 4 Insertion	11	-	18	-	-		0%	-	18	-	28	28
Non-PSI Implant 4 Inserted	11	-	18	-	-		-%	-	18	-	28	28
Implant 5	-	(3)	(8)	-	-		0%	-	(8)	-	(13)	(13)
PSI Implant 5 Distributed Inserted (	-	(3)	(8)	-	-		-%	-	(8)	-	(13)	(13)
Implant 5 Insertion	7	12	87	-	-		0%	-	87	-	158	158
PSI Implant 5 Inserted	-	3	8	-	-		-%	-	8	-	15	15
Non-PSI Implant 5 Inserted	7	9	79	-	-		-%	-	79	-	144	144
Injectable 3	-	554	2,615	30,000	300		772%	300	45,221	-	208	208
Depo-Provera	-	-	-	-	300	11/12	(100)%	300	42,606	-	-	-
Securil Press	-	554	2,615	30,000	-		-%	-	2,615	-	208	208
Injectable 3 Provided	14	8	101	-	-		0%	-	101	-	9	9
Non-PSI Injectable 3 Provided	14	8	101	-	-		-%	-	101	-	9	9
IPTp2	-	-	54	-	-		0%	-	54	-	3	3

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IPTp2	-	-	54	-	-		-%	-	54	-	3	3
IUD 10	-	-	(1)	-	-		0%	-	(1)	-	(2)	(2)
PSI IUD 10 Distributed Inserted (1)	-	-	(1)	-	-		-%	-	(1)	-	(2)	(2)
IUD 10 Insertion	11	2	20	-	-		0%	-	20	-	45	45
PSI IUD 10 Inserted	-	-	1	-	-		-%	-	1	-	2	2
Non-PSI IUD 10 Inserted	11	2	19	-	-		-%	-	19	-	43	43
LLIN	-	13,091	49,016	300,000	155,089		(68)%	155,089	714,747	-	1,667	1,667
MILDA	-	13,091	49,016	300,000	155,089	8/13	(68)%	155,089	714,747	-	1,667	1,667
OCs	-	28,226	234,166	500,000	509,798		(54)%	509,798	2,537,751	-	5,053	5,053
Securil	-	28,226	234,166	500,000	509,798	11/12	(54)%	509,798	2,537,751	-	5,053	5,053
OCs Provided	-	-	6	-	-		0%	-	6	-	-	-
Non-PSI OCs Provided	-	-	6	-	-		-%	-	6	-	-	-
Treatment for Severe Acute Malnutritic	-	-	4	-	-		0%	-	4	-	-	-
Treatment for Severe Acute Malnutri	-	-	4	-	-		-%	-	4	-	-	-
Water Treatment Tablets	-	190,333	794,850	1,650,000	2,678,060		(70)%	2,678,060	7,486,266	-	39	39
Aquatabs 67 mg (20 L)	-	190,333	794,850	1,650,000	2,678,060	11/12	(70)%	2,678,060	7,486,266	-	39	39

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>West and Central Africa</b>														
<b>Benin</b>							\$30,360		\$41,222	\$43,797	0.94			
<b>Medicines &amp; Supplies</b>														
MVA Kit	12/2017	4	0	0	4	0%	\$115	0%	\$0	\$280	NA	447	9	47.89
<b>Other Revenues</b>														
Amour et Vie +	12/2017	8,500	1,500	-310	9,690	15%	\$748	0%	\$0	\$3,330	NA	159,371	40,067	3.98
<b>Toilet Component</b>														
SaTo Pan	12/2017	0	320	0	320	100%	\$0	NA	\$0	NA	NA	3,406	NA	NA
<b>Condom</b>														
Kool	12/2017	80,424	1,252	-432	81,244	2%	\$4,201	15%	\$1,046	\$6,865	0.15	608,505	132,349	4.60
Prudence Plus	12/2017	463,824	14,200	323	478,347	3%	\$10,086	1%	\$1,099	\$9,226	0.12	2,464,145	433,643	5.68
<b>Female Condom</b>														
Cupid	12/2017	0	10	0	10	100%	\$0	NA	\$1	\$0	NA	10,009	5	2,001.80
<b>Free Condom</b>														
No Logo	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	13,099,916	24,312	538.83
<b>Lubricant A</b>														
Gel Lubricant 5 mL	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	9,920	38,165	0.26
<b>LLIN</b>														
Super Moustiquaire Longue Durée	12/2017	0	0	0	0	NA	\$0	NA	\$314	\$2,391	0.13	2,665	512	5.20
SuperMoustiquaire (blanche 1 plac	12/2017	5	0	1	6	0%	\$19	0%	\$189	\$534	0.35	1,403	120	11.69
SuperMoustiquaire (blanche 3 plac	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$28	NA	20	5	3.75
<b>Retreatment</b>														
Alafia	12/2017	0	0	0	0	NA	\$0	NA	\$2,430	\$0	NA	0	0	NA
<b>Diarrhea Treatment Kit</b>														
Orasel Zinc DTK	12/2017	8,092	0	0	8,092	0%	\$4,269	73%	\$5,959	\$4,076	1.46	603,441	7,763	77.73
<b>Misoprostol for PAC (Oral)</b>														
Misoprostol for PAC (oral)	12/2017	11,800	0	0	11,800	0%	\$2,102	24%	\$793	\$2,386	0.33	33,276	13,447	2.47
<b>ORS</b>														
Orasel	12/2017	0	0	0	0	NA	\$0	NA	\$1,337	\$0	NA	0	0	NA
<b>Water Treatment Tablets</b>														
Aquatab	12/2017	214,800	0	-430	214,370	0%	\$3,207	23%	\$15,775	\$7,746	2.04	26,310	524,200	0.05
<b>Implant 3</b>														
Implanon	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5,000	0	NA
<b>Implant 5</b>														
Implant 5 (insertion)	12/2017	642	2,060	1	2,703	76%	\$418	0%	\$11	\$466	0.02	17,555	5,990	2.93

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Benin</b>							\$30,360		\$41,222	\$43,797	0.94				
<u><b>Injectable 2</b></u>															
Noristerat	12/2017	3,325	100	1	3,426	3%	\$2,462	45%	\$1,810	\$2,843	0.64	37,025	4,307	8.60	
<u><b>Injectable 3</b></u>															
Equilibre	12/2017	0	0	0	0	NA	\$0	NA	\$2,135	\$0	NA	0	0	NA	
<u><b>IUD 10</b></u>															
IUD (insertion)	12/2017	1,079	200	216	1,495	16%	\$277	10%	\$26	\$254	0.10	3,172	2,100	1.51	
IUD Copper-T TCU 380A	12/2017	0	950	-204	746	100%	\$0	NA	\$0	\$41	NA	43,307	1,587	27.28	
<u><b>OCs</b></u>															
Harmonie	12/2017	0	0	0	0	NA	\$0	NA	\$1,626	\$0	NA	0	0	NA	
Laafia Pilule	12/2017	10,611	90	0	10,701	1%	\$2,414	75%	\$6,352	\$3,201	1.98	214,219	14,756	14.52	
Microgynon	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	148,551	0	NA	
<u><b>SDM (Cycle Beads)</b></u>															
CycleBeads	12/2017	76	0	0	76	0%	\$42	47%	\$320	\$130	2.46	4,600	224	20.51	
<b>Cameroon</b>							\$69,141		\$87,030	\$65,733	1.32				
<u><b>HIV Test Kit</b></u>															
HIV Determine Test	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	500	3,337	0.15	
HIV ORAQUICK	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	264	334	0.79	
<u><b>Medicines &amp; Supplies</b></u>															
MEDBAR AMIU KIT	12/2017	22	0	0	22	0%	\$591	0%	-\$70	\$625	-0.11	166	23	7.11	
<u><b>Other Revenues</b></u>															
100% Jeune	12/2017	0	200	0	200	100%	\$0	NA	-\$22	\$0	NA	44,726	3,600	12.42	
<u><b>Condom</b></u>															
Lovers Plus	12/2017	0	0	-16,827	-16,827	NA	\$0	NA	\$2,598	\$0	NA	246,475	0	NA	
Préservatif Masculin Aromatisé UN	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	48,326	0	NA	
Préservatif Masculin UNFPA	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,211,960	0	NA	
Prudence Plus	12/2017	0	0	0	0	NA	\$0	NA	\$811	\$0	NA	2,160	0	NA	
Prudence Plus Nouveau	12/2017	2,034,726	0	31,232	2,065,958	0%	\$12,834	62%	\$8,150	\$31,661	0.26	40,858,706	1,689,626	24.18	
<u><b>Female Condom</b></u>															
Préservatif Féminin CUPID	12/2017	0	163,890	0	163,890	100%	\$0	NA	\$2,446	\$12	210.50	160,327	116,878	1.37	
Préservatif Féminins UNFPA	12/2017	4,200	0	270	4,470	0%	\$175	14%	-\$1,452	\$110	-13.20	639,575	3,004	212.91	
Protectiv Plus	12/2017	0	0	0	0	NA	\$0	NA	\$7	\$0	NA	675,884	0	NA	
Securite Plus Female Condom	12/2017	80	0	-360	-280	0%	\$7	313%	-\$793	\$19	-41.45	1,431,640	340	4,210.71	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$69,141		\$87,030	\$65,733	1.32				
<b>Free Condom</b>															
Generic MC	12/2017	0	31,800	0	31,800	100%	\$0	NA	\$0	\$0	NA	423,455	53,587	7.90	
<b>Free Female Condom</b>															
Generic FC	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	115,400	200	577.00	
<b>Lubricant A</b>															
Water-based Lubricant, 4 mL sach	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10,125	333	30.38	
<b>Lubricant E</b>															
Lubricant 60 mL bottle	12/2017	270	0	0	270	0%	\$207	2%	-\$2,505	\$172	-14.60	6,916	230	30.11	
<b>LLIN</b>															
Super Moustiquaire	12/2017	6,271	0	0	6,271	0%	\$47,074	97%	\$53,693	\$23,299	2.30	110,109	3,136	35.12	
Super Moustiquaire Interceptor	12/2017	0	4	0	4	100%	\$0	NA	\$0	\$0	NA	7,526	1	5,644.50	
<b>Malaria PPT (ACT)</b>															
ACT 1 (ASAQ 25 / 67.5 mg, 3 table	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	101	500	0.20	
ACT 2 (ASAQ 50 / 135.5 mg, 3 tabl	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,618	1,608	2.25	
ACT 3 (ASAQ 100 / 270 mg, 3 tabl	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	910	733	1.24	
<b>Diarrhea Treatment Kit</b>															
Orasel Zinc	12/2017	1,210	0	0	1,210	0%	\$910	25%	\$2,740	\$2,128	1.29	6,788	3,244	2.09	
<b>Micronutrient Powder</b>															
Super Bebe	12/2017	75,630	0	0	75,630	0%	\$2,030	47%	\$783	\$1,301	0.60	440,756	55,171	7.99	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	8,340	40	0	8,380	0%	\$2,150	0%	\$15,312	\$2,853	5.37	158,820	11,020	14.41	
<b>ORS</b>															
Orasel	12/2017	0	0	0	0	NA	\$0	NA	\$2,876	\$0	NA	1,515	0	NA	
<b>Safe Water Solution</b>															
Sur'Eau Water Guard	12/2017	0	0	0	0	NA	\$0	NA	\$345	\$0	NA	0	0	NA	
<b>Water Treatment Tablets</b>															
Aquatabs 67 mg (20 L)	12/2017	400	0	0	400	0%	\$9	0%	-\$46	\$3	-14.94	2,498,010	181	13,801.16	
<b>Zinc</b>															
Zinc	12/2017	0	0	0	0	NA	\$0	NA	\$10	\$0	NA	0	37	NA	
<b>Emergency Contraception</b>															
Norlevo	12/2017	1,627	0	-1	1,626	0%	\$1,535	16%	\$1,170	\$1,576	0.74	89,002	1,718	51.80	
<b>Implant 3</b>															
Implanon NXT	12/2017	426	120	0	546	22%	\$444	39%	\$632	\$566	1.12	17,768	718	24.76	
<b>Implant 5</b>															
Jadelle UNFPA	12/2017	471	100	0	571	18%	\$494	0%	-\$75	\$676	-0.11	550	677	0.81	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$69,141		\$87,030	\$65,733	1.32				
<b><u>Injectable 3</u></b>															
Depo-Provera UNFPA	12/2017	0	0	0	0	NA	\$0	NA	-\$402	\$51	-7.82	0	383	NA	
Equilibre	12/2017	2,027	69	0	2,096	3%	\$272	0%	\$292	\$255	1.15	428,767	2,182	196.50	
<b><u>IUD 10</u></b>															
DIU UNFPA	12/2017	0	0	-40	-40	NA	\$0	NA	-\$1	\$0	NA	2,077	13	155.78	
IUD	12/2017	1,900	200	0	2,100	10%	\$85	0%	\$47	\$102	0.46	60,632	2,347	25.84	
IUD Copper T 380A	12/2017	710	0	40	750	0%	\$26	81%	\$6	\$15	0.38	13,846	559	24.75	
<b><u>OCs</u></b>															
Microgynon Ed Fe	12/2017	0	0	0	0	NA	\$0	NA	\$30	\$9	3.46	20,001	320	62.50	
Novelle Duo	12/2017	5,952	1,918	0	7,870	24%	\$298	54%	\$447	\$300	1.49	343,678	6,832	50.31	
<b><u>Pneumonia PPT</u></b>															
Amoxicillin 500mg x 15's -- Childre	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,870	5,867	0.32	
Amoxicillin 500mg x 7's - Children	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,200	400	3.00	
<b>Congo-Kinshasa</b>							\$0		\$0	\$24,913	NA				
<b><u>HIV Test Kit</u></b>															
Determine	12/2017	0	0	-2,100	-2,100	NA	\$0	NA	\$0	\$0	NA	2,100	0	NA	
<b><u>Medicines &amp; Supplies</u></b>															
Amoxicillin 250 mg	12/2017	0	0	-26,443	-26,443	NA	\$0	NA	\$0	\$0	NA	158,659	32,676	4.86	
Artésunate 200mg Suppositoire	12/2017	0	0	-10,375	-10,375	NA	\$0	NA	\$0	\$0	NA	14,652	1,971	7.43	
Artesunate 60 mg Injectable	12/2017	0	9,318	5,567	14,885	100%	\$0	NA	\$0	\$0	NA	24,976	13,225	1.89	
La Sulfadoxine-Pyriméthamine	12/2017	0	54	-532,054	-532,000	100%	\$0	NA	\$0	\$0	NA	586,000	1,351	433.65	
Mebendazole 100 mg	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	893,000	40,000	22.33	
NEVIRAPINE Comprimés de 200	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	268	0	NA	
<b><u>Other Revenues</u></b>															
100% Jeune	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	200	1,525	0.13	
<b><u>Condom</u></b>															
Prudence	12/2017	0	318,032	-8,879	309,153	100%	\$0	NA	\$0	\$7,401	NA	28,701,090	151,627	189.29	
Prudence Sensuel	12/2017	0	278,568	-249	278,319	100%	\$0	NA	\$0	\$74	NA	19,620,933	115,880	169.32	
<b><u>Free Condom</u></b>															
Generic MC	12/2017	0	60,000	-8	59,992	100%	\$0	NA	\$0	\$0	NA	1,795,045	71,003	25.28	
<b><u>Free Female Condom</u></b>															
Generic FC	12/2017	0	5,000	0	5,000	100%	\$0	NA	\$0	\$0	NA	359,843	10,333	34.82	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$0		\$0	\$24,913	NA				
<u>LLIN</u>															
Dawa Plus Large Rectangular Mos	12/2017	0	36,216	1,163,479	1,199,695	100%	\$0	NA	\$0	\$0	NA	285,455	12,072	23.65	
Dawa Plus Rectangular Mosquito	12/2017	0	980,141	3,447,430	4,427,571	100%	\$0	NA	\$0	\$0	NA	1,454,095	326,714	4.45	
PermaNet-Rectangular	12/2017	0	4,854	-27,704	-22,850	100%	\$0	NA	\$0	\$0	NA	23,848	10,086	2.36	
Yorkool Rectangular Mosquito Net-	12/2017	0	523,716	351,405	875,121	100%	\$0	NA	\$0	\$0	NA	20,929	174,572	0.12	
Yorkool Rectangular Mosquito Net-	12/2017	0	771,742	1,054,338	1,826,080	100%	\$0	NA	\$0	\$0	NA	45,172	257,247	0.18	
<u>Malaria PPT (ACT)</u>															
ACT 1 (2 to 11 months)	12/2017	0	133,484	12,376	145,860	100%	\$0	NA	\$0	\$0	NA	29,409	76,432	0.38	
ACT 2 (1 to 5 years)	12/2017	0	189,568	-23,354	166,214	100%	\$0	NA	\$0	\$0	NA	563,675	153,754	3.67	
ACT 3 (6 to 13 years)	12/2017	0	222,957	-81,035	141,922	100%	\$0	NA	\$0	\$0	NA	567,550	146,999	3.86	
ACT 4 (over 13 years)	12/2017	0	245,704	-70,975	174,729	100%	\$0	NA	\$0	\$0	NA	491,950	153,254	3.21	
<u>Malaria RDK</u>															
SD Bioline	12/2017	0	345,264	-57,600	287,664	100%	\$0	NA	\$0	\$0	NA	901,200	282,405	3.19	
<u>Diarrhea Treatment Kit</u>															
ORA-ZINC	12/2017	0	38,484	-14,194	24,290	100%	\$0	NA	\$0	\$0	NA	956	16,035	0.06	
<u>ORS</u>															
ORS	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2	0	NA	
<u>PUR</u>															
P&G Purifiant Water	12/2017	0	566,640	-40,560	526,080	100%	\$0	NA	\$0	\$3,787	NA	306,450	274,480	1.12	
<u>Water Treatment Tablets</u>															
Aquatab	12/2017	0	1,840,160	-94,880	1,745,280	100%	\$0	NA	\$0	\$11,874	NA	12,823,232	1,075,499	11.92	
<u>Zinc</u>															
Zinc Sulfate 20 mg	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,600	42,667	0.15	
<u>Emergency Contraception</u>															
Norlevo	12/2017	0	1,440	0	1,440	100%	\$0	NA	\$0	\$372	NA	1,680	1,120	1.50	
<u>Implant 3</u>															
Implanon	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	590	207	2.85	
<u>Implant 5</u>															
Jadelle	12/2017	0	13,706	0	13,706	100%	\$0	NA	\$0	\$0	NA	3,308	4,772	0.69	
<u>Injectable 3</u>															
Confiance Depo-Provera	12/2017	0	37,399	0	37,399	100%	\$0	NA	\$0	\$840	NA	187,297	18,876	9.92	
Sayana Press	12/2017	0	9,000	2	9,002	100%	\$0	NA	\$0	\$0	NA	241,070	4,000	60.27	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$0		\$0	\$24,913	NA				
<u>IUD 10</u>															
Confiance	12/2017	0	0	-38	-38	NA	\$0	NA	\$0	\$0	NA	7,242	41	175.21	
<u>OCs</u>															
Combination 3	12/2017	0	102,421	-1,817	100,604	100%	\$0	NA	\$0	\$565	NA	180,283	42,540	4.24	
Microgynon	12/2017	0	0	10	10	NA	\$0	NA	\$0	\$0	NA	53,758	3,324	16.17	
Microlut	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	150	0	NA	
<u>SDM (Cycle Beads)</u>															
CycleBeads	12/2017	0	2,267	-6	2,261	100%	\$0	NA	\$0	\$0	NA	15,215	821	18.52	
<b>Cote d'Ivoire</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Free Distribution	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	193,536	8,000	24.19	
<u>Free Female Condom</u>															
Female Condom Free	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10,236	0	NA	
<u>Lubricant A</u>															
Gel Lubricant 4.5 g	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	18,918	0	NA	
<u>LifeStraw</u>															
Life Straw - PLWHIV	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5	0	NA	
<b>Ghana</b>							\$39,716		\$42,573	\$23,196	1.84				
<u>Toilet Component</u>															
Collection Box	12/2017	0	9	0	9	100%	\$0	NA	\$0	NA	NA	495	NA	NA	
SaTo Pan	12/2017	9	9	0	18	50%	\$35	0%	\$0	NA	NA	2,826	NA	NA	
<u>Condom</u>															
Protector	12/2017	0	8,860	0	8,860	100%	\$0	NA	\$11,097	\$0	NA	3,101,832	2,953	1,050.28	
<u>Water Treatment Tablets</u>															
Aquatabs 67 mg (20 L)	12/2017	7,300	13,600	0	20,900	65%	\$242	0%	\$0	\$580	NA	1,438,600	26,133	55.05	
<u>Injectable 3</u>															
Famplan	12/2017	26,950	0	0	26,950	0%	\$1,244	0%	\$0	\$1,482	NA	629,142	31,751	19.81	
<u>OCs</u>															
Secure	12/2017	315,360	240	0	315,600	0%	\$38,195	46%	\$31,477	\$21,123	1.49	2,559,777	172,420	14.85	
<b>Guinea</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Condom Combo	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	101,214	0	NA	
Generic Condom	12/2017	0	1,908,000	0	1,908,000	100%	\$0	NA	\$0	\$0	NA	18,918,068	1,855,200	10.20	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guinea</b>							\$0		\$0	\$0	NA				
<u>Free Female Condom</u>															
Condom Feminin	12/2017	0	10,000	0	10,000	100%	\$0	NA	\$0	\$0	NA	250,325	4,500	55.63	
<u>Lubricant A</u>															
Vanilla Scented Lubricant Sachet,	12/2017	0	464,000	0	464,000	100%	\$0	NA	\$0	\$0	NA	8,456,671	266,667	31.71	
<b>Liberia</b>							\$3,671		\$458	\$4,302	0.11				
<u>Condom</u>															
STAR	12/2017	59,904	0	23,010	82,914	0%	\$2,850	0%	\$458	\$3,357	0.14	1,175,656	141,312	8.32	
<u>Free Condom</u>															
Generic Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	307,247	33,800	9.09	
<u>Lubricant A</u>															
Lube Sachet Free	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,527,000	47,248	74.65	
<u>Safe Water Solution</u>															
WaterGuard	12/2017	4,488	0	528	5,016	0%	\$821	0%	\$0	\$945	NA	27,000	4,952	5.45	
<b>Niger</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Generic Condom	12/2017	0	87,800	0	87,800	100%	\$0	NA	\$0	\$0	NA	5,760	77,267	0.07	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	12/2017	0	280	1,472	1,752	100%	\$0	NA	\$0	\$0	NA	95,548	423	226.06	
<u>IUD 10</u>															
Generic IUD 10	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,820	0	NA	
<b>Nigeria</b>							\$341,452		\$0	\$350,972	NA				
<u>HIV Test Kit</u>															
Determine	12/2017	0	683,519	-558,691	124,828	100%	\$0	NA	\$0	\$0	NA	48,700	227,840	0.21	
Stat Pak	12/2017	0	7,997	-3,494	4,503	100%	\$0	NA	\$0	\$0	NA	460	2,666	0.17	
Uni Gold Kit	12/2017	0	21,262	-21,090	172	100%	\$0	NA	\$0	\$0	NA	3,320	7,087	0.47	
<u>Medicines &amp; Supplies</u>															
Fersolate (Iron 200 mg)	12/2017	0	1,720	0	1,720	100%	\$0	NA	\$0	\$0	NA	4,450	6,033	0.74	
Sulfadoxine 500mg/ Pyrimethamin	12/2017	0	2,500	0	2,500	100%	\$0	NA	\$0	\$0	NA	91,681	1,760	52.09	
<u>Condom</u>															
Gold Circle	12/2017	5,423,328	0	0	5,423,328	0%	\$174,350	0%	\$0	\$164,021	NA	126,214,821	5,614,464	22.48	
Gold Circle Flex	12/2017	345,816	0	0	345,816	0%	\$32,018	0%	\$0	\$29,844	NA	11,186,091	339,552	32.94	
Lifestyle - Flavours	12/2017	5,184	0	0	5,184	0%	\$589	0%	\$0	\$743	NA	27,267	6,480	4.21	
Lifestyle - Original Small Cartons	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$175	NA	9,780	1,512	6.47	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$341,452		\$0	\$350,972	NA				
<b>Condom</b>															
Lifestyle - Ribbed	12/2017	7,128	0	0	7,128	0%	\$810	0%	\$0	\$1,118	NA	93,078	9,720	9.58	
Lifestyle - Ultra Thin	12/2017	9,720	0	0	9,720	0%	\$1,104	0%	\$0	\$1,140	NA	92,874	9,936	9.35	
<b>Female Condom</b>															
Female Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$18	NA	1,435,971	624	2,301.24	
<b>Free Condom</b>															
GF HIV Condom	12/2017	0	7,178,400	-2,571,212	4,607,188	100%	\$0	NA	\$0	\$0	NA	2,150,791	2,392,800	0.90	
<b>Lubricant C</b>															
Lubricant 30 ml Sachet	12/2017	0	13,312	0	13,312	100%	\$0	NA	\$0	\$0	NA	136,782	4,437	30.83	
<b>Lubricant E</b>															
Lubrica	12/2017	4,375	0	0	4,375	0%	\$6,684	0%	\$0	\$8,598	NA	155,792	5,588	27.88	
<b>LLIN</b>															
PermaNet-Conical	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	425	0	NA	
PermaNet-Rectangular	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$119	NA	9,380	20	469.00	
Permanet Rectangular (220 x210x	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	769,012	0	NA	
PermaNet Student	12/2017	25	0	0	25	0%	\$83	0%	\$0	\$56	NA	158	17	9.48	
<b>Malaria PPT (ACT)</b>															
ACT 1 (Lumartem 6's)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	39,450	0	NA	
ACT 2 (Lumartem 12's)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	45,006	0	NA	
ACT 3 (Lumartem 18's)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	42,880	0	NA	
ACT 4 (Lumartem 24's)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	88,326	0	NA	
<b>Chlorhexidine</b>															
Chlorxy-G Gel 25 gm tube	12/2017	1,600	0	0	1,600	0%	\$747	0%	\$0	\$1,420	NA	511,594	3,000	170.53	
<b>Clean Delivery Kit</b>															
Clean Delivery Kit	12/2017	0	1,360	0	1,360	100%	\$0	NA	\$0	\$0	NA	4,150	1,398	2.97	
<b>Diarrhea Treatment Kit</b>															
Pediatric Zinc Sulphate Tabs/ORS	12/2017	11,300	0	0	11,300	0%	\$3,923	0%	\$0	\$4,579	NA	343	13,067	0.03	
<b>Iron Folic Acid Tablet</b>															
Folic Acid 5 mg	12/2017	0	540	0	540	100%	\$0	NA	\$0	\$0	NA	3,665	2,980	1.23	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	744,100	0	0	744,100	0%	\$153	0%	\$0	\$2,606	NA	245,280	263,133	0.93	
<b>PUR</b>															
PuR	12/2017	1,920	0	0	1,920	0%	\$80	0%	\$0	\$54	NA	3,713,623	1,280	2,901.27	



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$341,452		\$0	\$350,972	NA				
<u>Safe Water Solution</u>															
WaterGuard Plus (1000L)	12/2017	3,696	0	0	3,696	0%	\$2,567	0%	\$0	\$3,758	NA	63,368	5,360	11.82	
<u>Emergency Contraception</u>															
Postinor II	12/2017	163,008	0	0	163,008	0%	\$104,138	0%	\$0	\$105,447	NA	443,690	163,648	2.71	
<u>Implant 5</u>															
Jadelle	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$50	NA	35,943	47	770.21	
<u>Injectable 2</u>															
Noristerat	12/2017	47,500	0	0	47,500	0%	\$11,874	0%	\$0	\$16,793	NA	1,030,451	66,533	15.49	
<u>Injectable 3</u>															
Depo-Provera	12/2017	8,400	0	0	8,400	0%	\$2,333	0%	\$0	\$8,719	NA	2,116,779	30,933	68.43	
<u>IUD 10</u>															
IUD	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$39	NA	157,291	140	1,123.51	
<u>OCs</u>															
Combination 3	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$1,654	NA	4,519,006	26,550	170.21	
<u>SDM (Cycle Beads)</u>															
CycleBeads	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$20	NA	6,424	100	64.24	
<b>Senegal</b>							\$0		\$0	\$19,432	NA				
<u>Condom</u>															
Fagaru	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$3,148	NA	1,853,749	68,160	27.20	
Protec Fraise	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$107	NA	139,535	1,600	87.21	
Protec Naturel	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$3,102	NA	1,128,323	69,264	16.29	
Protec Vanille	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,396	0	NA	
<u>LLIN</u>															
MILDA	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$6,438	NA	-36,990	7,152	-5.17	
MILDA-Rectangular	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	-9,744	0	NA	
<u>Water Treatment Tablets</u>															
Aquatabs 67 mg (20 L)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	278,902	0	NA	
<u>Injectable 3</u>															
Depo-Provera	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	-300	0	NA	
Securil Press	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$472	NA	-2,615	349	-7.50	
<u>OCs</u>															
Securil	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$6,164	NA	671,101	16,992	39.50	
Securil-1 cycle	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	-74,724	0	NA	



# East Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
East Africa	69,776	14	-	-	5,346,738	3,978	1,395,117	26,013	990	3,345	-	36,938
Burundi	1,180	3	-	-	65,930	57	11,795	884	-	-	-	893
Ethiopia	3,632	11	-	-	160,779	44	22,868	-	117	-	-	128
Kenya	27,985	-	-	-	1,094,246	923	255,120	945	123	102	-	1,500
Malawi	17,113	-	-	-	915,436	1,044	226,090	171	20	-	-	191
Rwanda	3,760	-	-	-	112,512	32	17,322	-	6	-	-	6
Somaliland	-	-	-	-	1,839	2	497	-	271	96	-	370
South Sudan	-	-	-	-	-	-	-	20,683	413	3,147	-	24,477
Tanzania	12,729	-	-	-	1,632,986	976	419,940	3,295	9	-	-	3,842
Uganda	3,378	-	-	-	1,363,009	900	441,486	36	32	-	-	5,530

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>									<b>2,839,994</b>	<b>5,424,319</b>	<b>8,264,313</b>
Antiretroviral Treatment (C	2,135	4,156	40,208	6,986	5,564	623%	5,564	45,772	7,969	-	7,969
Antiretroviral Treatment (I	156	268	3,161	-	901	251%	901	4,062	-	-	-
Basic Care Package	-	-	400	-	52,637,120	(100)%	52,637,120	172,110,122	-	-	-
CD4 Tests Provided to HIV	-	-	485	-	-	-%	-	485	-	-	-
Cervical Cancer-Pap Sme:	-	-	173	-	-	-%	-	173	-	-	-
Cervical Cancer-VIA and C	61	86	1,224	2,545	2,707	(55)%	2,707	6,728	-	380	380
Cervical Cancer-VIA and F	-	-	-	102	-	-%	-	19	-	-	-
Cervical Cancer-VIA/VILI §	8,792	9,401	109,307	-	228,181	(52)%	228,181	426,418	-	-	-
Chlorhexidine	507	595	6,361	40,000	6,682	(5)%	6,682	13,043	-	397	397
Clean Delivery Kit	704	1,792	31,611	-	53,992	(41)%	53,992	466,554	-	2,194	2,194
Condom	4,434,934	14,903,530	119,525,724	147,400,070	168,965,758	(29)%	168,965,758	2,183,738,485	1,686,763	252,232	1,938,995
Condom Provided	-	-	-	-	2,231,548	(100)%	2,231,548	2,283,254	-	-	-
Counseling & Tx for Mode	-	-	155,147	-	-	-%	-	155,147	-	-	-
Diarrhea Treatment Kit	14,810	19,873	188,408	188,671	176,147	7%	176,147	1,028,785	-	20,196	20,196
Diarrhea Treatment Kit Pri	1,175	1,692	18,693	-	17,338	8%	17,338	36,031	-	752	752
Emergency Contraception	2,872	1,182	126,615	154,000	73,906	71%	73,906	403,246	-	1,048	1,048
Emergency Contraception	231	105	1,720	2,000	246	599%	246	1,968	-	14	14
Expanded Clean Delivery	11,840	-	11,840	25,000	-	-%	-	11,840	-	1,617	1,617
Expanded Clean Delivery	171	149	617	14,000	-	-%	-	617	-	78	78
Family Planning Counseli	-	-	-	-	17,574	(100)%	17,574	17,574	-	-	-
Female Condom	840	4,053	391,746	140,000	1,099,340	(64)%	1,099,340	11,188,478	3,315	648	3,963

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fever Cases Attended	-	-	664	-	26,315	(97)%	26,315	26,979	-	-	-
Fever Cases Tested with I	-	-	121	-	7,353	(98)%	7,353	7,474	-	-	-
Fever Cases Tested with F	-	-	543	-	18,608	(97)%	18,608	19,151	-	-	-
Free Condom	6,640,104	9,445,611	66,077,570	57,032,717	85,946,047	(23)%	85,946,047	562,692,516	974,194	143,061	1,117,255
Free Female Condom	86,987	52,153	1,034,969	1,419,000	107,658	861%	107,658	3,318,503	9,864	1,784	11,648
HIV Self-Testing Kit	25,291	21,235	88,997	-	-	-%	-	88,997	-	-	-
HIV Testing Services	26,282	33,983	411,597	332,377	450,690	(9)%	450,690	2,605,463	12,105	-	12,105
Hypertension Diagnosis	-	-	5,790	-	31,404	(82)%	31,404	37,194	-	-	-
Hypertension Screening	-	-	57,107	-	129,978	(56)%	129,978	187,085	-	-	-
Hypertension_Controlled	-	-	3,495	-	25,842	(86)%	25,842	29,337	-	-	-
Implant 3	(4,025)	(2,400)	58,860	331,101	143,202	(59)%	143,202	710,126	-	78,646	78,646
Implant 3 Insertion	14,699	21,790	215,907	21,248	127,841	69%	127,841	459,445	-	374,694	374,694
Implant 4 Insertion	-	-	-	-	1,460	(100)%	1,460	1,460	-	-	-
Implant 5	5,556	(1,087)	18,187	180,121	63,837	(72)%	63,837	158,055	-	44,645	44,645
Implant 5 Insertion	6,859	16,562	138,279	38,768	104,800	32%	104,800	578,947	-	319,436	319,436
Injectable 3	60,728	101,879	2,258,231	1,894,283	857,441	163%	857,441	9,730,048	-	228,617	228,617
Injectable 3 Provided	15,006	18,101	200,670	155,758	62,588	221%	62,588	281,365	-	20,725	20,725
IPTp2	360	722	7,152	-	19,006	(62)%	19,006	55,152	-	353	353
IUD 10	11,424	(5,076)	15,830	(17,071)	(6,010)	-%	(6,010)	148,099	-	60,097	60,097
IUD 10 Insertion	19,282	28,491	266,445	242,836	195,352	36%	195,352	1,054,527	-	805,162	805,162
IUD 5	(18)	(24)	(243)	-	484	(150)%	484	(3,936)	-	(542)	(542)
IUD 5 Insertion	18	24	485	-	691	(30)%	691	28,228	-	1,202	1,202

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 12  
Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>LLIN</b>	<b>4,393,209</b>	<b>925,841</b>	<b>11,224,693</b>	<b>7,978,360</b>	<b>9,344,931</b>	<b>20%</b>	<b>9,344,931</b>	<b>74,934,530</b>	-	<b>1,107,218</b>	<b>1,107,218</b>
Lubricant	15,600	93,873	1,006,747	-	538,215	87%	538,215	2,406,459	-	-	-
Malaria PPT (ACT)	21,169	189,901	3,184,246	3,117,784	4,074,406	(22)%	4,074,406	12,824,981	-	979,783	979,783
Malaria RDK	20,000	186,092	1,812,525	1,881,088	1,596,819	14%	1,596,819	5,959,268	-	-	-
Male Circumcision (HIV-Pr	-	-	-	-	287	(100)%	287	607	-	-	-
Manual Vacuum Aspiratio	28	140	1,824	250	1,253	46%	1,253	3,077	-	358	358
Medical Abortion	7,648	1,112	11,011	25,000	-	-%	-	11,011	-	3,368	3,368
Medical Abortion Provider	40	110	621	-	-	-%	-	621	-	211	211
Micronutrient Powder	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PAC (Oral	257,513	61,607	824,353	750,300	1,265,369	(35)%	1,265,369	4,852,146	-	29,423	29,423
Misoprostol for PAC (oral)	99	308	3,855	-	129	2,888%	129	3,984	-	387	387
Misoprostol for PAC (Subl	2,434,306	61	2,434,732	2,480,200	156	560,626%	156	2,434,888	-	303,875	303,875
Misoprostol for PAC (subl	2	7	80	-	-	-%	-	80	-	24	24
Misoprostol for PPH	(2,353,240)	201,293	159,400	30,000	1,634,400	(90)%	1,634,400	4,480,939	-	523	523
OCs	965,201	301,676	6,590,767	6,170,698	7,878,628	(16)%	7,878,628	59,331,638	-	168,206	168,206
OCs Provided	4,812	5,765	72,500	39,344	58,379	24%	58,379	143,566	-	2,191	2,191
ORS	-	232,082	873,533	1,086,611	752,366	16%	752,366	20,662,514	-	28,474	28,474
ORS Provided	348	443	124,926	-	5,546	2,153%	5,546	130,472	-	4,485	4,485
Pneumonia PPT	1,858	55,383	221,387	910,330	266,190	(17)%	266,190	1,410,738	-	195,628	195,628
Pneumonia PPT Provided	1,082	1,573	101,564	-	19,854	412%	19,854	121,418	-	90,148	90,148
Positive RDTs	-	-	110	-	3,656	(97)%	3,656	3,766	-	-	-
Positive RDTs Given First	-	-	110	-	3,489	(97)%	3,489	3,599	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>PUR</b>	<b>5,135,820</b>	<b>6,134,896</b>	<b>79,186,077</b>	<b>49,069,647</b>	<b>65,302,222</b>	<b>21%</b>	<b>65,302,222</b>	<b>321,563,786</b>	-	<b>2,935</b>	<b>2,935</b>
QAACts Provided after C	-	-	110	-	3,815	(97)%	3,815	3,925	-	18	18
Referral to CD4/Clinical St	-	-	-	2,043	2,210	(100)%	2,210	3,364	-	-	-
Referral to Clinical Stagin	-	-	-	-	107	(100)%	107	1,893	-	-	-
Referral to Emergency Co	-	-	5	-	37	(86)%	37	133	-	-	-
Referral to HIV Testing Se	393	774	14,448	113,410	12,052	20%	12,052	120,049	38	-	38
Referral to Implant 3 Inser	-	-	19	8,500	586	(97)%	586	1,603	-	15	15
Referral to Implant 5 Inser	-	-	23	1,500	1,717	(99)%	1,717	1,997	-	26	26
Referral to Injectable 3	-	-	39	10,000	12,012	(100)%	12,012	13,715	-	2	2
Referral to IUD 10 Insertio	-	-	-	11,200	343	(100)%	343	704	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	(100)%	9	49	-	-	-
Referral to Linkage to HIV	313	376	2,800	-	-	-%	-	2,800	1,423	-	1,423
Referral to OCs	-	-	7	1,500	2,049	(100)%	2,049	2,725	-	-	-
Referral to STI Diagnosis	-	-	332	-	-	-%	-	332	-	-	-
Referral to STI Screening	372	532	14,307	-	-	-%	-	14,307	-	-	-
Referral to STI Treatment	-	-	1	142,281	5	(80)%	5	664	-	-	-
Referral to TB Diagnosis	-	71	628	-	-	-%	-	8,326	-	-	-
Referral to TB DOTS (com	-	-	-	-	26	(100)%	26	1,617	-	-	-
Referral to TB Screening	372	817	13,484	-	-	-%	-	13,484	-	-	-
Referral to Treatment for I	-	-	29	-	-	-%	-	134	-	-	-
Referral to Treatment for I	-	2	36	-	5	620%	5	109	-	-	-
Referral to Treatment for I	4	8	131	-	-	-%	-	2,546	-	1	1

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 12  
Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Treatment for \	-	10	197	-	136	45%	136	7,235	-	2	2
Referral to Tubal Ligation	-	-	-	-	3	(100)%	3	3	-	-	-
Referral to Tx for Nonherp	-	-	40	-	22	82%	22	1,002	-	3	3
Referral to Tx for Urethral	-	1	2	-	66	(97)%	66	726	-	-	-
Referral to Voluntary Medi	-	-	-	-	42	(100)%	42	42	-	-	-
Safe Water Solution	421,345	261,099	3,337,393	4,239,239	4,616,248	(28)%	4,616,248	56,401,113	-	11,799	11,799
SDM (Cycle Beads)	-	-	-	-	5	(100)%	5	418	-	-	-
Skilled Birth Attendance	1,324	3,346	30,038	16,237	28,307	6%	28,307	92,621	-	25,180	25,180
STI Kit (Non-Ulcerative)	760	347	5,640	9,070	18,139	(69)%	18,139	824,876	-	342	342
STI Kit (Ulcerative)	-	3	700	1,121	3,373	(79)%	3,373	72,228	-	134	134
STI Screening	10,650	12,268	122,608	3,000	153,790	(20)%	153,790	413,436	-	-	-
TB Screening	9,794	11,484	109,508	-	143,594	(24)%	143,594	387,078	-	-	-
Treatment for Cervicitis	-	1	13	-	-	-%	-	13	-	-	-
Treatment for Genital Herp	-	6	39	300	2	1,850%	2	41	-	1	1
Treatment for Inguinal Bul	1	6	34	-	-	-%	-	34	-	-	-
Treatment for Lower Abdc	34	32	433	400	4	10,725%	4	437	-	-	-
Treatment for Nonherpetic	45	66	803	300	14	5,636%	14	817	-	120	120
Treatment for Pre-Eclamp	2	10	93	39	28	232%	28	121	-	63	63
Treatment for Severe Acu	-	-	16,202	-	25,444	(36)%	25,444	41,646	-	20,370	20,370
Treatment for Urethral Dis	113	116	1,348	700	1	134,700%	1	1,349	-	16	16
Treatment for Urethral Dis	125	118	1,395	900	2	69,650%	2	1,397	-	45	45
Treatment for Vaginitis	53	85	1,057	-	67	1,478%	67	1,124	-	22	22



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Tubal Ligation</b>	-	<b>1,838</b>	<b>14,190</b>	<b>5,500</b>	<b>4,523</b>	<b>214%</b>	<b>4,523</b>	<b>19,252</b>	-	<b>83,423</b>	<b>83,423</b>
<b>Vasectomy</b>	-	-	7	-	2	<b>250%</b>	2	11	-	43	43
<b>Voluntary Medical Male Ci</b>	<b>1,578</b>	<b>3,387</b>	<b>40,038</b>	<b>68,253</b>	<b>30,631</b>	<b>31%</b>	<b>30,631</b>	<b>129,072</b>	<b>144,322</b>	-	<b>144,322</b>
<b>Water Treatment Tablets</b>	<b>845,840</b>	<b>990,027</b>	<b>24,482,710</b>	<b>23,405,999</b>	<b>47,341,850</b>	<b>(48)%</b>	<b>47,341,850</b>	<b>214,915,833</b>	-	<b>4,169</b>	<b>4,169</b>
<b>Zinc</b>	-	<b>50,530</b>	<b>315,947</b>	<b>312,992</b>	<b>53,910</b>	<b>486%</b>	<b>53,910</b>	<b>1,389,560</b>	-	<b>3,450</b>	<b>3,450</b>
<b>Zinc Provided</b>	-	-	<b>33,075</b>	-	-	<b>-%</b>	-	<b>33,075</b>	-	<b>401</b>	<b>401</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>										<b>2,839,994</b>	<b>5,424,319</b>	<b>8,264,313</b>
<b>Burundi</b>										<b>46,168</b>	<b>96,294</b>	<b>142,462</b>
Antiretroviral Treatment (Currently Enr	696	651	6,630	-	-		0%	-	6,630	1,245	-	1,245
Antiretroviral Treatment (Currently E	696	651	6,630	-	-		-%	-	6,630	1,245	-	1,245
Antiretroviral Treatment (Newly Enrolle	33	23	414	-	-		0%	-	414	-	-	-
Antiretroviral Treatment (Newly Enrc	33	23	414	-	-		-%	-	414	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	483	-	-		0%	-	483	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	483	-	-		-%	-	483	-	-	-
Condom	15,750	494,430	3,576,960	3,500,000	4,273,233		(16)%	4,273,233	24,019,282	26,164	10,046	36,209
PSI Condom Distributed Provided	-	-	-	-	(7,020)		-%	(7,020)	(9,371)	-	-	-
Prudence Class	15,750	494,430	3,576,960	3,500,000	4,280,253	12/09	(16)%	4,280,253	24,028,653	26,164	10,046	36,209
Condom Provided	-	-	-	-	7,020		(100)%	7,020	9,371	-	-	-
PSI Condom Provided	-	-	-	-	7,020		(100)%	7,020	9,371	-	-	-
Emergency Contraception	1	100	300	-	-		0%	-	300	-	3	3
PSI Emergency Contraception Distr	(77)	(27)	(159)	-	-		-%	-	(159)	-	(2)	(2)
Nowill	78	127	459	-	-	9/17	-%	-	459	-	5	5
Emergency Contraception Provided	77	27	159	-	-		0%	-	159	-	2	2
PSI Emergency Contraception Prov	77	27	159	-	-		-%	-	159	-	2	2
Family Planning Counseling	-	-	-	-	1,692		(100)%	1,692	1,692	-	-	-
Family Planning Counseling	-	-	-	-	1,692		(100)%	1,692	1,692	-	-	-
Free Condom	-	590,400	2,498,400	1,500,000	1,591,736		57%	1,591,736	9,270,416	18,275	7,017	25,291
Free Male Condoms	-	590,400	2,498,400	1,500,000	1,591,736	5/11	57%	1,591,736	9,270,416	18,275	7,017	25,291
Free Female Condom	-	6,667	43,000	8,000	46,000		(7)%	46,000	144,930	315	93	407
Free Female Condoms	-	6,667	43,000	8,000	46,000	5/11	(7)%	46,000	144,930	315	93	407
HIV Testing Services	2,385	1,701	25,625	20,300	20,909		23%	20,909	110,104	169	-	169

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Concordant Couple (HIV-Nega	-	-	-	-	971	12/09	(100)%	971	3,253	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	13	5/15	(100)%	13	15	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	20	2/12	(100)%	20	26	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	20	2/12	(100)%	20	26	-	-	-
VCT Individual (HIV-Negative)	2,344	1,676	25,178	20,000	19,658	12/09	28%	19,658	105,431	166	-	166
VCT Individual (HIV-Positive)	41	25	447	300	227	12/09	97%	227	1,353	3	-	3
Implant 5	(84)	24	270	600	(97)		0%	(97)	995	-	735	735
PSI Implant 5 Distributed Inserted (	(149)	(140)	(1,301)	(1,400)	(1,062)		-%	(1,062)	(3,350)	-	(3,540)	(3,540)
Jadelle	65	165	1,571	2,000	965	2/14	63%	965	4,345	-	4,274	4,274
Implant 5 Insertion	149	140	1,301	1,400	1,062		23%	1,062	3,350	-	3,933	3,933
PSI Implant 5 Inserted	149	140	1,301	1,400	1,062		23%	1,062	3,350	-	3,933	3,933
Injectable 3	(391)	215	3,023	5,000	3,701		(18)%	3,701	9,370	-	400	400
PSI Injectable 3 Distributed Provide	(1,503)	(1,482)	(15,475)	(12,000)	(11,094)		-%	(11,094)	(33,132)	-	(2,048)	(2,048)
DMPA 3-month Injectable	1,112	1,697	18,498	17,000	14,795	2/14	25%	14,795	42,502	-	2,448	2,448
Injectable 3 Provided	1,503	1,482	15,475	12,000	11,094		39%	11,094	33,132	-	2,275	2,275
PSI Injectable 3 Provided	1,503	1,482	15,475	12,000	11,094		39%	11,094	33,132	-	2,275	2,275
IUD 10	(36)	39	289	200	240		20%	240	1,154	-	970	970
PSI IUD 10 Distributed Inserted (1)	(60)	(54)	(451)	(500)	(409)		-%	(409)	(1,130)	-	(1,514)	(1,514)
Copper-T 380-A IUD	24	92	740	700	649	2/14	14%	649	2,284	-	2,484	2,484
IUD 10 Insertion	60	54	451	500	409		10%	409	1,130	-	1,682	1,682
PSI IUD 10 Inserted	60	54	451	500	409		10%	409	1,130	-	1,682	1,682
LLIN	-	62,079	750,137	1,063,950	604,482		24%	604,482	7,156,745	-	68,101	68,101
MII Peranet Free	-	-	268,350	1,063,950	603,200	4/10	(56)%	603,200	6,624,958	-	24,362	24,362
MIILDA - DAWA PLUS 2.0	-	62,079	481,787	-	-	5/17	-%	-	481,787	-	43,739	43,739
Supanet (LLIN)	-	-	-	-	1,282	9/13	(100)%	1,282	50,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Manual Vacuum Aspiration for PAC	4	4	68	30	19		258%	19	87	-	40	40
MVA for PAC	4	4	68	30	19	6/16	258%	19	87	-	40	40
Misoprostol for PAC (Oral)	3	87	469	300	234		100%	234	703	-	84	84
PSI Misoprostol for PAC Oral Dist F	(9)	(15)	(369)	-	-		-%	-	(369)	-	(66)	(66)
Misoprostol for PAC (oral)	12	102	838	300	234	7/16	258%	234	1,072	-	149	149
Misoprostol for PAC (oral) Provided	9	15	369	-	-		0%	-	369	-	73	73
PSI Misoprostol for PAC (oral) Prov	9	15	369	-	-		-%	-	369	-	73	73
Misoprostol for PAC (Sublingual)	6	61	432	200	156		177%	156	588	-	115	115
PSI Misoprostol for PAC Sublingual	(2)	(7)	(80)	-	-		-%	-	(80)	-	(21)	(21)
Misoprostol for PAC (Sublingual)	8	68	512	200	156	7/16	228%	156	668	-	137	137
Misoprostol for PAC (sublingual) Provi	2	7	80	-	-		0%	-	80	-	24	24
PSI Misoprostol for PAC (sublingua	2	7	80	-	-		-%	-	80	-	24	24
OCs	24	505	5,103	8,000	4,992		2%	4,992	14,563	-	183	183
PSI OCs Distributed Provided	(957)	(838)	(8,739)	(8,000)	(6,795)		-%	(6,795)	(20,600)	-	(313)	(313)
Confiance OC	981	1,343	13,842	16,000	11,787	2/14	17%	11,787	35,163	-	496	496
OCs Provided	957	838	8,739	8,000	6,795		29%	6,795	20,600	-	348	348
PSI OCs Provided	957	838	8,739	8,000	6,795		29%	6,795	20,600	-	348	348
Referral to Implant 5 Insertion	-	-	-	1,500	1,100		(100)%	1,100	1,100	-	-	-
Referral to Implant 5 Insertion	-	-	-	1,500	1,100		(100)%	1,100	1,100	-	-	-
Referral to Injectable 3	-	-	-	10,000	8,547		(100)%	8,547	8,547	-	-	-
Referral to Injectable 3	-	-	-	10,000	8,547		(100)%	8,547	8,547	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	192		(100)%	192	192	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	192		(100)%	192	192	-	-	-
Referral to OCs	-	-	-	1,500	1,381		(100)%	1,381	1,381	-	-	-
Referral to OCs	-	-	-	1,500	1,381		(100)%	1,381	1,381	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to STI Treatment (unknown)	-	-	-	60	-		0%	-	-	-	-	-
Referral to STI Treatment (unknown	-	-	-	60	-		-%	-	-	-	-	-
STI Screening	286	319	4,348	3,000	2,374		83%	2,374	6,722	-	-	-
STI Screening	286	319	4,348	3,000	2,374		83%	2,374	6,722	-	-	-
Treatment for Cervicitis	-	1	13	-	-		0%	-	13	-	-	-
Treatment for Cervicitis	-	1	13	-	-		-%	-	13	-	-	-
Treatment for Genital Herpes	-	-	22	300	-		0%	-	22	-	1	1
Treatment for Genital Herpes	-	-	22	300	-		-%	-	22	-	1	1
Treatment for Inguinal Bubo	1	6	34	-	-		0%	-	34	-	-	-
Treatment for Inguinal Bubo	1	6	34	-	-		-%	-	34	-	-	-
Treatment for Lower Abdominal Pain	32	28	374	400	-		0%	-	374	-	-	-
Treatment for Lower Abdominal Pair	32	28	374	400	-		-%	-	374	-	-	-
Treatment for Nonherpetic Genital Ulc	43	65	762	300	-		0%	-	762	-	114	114
Treatment for Nonherpetic Genital U	43	65	762	300	-		-%	-	762	-	114	114
Treatment for Urethral Discharge (Mer	98	105	1,209	700	-		0%	-	1,209	-	14	14
Treatment for Urethral Discharge (M	98	105	1,209	700	-		-%	-	1,209	-	14	14
Treatment for Urethral Discharge (Wor	112	114	1,333	900	-		0%	-	1,333	-	43	43
Treatment for Urethral Discharge (W	112	114	1,333	900	-		-%	-	1,333	-	43	43
Treatment for Vaginitis	-	-	5	-	-		0%	-	5	-	-	-
Treatment for Vaginitis	-	-	5	-	-		-%	-	5	-	-	-
<b>Ethiopia</b>										142,003	47,631	189,634
Antiretroviral Treatment (Currently Enr	1,439	1,346	10,101	900	211		4687%	211	10,312	1,616	-	1,616
Antiretroviral Treatment (Currently E	1,439	1,346	10,101	900	211		4,687%	211	10,312	1,616	-	1,616
Antiretroviral Treatment (Newly Enrolle	123	122	1,379	-	76		1714%	76	1,455	-	-	-
Antiretroviral Treatment (Newly Enrc	123	122	1,379	-	76		1,714%	76	1,455	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
CD4 Tests Provided to HIV+ Clients	-	-	2	-	-		0%	-	2	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	2	-	-		-%	-	2	-	-	-
Free Condom	-	4,133,074	18,630,321	19,678,921	31,422,325		(41)%	31,422,325	137,355,358	133,611	39,445	173,056
Generic Male Condom	-	-	-	-	1,439,620	8/16	(100)%	1,439,620	1,439,620	-	-	-
Protector Plus	-	4,133,074	18,630,321	19,678,921	29,982,705	12/12	(38)%	29,982,705	135,915,738	133,611	39,445	173,056
Free Female Condom	-	29,776	654,487	1,241,000	24,500		2571%	24,500	713,089	4,694	1,066	5,760
Free Female Condoms	-	29,776	654,487	1,241,000	24,500	10/13	2,571%	24,500	713,089	4,694	1,066	5,760
HIV Testing Services	10,396	12,074	116,686	129,100	167,787		(30)%	167,787	970,925	621	-	621
VCT Concordant Couple (HIV-Nega	-	-	-	-	269	4/13	(100)%	269	1,373	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	26	4/13	(100)%	26	150	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	13	5/13	(100)%	13	26	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	13	5/13	(100)%	13	26	-	-	-
VCT Individual (HIV-Negative)	10,061	11,594	112,344	129,100	163,986	3/13	(31)%	163,986	947,247	598	-	598
VCT Individual (HIV-Positive)	335	480	4,342	-	3,480	3/13	25%	3,480	22,103	23	-	23
Implant 3	-	-	-	-	3		(100)%	3	1,088	-	-	-
Implanon	-	-	-	-	3	7/14	(100)%	3	1,088	-	-	-
Injectable 3	-	-	-	-	83		(100)%	83	16,400	-	-	-
Depo-Provera	-	-	-	-	83	7/14	(100)%	83	16,400	-	-	-
PUR	1,323,400	586,155	27,078,057	22,469,647	31,608,878		(14)%	31,608,878	64,265,721	-	1,040	1,040
P&G Purifier of Water	1,323,400	586,155	27,078,057	22,469,647	31,608,878	11/15	(14)%	31,608,878	64,265,721	-	1,040	1,040
Referral to CD4/Clinical Staging	-	-	-	2,043	164		(100)%	164	1,205	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,043	164	12/14	(100)%	164	1,205	-	-	-
Referral to Clinical Staging	-	-	-	-	107		(100)%	107	1,893	-	-	-
Referral to Clinical Staging	-	-	-	-	107	12/14	(100)%	107	1,893	-	-	-
Referral to Emergency Contraception	-	-	5	-	37		(86)%	37	133	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Emergency Contraceptio	-	-	5	-	37	2/15	(86)%	37	133	-	-	-
Referral to HIV Testing Services	393	774	14,448	113,230	11,934		21%	11,934	119,931	38	-	38
Referral to HIV Testing & Counselin	393	774	14,448	113,230	11,934	12/13	21%	11,934	119,931	38	-	38
Referral to Implant 3 Insertion	-	-	19	-	277		(93)%	277	1,137	-	15	15
Referral to Implant 3 Insertion	-	-	19	-	277	12/14	(93)%	277	1,137	-	15	15
Referral to Implant 5 Insertion	-	-	23	-	24		(4)%	24	304	-	26	26
Referral to Implant 5 Insertion	-	-	23	-	24	12/14	(4)%	24	304	-	26	26
Referral to Injectable 3	-	-	39	-	711		(95)%	711	2,414	-	2	2
Referral to Injectable 3	-	-	39	-	711	1/15	(95)%	711	2,414	-	2	2
Referral to IUD 10 Insertion	-	-	-	-	9		(100)%	9	139	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	9	12/14	(100)%	9	139	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9		(100)%	9	49	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	12/14	(100)%	9	49	-	-	-
Referral to Linkage to HIV Care	313	376	2,800	-	-		0%	-	2,800	1,423	-	1,423
Referral to Linkage to HIV Care	313	376	2,800	-	-		-%	-	2,800	1,423	-	1,423
Referral to OCs	-	-	7	-	214		(97)%	214	890	-	-	-
Referral to OCs	-	-	7	-	214	1/15	(97)%	214	890	-	-	-
Referral to STI Diagnosis (lab confirme	-	-	332	-	-		0%	-	332	-	-	-
Referrals to STI Diagnosis (lab confi	-	-	332	-	-		-%	-	332	-	-	-
Referral to STI Screening (syndromic)	372	532	14,307	-	-		0%	-	14,307	-	-	-
Referrals to STI Screening (syndronr	372	532	14,307	-	-		-%	-	14,307	-	-	-
Referral to STI Treatment (unknown)	-	-	1	142,221	5		(80)%	5	664	-	-	-
Referral to STI Treatment (unknown	-	-	1	142,221	5	12/14	(80)%	5	664	-	-	-
Referral to TB Diagnosis	-	71	628	-	-		0%	-	8,326	-	-	-
Referral to TB Diagnosis	-	71	628	-	-	12/14	-%	-	8,326	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB DOTS (completion unkr	-	-	-	-	26		(100)%	26	1,617	-	-	-
Referral to TB DOTS (completion un	-	-	-	-	26	12/13	(100)%	26	1,617	-	-	-
Referral to TB Screening	372	817	13,484	-	-		0%	-	13,484	-	-	-
Referrals to TB Screening	372	817	13,484	-	-		-%	-	13,484	-	-	-
Referral to Treatment for Inguinal Bubc	-	-	29	-	-		0%	-	134	-	-	-
Referral to Treatment for Inguinal Bu	-	-	29	-	-	12/14	-%	-	134	-	-	-
Referral to Treatment for Lower Abdon	-	2	36	-	5		620%	5	109	-	-	-
Referral to Treatment for Lower Abd	-	2	36	-	5	12/14	620%	5	109	-	-	-
Referral to Treatment for Urethral Disc	4	8	131	-	-		0%	-	2,546	-	1	1
Referral to Treatment for Urethral Di	4	8	131	-	-	12/14	-%	-	2,546	-	1	1
Referral to Treatment for Vaginitis	-	10	197	-	136		45%	136	7,235	-	2	2
Referral to Treatment for Vaginitis	-	10	197	-	136	12/14	45%	136	7,235	-	2	2
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tx for Nonherpetic Genital	-	-	40	-	22		82%	22	1,002	-	3	3
Referral to Tx for Nonherpetic Genit:	-	-	40	-	22	12/14	82%	22	1,002	-	3	3
Referral to Tx for Urethral Discharge (\	-	1	2	-	66		(97)%	66	726	-	-	-
Referral to Tx for Urethral Discharge	-	1	2	-	66	12/14	(97)%	66	726	-	-	-
Safe Water Solution	195,795	83,489	1,437,588	2,267,989	2,928,090		(51)%	2,928,090	23,782,183	-	5,523	5,523
Wuha Agar	195,795	83,489	1,437,588	2,267,989	2,928,090	2/06	(51)%	2,928,090	23,782,183	-	5,523	5,523
STI Kit (Non-Ulcerative)	760	347	5,640	9,070	18,139		(69)%	18,139	824,876	-	342	342
STI kit for Urethral Discharge	760	347	4,060	4,280	7,053	11/10	(42)%	7,053	447,702	-	223	223
STI Kit for Vaginal Discharge	-	-	1,580	4,790	11,086	11/10	(86)%	11,086	377,174	-	119	119
STI Kit (Ulcerative)	-	3	700	1,121	3,373		(79)%	3,373	72,228	-	134	134
STI Kit for Genital Ulcer	-	3	700	1,121	3,373	11/10	(79)%	3,373	72,228	-	134	134

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
STI Screening	10,364	11,949	118,260	-	151,416		(22)%	151,416	406,714	-	-	-
STI Screening	10,364	11,949	118,260	-	151,416		(22)%	151,416	406,714	-	-	-
TB Screening	9,794	11,484	109,508	-	143,594		(24)%	143,594	387,078	-	-	-
TB Screening	9,794	11,484	109,508	-	143,594		(24)%	143,594	387,078	-	-	-
Treatment for Genital Herpes	-	6	17	-	2		750%	2	19	-	-	-
Treatment for Genital Herpes	-	6	17	-	2		750%	2	19	-	-	-
Treatment for Lower Abdominal Pain	2	4	59	-	4		1375%	4	63	-	-	-
Treatment for Lower Abdominal Pair	2	4	59	-	4		1,375%	4	63	-	-	-
Treatment for Nonherpetic Genital Ulc	2	1	41	-	14		193%	14	55	-	6	6
Treatment for Nonherpetic Genital U	2	1	41	-	14		193%	14	55	-	6	6
Treatment for Urethral Discharge (Mer	15	11	139	-	1		13800%	1	140	-	2	2
Treatment for Urethral Discharge (M	15	11	139	-	1		13,800%	1	140	-	2	2
Treatment for Urethral Discharge (Wor	13	4	62	-	2		3000%	2	64	-	2	2
Treatment for Urethral Discharge (W	13	4	62	-	2		3,000%	2	64	-	2	2
Treatment for Vaginitis	53	85	1,052	-	67		1470%	67	1,119	-	21	21
Treatment for Vaginitis	53	85	1,052	-	67		1,470%	67	1,119	-	21	21
<b>Kenya</b>										1,216,667	504,948	1,721,615
Antiretroviral Treatment (Currently Enr	-	2,158	23,477	6,086	5,353		339%	5,353	28,830	5,108	-	5,108
Antiretroviral Treatment (Currently E	-	2,158	23,477	6,086	5,353		339%	5,353	28,830	5,108	-	5,108
Antiretroviral Treatment (Newly Enrolle	-	123	1,368	-	825		66%	825	2,193	-	-	-
Antiretroviral Treatment (Newly Encr	-	123	1,368	-	825		66%	825	2,193	-	-	-
Cervical Cancer-VIA and Cryotherapy	18	20	476	384	1,634		(71)%	1,634	3,089	-	101	101
Cervical Cancer-VIA and Cryotherap	18	20	476	384	1,634	7/13	(71)%	1,634	3,089	-	101	101
Cervical Cancer-VIA and Refer to Cryc	-	-	-	102	-		0%	-	19	-	-	-
Cervical Cancer-VIA and Refer to Ci	-	-	-	102	-	12/14	-%	-	19	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-VIA/VILI Screening	2,179	3,645	56,161	-	161,217		(65)%	161,217	248,571	-	-	-
Cervical Cancer-VIA/VILI Screening	2,179	3,645	56,161	-	161,217		(65)%	161,217	248,571	-	-	-
Condom	2,259,360	2,484,948	29,414,645	31,966,695	31,610,311		(7)%	31,610,311	536,818,006	777,841	54,090	831,931
Mid-tier condom	-	-	-	963,413	-		-%	-	-	-	-	-
Trust	1,680,480	1,988,856	22,814,208	23,500,000	25,384,554	10/93	(10)%	25,384,554	482,213,273	603,299	41,952	645,251
Trust Ribbed	207,360	71,924	822,801	806,046	762,510	5/14	8%	762,510	2,907,472	21,758	1,513	23,271
Trust Scented	34,776	52,089	848,258	842,747	609,834	5/14	39%	609,834	2,704,113	22,431	1,560	23,991
Trust Studded	336,744	372,079	4,929,378	5,854,489	4,853,413	1/08	2%	4,853,413	48,993,148	130,353	9,064	139,417
Diarrhea Treatment Kit	-	-	-	18,744	6,000		(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit	-	-	-	18,744	6,000	12/15	(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit Provided	1,175	1,692	18,693	-	17,338		8%	17,338	36,031	-	752	752
Non-PSI Diarrhea Treatment Kit Pro	1,175	1,692	18,693	-	17,338		8%	17,338	36,031	-	752	752
Emergency Contraception	(149)	(73)	(1,292)	-	(136)		0%	(136)	(1,428)	-	(9)	(9)
PSI Emergency Contraception Distr	(149)	(73)	(1,292)	-	(136)		-%	(136)	(1,428)	-	(9)	(9)
Emergency Contraception Provided	149	73	1,292	2,000	136		850%	136	1,428	-	10	10
PSI Emergency Contraception Prov	149	73	1,292	-	136		850%	136	1,428	-	10	10
Non-PSI Emergency Contraception I	-	-	-	2,000	-		-%	-	-	-	-	-
Fever Cases Attended	-	-	664	-	26,315		(97)%	26,315	26,979	-	-	-
Fever Cases Attended	-	-	664	-	26,315		(97)%	26,315	26,979	-	-	-
Fever Cases Tested with Microscopy	-	-	121	-	7,353		(98)%	7,353	7,474	-	-	-
Fever Cases Tested with Microscop	-	-	121	-	7,353		(98)%	7,353	7,474	-	-	-
Fever Cases Tested with RDTs	-	-	543	-	18,608		(97)%	18,608	19,151	-	-	-
Fever Cases Tested with RDTs	-	-	543	-	18,608		(97)%	18,608	19,151	-	-	-
Free Condom	4,766,400	3,064,800	16,113,600	20,070,796	8,237,600		96%	8,237,600	222,424,414	426,108	29,631	455,739
Free Male Condom - GOK	-	-	-	-	7,085,600	2/14	(100)%	7,085,600	80,771,600	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Male Condom - NASCOP	4,766,400	3,064,800	16,113,600	20,070,796	-	5/11	-%	-	59,068,717	426,108	29,631	455,739
Free Male Condom - UNFPA	-	-	-	-	1,152,000	5/11	(100)%	1,152,000	82,584,097	-	-	-
<b>HIV Testing Services</b>	<b>12,441</b>	<b>15,571</b>	<b>182,193</b>	<b>99,135</b>	<b>184,245</b>		<b>(1)%</b>	<b>184,245</b>	<b>1,111,286</b>	<b>7,610</b>	<b>-</b>	<b>7,610</b>
VCT Concordant Couple (HIV-Negati	-	-	-	-	28,529	9/11	(100)%	28,529	129,685	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	282	9/11	(100)%	282	3,656	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	231	9/11	(100)%	231	1,690	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	231	9/11	(100)%	231	1,690	-	-	-
VCT Individual (HIV-Negative)	12,239	15,313	178,847	96,039	151,408	9/11	18%	151,408	943,435	7,471	-	7,471
VCT Individual (HIV-Positive)	202	258	3,346	3,096	3,565	9/11	(6)%	3,565	31,130	140	-	140
<b>Hypertension Diagnosis</b>	<b>-</b>	<b>-</b>	<b>5,790</b>	<b>-</b>	<b>31,404</b>		<b>(82)%</b>	<b>31,404</b>	<b>37,194</b>	<b>-</b>	<b>-</b>	<b>-</b>
Hypertension Diagnosis	-	-	5,790	-	31,404		(82)%	31,404	37,194	-	-	-
<b>Hypertension Screening</b>	<b>-</b>	<b>-</b>	<b>57,107</b>	<b>-</b>	<b>129,978</b>		<b>(56)%</b>	<b>129,978</b>	<b>187,085</b>	<b>-</b>	<b>-</b>	<b>-</b>
Hypertension Screening	-	-	57,107	-	129,978		(56)%	129,978	187,085	-	-	-
<b>Hypertension_Controlled Condition</b>	<b>-</b>	<b>-</b>	<b>3,495</b>	<b>-</b>	<b>25,842</b>		<b>(86)%</b>	<b>25,842</b>	<b>29,337</b>	<b>-</b>	<b>-</b>	<b>-</b>
Hypertension_Controlled Condition	-	-	3,495	-	25,842		(86)%	25,842	29,337	-	-	-
<b>Implant 3</b>	<b>-</b>	<b>-</b>	<b>47,848</b>	<b>279,025</b>	<b>140,306</b>		<b>(66)%</b>	<b>140,306</b>	<b>587,356</b>	<b>-</b>	<b>57,934</b>	<b>57,934</b>
Implanon	-	-	47,848	279,025	140,306	3/14	(66)%	140,306	587,356	-	57,934	57,934
<b>Implant 5</b>	<b>6,201</b>	<b>106</b>	<b>1,552</b>	<b>132,137</b>	<b>51,185</b>		<b>(97)%</b>	<b>51,185</b>	<b>48,674</b>	<b>-</b>	<b>2,756</b>	<b>2,756</b>
PSI Implant 5 Distributed Inserted (	(729)	(814)	(10,364)	(9,180)	(11,324)		-%	(11,324)	(109,758)	-	(18,402)	(18,402)
Jadelle	6,930	920	11,916	13,317	62,509	1/09	(81)%	62,509	158,432	-	21,158	21,158
Jadelle - GOK	-	-	-	128,000	-		-%	-	-	-	-	-
<b>Implant 5 Insertion</b>	<b>2,342</b>	<b>3,291</b>	<b>35,501</b>	<b>27,000</b>	<b>32,830</b>		<b>8%</b>	<b>32,830</b>	<b>241,285</b>	<b>-</b>	<b>70,039</b>	<b>70,039</b>
PSI Implant 5 Inserted	729	814	10,364	9,180	11,324		(8)%	11,324	109,758	-	20,447	20,447
Non-PSI Implant 5 Inserted	1,613	2,477	25,137	17,820	21,506		17%	21,506	131,527	-	49,592	49,592
<b>Injectable 3</b>	<b>50,242</b>	<b>56,797</b>	<b>391,293</b>	<b>325,875</b>	<b>447,968</b>		<b>(13)%</b>	<b>447,968</b>	<b>5,812,265</b>	<b>-</b>	<b>33,901</b>	<b>33,901</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Distributed Provided	11,534	(13,631)	(148,654)	-	(11,680)		-%	(11,680)	(160,334)	-	(12,879)	(12,879)
Femiplan Injectable	61,776	70,427	539,947	320,000	459,648	3/00	17%	459,648	5,972,599	-	46,781	46,781
GOK Injectable	-	-	-	5,875	-		-%	-	-	-	-	-
Injectable 3 Provided	11,534	13,631	148,654	141,166	11,680		1173%	11,680	160,334	-	14,310	14,310
PSI Injectable 3 Provided	11,534	13,631	148,654	-	11,680		1,173%	11,680	160,334	-	14,310	14,310
Non-PSI Injectable 3 Provided	-	-	-	141,166	-		-%	-	-	-	-	-
IPTp2	360	722	6,809	-	3,595		89%	3,595	10,404	-	337	337
IPTp2	360	722	6,809	-	3,595		89%	3,595	10,404	-	337	337
IUD 10	5,188	62	4,806	5,540	(1,578)		0%	(1,578)	7,811	-	10,505	10,505
PSI IUD 10 Distributed Inserted (1)	(511)	(567)	(6,835)	(4,900)	(6,273)		-%	(6,273)	(79,251)	-	(14,939)	(14,939)
CU 380A (Copper T)	5,699	629	11,641	10,440	4,695	3/09	148%	4,695	87,062	-	25,444	25,444
IUD 10 Insertion	1,071	1,391	16,343	14,000	17,920		(9)%	17,920	161,907	-	39,690	39,690
PSI IUD 10 Inserted	511	567	6,835	4,900	6,273		9%	6,273	79,251	-	16,599	16,599
Non-PSI IUD 10 Inserted	560	824	9,508	9,100	11,647		(18)%	11,647	82,656	-	23,091	23,091
LLIN	310,407	198,063	2,250,820	1,877,333	2,272,960		(1)%	2,272,960	36,873,215	-	72,219	72,219
ANC LLIN	-	-	-	1,716,333	2,111,533	7/08	(100)%	2,111,533	19,189,925	-	-	-
Mass LLIN	-	-	560	-	28,440	4/11	(98)%	28,440	6,481,520	-	18	18
Social Marketed LLIN	-	-	-	-	131,268	8/08	(100)%	131,268	4,692,664	-	-	-
Supanet Conical	506	335	6,307	90,500	874	10/16	622%	874	7,181	-	202	202
Supanet Rectangular	501	241	3,865	70,500	845	10/16	357%	845	4,710	-	124	124
Supanet Xtra Power (Olyset)	-	-	129,420	-	-	4/05	-%	-	4,386,547	-	4,153	4,153
Supanet XtraPower BL PNET USA	109,400	197,487	2,110,668	-	-	3/14	-%	-	2,110,668	-	67,722	67,722
Malaria PPT (ACT)	-	-	-	147,378	330		(100)%	330	23,010	-	-	-
Artemether 200mg x 12 (15-24 KG)	-	-	-	113,381	-	3/15	-%	-	9,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Artemether 200mg x 24 (> 34 KG)	-	-	-	-	330	3/15	(100)%	330	11,010	-	-	-
Artemether 200mg x 6 (5-14 KG)	-	-	-	33,997	-	3/15	-%	-	3,000	-	-	-
Malaria RDK	-	-	-	-	40		(100)%	40	499,905	-	-	-
Malaria Rapid Diagnostic Kit	-	-	-	-	40	11/13	(100)%	40	499,905	-	-	-
<b>OCs</b>	<b>210,559</b>	<b>238,207</b>	<b>3,305,279</b>	<b>3,638,290</b>	<b>5,417,505</b>		<b>(39)%</b>	<b>5,417,505</b>	<b>34,980,791</b>	-	<b>77,539</b>	<b>77,539</b>
PSI OCs Distributed Provided	(2,201)	(2,489)	(26,983)	-	(2,096)		-%	(2,096)	(29,079)	-	(633)	(633)
Femi Girl Oral Pills	1,080	240	5,232	208,000	4,512	11/16	16%	4,512	9,744	-	123	123
Femiplan Pill	211,680	240,456	3,327,030	3,430,290	5,415,089	3/00	(39)%	5,415,089	35,000,126	-	78,049	78,049
<b>OCs Provided</b>	<b>2,201</b>	<b>2,489</b>	<b>26,983</b>	<b>28,752</b>	<b>2,096</b>		<b>1187%</b>	<b>2,096</b>	<b>29,079</b>	-	<b>703</b>	<b>703</b>
PSI OCs Provided	2,201	2,489	26,983	-	2,096		1,187%	2,096	29,079	-	703	703
Non-PSI OCs Provided	-	-	-	28,752	-		-%	-	-	-	-	-
<b>ORS Provided</b>	<b>348</b>	<b>443</b>	<b>4,794</b>	-	<b>5,546</b>		<b>(14)%</b>	<b>5,546</b>	<b>10,340</b>	-	<b>94</b>	<b>94</b>
Non-PSI ORS Provided	348	443	4,794	-	5,546		(14)%	5,546	10,340	-	94	94
Pneumonia PPT	-	-	-	27,065	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	27,065	-		-%	-	-	-	-	-
<b>Pneumonia PPT Provided</b>	<b>1,082</b>	<b>1,573</b>	<b>18,040</b>	-	<b>19,854</b>		<b>(9)%</b>	<b>19,854</b>	<b>37,894</b>	-	<b>8,677</b>	<b>8,677</b>
Non-PSI Pneumonia PPT Provided	1,082	1,573	18,040	-	19,854		(9)%	19,854	37,894	-	8,677	8,677
Positive RDTs	-	-	110	-	3,656		(97)%	3,656	3,766	-	-	-
Positive RDTs	-	-	110	-	3,656		(97)%	3,656	3,766	-	-	-
Positive RDTs Given First Line Treatm	-	-	110	-	3,489		(97)%	3,489	3,599	-	-	-
Positive RDTs Given First Line Trea	-	-	110	-	3,489		(97)%	3,489	3,599	-	-	-
<b>PUR</b>	<b>1,480,320</b>	<b>4,187,840</b>	<b>40,269,480</b>	<b>15,600,000</b>	<b>25,634,046</b>		<b>57%</b>	<b>25,634,046</b>	<b>137,336,956</b>	-	<b>1,276</b>	<b>1,276</b>
PuR	1,480,320	4,187,840	40,269,480	15,600,000	25,634,046	2/06	57%	25,634,046	137,336,956	-	1,276	1,276
QAACTs Provided after Confirmatory I	-	-	110	-	3,815		(97)%	3,815	3,925	-	18	18
Non-PSI QAACTs Provided after Co	-	-	110	-	3,815		(97)%	3,815	3,925	-	18	18

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Safe Water Solution	207,822	154,716	1,612,479	1,601,250	1,401,214		15%	1,401,214	20,451,700	-	5,110	5,110
WaterGuard	207,822	154,716	1,612,479	1,601,250	1,401,214	5/03	15%	1,401,214	20,451,700	-	5,110	5,110
Skilled Birth Attendance	1,324	3,346	30,038	16,237	12,016		150%	12,016	42,054	-	25,180	25,180
Skilled Birth Attendance	1,324	3,346	30,038	16,237	12,016		150%	12,016	42,054	-	25,180	25,180
Treatment for Pre-Eclampsia (with Mg)	2	10	93	39	28		232%	28	121	-	63	63
Treatment for Pre-Eclampsia (with Mg)	2	10	93	39	28		232%	28	121	-	63	63
Voluntary Medical Male Circumcision	-	-	-	700	2		(100)%	2	734	-	-	-
Male Circumcision (HIV-Negative)	-	-	-	-	2	3/12	(100)%	2	734	-	-	-
Voluntary Medical Male Circumcision	-	-	-	700	-		-%	-	-	-	-	-
Water Treatment Tablets	2,160	45,360	326,370	239,280	840,790		(61)%	840,790	5,453,370	-	21	21
Aquatab	2,160	45,360	326,370	239,280	840,790	3/09	(61)%	840,790	5,453,370	-	21	21
<b>Malawi</b>										678,522	442,586	1,121,108
Condom	704,080	1,465,387	18,268,960	19,000,000	22,203,160		(18)%	22,203,160	208,212,102	302,112	41,318	343,429
Chishango	704,080	1,465,387	18,268,960	19,000,000	22,203,160	10/94	(18)%	22,203,160	208,212,102	302,112	41,318	343,429
Emergency Contraception	-	993	10,228	40,000	34,107		(70)%	34,107	97,220	-	87	87
PSI Emergency Contraception Distr	-	-	(241)	-	-		-%	-	(241)	-	(2)	(2)
NORLEVO (Norlevo 1.5mg)	-	993	10,469	40,000	34,107	2/14	(69)%	34,107	97,461	-	89	89
Emergency Contraception Provided	-	-	241	-	-		0%	-	241	-	2	2
PSI Emergency Contraception Prov	-	-	241	-	-		-%	-	241	-	2	2
Female Condom	840	4,053	34,586	55,000	55,100		(37)%	55,100	708,412	572	60	632
Care	840	4,053	33,406	45,000	54,148	1/08	(38)%	54,148	706,280	552	58	611
Whisper Female Condom	-	-	1,180	10,000	952	11/16	24%	952	2,132	20	2	22
Free Condom	297,888	1,577,330	13,642,502	5,045,000	4,015,632		240%	4,015,632	19,113,617	225,604	30,854	256,459
Blue Gold Condoms	144,000	263,567	1,265,910	-	-	8/17	-%	-	1,265,910	20,934	2,863	23,797
Free Male Condoms	-	-	7,200	-	322,289	2/14	(98)%	322,289	1,659,772	119	16	135

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Key Population Male Condom	153,888	1,086,244	8,865,398	3,000,000	2,271,734	7/16	290%	2,271,734	11,137,132	146,606	20,050	166,656
One Community Male Condom	-	227,520	3,459,739	2,000,000	1,044,215	7/16	231%	1,044,215	4,503,954	57,213	7,825	65,038
VMMC Male Condom	-	-	44,255	45,000	377,394	1/15	(88)%	377,394	546,849	732	100	832
Free Female Condom	22,062	12,353	133,482	100,000	36,158		269%	36,158	255,849	2,207	232	2,440
Free Female Condoms	5,400	12,353	116,820	100,000	36,158	2/14	223%	36,158	239,187	1,932	203	2,135
Key Population Female Condom	16,662	-	16,662	-	-	12/17	-%	-	16,662	276	29	305
HIV Self-Testing Kit	25,291	21,235	88,997	-	-		0%	-	88,997	-	-	-
ORAQUICK HIV Self-Testing Kit (Pc	25,291	21,235	88,997	-	-	8/17	-%	-	88,997	-	-	-
HIV Testing Services	1,060	4,637	87,093	77,000	69,431		25%	69,431	165,848	3,705	-	3,705
VCT Individual (HIV-Negative)	1,018	4,465	84,142	73,261	69,379	12/14	21%	69,379	162,804	3,579	-	3,579
VCT Individual (HIV-Positive)	42	172	2,951	3,739	52	12/14	5,575%	52	3,044	126	-	126
Implant 3	82	(813)	(2,638)	17,000	5,225		(150)%	5,225	18,114	-	(3,949)	(3,949)
PSI Implant 3 Distributed Inserted (	-	(1,691)	(25,880)	-	(13,019)		-%	(13,019)	(47,147)	-	(38,737)	(38,737)
Implanon	82	878	23,242	17,000	18,244	10/12	27%	18,244	65,261	-	34,788	34,788
Implant 3 Insertion	-	1,691	25,880	-	13,019		99%	13,019	47,147	-	43,041	43,041
PSI Implant 3 Inserted	-	1,691	25,880	-	13,019		99%	13,019	47,147	-	43,041	43,041
Implant 5	170	(1,250)	(3,459)	24,000	9,934		(135)%	9,934	19,574	-	(7,628)	(7,628)
PSI Implant 5 Distributed Inserted (	-	(7,206)	(46,931)	-	(17,447)	3/16	-%	(17,447)	(73,821)	-	(103,491)	(103,491)
Jadelle	170	5,955	43,472	24,000	27,381	10/12	59%	27,381	93,395	-	95,864	95,864
Implant 5 Insertion	-	7,206	46,931	-	17,447		169%	17,447	73,821	-	114,991	114,991
PSI Implant 5 Inserted	-	7,206	46,931	-	17,447	3/16	169%	17,447	73,821	-	114,991	114,991
Injectable 3	425	25,409	952,164	890,500	216,611		340%	216,611	1,768,261	-	101,461	101,461
PSI Injectable 3 Distributed Provide	-	-	(7,340)	-	-		-%	-	(7,340)	-	(782)	(782)
SafePlan Inj3	425	25,409	959,504	890,500	216,611	1/08	343%	216,611	1,775,601	-	102,243	102,243
Injectable 3 Provided	-	-	7,340	-	-		0%	-	7,340	-	869	869

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Provided	-	-	7,340	-	-		-%	-	7,340	-	869	869
IUD 10	90	(41)	2,082	1,600	532		291%	532	6,070	-	5,691	5,691
PSI IUD 10 Distributed Inserted (1)	-	(568)	(3,446)	-	(1,356)	3/16	-%	(1,356)	(5,925)	-	(9,419)	(9,419)
IUD Copper T 380A	90	527	5,528	1,600	1,888	10/12	193%	1,888	11,995	-	15,110	15,110
IUD 10 Insertion	-	568	3,446	-	1,356		154%	1,356	5,925	-	10,465	10,465
PSI IUD 10 Inserted	-	568	3,446	-	1,356	3/16	154%	1,356	5,925	-	10,465	10,465
LLIN	806	4,786	129,279	45,000	979,679		(87)%	979,679	8,827,256	-	13,138	13,138
PMI Permanets	-	-	88,852	-	944,049	4/07	(91)%	944,049	8,429,422	-	9,029	9,029
Super Chitetezo Net	806	4,786	40,427	45,000	35,630	2/11	13%	35,630	397,834	-	4,108	4,108
Lubricant	15,600	93,873	1,006,747	-	509,715		98%	509,715	2,006,459	-	-	-
Personal Lubricant Water 4.5 g	15,600	93,873	1,006,747	-	509,715	12/12	98%	509,715	2,006,459	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	287		(100)%	287	607	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	287		(100)%	287	607	-	-	-
OCs	17,753	42,791	246,212	35,000	104,659		135%	104,659	652,028	-	7,104	7,104
PSI OCs Distributed Provided	-	-	(14,184)	-	-		-%	-	(14,184)	-	(409)	(409)
Microgynon	17,747	39,132	249,320	35,000	104,659	11/11	138%	104,659	655,136	-	7,194	7,194
Microlut	6	3,659	11,076	-	-	8/17	-%	-	11,076	-	320	320
OCs Provided	-	-	14,184	-	-		0%	-	14,184	-	455	455
PSI OCs Provided	-	-	14,184	-	-		-%	-	14,184	-	455	455
ORS	-	-	-	-	208,492		(100)%	208,492	16,373,449	-	-	-
Thanzi	-	-	-	-	208,492	5/99	(100)%	208,492	16,373,449	-	-	-
PUR	1,500,000	234,720	5,740,645	6,500,000	3,060,140		88%	3,060,140	54,327,255	-	315	315
PuR WaterGuard Waufa	1,500,000	234,720	5,740,645	6,500,000	3,060,140	3/06	88%	3,060,140	54,327,255	-	315	315
Referral to CD4/Clinical Staging	-	-	-	-	2,046		(100)%	2,046	2,159	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	2,046		(100)%	2,046	2,159	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Implant 3 Insertion	-	-	-	-	309		(100)%	309	309	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	309		(100)%	309	309	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	593		(100)%	593	593	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	593		(100)%	593	593	-	-	-
Referral to Injectable 3	-	-	-	-	2,754		(100)%	2,754	2,754	-	-	-
Referral to Injectable 3	-	-	-	-	2,754		(100)%	2,754	2,754	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	142		(100)%	142	142	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	142		(100)%	142	142	-	-	-
Referral to OCs	-	-	-	-	454		(100)%	454	454	-	-	-
Referral to OCs	-	-	-	-	454		(100)%	454	454	-	-	-
Safe Water Solution	11,632	10,969	152,515	150,000	153,179		0%	153,179	8,352,470	-	836	836
WaterGuard	11,632	10,969	152,515	150,000	153,179	12/02	-%	153,179	8,352,470	-	836	836
Tubal Ligation	-	1,835	14,158	5,500	4,500		215%	4,500	19,139	-	83,220	83,220
Tubal Ligation	-	1,835	14,158	5,500	4,500	1/15	215%	4,500	19,139	-	83,220	83,220
Vasectomy	-	-	4	-	-		0%	-	5	-	24	24
Vasectomy	-	-	4	-	-		-%	-	5	-	24	24
Voluntary Medical Male Circumcision	1,578	3,387	40,038	67,553	30,629		31%	30,629	128,338	144,322	-	144,322
Male Circumcision (HIV-Negative)	-	-	-	-	30,240	3/13	(100)%	30,240	87,911	-	-	-
Voluntary Medical Male Circumcision	1,578	3,387	40,038	67,553	389		10,193%	389	40,427	144,322	-	144,322
<b>Rwanda</b>										143,759	31,929	175,688
Condom	1,154,208	1,088,317	11,495,344	13,567,226	14,307,089		(20)%	14,307,089	187,231,227	140,297	25,026	165,323
Plaisir	426,240	14,742	822,646	1,067,226	1,707,579	1/08	(52)%	1,707,579	14,891,499	10,040	1,791	11,831
Prudence Plus	727,968	1,073,575	10,672,698	12,500,000	12,599,510	3/93	(15)%	12,599,510	172,339,728	130,257	23,235	153,492
Condom Provided	-	-	-	-	2,207,978		(100)%	2,207,978	2,208,125	-	-	-
Non-PSI Condom Provided	-	-	-	-	2,207,978		(100)%	2,207,978	2,208,125	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Condom	-	1,920	283,641	1,350,000	993,900		(71)%	993,900	3,675,746	3,462	617	4,079
Military Condom	-	1,920	283,641	1,350,000	993,900	11/13	(71)%	993,900	3,675,746	3,462	617	4,079
HIV Testing Services	-	-	-	6,842	8,318		(100)%	8,318	247,300	-	-	-
VCT Concordant Couple (HIV-Nega	-	-	-	-	6	1/10	(100)%	6	22,320	-	-	-
VCT Individual (HIV-Negative)	-	-	-	6,586	7,511	1/10	(100)%	7,511	212,258	-	-	-
VCT Individual (HIV-Positive)	-	-	-	256	801	1/10	(100)%	801	12,722	-	-	-
Injectable 3	480	2,637	22,790	22,000	17,328		32%	17,328	182,243	-	2,338	2,338
Confiance Depo-Provera	480	2,637	22,790	-	16,802	1/08	36%	16,802	39,592	-	2,338	2,338
Depo-Provera (3 Month)	-	-	-	22,000	526	1/06	(100)%	526	142,651	-	-	-
Injectable 3 Provided	-	-	-	-	11,566		(100)%	11,566	11,728	-	-	-
Non-PSI Injactable 3 Provided	-	-	-	-	11,566	3/16	(100)%	11,566	11,728	-	-	-
OCs	7,350	11,550	129,840	66,000	95,109		37%	95,109	365,288	-	3,606	3,606
Confiance Duofem	-	-	-	-	28,320	1/08	(100)%	28,320	168,656	-	-	-
Microgynon	7,350	11,550	129,840	66,000	66,789		94%	66,789	196,632	-	3,606	3,606
OCs Provided	-	-	-	-	34,593		(100)%	34,593	34,782	-	-	-
Non-PSI OCs Provided	-	-	-	-	34,593		(100)%	34,593	34,782	-	-	-
PUR	412,800	8,804	503,791	500,000	224,214		125%	224,214	11,574,208	-	12	12
PuR	412,800	8,804	503,791	500,000	224,214	1/11	125%	224,214	11,574,208	-	12	12
Referral to HIV Testing Services	-	-	-	180	118		(100)%	118	118	-	-	-
Referral to HIV Testing & Counselin	-	-	-	180	118	12/14	(100)%	118	118	-	-	-
Referral to Voluntary Medical Male Cir	-	-	-	-	42		(100)%	42	42	-	-	-
Referral to Voluntary Medical Male C	-	-	-	-	42		(100)%	42	42	-	-	-
Safe Water Solution	6,096	11,924	134,811	220,000	133,765		1%	133,765	3,814,760	-	330	330
Sur Eau	6,096	11,924	134,811	220,000	133,765	8/02	1%	133,765	3,814,760	-	330	330
SDM (Cycle Beads)	-	-	-	-	5		(100)%	5	418	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Collier	-	-	-	-	5	1/08	(100)%	5	418	-	-	-
<b>Somaliland</b>										-	32,006	32,006
Diarrhea Treatment Kit	14,810	19,873	188,408	161,500	161,568		17%	161,568	967,598	-	20,196	20,196
SD OFLV-DTK	14,810	19,873	188,408	-	161,568	9/11	17%	161,568	822,077	-	20,196	20,196
Shuban Daweeye_DTK	-	-	-	161,500	-	6/11	-%	-	145,521	-	-	-
Implant 3	(24)	17	(15)	-	197		(108)%	197	267	-	(25)	(25)
PSI Implant 3 Distributed Inserted ('	(24)	(24)	(250)	(360)	(66)		-%	(66)	(316)	-	(424)	(424)
Nasiye Implant (Implanon)	-	42	235	360	263	12/15	(11)%	263	583	-	398	398
Implant 3 Insertion	24	24	264	360	87		203%	87	351	-	497	497
PSI Implant 3 Inserted	24	24	250	360	66		279%	66	316	-	471	471
Non-PSI Implant 3 Inserted	-	-	14	-	21		(33)%	21	35	-	26	26
Injectable 3	-	117	1,470	3,500	4,464		(67)%	4,464	22,959	-	178	178
Nasiye - Inj 3	-	117	1,470	3,500	4,464	6/11	(67)%	4,464	22,959	-	178	178
Micronutrient Powder	-	-	-	100,000	3,500		(100)%	3,500	1,238,055	-	-	-
Super Fariid	-	-	-	100,000	3,500	11/14	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PPH	2,500	2,233	23,800	30,000	17,750		34%	17,750	163,908	-	150	150
Ummul-gargaar	2,500	2,233	23,800	30,000	17,750	3/10	34%	17,750	163,908	-	150	150
OCs	2,205	825	12,735	26,000	27,705		(54)%	27,705	126,951	-	417	417
Nasiye - OC	2,205	825	12,735	26,000	27,705	3/12	(54)%	27,705	126,951	-	417	417
ORS	-	-	-	-	5,750		(100)%	5,750	5,755	-	-	-
Shuban Daweeye_ORs	-	-	-	-	5,750	6/11	(100)%	5,750	5,755	-	-	-
Pneumonia PPT	1,250	-	7,894	11,000	11,050		(29)%	11,050	38,713	-	8,209	8,209
Pneomox 125mg tablet (Amoxicillin)	250	-	1,636	2,500	2,220	11/14	(26)%	2,220	7,816	-	1,701	1,701
Pneomox 250mg tablet (Amoxicillin)	1,000	-	6,258	8,500	8,830	11/14	(29)%	8,830	30,897	-	6,508	6,508
Water Treatment Tablets	420,000	432,000	5,788,160	4,188,000	3,330,000		74%	3,330,000	70,197,462	-	2,385	2,385

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Aquatab	-	-	638,000	864,000	-	9/10	-%	-	35,574,790	-	263	263
Biyosifeeye	420,000	432,000	5,150,160	3,324,000	3,330,000	7/08	55%	3,330,000	34,622,672	-	2,122	2,122
<b>South Sudan</b>										-	2,002,731	2,002,731
Counseling & Tx for Moderate Acute M	-	-	155,147	-	-		0%	-	155,147	-	-	-
Counseling & Tx for Moderate Acute	-	-	155,147	-	-		-%	-	155,147	-	-	-
LLIN	571,814	276,988	2,728,577	1,979,109	2,778,617		(2)%	2,778,617	5,854,414	-	700,400	700,400
Mass LLIN - WES	571,814	276,988	2,728,577	1,979,109	2,778,617	6/14	(2)%	2,778,617	5,854,414	-	700,400	700,400
Malaria PPT (ACT)	21,169	186,312	3,170,177	2,956,134	4,047,867		(22)%	4,047,867	12,691,911	-	976,687	976,687
ACT Adult - CAIPA	-	-	-	-	758,119	12/15	(100)%	758,119	799,369	-	-	-
ACT Child - CAIPA	-	-	-	-	424,500	12/15	(100)%	424,500	424,500	-	-	-
ACT Infant - CAIPA	-	-	-	-	399,000	12/15	(100)%	399,000	423,000	-	-	-
ACTs for Adult (14+ years)	8,660	71,133	792,385	725,465	572,600	2/13	38%	572,600	2,410,040	-	244,123	244,123
ACTs for Child (6-14 years)	8,080	39,133	417,205	458,173	247,425	2/13	69%	247,425	1,297,061	-	128,535	128,535
ACTs for Infant (2-12 months)	2,960	13,639	746,590	736,237	685,249	2/13	9%	685,249	2,795,191	-	230,014	230,014
ACTs for Toddler (1-5 years)	1,469	62,406	1,213,997	1,036,259	960,974	2/13	26%	960,974	4,542,750	-	374,016	374,016
Malaria RDK	20,000	186,092	1,812,525	1,881,088	1,596,694		14%	1,596,694	5,244,278	-	-	-
Malaria Rapid Diagnostic Kit	20,000	186,092	1,812,525	1,881,088	1,588,269	9/14	14%	1,588,269	5,235,853	-	-	-
mRDT Test Kits - CAIPA	-	-	-	-	8,425	12/15	(100)%	8,425	8,425	-	-	-
ORS	-	232,082	855,533	1,068,611	538,124		59%	538,124	4,190,129	-	28,144	28,144
PSI ORS Distributed Provided	-	-	(120,132)	-	-		-%	-	(120,132)	-	(3,952)	(3,952)
ORS	-	232,082	975,665	1,068,611	538,124	9/08	81%	538,124	4,310,261	-	32,096	32,096
ORS Provided	-	-	120,132	-	-		0%	-	120,132	-	4,391	4,391
PSI ORS Provided	-	-	120,132	-	-		-%	-	120,132	-	4,391	4,391
Pneumonia PPT	608	55,383	213,493	867,265	251,497		(15)%	251,497	1,345,014	-	187,419	187,419

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Pneumonia PPT Distributed Pr	-	-	(83,524)	-	-		-%	-	(83,524)	-	(73,323)	(73,323)
Amoxicillin for Children (1-5 years)	608	37,220	230,322	715,056	161,804	10/12	42%	161,804	997,080	-	202,193	202,193
Amoxicillin for Infant (2-12 months)	-	18,164	66,695	152,209	89,693	10/12	(26)%	89,693	431,458	-	58,550	58,550
Pneumonia PPT Provided	-	-	83,524	-	-		0%	-	83,524	-	81,470	81,470
PSI Pneumonia PPT Provided	-	-	83,524	-	-		-%	-	83,524	-	81,470	81,470
PUR	-	-	-	-	1,099,046		(100)%	1,099,046	13,499,706	-	-	-
PuR	-	-	-	-	1,099,046	1/09	(100)%	1,099,046	13,499,706	-	-	-
Treatment for Severe Acute Malnutritic	-	-	16,202	-	25,444		(36)%	25,444	41,646	-	20,370	20,370
Treatment for Severe Acute Malnutri	-	-	16,202	-	25,444		(36)%	25,444	41,646	-	20,370	20,370
Zinc	-	50,530	315,617	307,202	53,910		485%	53,910	1,360,325	-	3,448	3,448
PSI Zinc Distributed Provided	-	-	(33,075)	-	-		-%	-	(33,075)	-	(361)	(361)
Zinc	-	50,530	348,692	307,202	53,910	1/08	547%	53,910	1,393,400	-	3,809	3,809
Zinc Provided	-	-	33,075	-	-		0%	-	33,075	-	401	401
PSI Zinc Provided	-	-	33,075	-	-		-%	-	33,075	-	401	401
<b>Tanzania</b>										470,925	1,031,049	1,501,975
Cervical Cancer-VIA and Cryotherapy	-	12	193	237	445		(57)%	445	1,353	-	73	73
Cervical Cancer-VIA and Cryotherap	-	12	193	237	445	12/13	(57)%	445	1,353	-	73	73
Cervical Cancer-VIA/VILI Screening	56	263	5,099	-	12,039		(58)%	12,039	19,771	-	-	-
Cervical Cancer-VIA/VILI Screening	56	263	5,099	-	12,039		(58)%	12,039	19,771	-	-	-
Clean Delivery Kit	-	-	10,415	-	19,430		(46)%	19,430	32,892	-	769	769
Clean Delivery Pack-CDP	-	-	10,415	-	19,430	9/13	(46)%	19,430	32,892	-	769	769
Condom	156,384	9,288,920	55,963,991	76,774,149	95,295,423		(41)%	95,295,423	1,180,687,997	429,887	119,737	549,624
PSI Condom Distributed Provided	-	-	-	-	(6,150)		-%	(6,150)	(29,510)	-	-	-
Dume Condom	-	-	2,019,168	2,019,168	22,103,107	8/11	(91)%	22,103,107	86,748,019	15,510	4,320	19,830
Familia	-	-	-	4,985,280	-	10/07	-%	-	40,194,688	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Salama	-	7,333	461,164	-	72	12/93	640,406%	72	448,755,924	3,542	987	4,529
Salama Halisi	69,552	7,441,411	41,160,728	50,286,682	48,705,408	2/11	(15)%	48,705,408	341,536,808	316,176	88,065	404,241
Salama Scented	432	890,208	6,983,843	13,053,563	13,642,802	8/06	(49)%	13,642,802	132,520,332	53,646	14,942	68,589
Salama Studded	86,400	949,968	5,339,088	6,429,456	10,850,184	6/04	(51)%	10,850,184	130,961,736	41,012	11,423	52,435
<b>Condom Provided</b>	-	-	-	-	16,550		(100)%	16,550	65,758	-	-	-
PSI Condom Provided	-	-	-	-	6,150		(100)%	6,150	29,510	-	-	-
Non-PSI Condom Provided	-	-	-	-	10,400		(100)%	10,400	36,248	-	-	-
<b>Emergency Contraception</b>	3,000	(4)	102,545	99,000	39,769		158%	39,769	292,154	-	827	827
PSI Emergency Contraception Distr	-	(4)	(17)	-	(32)		-%	(32)	(49)	-	-	-
Emergency Contraception	3,000	-	102,562	99,000	39,801	7/12	158%	39,801	292,203	-	827	827
<b>Emergency Contraception Provided</b>	5	4	28	-	110		(75)%	110	140	-	-	-
PSI Emergency Contraception Prov	-	4	17	-	32		(47)%	32	49	-	-	-
Non-PSI Emergency Contraception I	5	1	11	-	78		(86)%	78	91	-	-	-
<b>Female Condom</b>	-	-	357,160	85,000	1,044,240		(66)%	1,044,240	10,480,066	2,744	588	3,331
Care	-	-	84,960	85,000	602,670	11/98	(86)%	602,670	6,045,516	653	140	792
Lady Pepeta	-	-	272,200	-	441,570	11/11	(38)%	441,570	4,434,550	2,091	448	2,539
<b>Free Condom</b>	-	-	4,985,280	-	38,368,944		(87)%	38,368,944	104,184,186	38,294	10,666	48,961
Free Familia	-	-	4,985,280	-	17,455,680	7/10	(71)%	17,455,680	83,270,922	38,294	10,666	48,961
Zana Male Condom	-	-	-	-	20,913,264	5/16	(100)%	20,913,264	20,913,264	-	-	-
<b>Implant 3</b>	(2,643)	(572)	(8,769)	35,076	(18,057)		0%	(18,057)	(7,651)	-	(12,350)	(12,350)
PSI Implant 3 Distributed Inserted	(2,643)	(3,269)	(31,513)	-	(28,041)		-%	(28,041)	(66,747)	-	(44,383)	(44,383)
Implanon	-	2,696	22,744	35,076	9,984	1/09	128%	9,984	59,096	-	32,033	32,033
<b>Implant 3 Insertion</b>	4,904	7,281	62,841	-	54,069		16%	54,069	147,412	-	98,339	98,339
PSI Implant 3 Inserted	2,643	3,269	31,513	-	28,041		12%	28,041	66,747	-	49,314	49,314
Non-PSI Implant 3 Inserted	2,261	4,012	31,328	-	26,028		20%	26,028	80,665	-	49,025	49,025

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 4	-	-	-	-	(369)		0%	(369)	(369)	-	-	-
PSI Implant 4 Distributed Inserted (1)	-	-	-	-	(369)		-%	(369)	(369)	-	-	-
Implant 4 Insertion	-	-	-	-	1,460		(100)%	1,460	1,460	-	-	-
PSI Implant 4 Inserted	-	-	-	-	369		(100)%	369	369	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	1,091		(100)%	1,091	1,091	-	-	-
Implant 5	(1,706)	922	(1,937)	23,384	(27,478)		0%	(27,478)	(11,709)	-	(4,000)	(4,000)
PSI Implant 5 Distributed Inserted (1)	(1,706)	(3,011)	(28,677)	-	(31,398)		-%	(31,398)	(95,709)	-	(59,215)	(59,215)
Jadelle	-	3,933	26,740	23,384	3,920	11/09	582%	3,920	84,000	-	55,216	55,216
Implant 5 Insertion	2,932	4,785	41,255	-	43,975		(6)%	43,975	151,630	-	94,653	94,653
PSI Implant 5 Inserted	1,706	3,011	28,677	-	31,398		(9)%	31,398	95,709	-	65,795	65,795
Non-PSI Implant 5 Inserted	1,226	1,774	12,578	-	12,577		-%	12,577	55,921	-	28,858	28,858
Injectable 3	(178)	9,879	836,196	647,408	70,933		1079%	70,933	1,658,927	-	84,293	84,293
PSI Injectable 3 Distributed Provide (1)	(178)	(281)	(2,684)	(2,592)	(4,367)		-%	(4,367)	(8,424)	-	(271)	(271)
Familia Injectable 3 Kit	-	10,160	838,880	650,000	75,300	1/10	1,014%	75,300	1,667,351	-	84,563	84,563
Injectable 3 Provided	1,969	2,988	29,201	2,592	28,248		3%	28,248	68,831	-	3,271	3,271
PSI Injectable 3 Provided	178	281	2,684	2,592	4,367		(39)%	4,367	8,424	-	301	301
Non-PSI Injectable 3 Provided	1,791	2,707	26,517	-	23,881		11%	23,881	60,407	-	2,970	2,970
IUD 10	(5,032)	(6,279)	(37,563)	(33,328)	(51,103)		0%	(51,103)	(74,535)	-	(95,446)	(95,446)
PSI IUD 10 Distributed Inserted (1)	(5,032)	(8,474)	(89,059)	(39,828)	(107,414)		-%	(107,414)	(332,681)	-	(226,296)	(226,296)
Familia IUD Kit	-	1,111	34,159	6,500	56,311	11/09	(39)%	56,311	240,809	-	86,797	86,797
Pregna IUD (no safe load)	-	1,084	17,337	-	-	3/17	-%	-	17,337	-	44,053	44,053
IUD 10 Insertion	10,367	14,904	130,599	99,828	124,475		5%	124,475	482,800	-	368,720	368,720
PSI IUD 10 Inserted	5,032	8,474	89,059	39,828	107,414		(17)%	107,414	332,681	-	251,440	251,440
Non-PSI IUD 10 Inserted	5,335	6,430	41,540	60,000	17,061		143%	17,061	150,119	-	117,280	117,280
IUD 5	-	-	-	-	(7)		0%	(7)	(7)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	(7)		-%	(7)	(7)	-	-	-
IUD 5 Insertion	-	-	-	-	8		(100)%	8	8	-	-	-
PSI IUD 5 Inserted	-	-	-	-	7		(100)%	7	7	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	1		(100)%	1	1	-	-	-
<b>LLIN</b>	<b>3,510,182</b>	<b>383,926</b>	<b>5,365,880</b>	<b>2,434,025</b>	<b>2,075,002</b>		<b>159%</b>	<b>2,075,002</b>	<b>7,440,882</b>	-	<b>253,360</b>	<b>253,360</b>
"New Brand" (School Net Program)	-	324,259	1,157,858	2,434,025	-		-%	-	1,157,858	-	54,670	54,670
Permanet (180x160x180 CM) SI	3,510,182	59,667	4,208,022	-	2,075,002	2/16	103%	2,075,002	6,283,024	-	198,690	198,690
Lubricant	-	-	-	-	28,500		(100)%	28,500	400,000	-	-	-
SHOSTI Lubricant 5mL Sachet	-	-	-	-	28,500	12/14	(100)%	28,500	400,000	-	-	-
Malaria RDK	-	-	-	-	85		(100)%	85	215,085	-	-	-
Malaria Rapid Diagnostic Kit	-	-	-	-	85	2/14	(100)%	85	215,085	-	-	-
Manual Vacuum Aspiration for PAC	-	83	1,074	-	-		0%	-	1,074	-	128	128
MVA for PAC	-	83	1,074	-	-		-%	-	1,074	-	128	128
Misoprostol for PAC (Oral)	257,600	61,809	827,163	750,000	1,265,264		(35)%	1,265,264	4,854,851	-	29,613	29,613
PSI Misoprostol for PAC Oral Dist F	-	(4)	(153)	-	-		-%	-	(153)	-	(5)	(5)
Misoprostol for PAC (oral)	257,600	61,813	827,316	750,000	1,265,264	9/12	(35)%	1,265,264	4,855,004	-	29,618	29,618
Misoprostol for PAC (oral) Provided	-	4	153	-	-		0%	-	153	-	6	6
PSI Misoprostol for PAC (oral) Prov	-	4	153	-	-		-%	-	153	-	6	6
Misoprostol for PPH	78,560	6,760	100,000	-	-		0%	-	100,000	-	251	251
Misoprostol for PPH	78,560	6,760	100,000	-	-	9/17	-%	-	100,000	-	251	251
<b>OCs</b>	<b>712,460</b>	<b>(521)</b>	<b>2,798,409</b>	<b>2,397,408</b>	<b>2,184,870</b>		<b>28%</b>	<b>2,184,870</b>	<b>22,768,633</b>	-	<b>76,382</b>	<b>76,382</b>
PSI OCs Distributed Provided	(340)	(523)	(4,876)	(2,592)	(5,226)		-%	(5,226)	(12,864)	-	(133)	(133)
Familia [OC]	712,800	2	2,802,853	2,400,000	309,168	2/08	807%	309,168	9,932,953	-	76,503	76,503
Flexi P	-	-	432	-	1,880,928	11/11	(100)%	1,880,928	12,848,544	-	12	12
<b>OCs Provided</b>	<b>1,654</b>	<b>2,438</b>	<b>22,594</b>	<b>2,592</b>	<b>14,895</b>		<b>52%</b>	<b>14,895</b>	<b>44,921</b>	-	<b>685</b>	<b>685</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI OCs Provided	340	523	4,876	2,592	5,226		(7)%	5,226	12,864	-	148	148
Non-PSI OCs Provided	1,314	1,915	17,718	-	9,669		83%	9,669	32,057	-	537	537
Referral to Implant 3 Insertion	-	-	-	8,500	-		0%	-	157	-	-	-
Referral to Implant 3 Insertion	-	-	-	8,500	-	12/12	-%	-	157	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-		0%	-	231	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-	12/12	-%	-	231	-	-	-
Water Treatment Tablets	408,000	421,920	6,104,660	6,700,000	18,015,300		(66)%	18,015,300	45,539,960	-	486	486
Aquatab Tubs 8.68g	-	20	1,560	-	444,000	3/16	(100)%	444,000	445,560	-	15	15
WaterGuard Tablet ENF	408,000	421,900	6,103,100	6,700,000	17,571,300	7/12	(65)%	17,571,300	45,094,400	-	471	471
<b>Uganda</b>										141,951	1,235,144	1,377,094
Basic Care Package	-	-	400	-	52,637,120		(100)%	52,637,120	172,110,122	-	-	-
PLP Condom Resupply	-	-	-	-	22,375,504	10/11	(100)%	22,375,504	92,567,418	-	-	-
PLP Female Condom	-	-	-	-	133,580	2/12	(100)%	133,580	2,188,513	-	-	-
PLP Kit - FB (with WaterGuard Tab)	-	-	-	-	11,132	11/11	(100)%	11,132	60,803	-	-	-
PLP Kit - NFB (with Female Condor	-	-	-	-	4,371	5/12	(100)%	4,371	9,411	-	-	-
PLP Kit - NFB (with WaterGuard Tat	-	-	-	-	78,698	11/11	(100)%	78,698	588,754	-	-	-
PLP LLIN Resupply	-	-	-	-	18,235	10/11	(100)%	18,235	55,623	-	-	-
PLP Waterguard Tablet (67mg) Res	-	-	400	-	30,015,600	10/11	(100)%	30,015,600	76,639,600	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	173	-	-		0%	-	173	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	173	-	-		-%	-	173	-	-	-
Cervical Cancer-VIA and Cryotherapy	43	54	555	1,924	628		(12)%	628	2,286	-	205	205
Cervical Cancer-VIA and Cryotherap	43	54	555	1,924	628	11/13	(12)%	628	2,286	-	205	205
Cervical Cancer-VIA/VILI Screening	6,557	5,492	48,047	-	54,925		(13)%	54,925	158,076	-	-	-
Cervical Cancer-VIA/VILI Screening	6,557	5,492	48,047	-	54,925		(13)%	54,925	158,076	-	-	-
Chlorhexidine	507	595	6,361	40,000	6,682		(5)%	6,682	13,043	-	397	397

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Chlorhexidine Gel, 5 g tube	507	595	6,361	40,000	6,682	11/16	(5)%	6,682	13,043	-	397	397
Clean Delivery Kit	704	1,792	21,196	-	34,562		(39)%	34,562	433,662	-	1,425	1,425
Maama Kit	51	165	2,627	-	2,356	11/01	12%	2,356	255,346	-	177	177
Maama Kit Extra Clean Delivery	653	1,628	18,569	-	32,206	8/10	(42)%	32,206	178,316	-	1,248	1,248
Condom	145,152	81,528	805,824	2,592,000	1,263,372		(36)%	1,263,372	46,730,990	10,462	2,016	12,478
Trust	22,104	18,552	126,288	2,592,000	417,228	6/06	(70)%	417,228	44,938,478	1,640	316	1,956
Trust Ribbed	43,776	23,784	248,256	-	227,736	11/15	9%	227,736	571,104	3,223	621	3,844
Trust Scented	28,944	14,496	162,000	-	359,280	11/15	(55)%	359,280	606,816	2,103	405	2,509
Trust Studded	50,328	24,696	269,280	-	259,128	11/15	4%	259,128	614,592	3,496	674	4,170
Diarrhea Treatment Kit	-	-	-	8,427	8,579		(100)%	8,579	12,509	-	-	-
A2L Diarrhea Pack	-	-	-	8,427	8,579	7/15	(100)%	8,579	12,509	-	-	-
Emergency Contraception	20	167	14,834	15,000	166		8836%	166	15,000	-	140	140
ECP	20	167	14,834	15,000	166	6/16	8,836%	166	15,000	-	140	140
Expanded Clean Delivery Kit	11,840	-	11,840	25,000	-		0%	-	11,840	-	1,617	1,617
Mama Kit Expanded(Chlorhexidine	11,840	-	11,840	25,000	-		-%	-	11,840	-	1,617	1,617
Expanded Clean Delivery Kit (+CHX)	171	149	617	14,000	-		0%	-	617	-	78	78
Mama Kit with Chlorhexidine	171	149	617	14,000	-	11/17	-%	-	617	-	78	78
Family Planning Counseling	-	-	-	-	15,882		(100)%	15,882	15,882	-	-	-
Family Planning Counseling	-	-	-	-	15,882		(100)%	15,882	15,882	-	-	-
Free Condom	1,575,816	78,087	9,923,826	9,388,000	1,315,910		654%	1,315,910	66,668,779	128,840	24,830	153,671
Generic	1,575,816	78,087	9,923,826	9,388,000	1,315,910	1/99	654%	1,315,910	66,668,779	128,840	24,830	153,671
Free Female Condom	64,925	3,358	204,000	70,000	1,000		20300%	1,000	2,204,635	2,649	393	3,041
Female Condom Free	64,925	3,358	204,000	70,000	1,000	11/09	20,300%	1,000	2,204,635	2,649	393	3,041
Implant 3	(1,440)	(1,032)	22,434	-	15,528		44%	15,528	110,952	-	37,036	37,036
PSI Implant 3 Distributed Inserted ('	(2,064)	(1,725)	(22,939)	(10,368)	(23,353)		-%	(23,353)	(80,750)	-	(37,870)	(37,870)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implanon	624	693	45,373	10,368	38,881	12/08	17%	38,881	191,702	-	74,906	74,906
Implant 3 Insertion	9,771	12,795	126,922	20,888	60,666		109%	60,666	264,535	-	232,817	232,817
PSI Implant 3 Inserted	2,064	1,725	22,939	10,368	23,353		(2)%	23,353	80,750	-	42,078	42,078
Non-PSI Implant 3 Inserted	7,707	11,070	103,983	10,520	37,313		179%	37,313	183,785	-	190,739	190,739
Implant 5	975	(889)	21,761	-	30,293		(28)%	30,293	100,521	-	52,782	52,782
PSI Implant 5 Distributed Inserted (1)	(1,425)	(1,112)	(13,039)	(10,368)	(9,209)		-%	(9,209)	(80,038)	-	(31,627)	(31,627)
Jadelle	2,400	223	34,800	10,368	39,502	12/08	(12)%	39,502	180,559	-	84,409	84,409
Implant 5 Insertion	1,436	1,140	13,291	10,368	9,486		40%	9,486	108,861	-	35,820	35,820
PSI Implant 5 Inserted	1,425	1,112	13,039	10,368	9,209		42%	9,209	80,038	-	35,141	35,141
Non-PSI Implant 5 Inserted	11	27	252	-	277		(9)%	277	28,823	-	679	679
Injectable 3	10,150	6,825	51,295	-	96,353		(47)%	96,353	259,623	-	6,047	6,047
Depo-Provera	10,150	6,825	51,295	-	96,353	11/11	(47)%	96,353	259,623	-	6,047	6,047
IPTp2	-	-	343	-	15,411		(98)%	15,411	44,748	-	16	16
IPTp2	-	-	343	-	15,411	1/13	(98)%	15,411	44,748	-	16	16
IUD 10	11,214	1,144	46,216	8,917	45,899		1%	45,899	207,599	-	138,378	138,378
PSI IUD 10 Distributed Inserted (1)	(5,185)	(4,306)	(49,604)	(53,083)	(36,427)		-%	(36,427)	(219,353)	-	(148,523)	(148,523)
Copper T 380	11,250	1,533	57,104	62,000	44,580	12/08	28%	44,580	189,501	-	170,979	170,979
IUD PACK CU T380A	5,149	3,917	38,716	-	37,746	4/11	3%	37,746	237,451	-	115,922	115,922
IUD 10 Insertion	7,784	11,574	115,606	128,508	51,192		126%	51,192	402,765	-	384,604	384,604
PSI IUD 10 Inserted	5,185	4,306	49,604	53,083	36,427		36%	36,427	219,353	-	165,025	165,025
Non-PSI IUD 10 Inserted	2,599	7,267	66,002	75,425	14,765		347%	14,765	183,413	-	219,579	219,579
IUD 5	(18)	(24)	(243)	-	484		(150)%	484	(3,936)	-	(542)	(542)
PSI IUD 5 Distributed Inserted (1)	(18)	(24)	(483)	-	(626)		-%	(626)	(17,213)	-	(1,077)	(1,077)
Multiload CU T375	-	-	240	-	1,110	8/10	(78)%	1,110	13,277	-	535	535
IUD 5 Insertion	18	24	485	-	683		(29)%	683	28,220	-	1,202	1,202

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 5 Inserted	18	24	483	-	626		(23)%	626	17,213	-	1,197	1,197
Non-PSI IUD 5 Inserted	-	-	2	-	57		(96)%	57	11,006	-	5	5
LLIN	-	-	-	578,943	634,191		(100)%	634,191	8,782,018	-	-	-
LLIN - Global Fund (SI)	-	-	-	578,943	634,191	12/10	(100)%	634,191	8,782,018	-	-	-
Malaria PPT (ACT)	-	3,590	14,069	14,272	26,209		(46)%	26,209	110,060	-	3,096	3,096
5 & A Malaria Pack-Child	-	-	-	-	4,995	4/11	(100)%	4,995	33,668	-	-	-
5 & A Malaria Pack-Infant	-	-	-	-	4,999	5/11	(100)%	4,999	33,863	-	-	-
ACT, Lumartem (12 Tabs)	-	3,590	14,069	14,272	15,771	7/15	(11)%	15,771	33,439	-	3,096	3,096
ACT, Lumartem (6 Tabs)	-	-	-	-	444	7/15	(100)%	444	9,090	-	-	-
Manual Vacuum Aspiration for PAC	24	52	682	220	1,234		(45)%	1,234	1,916	-	189	189
MVA for PAC	24	52	682	220	1,234	3/16	(45)%	1,234	1,916	-	189	189
Medical Abortion	7,648	1,112	11,011	25,000	-		0%	-	11,011	-	3,368	3,368
PSI Medical Abortion Distributed Pr	(40)	(110)	(621)	-	-		-%	-	(621)	-	(190)	(190)
Divabo - Combipack (1+4's)	7,688	1,221	11,632	-	-	5/17	-%	-	11,632	-	3,558	3,558
Miso - Mifeprestone pack	-	-	-	25,000	-		-%	-	-	-	-	-
Medical Abortion Provided	40	110	621	-	-		0%	-	621	-	211	211
PSI Medical Abortion Provided	40	110	621	-	-		-%	-	621	-	211	211
Misoprostol for PAC (Oral)	(90)	(289)	(3,279)	-	(129)		0%	(129)	(3,408)	-	(273)	(273)
PSI Misoprostol for PAC Oral Dist F	(90)	(289)	(3,279)	-	(129)		-%	(129)	(3,408)	-	(273)	(273)
Misoprostol for PAC (oral) Provided	90	289	3,333	-	129		2484%	129	3,462	-	308	308
PSI Misoprostol for PAC (oral) Prov	90	289	3,279	-	129		2,442%	129	3,408	-	303	303
Non-PSI Misoprostol for PAC (oral) I	-	-	54	-	-		-%	-	54	-	5	5
Misoprostol for PAC (Sublingual)	2,434,300	-	2,434,300	2,480,000	-		0%	-	2,434,300	-	303,760	303,760
Misoprostol for PAC (Sublingual)	2,434,300	-	2,434,300	2,480,000	-	12/17	-%	-	2,434,300	-	303,760	303,760
Misoprostol for PPH	(2,434,300)	192,300	35,600	-	1,616,650		(98)%	1,616,650	4,217,031	-	123	123

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol Tablet	<b>(2,434,300)</b>	<b>192,300</b>	<b>35,600</b>	-	<b>1,616,650</b>	7/09	(98)%	<b>1,616,650</b>	<b>4,217,031</b>	-	<b>123</b>	<b>123</b>
OCs	<b>14,850</b>	<b>8,320</b>	<b>93,189</b>	-	<b>43,788</b>		<b>113%</b>	<b>43,788</b>	<b>423,384</b>	-	<b>2,975</b>	<b>2,975</b>
Family Planning Pills	<b>14,850</b>	<b>8,320</b>	<b>85,755</b>	-	<b>32,118</b>	11/11	167%	<b>32,118</b>	<b>392,661</b>	-	<b>2,737</b>	<b>2,737</b>
Microlut - Oral Contraceptive	-	-	<b>7,434</b>	-	<b>11,670</b>	6/14	(36)%	<b>11,670</b>	<b>30,723</b>	-	<b>237</b>	<b>237</b>
ORS	-	-	<b>18,000</b>	<b>18,000</b>	-		<b>0%</b>	-	<b>93,181</b>	-	<b>330</b>	<b>330</b>
ORS	-	-	<b>18,000</b>	<b>18,000</b>	-	12/10	-%	-	<b>93,181</b>	-	<b>330</b>	<b>330</b>
Pneumonia PPT	-	-	-	<b>5,000</b>	<b>3,643</b>		<b>(100)%</b>	<b>3,643</b>	<b>27,011</b>	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	<b>2,500</b>	-	6/11	-%	-	<b>11,299</b>	-	-	-
5 & A Pneumonia Pack-Infant	-	-	-	<b>2,500</b>	-	6/11	-%	-	<b>7,332</b>	-	-	-
A2L Pneumonia Pack, Child	-	-	-	-	<b>2,142</b>	7/15	(100)%	<b>2,142</b>	<b>5,993</b>	-	-	-
A2L Pneumonia Pack, Infant	-	-	-	-	<b>1,501</b>	8/15	(100)%	<b>1,501</b>	<b>2,387</b>	-	-	-
PUR	<b>419,300</b>	<b>1,117,378</b>	<b>5,594,104</b>	<b>4,000,000</b>	<b>3,675,898</b>		<b>52%</b>	<b>3,675,898</b>	<b>40,559,940</b>	-	<b>291</b>	<b>291</b>
PuR	<b>419,300</b>	<b>1,117,378</b>	<b>5,594,104</b>	<b>4,000,000</b>	<b>3,675,898</b>	10/04	52%	<b>3,675,898</b>	<b>40,559,940</b>	-	<b>291</b>	<b>291</b>
Skilled Birth Attendance	-	-	-	-	<b>16,291</b>		<b>(100)%</b>	<b>16,291</b>	<b>50,567</b>	-	-	-
Skilled Birth Attendance	-	-	-	-	<b>16,291</b>	1/13	(100)%	<b>16,291</b>	<b>50,567</b>	-	-	-
Tubal Ligation	-	<b>3</b>	<b>32</b>	-	<b>23</b>		<b>39%</b>	<b>23</b>	<b>113</b>	-	<b>203</b>	<b>203</b>
Tubal Ligation	-	<b>3</b>	<b>32</b>	-	<b>23</b>		39%	<b>23</b>	<b>113</b>	-	<b>203</b>	<b>203</b>
Vasectomy	-	-	<b>3</b>	-	<b>2</b>		<b>50%</b>	<b>2</b>	<b>6</b>	-	<b>19</b>	<b>19</b>
Vasectomy	-	-	<b>3</b>	-	<b>2</b>		50%	<b>2</b>	<b>6</b>	-	<b>19</b>	<b>19</b>
Water Treatment Tablets	<b>15,680</b>	<b>90,747</b>	<b>12,263,520</b>	<b>12,278,719</b>	<b>25,155,760</b>		<b>(51)%</b>	<b>25,155,760</b>	<b>93,725,041</b>	-	<b>1,278</b>	<b>1,278</b>
WaterGuard Tablets	<b>15,680</b>	<b>90,747</b>	<b>12,263,520</b>	<b>12,278,719</b>	<b>25,155,760</b>	12/06	(51)%	<b>25,155,760</b>	<b>93,725,041</b>	-	<b>1,278</b>	<b>1,278</b>
Zinc	-	-	<b>330</b>	<b>5,790</b>	-		<b>0%</b>	-	<b>29,235</b>	-	<b>2</b>	<b>2</b>
Zinc 20 mg	-	-	<b>330</b>	<b>5,790</b>	-	12/10	-%	-	<b>29,235</b>	-	<b>2</b>	<b>2</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>East Africa</b>														
<b>Burundi</b>							\$990		\$53	\$9,481	0.01			
<b>Condom</b>														
Prudence Class	12/2017	15,750	0	0	15,750	0%	\$282	0%	\$0	\$8,683	NA	900	499,680	0.00
<b>Free Female Condom</b>														
Free Female Condoms	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	11,000	3,000	3.67
<b>LLIN</b>														
MILDA - DAWA PLUS 2.0	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	902,963	5,400	167.22
<b>Misoprostol for PAC (Oral)</b>														
Misoprostol for PAC (oral)	12/2017	0	12	12	24	100%	\$0	NA	\$0	\$32	NA	116	74	1.57
<b>Misoprostol for PAC (Sublingual)</b>														
Misoprostol for PAC (Sublingual)	12/2017	0	8	8	16	100%	\$0	NA	\$0	\$22	NA	124	49	2.51
<b>Emergency Contraception</b>														
Nowill	12/2017	75	3	0	78	4%	\$69	12%	\$9	\$93	0.09	12,231	102	119.52
<b>Implant 5</b>														
Jadelle	12/2017	58	7	0	65	11%	\$69	0%	\$0	\$143	NA	775	137	5.64
<b>Injectable 3</b>														
DMPA 3-month Injectable	12/2017	1,105	7	0	1,112	1%	\$427	8%	\$34	\$325	0.11	14,875	1,598	9.31
<b>IUD 10</b>														
Copper-T 380-A IUD	12/2017	17	7	0	24	29%	\$20	0%	\$0	\$62	NA	4,586	62	73.97
<b>OCs</b>														
Confiance OC	12/2017	960	21	0	981	2%	\$124	8%	\$10	\$120	0.09	32,562	1,056	30.84
<b>Ethiopia</b>							\$69,726		\$1,011,215	\$64,692	15.63			
<b>HIV Test Kit</b>														
Diagnostic kit for HIV(1+2) Antibod	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,350	0	NA
First Response, HIV-1/2	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,410	0	NA
<b>Medicines &amp; Supplies</b>														
Isoniazid 300mg Tablet	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,016	0	NA
Lamivudine150mg+Nevirapine200	12/2017	0	30	0	30	100%	\$0	NA	\$0	\$0	NA	1,890	170	11.12
<b>Water Vessel</b>														
Water Vessel for PCP Kit	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	197	0	NA
<b>Free Condom</b>														
Blue Denim	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	426	0	NA
Protector Plus	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	14,031,981	4,133,074	3.40

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Ethiopia</b>							\$69,726		\$1,011,215	\$64,692	15.63				
<b>Free Female Condom</b>															
Free Female Condoms	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	346,803	29,776	11.65	
<b>STI Kit (Non-Ulcerative)</b>															
STI Kit for Urethral Discharge	12/2017	0	760	0	760	100%	\$0	NA	\$0	\$0	NA	2,863	600	4.77	
STI Kit for Vaginal Discharge	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,083	0	NA	
<b>STI Kit (Ulcerative)</b>															
STI Kit for Genital Ulcer	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	265	3	79.50	
<b>LLIN</b>															
PermaNet NGO Bag-Light Blue	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15	0	NA	
<b>PUR</b>															
P&G Purifier of Water	12/2017	661,700	661,700	0	1,323,400	50%	\$31,845	33%	\$746,524	\$41,737	17.89	6,116,200	959,571	6.37	
<b>Safe Water Solution</b>															
Wuha Agar	12/2017	195,795	0	0	195,795	0%	\$37,880	86%	\$264,691	\$22,954	11.53	-16,733	107,901	-0.16	
<b>OCs</b>															
Microgynon	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6	0	NA	
<b>Kenya</b>							\$302,105		\$302,105	\$457,034	0.66				
<b>Condom</b>															
Trust	12/2017	1,680,480	0	0	1,680,480	0%	\$78,349	100%	\$78,349	\$104,690	0.75	1,417,277	2,533,824	0.56	
Trust Ribbed	12/2017	207,360	0	0	207,360	0%	\$5,791	100%	\$5,791	\$6,350	0.91	368,515	116,641	3.16	
Trust Scented	12/2017	34,776	0	0	34,776	0%	\$3,503	100%	\$3,503	\$4,755	0.74	934,977	50,184	18.63	
Trust Studded	12/2017	336,744	0	-35,472	301,272	0%	\$32,851	100%	\$32,851	\$32,979	1.00	6,412,950	389,280	16.47	
<b>Free Condom</b>															
Free Male Condom - NASCOP	12/2017	4,766,400	0	0	4,766,400	0%	\$0	NA	\$0	\$0	NA	1,676,800	2,954,400	0.57	
<b>LLIN</b>															
Supanet Conical	12/2017	506	0	0	506	0%	\$2,709	100%	\$2,709	\$2,411	1.12	92,835	453	204.78	
Supanet Rectangular	12/2017	501	0	0	501	0%	\$2,669	100%	\$2,669	\$1,964	1.36	40,937	370	110.64	
Supanet XtraPower BL PNET USAI	12/2017	309,400	0	0	309,400	0%	\$0	NA	\$0	\$0	NA	156,406	278,980	0.56	
<b>Olyset</b>															
Supanet Xtra Power (Olyset)-Conic	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	173,118	0	NA	
<b>PUR</b>															
PuR	12/2017	1,480,320	0	-24	1,480,296	0%	\$65,259	100%	\$65,259	\$186,557	0.35	12,420,785	4,251,760	2.92	
<b>Safe Water Solution</b>															
WaterGuard	12/2017	207,822	0	-15,246	192,576	0%	\$30,685	100%	\$30,685	\$26,782	1.15	193,479	191,114	1.01	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Kenya</b>							\$302,105		\$302,105	\$457,034	0.66				
<b>Water Treatment Tablets</b>															
Aquatab	12/2017	2,160	0	-14,426	-12,266	0%	\$43	100%	\$43	\$457	0.09	155,690	28,080	5.54	
<b>Implant 3</b>															
Implanon	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	231,177	0	NA	
<b>Implant 5</b>															
Jadelle	12/2017	6,930	0	-73,062	-66,132	0%	\$473	100%	\$473	\$171	2.77	67,092	2,390	28.07	
<b>Injectable 3</b>															
Femiplan Injectable	12/2017	61,776	0	0	61,776	0%	\$473	100%	\$473	\$158	3.00	86,281	-23,158	-3.73	
<b>IUD 10</b>															
CU 380A (Copper T)	12/2017	5,699	0	0	5,699	0%	\$229	100%	\$229	\$80	2.85	12,334	1,948	6.33	
<b>OCs</b>															
Femi Girl Oral Pills	12/2017	1,080	0	0	1,080	0%	\$1,241	100%	\$1,241	\$690	1.80	162,792	600	271.32	
Femiplan Pill	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$247	NA	151,332	576	262.73	
Femiplan Pill-1 cycle	12/2017	151,200	0	0	151,200	0%	\$56,932	100%	\$56,932	\$65,043	0.88	903,789	172,010	5.25	
Femiplan Pill-3 cycles	12/2017	60,480	0	0	60,480	0%	\$20,899	100%	\$20,899	\$23,701	0.88	141,999	68,400	2.08	
<b>Malawi</b>							\$111,793		\$148,582	\$87,159	1.70				
<b>Condom</b>															
Chishango	12/2017	625,320	78,760	0	704,080	11%	\$7,748	12%	\$9,903	\$13,779	0.72	3,451,280	1,192,960	2.89	
<b>Female Condom</b>															
Care	12/2017	840	0	0	840	0%	\$23	0%	\$0	\$84	NA	13,960	3,167	4.41	
Whisper Female Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,597	0	NA	
<b>Free Condom</b>															
Blue Gold Condoms	12/2017	0	144,000	0	144,000	100%	\$0	NA	\$0	\$0	NA	590,724	251,333	2.35	
Free Male Condoms	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	13,243	0	NA	
Key Population Male Condom	12/2017	0	153,888	0	153,888	100%	\$0	NA	\$0	\$0	NA	459,739	709,390	0.65	
One Community Male Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	735,157	0	NA	
<b>Free Female Condom</b>															
Free Female Condoms	12/2017	0	5,400	0	5,400	100%	\$0	NA	\$0	\$0	NA	87,221	10,747	8.12	
Key Population Female Condom	12/2017	0	16,662	0	16,662	100%	\$0	NA	\$0	NA	NA	33,341	NA	NA	
<b>HIV Self-Testing Kit</b>															
ORAQUICK HIV Self-Testing Kit (P	12/2017	0	25,291	5	25,296	100%	\$0	NA	\$0	\$0	NA	13,493	29,666	0.45	
<b>Lubricant A</b>															
Personal Lubricant Water 4.5 g	12/2017	0	15,600	0	15,600	100%	\$0	NA	\$0	\$0	NA	2,303,558	71,261	32.33	



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Malawi</b>							\$111,793		\$148,582	\$87,159	1.70				
<u>LLIN</u>															
Super Chitetezo Net	12/2017	806	0	0	806	0%	\$4,680	58%	\$37,129	\$23,607	1.57	102,718	3,995	25.71	
<u>PUR</u>															
PuR WaterGuard Waufa	12/2017	1,500,000	0	0	1,500,000	0%	\$91,068	100%	\$91,127	\$40,342	2.26	1,240,337	700,000	1.77	
<u>Safe Water Solution</u>															
WaterGuard	12/2017	11,632	0	0	11,632	0%	\$5,216	86%	\$5,991	\$5,048	1.19	8,232	11,275	0.73	
<u>Emergency Contraception</u>															
NORLEVO (Norlevo 1.5mg)	12/2017	0	0	0	0	NA	\$0	NA	\$1,052	\$8	139.01	35,183	717	49.05	
<u>Implant 3</u>															
Implanon	12/2017	10	72	0	82	88%	\$7	0%	\$0	\$14	NA	12,449	524	23.77	
<u>Implant 5</u>															
Jadelle	12/2017	30	140	0	170	82%	\$21	0%	\$0	\$25	NA	18,830	4,149	4.54	
<u>Injectable 3</u>															
SafePlan Inj3	12/2017	200	225	0	425	53%	\$110	0%	\$414	\$994	0.42	117,430	23,742	4.95	
<u>IUD 10</u>															
IUD Copper T 380A	12/2017	50	40	0	90	44%	\$69	0%	\$0	\$30	NA	29,191	291	100.31	
<u>OCs</u>															
Microgynon	12/2017	8,050	9,697	0	17,747	55%	\$2,849	48%	\$2,967	\$3,229	0.92	115,586	40,509	2.85	
Microlut	12/2017	0	6	0	6	100%	\$0	NA	\$0	\$0	NA	40,203	3,423	11.74	
<b>SFH Rwanda</b>							\$36,190		\$4,172	\$22,594	0.18				
<u>Condom</u>															
Plaisir	12/2017	421,920	4,320	0	426,240	1%	\$22,224	19%	\$4,172	\$7,442	0.56	3,601,200	145,515	24.75	
Prudence Plus	12/2017	706,968	21,000	0	727,968	3%	\$11,116	0%	\$0	\$11,572	NA	4,622,200	744,136	6.21	
<u>Free Condom</u>															
Military Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	30,248	1,900	15.92	
<u>PUR</u>															
PuR	12/2017	7,440	405,360	0	412,800	98%	\$418	0%	\$0	\$198	NA	1,286,421	146,240	8.80	
<u>Safe Water Solution</u>															
Sur Eau	12/2017	6,096	0	0	6,096	0%	\$1,927	0%	\$0	\$2,617	NA	166,766	8,192	20.36	
<u>Injectable 3</u>															
Confiance Depo-Provera	12/2017	480	0	0	480	0%	\$84	0%	\$0	\$312	NA	68,608	1,767	38.83	
<u>OCs</u>															
Microgynon	12/2017	7,200	150	0	7,350	2%	\$421	0%	\$0	\$453	NA	190,008	7,750	24.52	
<u>SDM (Cycle Beads)</u>															
Collier	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Somaliland</b>							\$4,440		\$0	\$5,199	NA				
<b>Diarrhea Treatment Kit</b>															
SD OFLV-DTK	12/2017	14,810	0	0	14,810	0%	\$1,357	0%	\$0	\$1,825	NA	2,608	19,873	0.13	
<b>Misoprostol for PPH</b>															
Ummul-gargaar	12/2017	2,500	0	3,600	6,100	0%	\$119	0%	\$0	\$91	NA	7,800	1,900	4.11	
<b>ORS</b>															
SD OFLV-ORS	12/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	91,500	0	NA	
<b>Water Treatment Tablets</b>															
Aquatab	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,602	0	NA	
Biyosifeeye	12/2017	420,000	0	0	420,000	0%	\$2,315	0%	\$0	\$2,496	NA	923,760	452,000	2.04	
<b>Zinc</b>															
Shuban Daweeye_Zinc	12/2017	0	0	15,000	15,000	NA	\$0	NA	\$0	\$0	NA	59,839	0	NA	
<b>Implant 3</b>															
Nasiye Implant (Implanon)	12/2017	0	0	1,430	1,430	NA	\$0	NA	\$0	\$262	NA	0	42	NA	
<b>Injectable 3</b>															
Nasiye - Inj 3	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$64	NA	4,687	117	40.17	
<b>OCs</b>															
Nasiye - OC	12/2017	2,205	0	0	2,205	0%	\$649	0%	\$0	\$461	NA	9	1,560	0.01	
<b>Pneumonia PPT</b>															
Pneomox 125mg tablet (Amoxicillin)	12/2017	0	250	0	250	100%	\$0	NA	\$0	\$0	NA	3,809	83	45.71	
Pneomox 250mg tablet (Amoxicillin)	12/2017	0	1,000	0	1,000	100%	\$0	NA	\$0	\$0	NA	15,237	333	45.71	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<b>Medicines &amp; Supplies</b>															
Artesunate 60 mg vial	12/2017	0	2,000	0	2,000	100%	\$0	NA	\$0	\$0	NA	190,265	10,938	17.39	
Falcistat Tablet (SP 500/25 mg)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,000	0	NA	
<b>LLIN</b>															
Mass LLIN - WES-Green Rectangu	12/2017	0	571,814	0	571,814	100%	\$0	NA	\$0	\$0	NA	1,717,822	467,592	3.67	
<b>Malaria PPT (ACT)</b>															
ACTs for Adult (14+ years)	12/2017	0	8,660	0	8,660	100%	\$0	NA	\$0	\$0	NA	90,340	10,220	8.84	
ACTs for Child (6-14 years)	12/2017	0	8,080	0	8,080	100%	\$0	NA	\$0	\$0	NA	109,320	8,093	13.51	
ACTs for Infant (2-12 months)	12/2017	0	2,960	0	2,960	100%	\$0	NA	\$0	\$0	NA	1,840	3,964	0.46	
ACTs for Toddler (1-5 years)	12/2017	0	1,469	0	1,469	100%	\$0	NA	\$0	\$0	NA	507	7,158	0.07	
<b>Malaria RDK</b>															
Malaria Rapid Diagnostic Kit	12/2017	0	20,000	0	20,000	100%	\$0	NA	\$0	\$0	NA	68,273	43,425	1.57	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<b>ORS</b>															
ORS	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	96,984	217,733	0.45	
<b>Zinc</b>															
Zinc	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	30,710	44,867	0.68	
<b>Pneumonia PPT</b>															
Amoxicillin for Children (1-5 years)	12/2017	0	608	0	608	100%	\$0	NA	\$0	\$0	NA	26,648	19,106	1.39	
Amoxicillin for Infant (2-12 months)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5,200	17,988	0.29	
<b>Tanzania</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Salama Halisi	12/2017	43,200	26,352	0	69,552	38%	\$0	NA	\$0	NA	NA	10,753,344	NA	NA	
Salama Scented	12/2017	0	432	432	864	100%	\$0	NA	\$0	NA	NA	6,495,120	NA	NA	
Salama Studded	12/2017	86,400	0	0	86,400	0%	\$0	NA	\$0	NA	NA	1,534,464	NA	NA	
<b>LLIN</b>															
Permanet (180x160x180 CM) SI	12/2017	0	3,510,182	-3,510,182	0	100%	\$0	NA	\$0	NA	NA	432,366	NA	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	155,344	102,256	0	257,600	40%	\$0	NA	\$0	NA	NA	1,652	NA	NA	
<b>Misoprostol for PPH</b>															
Misoprostol for PPH	12/2017	0	78,560	0	78,560	100%	\$0	NA	\$0	NA	NA	0	NA	NA	
<b>Water Treatment Tablets</b>															
Aquatab Tubs 8.68g	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	960	NA	NA	
WaterGuard Tablet ENF	12/2017	408,000	0	0	408,000	0%	\$0	NA	\$0	NA	NA	2,354,400	NA	NA	
<b>Emergency Contraception</b>															
Emergency Contraception	12/2017	0	3,000	0	3,000	100%	\$0	NA	\$0	NA	NA	0	NA	NA	
<b>Implant 5</b>															
Jadelle	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	260	NA	NA	
<b>IUD 10</b>															
Familia IUD Kit	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	17,227	NA	NA	
Pregna IUD (no safe load)	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	1,313	NA	NA	
<b>OCs</b>															
Familia [OC]	12/2017	712,800	0	0	712,800	0%	\$0	NA	\$0	NA	NA	287,559	NA	NA	



# Southern Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Southern Africa	145,071	16	-	3	2,782,990	1,212	562,866	18,061	514	1,777	-	21,299
Angola	402	-	-	-	55,083	35	12,539	10,385	52	-	-	11,334
Botswana	552	-	-	-	13,091	2	1,875	-	-	-	-	-
Lesotho	7,569	-	-	2	67,822	35	10,194	-	-	-	-	2
Madagascar	1,251	5	-	-	913,704	494	216,733	7,375	248	1,777	-	9,435
Mozambique	8,173	-	-	-	395,534	280	96,839	301	148	-	-	449
Namibia	83	-	-	-	2,030	1	291	-	-	-	-	-
South Africa	69,278	-	-	-	864,215	125	123,656	-	-	-	-	-
Swaziland	18,154	5	-	-	138,106	57	19,815	-	-	-	-	5
Zambia	17,972	-	-	-	133,758	61	42,893	-	53	-	-	53
Zimbabwe	21,635	7	-	1	199,645	122	38,031	-	13	-	-	21

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>									<b>6,572,076</b>	<b>2,510,356</b>	<b>9,082,432</b>
Antiretroviral Treatment (C)	8,981	9,593	103,911	76,596	5,010	1,974%	5,010	108,921	18,461	-	18,461
Antiretroviral Treatment (I)	284	624	9,493	-	5,283	80%	5,283	14,776	-	-	-
CD4 Tests Provided to HIV	312	558	13,087	-	778	1,582%	778	13,865	-	-	-
Cervical Cancer-HPV DNA	-	-	11	-	-	-%	-	11	-	3	3
Cervical Cancer-HPV DNA	-	-	9	-	-	-%	-	9	-	2	2
Cervical Cancer-Pap and I	-	-	1	-	1	-%	1	2	-	-	-
Cervical Cancer-Pap and I	-	-	-	-	7	(100)%	7	9	-	-	-
Cervical Cancer-Pap Sme:	-	-	2	-	116	(98)%	116	118	-	-	-
Cervical Cancer-VIA and C	1	7	168	185	10	1,580%	10	178	-	48	48
Cervical Cancer-VIA and C	33	49	601	278	1,194	(50)%	1,194	3,672	-	169	169
Cervical Cancer-VIA and F	-	4	38	-	17	124%	17	286	-	5	5
Cervical Cancer-VIA and F	-	-	69	200	402	(83)%	402	1,936	-	10	10
Cervical Cancer-VIA and F	-	-	16	-	33	(52)%	33	449	-	2	2
Cervical Cancer-VIA/VILI §	1,023	1,499	17,369	-	26,740	(35)%	26,740	68,850	-	-	-
Chlorhexidine	271	1,208	24,705	53,741	241,094	(90)%	241,094	325,724	-	1,509	1,509
Condom	9,287,634	9,733,847	91,270,147	99,975,773	100,683,376	(9)%	100,683,376	1,390,391,617	1,765,421	145,518	1,910,939
Condom Provided	-	-	-	-	842,352	(100)%	842,352	1,075,691	-	-	-
Diarrhea Treatment Kit	18,551	7,096	251,650	318,195	479,996	(48)%	479,996	2,095,650	-	6,353	6,353
Diarrhea Treatment Kit Pri	299	404	5,596	-	4,866	15%	4,866	10,462	-	157	157
Early Infant Male Circumc	-	-	-	-	5	(100)%	5	5	-	-	-
Emergency Contraception	(28)	64	57,634	181,900	208,155	(72)%	208,155	808,369	-	296	296

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Emergency Contraception	50	75	1,026	170	1,660	(38)%	1,660	3,077	-	8	8
Family Planning Counseli	-	-	-	-	223	(100)%	223	223	-	-	-
Female Condom	69,892	40,953	663,604	1,020,724	2,709,105	(76)%	2,709,105	33,862,915	16,234	774	17,008
Female Condom Provided	-	-	-	-	80,452	(100)%	80,452	99,712	-	-	-
Fever Cases Attended	8,982	3,986	318,116	-	24,338	1,207%	24,338	342,454	-	-	-
Fever Cases Tested with I	580	175	5,050	-	1,885	168%	1,885	6,935	-	-	-
Fever Cases Tested with F	7,337	3,276	294,643	-	20,935	1,307%	20,935	315,578	-	-	-
Free Condom	10,069,281	7,658,227	87,501,654	78,425,768	93,108,576	(6)%	93,108,576	1,330,776,828	1,938,017	104,696	2,042,713
Free Female Condom	106,880	59,837	574,761	1,000,289	626,979	(8)%	626,979	6,741,383	11,562	411	11,974
HIV Self-Testing Kit	6,317	17,944	185,550	-	95,000	95%	95,000	280,550	-	-	-
HIV Testing Services	199,991	100,729	1,443,294	1,299,724	950,683	52%	950,683	8,524,622	94,084	-	94,084
Hypertension Diagnosis	22	405	2,087	-	4	52,075%	4	2,091	-	-	-
Hypertension Screening	7,938	11,829	337,699	-	12,961	2,506%	12,961	350,660	-	-	-
Hypertension_Controlled	5	3	63	-	3	2,000%	3	66	-	-	-
Implant 3	(168)	(139)	(1,257)	6,814	(1,712)	-%	(1,712)	246	-	(1,254)	(1,254)
Implant 3 Insertion	776	1,283	11,910	1,151	11,806	1%	11,806	47,513	-	13,737	13,737
Implant 4	(1)	(1)	(8)	51	(83)	-%	(83)	7,548	-	(10)	(10)
Implant 4 Insertion	1	1	25	169	329	(92)%	329	2,654	-	35	35
Implant 5	467	(170)	(4,121)	527	(175)	-%	(175)	(34,910)	-	(7,984)	(7,984)
Implant 5 Insertion	3,259	5,390	47,109	62,375	32,406	45%	32,406	321,887	-	123,057	123,057
Injectable 1 Provided	27	99	1,095	100	135	711%	135	1,230	-	40	40
Injectable 2 Provided	888	1,654	10,962	538	686	1,498%	686	11,648	-	926	926

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Injectable 3	174,115	165,756	1,777,834	1,138,166	2,240,708	(21)%	2,240,708	19,930,685	-	125,274	125,274
Injectable 3 Provided	28,672	35,597	351,408	193,875	210,309	67%	210,309	696,641	-	42,063	42,063
IPTp2	53	9,468	44,986	172,356	158,455	(72)%	158,455	203,441	-	2,665	2,665
IRS (# of household)	-	-	-	721,863	-	-%	-	-	-	-	-
IUD 10	20,543	(498)	21,014	14,334	3,654	475%	3,654	122,319	-	71,165	71,165
IUD 10 Insertion	3,609	3,253	31,791	48,331	25,159	26%	25,159	292,236	-	85,662	85,662
IUD 5 Insertion	-	-	8	150	241	(97)%	241	249	-	20	20
IUS 5	(4)	161	954	-	-	-%	-	954	-	1,964	1,964
IUS 5 Insertion	68	62	366	500	-	-%	-	366	-	694	694
LLIN	557,810	324,827	6,266,352	4,334,567	2,787,629	125%	2,787,629	36,559,717	-	860,159	860,159
Lubricant	228,525	163,921	1,551,218	-	621,962	149%	621,962	5,059,408	-	-	-
Malaria PPT (ACT)	877,351	229,790	1,985,703	1,237,169	991,622	100%	991,622	7,701,224	-	596,992	596,992
Malaria RDK	150	4,075	2,065,676	1,873,659	1,133,756	82%	1,133,756	10,120,801	-	-	-
Male Circumcision (HIV-P)	-	-	-	-	3,239	(100)%	3,239	10,222	-	-	-
Manual Vacuum Aspiratio	193	252	2,223	55	1,457	53%	1,457	3,680	-	665	665
Micronutrient Powder	29,490	121,223	5,553,590	4,858,780	4,044,450	37%	4,044,450	14,658,560	-	-	-
Misoprostol for PAC (Oral	(957)	(1,078)	(8,193)	-	(6,537)	-%	(6,537)	(14,730)	-	(735)	(735)
Misoprostol for PAC (oral)	957	1,078	8,193	-	6,537	25%	6,537	14,730	-	817	817
Misoprostol for PAC (Subl	1,732	2,193	240,928	15,000	6,000	3,915%	6,000	246,928	-	48,571	48,571
OCs	233,055	286,046	3,473,450	2,721,504	2,583,428	34%	2,583,428	42,455,469	-	67,341	67,341
OCs Provided	28,773	38,407	431,442	379,864	573,214	(25)%	573,214	1,484,047	-	13,492	13,492
Pneumonia PPT	22,980	23,527	413,740	419,927	376,369	10%	376,369	1,245,638	-	151,835	151,835



POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Positive RDTs	911	468	102,632	-	2,177	4,614%	2,177	104,809	-	-	-
PrEP	50	264	2,713	19,960	403	573%	403	3,116	88	-	88
Referral to Advanced Cen	1	5	57	85	142	(60)%	142	400	-	-	-
Referral to CD4/Clinical St	-	-	-	9,198	8,610	(100)%	8,610	18,607	-	-	-
Referral to Clinical Stagin	-	-	-	-	2,879	(100)%	2,879	5,010	-	-	-
Referral to Diabetes Mana	-	-	1	-	-	-%	-	1	-	-	-
Referral to Early Infant Ma	-	-	-	-	36	(100)%	36	94	-	-	-
Referral to Emergency Co	-	-	1	-	6	(83)%	6	9	-	-	-
Referral to HIV Testing Se	1,491	4,334	24,157	7,200	7,911	205%	7,911	41,054	1,268	-	1,268
Referral to Hypertension I	22	19	536	50	27	1,885%	27	563	-	-	-
Referral to Implant 3 Inse	2	2	12	-	1	1,100%	1	13	-	7	7
Referral to Implant 5 Inse	1	4	18	20	-	-%	-	992	-	14	14
Referral to Injectable 1	8	60	332	100	32	938%	32	364	-	6	6
Referral to Injectable 2	-	18	55	200	-	-%	-	55	-	2	2
Referral to Injectable 3	81	183	927	370	45	1,960%	45	1,704	-	50	50
Referral to IUD 10 Insertio	2	2	40	-	7	471%	7	204	-	37	37
Referral to IUD 5 Insertion	-	-	-	30	-	-%	-	-	-	-	-
Referral to IUD Insertion (	-	-	5	-	2	150%	2	7	-	3	3
Referral to IUS 3 Insertion	-	-	26	-	-	-%	-	26	-	13	13
Referral to Linkage to HIV	1,071	1,289	17,034	15,609	2,624	549%	2,624	19,658	10,139	-	10,139
Referral to OCs	52	189	942	330	79	1,092%	79	1,868	-	14	14
Referral to Pre-Exposure I	-	36	230	-	-	-%	-	230	4	-	4

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to STI Screening	9	6	97	338	8	1,113%	8	105	-	-	-
Referral to STI Treatment	1	3	55	-	952	(94)%	952	4,535	-	-	-
Referral to TB Diagnosis	7	25	252	6,750	11	2,191%	11	3,883	-	-	-
Referral to TB DOTS (com	-	-	1	-	2	(50)%	2	17	-	1	1
Referral to TB DOTS (com	22	14	244	300	484	(50)%	484	2,697	-	135	135
Referral to TB Screening	163	2,139	15,631	-	434	3,502%	434	16,065	-	-	-
Referral to Treatment for (	4	3	46	-	4	1,050%	4	69	-	2	2
Referral to Treatment for (	-	-	3	5	3	-%	3	6	-	-	-
Referral to Treatment for l	-	-	4	-	8	(50)%	8	27	-	-	-
Referral to Treatment for l	1	1	4	-	32	(88)%	32	60	-	-	-
Referral to Treatment for \	-	-	-	5	7	(100)%	7	12	-	-	-
Referral to Tubal Ligation	-	-	1	-	-	-%	-	1	-	2	2
Referral to Tx for Nonherp	-	-	25	-	13	92%	13	47	-	4	4
Referral to Tx for Urethral	2	-	100	-	156	(36)%	156	499	-	9	9
Referral to Vasectomy	-	-	-	3	-	-%	-	-	-	-	-
Referral to Voluntary Medi	64	14	462	2,249	3,849	(88)%	3,849	20,506	2,004	-	2,004
Safe Water Solution	233,876	244,509	3,689,981	5,699,598	4,291,617	(14)%	4,291,617	69,589,011	-	21,140	21,140
SDM (Cycle Beads)	7,815	114	28,036	17,307	11,341	147%	11,341	149,090	-	23,495	23,495
SDM (Cycle Beads) Provic	22	66	1,789	-	2,176	(18)%	2,176	4,654	-	1,346	1,346
STI Kit (Non-Ulcerative)	-	-	-	241	749	(100)%	749	3,764	-	-	-
STI Kit (Ulcerative)	-	-	-	184	119	(100)%	119	464	-	-	-
STI Screening	5,266	7,169	82,694	-	47,096	76%	47,096	144,046	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB Diagnosis	27	35	459	-	336	37%	336	1,194	-	-	-
TB DOTS	4	1	24	-	11	118%	11	66	-	141	141
TB Screening	19,172	24,747	305,263	-	284,453	7%	284,453	838,067	-	-	-
Treatment for Cervicitis	2	4	270	120	20	1,250%	20	290	-	25	25
Treatment for Genital Herp	1	2	47	12	5	840%	5	52	-	2	2
Treatment for Inguinal Bul	1	6	89	-	8	1,013%	8	97	-	-	-
Treatment for Lower Abdc	67	88	1,267	30	102	1,142%	102	1,369	-	-	-
Treatment for Nonherpetic	101	135	2,084	150	162	1,186%	162	2,246	-	359	359
Treatment for Urethral Dis	418	572	7,510	72	581	1,193%	581	8,091	-	97	97
Treatment for Urethral Dis	18	37	868	340	84	933%	84	952	-	160	160
Treatment for Vaginitis	360	467	7,038	5	604	1,065%	604	7,642	-	206	206
Tubal Ligation	9	25	245	-	-	-%	-	245	-	1,343	1,343
Type 2 Diabetes Diagnosi:	-	461	1,431	-	-	-%	-	1,431	-	-	-
Type 2 Diabetes Screenin:	885	1,492	9,879	-	-	-%	-	9,879	-	-	-
Type 2 Diabetes_Controlle	-	-	6	-	-	-%	-	6	-	-	-
Vasectomy	-	-	29	-	-	-%	-	29	-	188	188
Voluntary Medical Male Ci	51,003	22,482	382,928	317,426	249,280	54%	249,280	1,866,728	2,714,252	-	2,714,252
Water Treatment Tablets	1,554,100	1,103,553	18,610,072	24,505,402	20,557,660	(9)%	20,557,660	83,798,062	-	4,340	4,340
Woman Condom	4,296	2,640	32,232	81,624	9,600	236%	9,600	41,832	541	62	602

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>										<b>6,572,076</b>	<b>2,510,356</b>	<b>9,082,432</b>
<b>Angola</b>										<b>14,520</b>	<b>893,743</b>	<b>908,263</b>
Condom	555,120	471,480	3,506,220	4,700,000	6,252,912		(44)%	6,252,912	102,191,067	14,520	9,831	24,352
Legal	-	-	-	-	1,724,552	6/01	(100)%	1,724,552	85,409,357	-	-	-
Sensual Champagne	73,620	63,732	370,620	700,000	-		-%	-	370,620	1,535	1,039	2,574
Sensual Chocolate	119,880	105,852	789,480	1,000,000	142,380	12/12	454%	142,380	2,870,916	3,269	2,214	5,483
Sensual Maracuja	109,224	75,672	638,244	1,000,000	-		-%	-	638,244	2,643	1,790	4,433
Sensual Menta	129,960	115,632	892,908	1,000,000	848,476	12/12	5%	848,476	3,680,380	3,698	2,504	6,201
Sensual Morango	122,436	110,592	814,968	1,000,000	716,544	12/12	14%	716,544	3,666,447	3,375	2,285	5,660
Sensual Saliências	-	-	-	-	2,106,980	11/13	(100)%	2,106,980	3,593,643	-	-	-
Sensual Sensitive	-	-	-	-	713,980	11/13	(100)%	713,980	1,961,460	-	-	-
Family Planning Counseling	-	-	-	-	223		(100)%	223	223	-	-	-
Family Planning Counseling	-	-	-	-	223		(100)%	223	223	-	-	-
Implant 5	500	-	500	-	-		0%	-	500	-	1,360	1,360
Jadelle	500	-	500	-	-	12/17	-%	-	500	-	1,360	1,360
Implant 5 Insertion	-	-	-	-	47		(100)%	47	47	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	47		(100)%	47	47	-	-	-
IUD 10	(1,853)	(137)	2,546	3,000	1,272		100%	1,272	3,818	-	8,552	8,552
PSI IUD 10 Distributed Inserted (1)	(1,853)	(137)	(2,350)	(3,000)	(46)		-%	(46)	(2,396)	-	(7,894)	(7,894)
Coper T 380 A – ENOVA	-	-	4,896	6,000	1,318		271%	1,318	6,214	-	16,446	16,446
IUD 10 Insertion	1,853	137	2,350	3,000	105		2138%	105	2,455	-	8,771	8,771
PSI IUD 10 Inserted	1,853	137	2,350	3,000	46		5,009%	46	2,396	-	8,771	8,771
Non-PSI IUD 10 Inserted	-	-	-	-	59		(100)%	59	59	-	-	-
LLIN	293,935	259,852	4,026,999	2,120,000	1,362,451		196%	1,362,451	9,084,487	-	751,424	751,424
Generic LLINs	293,566	255,558	4,004,647	2,100,000	1,316,525	4/11	204%	1,316,525	8,749,544	-	747,253	747,253

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Joia	369	4,294	22,352	20,000	45,926	11/04	(51)%	45,926	334,943	-	4,171	4,171
Malaria PPT (ACT)	26,782	9,948	100,146	120,000	-		0%	-	521,490	-	60,890	60,890
ALU 20mg/120mg, 12's, 3-8Yrs (15-	3,293	1,906	29,427	-	-	6/17	-%	-	29,427	-	17,892	17,892
ALU 20mg/120mg, 18's, 9-14Yrs (25-	4,826	1,688	14,845	-	-	6/17	-%	-	14,845	-	9,026	9,026
ALU 20mg/120mg, 24's, >14Yrs (>3-	12,350	3,087	27,246	-	-	6/17	-%	-	27,246	-	16,566	16,566
ALU 20mg/120mg, 6's, >3Yrs (5-14+	6,313	3,267	28,628	-	-	6/17	-%	-	28,628	-	17,406	17,406
Coartem B12 (15-25 kg)	-	-	-	30,000	-	7/13	-%	-	147,395	-	-	-
Coartem B18 (25-35 kg)	-	-	-	30,000	-	7/13	-%	-	41,122	-	-	-
Coartem B24 (> 35 kg)	-	-	-	30,000	-	7/13	-%	-	71,658	-	-	-
Coartem B6 (5-15kg)	-	-	-	30,000	-	7/13	-%	-	161,169	-	-	-
Malaria RDK	150	4,075	285,750	100,000	127,550		124%	127,550	714,425	-	-	-
Bioline (RDT)	150	4,075	285,750	100,000	127,550	2/14	124%	127,550	714,425	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	55	223		(100)%	223	223	-	-	-
MVA for PAC	-	-	-	55	223	11/16	(100)%	223	223	-	-	-
Misoprostol for PAC (Sublingual)	1,732	2,193	240,928	15,000	6,000		3915%	6,000	246,928	-	48,571	48,571
ACE Miso (Misoprostol 200mcg tabl	1,732	2,193	240,928	15,000	6,000		3,915%	6,000	246,928	-	48,571	48,571
OCs	8,493	2,498	21,651	90,000	-		0%	-	21,651	-	774	774
MEURI	8,493	2,498	21,651	90,000	-		-%	-	21,651	-	774	774
Water Treatment Tablets	1,320,500	577,400	8,616,612	13,000,000	10,098,200		(15)%	10,098,200	60,231,062	-	3,569	3,569
Certeza Water Tabs	1,320,500	577,400	8,616,612	13,000,000	10,098,200	4/11	(15)%	10,098,200	60,231,062	-	3,569	3,569
<b>Botswana</b>										20,834	1,569	22,403
Condom	269,568	125,504	1,570,920	1,133,856	1,028,592		53%	1,028,592	67,093,997	20,834	1,569	22,403
Lovers Plus	20,736	13,824	145,152	141,696	139,968	6/93	4%	139,968	52,482,054	1,925	145	2,070
Lovers Plus C&F	10,368	13,824	139,896	145,152	133,056	8/06	5%	133,056	7,880,422	1,855	140	1,995

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lovers Plus Extra Play	10,368	8,640	114,048	103,680	82,944	3/16	38%	82,944	456,192	1,513	114	1,626
Lovers Plus R&S	20,736	8,640	134,784	117,504	108,864	10/13	24%	108,864	739,872	1,788	135	1,922
Trust	103,680	43,128	541,080	331,296	268,272	6/07	102%	268,272	3,636,361	7,176	540	7,716
Trust Studded	103,680	37,448	495,960	294,528	295,488	11/12	68%	295,488	1,899,096	6,578	495	7,073
<b>Lesotho</b>										<b>249,297</b>	<b>16,992</b>	<b>266,289</b>
Antiretroviral Treatment (Currently Enr	1,671	1,656	19,557	-	-		0%	-	19,557	3,702	-	3,702
Antiretroviral Treatment (Currently E	1,671	1,656	19,557	-	-		-%	-	19,557	3,702	-	3,702
Antiretroviral Treatment (Newly Enrolle	5	11	118	-	-		0%	-	118	-	-	-
Antiretroviral Treatment (Newly Enrc	5	11	118	-	-		-%	-	118	-	-	-
Condom	322,560	63,936	1,419,840	1,303,488	530,654		168%	530,654	31,318,927	37,445	2,804	40,250
PSI Condom Distributed Provided	-	-	-	-	(461,218)	3/16	-%	(461,218)	(520,647)	-	-	-
Lovers Plus	8,640	1,152	31,104	31,104	13,824	3/99	125%	13,824	2,755,093	820	61	882
Lovers Plus C&F	10,368	2,880	50,112	50,112	32,832	1/05	53%	32,832	721,528	1,322	99	1,421
Lovers Plus Extra Play	6,912	2,304	36,288	27,648	12,096	3/16	200%	12,096	51,840	957	72	1,029
Lovers Plus R&S	8,640	2,304	36,288	41,472	20,736	11/12	75%	20,736	146,952	957	72	1,029
Trust	-	-	-	46,080	31,104	5/01	(100)%	31,104	12,827,594	-	-	-
Trust Studded	288,000	55,296	1,266,048	1,107,072	881,280	1/05	44%	881,280	15,336,567	33,389	2,500	35,890
Condom Provided	-	-	-	-	496,850		(100)%	496,850	556,279	-	-	-
PSI Condom Provided	-	-	-	-	461,218	3/16	(100)%	461,218	520,647	-	-	-
Non-PSI Condom Provided	-	-	-	-	35,632		(100)%	35,632	35,632	-	-	-
Emergency Contraception Provided	2	35	130	50	21		519%	21	151	-	1	1
Non-PSI Emergency Contraception I	2	35	130	50	21		519%	21	151	-	1	1
Female Condom	2,454	6,255	21,256	200,000	1,505,148		(99)%	1,505,148	7,668,242	561	32	593
PSI Female Condom Distributed Pr	-	-	-	-	(49,852)	3/16	-%	(49,852)	(52,530)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom	-	-	-	<b>200,000</b>	<b>1,555,000</b>	7/06	(100)%	<b>1,555,000</b>	<b>5,306,236</b>	-	-	-
Generic	<b>2,454</b>	<b>6,255</b>	<b>21,256</b>	-	-	1/08	-%	-	<b>2,414,536</b>	<b>561</b>	<b>32</b>	<b>593</b>
Female Condom Provided	-	-	-	-	<b>54,540</b>		<b>(100)%</b>	<b>54,540</b>	<b>57,218</b>	-	-	-
PSI Female Condom Provided	-	-	-	-	<b>49,852</b>	3/16	(100)%	<b>49,852</b>	<b>52,530</b>	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	<b>4,688</b>		(100)%	<b>4,688</b>	<b>4,688</b>	-	-	-
Free Condom	<b>139,365</b>	<b>662,710</b>	<b>6,199,186</b>	<b>12,200,000</b>	<b>11,861,420</b>		<b>(48)%</b>	<b>11,861,420</b>	<b>106,625,422</b>	<b>163,491</b>	<b>12,243</b>	<b>175,734</b>
Blue & Gold Workplace	-	-	-	-	<b>4,413,000</b>	1/08	(100)%	<b>4,413,000</b>	<b>66,291,000</b>	-	-	-
Camouflage Free	-	<b>82,800</b>	<b>1,097,400</b>	<b>1,000,000</b>	<b>1,113,000</b>	1/16	(1)%	<b>1,113,000</b>	<b>2,210,400</b>	<b>28,942</b>	<b>2,167</b>	<b>31,109</b>
Generic	-	-	-	<b>6,200,000</b>	<b>2,292,480</b>	4/05	(100)%	<b>2,292,480</b>	<b>21,971,296</b>	-	-	-
Vibe Condom	<b>139,365</b>	<b>579,910</b>	<b>5,101,786</b>	<b>5,000,000</b>	<b>4,042,940</b>	9/14	26%	<b>4,042,940</b>	<b>16,152,726</b>	<b>134,549</b>	<b>10,076</b>	<b>144,625</b>
HIV Testing Services	<b>20,795</b>	<b>35,730</b>	<b>285,876</b>	<b>216,510</b>	<b>258,501</b>		<b>11%</b>	<b>258,501</b>	<b>958,933</b>	<b>29,949</b>	-	<b>29,949</b>
VCT Concordant Couple (HIV-Nega	-	-	-	-	<b>3,178</b>	12/09	(100)%	<b>3,178</b>	<b>12,206</b>	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	<b>164</b>	12/09	(100)%	<b>164</b>	<b>1,346</b>	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	<b>67</b>	12/09	(100)%	<b>67</b>	<b>666</b>	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	<b>67</b>	12/09	(100)%	<b>67</b>	<b>666</b>	-	-	-
VCT Individual (HIV-Negative)	<b>20,216</b>	<b>34,594</b>	<b>276,362</b>	<b>203,923</b>	<b>243,601</b>	12/09	13%	<b>243,601</b>	<b>883,776</b>	<b>28,952</b>	-	<b>28,952</b>
VCT Individual (HIV-Positive)	<b>579</b>	<b>1,136</b>	<b>9,514</b>	<b>12,587</b>	<b>11,424</b>	12/09	(17)%	<b>11,424</b>	<b>60,273</b>	<b>997</b>	-	<b>997</b>
Hypertension Diagnosis	-	<b>376</b>	<b>1,127</b>	-	-		<b>0%</b>	-	<b>1,127</b>	-	-	-
Hypertension Diagnosis	-	<b>376</b>	<b>1,127</b>	-	-		-%	-	<b>1,127</b>	-	-	-
Hypertension Screening	<b>612</b>	<b>991</b>	<b>11,202</b>	-	-		<b>0%</b>	-	<b>11,202</b>	-	-	-
Hypertension Screening	<b>612</b>	<b>991</b>	<b>11,202</b>	-	-		-%	-	<b>11,202</b>	-	-	-
Implant 3 Insertion	-	<b>1</b>	<b>6</b>	-	<b>828</b>		<b>(99)%</b>	<b>828</b>	<b>834</b>	-	<b>9</b>	<b>9</b>
Non-PSI Implant 3 Inserted	-	<b>1</b>	<b>6</b>	-	<b>828</b>		(99)%	<b>828</b>	<b>834</b>	-	<b>9</b>	<b>9</b>
Implant 4 Insertion	-	-	-	<b>169</b>	<b>24</b>		<b>(100)%</b>	<b>24</b>	<b>24</b>	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	<b>169</b>	<b>24</b>		(100)%	<b>24</b>	<b>24</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	8	5	99	338	16		519%	16	115	-	210	210
Non-PSI Implant 5 Inserted	8	5	99	338	16		519%	16	115	-	210	210
Injectable 1 Provided	-	-	8	-	-		0%	-	8	-	-	-
Non-PSI Injectable 1 Provided	-	-	8	-	-		-%	-	8	-	-	-
Injectable 2 Provided	1	287	1,372	338	686		100%	686	2,058	-	95	95
Non-PSI Injectable 2 Provided	1	287	1,372	338	686		100%	686	2,058	-	95	95
Injectable 3 Provided	1,056	1,366	8,880	7,573	3,255		173%	3,255	12,135	-	918	918
Non-PSI Injectable 3 Provided	1,056	1,366	8,880	7,573	3,255		173%	3,255	12,135	-	918	918
IUD 10 Insertion	-	-	-	1,658	78		(100)%	78	78	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	1,658	78		(100)%	78	78	-	-	-
Lubricant	8	3	16	-	48		(67)%	48	160	-	-	-
Lovers Plus Lube Natural (100mL)	8	3	16	-	48		(67)%	48	160	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	231		(100)%	231	363	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	231	3/16	(100)%	231	363	-	-	-
OCs Provided	220	3,602	18,442	6,774	8,616		114%	8,616	27,058	-	516	516
Non-PSI OCs Provided	220	3,602	18,442	6,774	8,616		114%	8,616	27,058	-	516	516
Referral to CD4/Clinical Staging	-	-	-	-	4,277		(100)%	4,277	6,355	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	4,277	3/16	(100)%	4,277	6,355	-	-	-
Referral to Clinical Staging	-	-	-	-	422		(100)%	422	975	-	-	-
Referral to Clinical Staging	-	-	-	-	422	3/16	(100)%	422	975	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to Emergency Contraception	-	-	1	-	-		0%	-	1	-	-	-
Referral to Emergency Contraceptio	-	-	1	-	-		-%	-	1	-	-	-
Referral to HIV Testing Services	1,491	4,317	23,886	4,800	1,256		1802%	1,256	25,163	1,251	-	1,251

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to HIV Testing & Counseling	1,491	4,317	23,886	4,800	1,256	3/16	1,802%	1,256	25,163	1,251	-	1,251
Referral to Implant 3 Insertion	-	1	4	-	-		0%	-	4	-	3	3
Referral to Implant 3 Insertion	-	1	4	-	-		-%	-	4	-	3	3
Referral to Implant 5 Insertion	-	1	2	-	-		0%	-	2	-	2	2
Referral to Implant 5 Insertion	-	1	2	-	-		-%	-	2	-	2	2
Referral to Injectable 2	-	18	55	-	-		0%	-	55	-	2	2
Referral to Injectable 2	-	18	55	-	-		-%	-	55	-	2	2
Referral to Injectable 3	56	102	363	-	-		0%	-	363	-	19	19
Referral to Injectable 3	56	102	363	-	-		-%	-	363	-	19	19
Referral to Linkage to HIV Care	403	671	7,308	8,811	112		6425%	112	7,420	4,394	-	4,394
Referral to Linkage to HIV Care	403	671	7,308	8,811	112		6,425%	112	7,420	4,394	-	4,394
Referral to OCs	28	173	546	-	-		0%	-	546	-	8	8
Referral to OCs	28	173	546	-	-		-%	-	546	-	8	8
Referral to STI Treatment (unknown)	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	174		(100)%	174	1,711	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	174	3/16	(100)%	174	1,711	-	-	-
SDM (Cycle Beads) Provided	-	-	-	-	10		(100)%	10	10	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	10		(100)%	10	10	-	-	-
TB Diagnosis	2	5	45	-	-		0%	-	45	-	-	-
TB Diagnosis	2	5	45	-	-		-%	-	45	-	-	-
TB DOTS	2	1	16	-	-		0%	-	16	-	130	130
TB DOTS	2	1	16	-	-		-%	-	16	-	130	130
TB Screening	582	510	6,699	-	-		0%	-	6,699	-	-	-
TB Screening	582	510	6,699	-	-		-%	-	6,699	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Type 2 Diabetes Diagnosis	-	461	1,384	-	-		0%	-	1,384	-	-	-
Type 2 Diabetes Diagnosis	-	461	1,384	-	-		-%	-	1,384	-	-	-
Type 2 Diabetes Screening	480	1,021	3,544	-	-		0%	-	3,544	-	-	-
Type 2 Diabetes Screening	480	1,021	3,544	-	-		-%	-	3,544	-	-	-
Voluntary Medical Male Circumcision	115	87	651	600	4,930		(87)%	4,930	13,445	8,504	-	8,504
Male Circumcision (HIV-Negative)	-	-	-	-	4,867	9/12	(100)%	4,867	12,718	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	45	10/12	(100)%	45	58	-	-	-
Voluntary Medical Male Circumcision	115	87	651	600	18		3,517%	18	669	8,504	-	8,504
<b>Madagascar</b>										65,353	1,070,627	1,135,980
Cervical Cancer-VIA and Cryotherapy	5	9	104	-	13		700%	13	117	-	31	31
Cervical Cancer-VIA and Cryotherapy	5	9	104	-	13		700%	13	117	-	31	31
Cervical Cancer-VIA/VILI Screening	78	114	1,387	-	146		850%	146	1,533	-	-	-
Cervical Cancer-VIA/VILI Screening	78	114	1,387	-	146		850%	146	1,533	-	-	-
Chlorhexidine	271	1,208	24,705	53,741	241,094		(90)%	241,094	325,724	-	1,509	1,509
Arofoitra	271	1,208	24,705	53,741	241,094	9/15	(90)%	241,094	325,724	-	1,509	1,509
Condom	534,576	233,686	2,968,800	3,234,277	5,892,786		(50)%	5,892,786	60,496,688	18,971	4,519	23,490
Protector Plus	534,576	233,056	1,620,360	1,947,769	4,995,576	1/08	(68)%	4,995,576	57,793,778	10,354	2,466	12,821
YES	-	630	1,348,440	1,286,508	897,210	9/14	50%	897,210	2,702,910	8,617	2,053	10,669
Diarrhea Treatment Kit	18,551	7,096	251,650	318,195	479,996		(48)%	479,996	2,095,650	-	6,353	6,353
PSI Diarrhea Treatment Kit Distribu	(299)	(404)	(5,596)	-	(4,866)		-%	(4,866)	(10,462)	-	(141)	(141)
Hydrazinc	17,550	5,310	103,201	71,592	166,308	1/10	(38)%	166,308	687,785	-	2,605	2,605
ORS-Zinc	400	3	27,641	-	187,651	8/14	(85)%	187,651	428,303	-	698	698
Viasur	900	2,187	126,404	246,603	130,903	1/10	(3)%	130,903	990,024	-	3,191	3,191
Diarrhea Treatment Kit Provided	299	404	5,596	-	4,866		15%	4,866	10,462	-	157	157
PSI Diarrhea Treatment Kit Provide	299	404	5,596	-	4,866		15%	4,866	10,462	-	157	157

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Emergency Contraception	(26)	67	55	61,900	11,536		(100)%	11,536	24,401	-	-	-
PSI Emergency Contraception Distr	(26)	(33)	(545)	-	(344)		-%	(344)	(1,057)	-	(3)	(3)
Norlevo	-	100	600	61,900	11,880	1/14	(95)%	11,880	25,458	-	3	3
Emergency Contraception Provided	26	33	545	-	344		58%	344	1,057	-	3	3
PSI Emergency Contraception Prov	26	33	545	-	344		58%	344	1,057	-	3	3
Female Condom	1,038	2,124	16,668	20,724	20,721		(20)%	20,721	372,863	107	20	126
Feeling	1,038	2,124	16,668	20,724	20,721	10/07	(20)%	20,721	372,863	107	20	126
Fever Cases Attended	8,982	3,986	318,116	-	24,338		1207%	24,338	342,454	-	-	-
Fever Cases Attended	8,982	3,986	318,116	-	24,338		1,207%	24,338	342,454	-	-	-
Fever Cases Tested with Microscopy	580	175	5,050	-	1,885		168%	1,885	6,935	-	-	-
Fever Cases Tested with Microscopy	580	175	5,050	-	1,885		168%	1,885	6,935	-	-	-
Fever Cases Tested with RDTs	7,337	3,276	294,643	-	20,935		1307%	20,935	315,578	-	-	-
Fever Cases Tested with RDTs	7,337	3,276	294,643	-	20,935		1,307%	20,935	315,578	-	-	-
Free Condom	24,014	76,254	7,066,561	7,780,853	344,547		1951%	344,547	52,794,606	45,156	10,756	55,913
Generic	-	167	38,600	7,780,853	152,700	1/02	(75)%	152,700	45,574,798	247	59	305
Generic Condom	24,014	76,088	7,027,961	-	191,847	10/16	3,563%	191,847	7,219,808	44,910	10,698	55,607
HIV Testing Services	5,879	38,697	331,956	151,639	55,027		503%	55,027	478,552	1,119	-	1,119
VCT Individual (HIV-Negative)	5,857	38,620	331,196	150,459	54,869	12/09	504%	54,869	477,525	1,116	-	1,116
VCT Individual (HIV-Positive)	22	77	760	1,180	158	12/09	381%	158	1,027	3	-	3
Implant 3	(165)	(196)	(1,207)	6,814	(1,590)		0%	(1,590)	(77)	-	(1,209)	(1,209)
PSI Implant 3 Distributed Inserted	(524)	(923)	(9,547)	-	(7,497)		-%	(7,497)	(36,724)	-	(9,566)	(9,566)
Implanon	122	58	4,813	6,814	5,907	7/06	(19)%	5,907	33,120	-	4,822	4,822
Implanon NXT	237	669	3,527	-	-	5/17	-%	-	3,527	-	3,534	3,534
Implant 3 Insertion	524	923	9,547	-	7,497		27%	7,497	36,724	-	10,628	10,628
PSI Implant 3 Inserted	524	923	9,547	-	7,497		27%	7,497	36,724	-	10,628	10,628

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 4	(1)	(1)	(8)	51	(83)		0%	(83)	7,548	-	(10)	(10)
PSI Implant 4 Distributed Inserted (1)	(1)	(1)	(25)	-	(189)		-%	(189)	(2,514)	-	(31)	(31)
Implant Zarin	-	-	17	-	106	7/11	(84)%	106	6,336	-	21	21
Zarin	-	-	-	51	-	11/10	-%	-	3,726	-	-	-
Implant 4 Insertion	1	1	25	-	189		(87)%	189	2,514	-	35	35
PSI Implant 4 Inserted	1	1	25	-	189		(87)%	189	2,514	-	35	35
Implant 5	173	(22)	67	527	492		(86)%	492	1,771	-	98	98
PSI Implant 5 Distributed Inserted (1)	(34)	(29)	(343)	-	(1,093)		-%	(1,093)	(1,912)	-	(504)	(504)
Jadelle	207	7	410	527	1,585	7/14	(74)%	1,585	3,683	-	602	602
Implant 5 Insertion	34	29	343	-	1,093		(69)%	1,093	1,912	-	560	560
PSI Implant 5 Inserted	34	29	343	-	1,093		(69)%	1,093	1,912	-	560	560
Injectable 3	170,920	164,975	1,793,959	1,126,166	2,221,330		(19)%	2,221,330	19,065,012	-	128,657	128,657
PSI Injectable 3 Distributed Provide (2,895)	(2,895)	(4,345)	(63,982)	-	(66,475)		-%	(66,475)	(165,141)	-	(4,589)	(4,589)
Confiance Injectable	125,285	120,401	1,340,374	804,410	1,966,049	10/98	(32)%	1,966,049	18,348,951	-	96,127	96,127
Sayana Press	48,530	48,919	517,567	321,756	321,756	9/15	61%	321,756	881,202	-	37,118	37,118
Injectable 3 Provided	2,895	4,345	63,982	-	66,475		(4)%	66,475	165,141	-	5,098	5,098
PSI Injectable 3 Provided	2,895	4,345	63,982	-	66,475		(4)%	66,475	165,141	-	5,098	5,098
IPTp2	53	9,468	44,986	172,356	158,455		(72)%	158,455	203,441	-	2,665	2,665
IPTp2	53	9,468	44,986	172,356	158,455		(72)%	158,455	203,441	-	2,665	2,665
IRS (# of household)	-	-	-	721,863	-		0%	-	-	-	-	-
IRS (# of household)	-	-	-	721,863	-		-%	-	-	-	-	-
IUD 10	445	(409)	(1,061)	11,334	2,663		(140)%	2,663	16,364	-	(1,918)	(1,918)
PSI IUD 10 Distributed Inserted (1)	(1,105)	(1,462)	(17,135)	-	(19,846)		-%	(19,846)	(187,485)	-	(30,971)	(30,971)
Copper T	70	81	9,242	9,604	21,749	5/06	(58)%	21,749	193,432	-	16,705	16,705
IUD 1 x 5	-	15	1,675	1,730	760	8/11	120%	760	5,260	-	3,028	3,028

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Pregna T Cu 380A	1,480	957	5,157	-	-	7/17	-%	-	5,157	-	9,321	9,321
IUD 10 Insertion	1,105	1,462	17,135	-	19,858		(14)%	19,858	188,577	-	34,413	34,413
PSI IUD 10 Inserted	1,105	1,462	17,135	-	19,846		(14)%	19,846	187,485	-	34,413	34,413
Non-PSI IUD 10 Inserted	-	-	-	-	12		(100)%	12	1,092	-	-	-
LLIN	263,857	62,895	2,164,376	1,848,923	494,582		338%	494,582	21,943,911	-	85,578	85,578
Generic net "PERMANET WHITE"	-	6,923	979,522	861,597	151,204	5/15	548%	151,204	9,214,276	-	38,729	38,729
Interceptor White	-	-	-	-	1	5/09	(100)%	1	1,099,951	-	-	-
Net Protect	-	-	502	-	20,851	12/13	(98)%	20,851	2,702,750	-	20	20
Olyset Net Blue	-	30	90	-	360	5/12	(75)%	360	675,643	-	4	4
Olyset Net White	-	-	-	-	930	5/12	(100)%	930	1,387,454	-	-	-
PermaNet	4	34,368	624,664	511,034	7,228	3/07	8,542%	7,228	2,449,773	-	24,699	24,699
Permanet Blue	-	20,668	170,208	-	-	2/17	-%	-	170,208	-	6,730	6,730
Super Moustiquaire	263,853	906	389,386	476,292	313,988	9/01	24%	313,988	3,178,032	-	15,396	15,396
Yorkool Blue (Generic Net)	-	1	4	-	20	7/15	(80)%	20	1,065,824	-	-	-
Lubricant	72,200	72,101	544,706	-	4,000		13518%	4,000	748,656	-	-	-
Gel Lubricant 5 mL	72,200	72,101	544,700	-	4,000	12/16	13,518%	4,000	548,700	-	-	-
Lubricant	-	-	6	-	-	8/11	-%	-	199,956	-	-	-
Malaria PPT (ACT)	850,569	219,842	1,885,557	1,117,169	991,622		90%	991,622	7,179,734	-	536,102	536,102
ACT 100 mg (1x3's)	-	20,600	61,800	50,813	34,235	7/15	81%	34,235	242,957	-	17,571	17,571
ACT 100 mg (1x6's)	78,125	8	78,150	58,630	7,701	7/15	915%	7,701	241,725	-	22,220	22,220
ACT 25 mg (1x3's)	3,300	52,233	174,400	156,830	46,499	7/15	275%	46,499	239,624	-	49,585	49,585
ACT 50 mg (1x3's)	207,800	147,001	648,802	676,082	17,218	7/15	3,668%	17,218	680,925	-	184,468	184,468
AL for Adolescent, 20/120mg, 18's	10,469	-	18,567	5,727	27,955	7/16	(34)%	27,955	46,522	-	5,279	5,279
AL for Adult, 20/120mg, 24's	15,398	-	23,994	15,434	46,381	7/16	(48)%	46,381	70,375	-	6,822	6,822

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
AL for Infant, 20/120mg, 6's	8,267	-	13,337	5,703	19,191	7/16	(31)%	19,191	32,528	-	3,792	3,792
AL for Toddler, 20/120mg, 12's	10,729	-	25,661	6,059	37,668	7/16	(32)%	37,668	63,329	-	7,296	7,296
Artesunate Amodiaquine 25 mg	-	-	-	-	16,425	10/10	(100)%	16,425	1,390,827	-	-	-
Artesunate Amodiaquine combo 50 mg	-	-	-	-	25,975	10/10	(100)%	25,975	2,617,702	-	-	-
ASAQ for Adolescent, 100/270mg, 6's	30,272	-	204,880	22,411	180,281	7/16	14%	180,281	385,161	-	58,252	58,252
ASAQ for Adult, 100/270mg, 6's	171,423	-	254,210	59,395	203,531	7/16	25%	203,531	457,741	-	72,277	72,277
ASAQ for Infant, 25/67.5mg, 3's	34,042	-	82,489	21,948	93,944	7/16	(12)%	93,944	176,433	-	23,453	23,453
ASAQ for Toddler, 50/135mg, 3's	180,744	-	299,267	38,137	234,618	7/16	28%	234,618	533,885	-	85,088	85,088
Malaria RDK	-	-	1,779,900	1,773,659	1,005,988		77%	1,005,988	9,401,438	-	-	-
RDT Malaria	-	-	1,779,900	1,773,659	1,005,988	8/11	77%	1,005,988	9,401,438	-	-	-
Manual Vacuum Aspiration for PAC	193	252	2,223	-	1,234		80%	1,234	3,457	-	665	665
MVA for PAC	193	252	2,223	-	1,234	12/16	80%	1,234	3,457	-	665	665
Micronutrient Powder	29,490	27,790	3,181,110	3,558,780	2,466,510		29%	2,466,510	10,707,660	-	-	-
ZAZATOMADY (ZZT)	29,490	27,790	3,181,110	3,558,780	2,466,510	2/13	29%	2,466,510	10,707,660	-	-	-
Misoprostol for PAC (Oral)	(957)	(1,078)	(8,193)	-	(6,537)		0%	(6,537)	(14,730)	-	(735)	(735)
PSI Misoprostol for PAC Oral Dist F	(957)	(1,078)	(8,193)	-	(6,537)		-%	(6,537)	(14,730)	-	(735)	(735)
Misoprostol for PAC (oral) Provided	957	1,078	8,193	-	6,537		25%	6,537	14,730	-	817	817
PSI Misoprostol for PAC (oral) Prov	957	1,078	8,193	-	6,537		25%	6,537	14,730	-	817	817
OCs	225,090	284,516	3,492,199	2,631,504	2,594,303		35%	2,594,303	38,769,793	-	67,814	67,814
PSI OCs Distributed Provided	(629)	(1,586)	(32,986)	-	(37,201)		-%	(37,201)	(80,421)	-	(641)	(641)
Pilplan	225,719	286,101	3,525,185	2,631,504	2,631,504	10/98	34%	2,631,504	38,850,214	-	68,455	68,455
OCs Provided	629	1,586	32,986	-	37,201		(11)%	37,201	80,421	-	712	712
PSI OCs Provided	629	1,586	32,986	-	37,201		(11)%	37,201	80,421	-	712	712
Pneumonia PPT	22,980	23,527	413,740	419,927	376,369		10%	376,369	1,245,638	-	151,835	151,835
PneumoStop Tablet (6 x 480 mg)	2,220	400	14,671	-	141,896	8/14	(90)%	141,896	612,096	-	5,384	5,384

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Pneumox 250 (10's) for Children un	20,760	23,127	399,069	419,927	234,473	7/16	70%	234,473	633,542	-	146,451	146,451
Positive RDTs	911	468	102,632	-	2,177		4614%	2,177	104,809	-	-	-
Positive RDTs	911	468	102,632	-	2,177		4,614%	2,177	104,809	-	-	-
Safe Water Solution	46,121	91,864	1,638,966	3,435,598	2,482,324		(34)%	2,482,324	23,859,745	-	9,021	9,021
Sur Eau 40 mL	6,630	163	20,877	-	327,383	12/11	(94)%	327,383	2,382,342	-	32	32
Sur Eau Vaovao	39,491	91,700	1,618,089	3,435,598	2,154,941	9/04	(25)%	2,154,941	21,477,403	-	8,989	8,989
SDM (Cycle Beads)	168	114	20,389	17,307	11,341		80%	11,341	138,396	-	13,807	13,807
PSI SDM (Cycle Beads) Distributed	(22)	(66)	(1,789)	-	(2,166)		-%	(2,166)	(4,644)	-	(1,211)	(1,211)
Rojo	190	180	22,178	17,307	13,507	3/12	64%	13,507	143,040	-	15,018	15,018
SDM (Cycle Beads) Provided	22	66	1,789	-	2,166		(17)%	2,166	4,644	-	1,346	1,346
PSI SDM (Cycle Beads) Provided	22	66	1,789	-	2,166		(17)%	2,166	4,644	-	1,346	1,346
STI Screening	875	1,179	16,890	-	33,852		(50)%	33,852	63,232	-	-	-
STI Screening	875	1,179	16,890	-	33,852		(50)%	33,852	63,232	-	-	-
Treatment for Inguinal Bubo	1	4	80	-	3		2567%	3	83	-	-	-
Treatment for Inguinal Bubo	1	4	80	-	3		2,567%	3	83	-	-	-
Treatment for Lower Abdominal Pain	58	82	1,198	-	99		1110%	99	1,297	-	-	-
Treatment for Lower Abdominal Pair	58	82	1,198	-	99		1,110%	99	1,297	-	-	-
Treatment for Nonherpetic Genital Ulc	75	102	1,590	-	111		1332%	111	1,701	-	178	178
Treatment for Nonherpetic Genital U	75	102	1,590	-	111		1,332%	111	1,701	-	178	178
Treatment for Urethral Discharge (Mer	395	548	7,090	-	531		1235%	531	7,621	-	41	41
Treatment for Urethral Discharge (M	395	548	7,090	-	531		1,235%	531	7,621	-	41	41
Treatment for Vaginitis	342	427	6,474	-	581		1014%	581	7,055	-	57	57
Treatment for Vaginitis	342	427	6,474	-	581		1,014%	581	7,055	-	57	57
Tubal Ligation	9	8	74	-	-		0%	-	74	-	253	253
Tubal Ligation	9	8	74	-	-		-%	-	74	-	253	253

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Water Treatment Tablets	233,600	545,193	9,993,460	11,505,402	10,315,940		(3)%	10,315,940	22,106,630	-	771	771
SUR'EAU PILINA (67mg tablet)	233,600	545,193	9,993,460	11,505,402	10,315,940	10/14	(3)%	10,315,940	22,106,630	-	771	771
<b>Mozambique</b>										315,561	260,443	576,005
Condom	927,048	2,595,204	20,194,632	17,339,724	9,175,026		120%	9,175,026	91,121,117	314,252	57,449	371,701
PSI Condom Distributed Provided	-	-	-	-	(96,814)	3/16	-%	(96,814)	(203,159)	-	-	-
J0.1	-	576,000	1,728,000	-	-	10/17	-%	-	1,728,000	26,890	4,916	31,805
J1	52,248	1,152,024	7,508,736	17,339,724	4,469,256	10/12	68%	4,469,256	43,004,832	116,845	21,361	138,205
J14	6,552	-	6,552	-	2,232	4/14	194%	2,232	141,840	102	19	121
J2	(111,456)	432	2,536,272	-	1,365,120	10/12	86%	1,365,120	15,929,640	39,467	7,215	46,682
J24	-	576,000	1,728,000	-	-	10/17	-%	-	1,728,000	26,890	4,916	31,805
J3	979,200	288,000	5,934,240	-	2,065,680	10/12	187%	2,065,680	19,499,472	92,344	16,881	109,225
Jeito 4	-	-	673,920	-	649,440	11/13	4%	649,440	3,442,896	10,487	1,917	12,404
Jeito 5	504	2,748	78,912	-	314,352	1/14	(75)%	314,352	1,348,236	1,228	224	1,452
Jzero	-	-	-	-	405,760	6/13	(100)%	405,760	4,501,360	-	-	-
Condom Provided	-	-	-	-	149,000		(100)%	149,000	255,345	-	-	-
PSI Condom Provided	-	-	-	-	96,814	3/16	(100)%	96,814	203,159	-	-	-
Non-PSI Condom Provided	-	-	-	-	52,186		(100)%	52,186	52,186	-	-	-
Emergency Contraception	-	-	(106)	-	(978)		0%	(978)	(1,084)	-	(1)	(1)
PSI Emergency Contraception Distr	-	-	(106)	-	(978)		-%	(978)	(1,084)	-	(1)	(1)
Emergency Contraception Provided	20	4	258	-	978		(74)%	978	1,236	-	3	3
PSI Emergency Contraception Prov	-	-	106	-	978		(89)%	978	1,084	-	1	1
Non-PSI Emergency Contraception I	20	4	152	-	-		-%	-	152	-	2	2
Female Condom	-	-	-	-	(3,436)		0%	(3,436)	(11,660)	-	-	-
PSI Female Condom Distributed Pr	-	-	-	-	(3,436)	3/16	-%	(3,436)	(11,660)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom Provided	-	-	-	-	4,182		(100)%	4,182	12,406	-	-	-
PSI Female Condom Provided	-	-	-	-	3,436	3/16	(100)%	3,436	11,660	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	746		(100)%	746	746	-	-	-
Free Condom	8,928	17,563	70,833	-	167,691		(58)%	167,691	27,423,761	1,102	202	1,304
Generic	-	-	-	-	141,051	1/03	(100)%	141,051	26,733,008	-	-	-
No Logo Condom Lubricant Combo	8,928	17,563	70,833	-	26,640	5/15	166%	26,640	690,753	1,102	202	1,304
Free Female Condom	-	4	3,281	-	4,868		(33)%	4,868	670,037	51	7	58
Female Condom Free	-	4	3,281	-	4,868	8/09	(33)%	4,868	670,037	51	7	58
HIV Testing Services	-	126	2,231	-	5,588		(60)%	5,588	908,185	156	-	156
VCT Concordant Couple (HIV-Nega	-	-	-	-	62	12/09	(100)%	62	91,187	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	2	12/09	(100)%	2	5,455	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	12	12/09	(100)%	12	2,168	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	12	12/09	(100)%	12	2,168	-	-	-
VCT Individual (HIV-Negative)	-	114	2,031	-	5,154	12/09	(61)%	5,154	758,364	142	-	142
VCT Individual (HIV-Positive)	-	12	200	-	347	12/09	(42)%	347	48,844	14	-	14
Implant 5	-	-	(2,259)	-	-		0%	-	(7,758)	-	(6,212)	(6,212)
PSI Implant 5 Distributed Inserted (	(181)	(193)	(4,680)	(5,148)	(3,871)		-%	(3,871)	(15,465)	-	(12,870)	(12,870)
Jadelle	181	193	2,421	5,148	3,871	12/15	(37)%	3,871	7,707	-	6,658	6,658
Implant 5 Insertion	1,542	1,931	17,983	24,750	11,106		62%	11,106	36,003	-	54,946	54,946
PSI Implant 5 Inserted	181	193	4,680	5,148	3,871		21%	3,871	15,465	-	14,300	14,300
Non-PSI Implant 5 Inserted	1,361	1,738	13,303	19,602	7,235		84%	7,235	20,538	-	40,647	40,647
Injectable 3	(1,384)	(838)	(33,639)	-	-		0%	-	(22,296)	-	(4,509)	(4,509)
PSI Injectable 3 Distributed Provide	(1,974)	(1,174)	(39,416)	(26,829)	(16,469)		-%	(16,469)	(97,977)	-	(5,283)	(5,283)
Enaf Injectable	590	336	5,777	26,829	16,469	6/13	(65)%	16,469	75,681	-	774	774
Injectable 3 Provided	15,076	14,575	145,973	137,070	70,022		108%	70,022	258,087	-	21,739	21,739

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Provided	1,974	1,174	39,416	26,829	16,469		139%	16,469	97,977	-	5,870	5,870
Non-PSI Injectable 3 Provided	13,102	13,401	106,557	110,241	53,553		99%	53,553	160,110	-	15,869	15,869
IUD 10	18,848	-	16,182	-	-		0%	-	16,637	-	54,821	54,821
PSI IUD 10 Distributed Inserted (1)	-	-	(2,666)	(19,000)	(1,436)		-%	(1,436)	(5,101)	-	(9,032)	(9,032)
DIU Copper T 380A	18,848	-	18,848	19,000	1,436	1/15	1,213%	1,436	21,738	-	63,852	63,852
IUD 10 Insertion	435	1,205	8,890	30,421	2,950		201%	2,950	13,341	-	33,464	33,464
PSI IUD 10 Inserted	-	-	2,666	19,000	1,436		86%	1,436	5,101	-	10,035	10,035
Non-PSI IUD 10 Inserted	435	1,205	6,224	11,421	1,514	3/16	311%	1,514	8,240	-	23,428	23,428
LLIN	18	2,080	74,977	43,000	66,603		13%	66,603	199,137	-	23,157	23,157
Serena	18	2,080	74,977	43,000	66,603	4/14	13%	66,603	199,137	-	23,157	23,157
Lubricant	137	-	7,125	-	2,742		160%	2,742	12,998	-	-	-
J8 (60 ml tube)	137	-	7,125	-	2,742	9/14	160%	2,742	12,998	-	-	-
Malaria RDK	-	-	26	-	218		(88)%	218	4,938	-	-	-
Teste Malaria Rapido	-	-	26	-	218	9/14	(88)%	218	4,938	-	-	-
Micronutrient Powder	-	93,433	2,372,480	1,300,000	1,558,480		52%	1,558,480	5,634,020	-	-	-
Super Bebe	-	-	-	-	(19,460)	9/13	-%	(19,460)	1,683,120	-	-	-
VITA MAIS	-	93,433	2,372,480	1,300,000	1,577,940	11/15	50%	1,577,940	3,950,900	-	-	-
OCs	-	-	(28,794)	-	(1,361)		0%	(1,361)	(352)	-	(1,045)	(1,045)
PSI OCs Distributed Provided	(4,967)	(5,260)	(82,363)	(73,524)	(71,863)		-%	(71,863)	(249,691)	-	(2,989)	(2,989)
Microginon Mobiz	-	-	2,055	-	2,163	5/15	(5)%	2,163	5,748	-	75	75
Microlenyn 30 Combined OC	3,772	3,955	38,782	73,524	47,700	6/13	(19)%	47,700	164,103	-	1,407	1,407
Progestyn OC	1,195	1,305	12,732	-	20,639	6/13	(38)%	20,639	79,488	-	462	462
OCs Provided	21,023	22,306	208,558	257,718	135,973		53%	135,973	439,996	-	8,410	8,410
PSI OCs Provided	4,967	5,260	82,363	73,524	71,863		15%	71,863	249,691	-	3,321	3,321
Non-PSI OCs Provided	16,056	17,046	126,195	184,194	64,110		97%	64,110	190,305	-	5,089	5,089

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Safe Water Solution</b>	<b>47,991</b>	<b>33,133</b>	<b>1,163,089</b>	<b>1,250,000</b>	<b>934,564</b>		<b>24%</b>	<b>934,564</b>	<b>9,166,248</b>	-	<b>8,325</b>	<b>8,325</b>
Certeza	-	-	-	<b>690,000</b>	-	10/04	-%	-	<b>3,931,349</b>	-	-	-
Certeza Commercial ISM	<b>51</b>	<b>1,887</b>	<b>427,483</b>	-	<b>428,338</b>	9/12	-%	<b>428,338</b>	<b>2,664,267</b>	-	<b>3,060</b>	<b>3,060</b>
Certeza Free ISM	<b>47,940</b>	<b>31,246</b>	<b>735,606</b>	<b>560,000</b>	<b>506,226</b>	9/12	45%	<b>506,226</b>	<b>2,570,632</b>	-	<b>5,265</b>	<b>5,265</b>
<b>SDM (Cycle Beads)</b>	<b>7,647</b>	-	<b>7,647</b>	-	-		<b>0%</b>	-	<b>10,694</b>	-	<b>9,688</b>	<b>9,688</b>
Missangas Ciclo	<b>7,647</b>	-	<b>7,647</b>	-	-	2/11	-%	-	<b>10,694</b>	-	<b>9,688</b>	<b>9,688</b>
<b>Water Treatment Tablets</b>	-	<b>(19,040)</b>	-	-	<b>143,520</b>		<b>(100)%</b>	<b>143,520</b>	<b>1,460,370</b>	-	-	-
Certeza Comprimido 20L	-	<b>(19,040)</b>	-	-	<b>90,960</b>	2/14	(100)%	<b>90,960</b>	<b>921,360</b>	-	-	-
Certeza Comprimido 5L	-	-	-	-	<b>11,550</b>	2/14	(100)%	<b>11,550</b>	<b>303,360</b>	-	-	-
Certeza Free Comprimido 20L	-	-	-	-	<b>41,010</b>	2/14	(100)%	<b>41,010</b>	<b>235,650</b>	-	-	-
<b>Namibia</b>										<b>3,167</b>	<b>275</b>	<b>3,442</b>
<b>Condom</b>	-	<b>2,880</b>	<b>243,648</b>	-	<b>69,984</b>		<b>248%</b>	<b>69,984</b>	<b>313,632</b>	<b>3,167</b>	<b>275</b>	<b>3,442</b>
Lovers Plus	-	<b>1,728</b>	<b>5,184</b>	-	<b>10,512</b>		(51)%	<b>10,512</b>	<b>15,696</b>	<b>67</b>	<b>6</b>	<b>73</b>
Lovers Plus C&F	-	<b>576</b>	<b>5,184</b>	-	<b>12,240</b>		(58)%	<b>12,240</b>	<b>17,424</b>	<b>67</b>	<b>6</b>	<b>73</b>
Lovers Plus R&S	-	<b>576</b>	<b>1,728</b>	-	<b>12,240</b>		(86)%	<b>12,240</b>	<b>13,968</b>	<b>22</b>	<b>2</b>	<b>24</b>
Trust	-	-	<b>115,776</b>	-	<b>17,496</b>		562%	<b>17,496</b>	<b>133,272</b>	<b>1,505</b>	<b>131</b>	<b>1,636</b>
Trust Studded	-	-	<b>115,776</b>	-	<b>17,496</b>		562%	<b>17,496</b>	<b>133,272</b>	<b>1,505</b>	<b>131</b>	<b>1,636</b>
<b>Free Condom</b>	-	-	-	-	<b>1,753,718</b>		<b>(100)%</b>	<b>1,753,718</b>	<b>16,546,045</b>	-	-	-
Smile	-	-	-	-	<b>1,753,718</b>	1/08	(100)%	<b>1,753,718</b>	<b>16,546,045</b>	-	-	-
<b>Free Female Condom</b>	-	-	-	-	<b>52,311</b>		<b>(100)%</b>	<b>52,311</b>	<b>510,066</b>	-	-	-
Femidom Free	-	-	-	-	<b>52,311</b>	2/07	(100)%	<b>52,311</b>	<b>510,066</b>	-	-	-
<b>Lubricant</b>	-	-	-	-	<b>306,588</b>		<b>(100)%</b>	<b>306,588</b>	<b>1,964,530</b>	-	-	-
Condom Lubricant (Water Based)	-	-	-	-	<b>306,588</b>	8/11	(100)%	<b>306,588</b>	<b>1,964,530</b>	-	-	-
<b>Referral to HIV Testing Services</b>	-	-	-	-	<b>201</b>		<b>(100)%</b>	<b>201</b>	<b>4,492</b>	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	<b>201</b>	12/14	(100)%	<b>201</b>	<b>4,492</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to STI Treatment (unknown)	-	-	-	-	11		(100)%	11	363	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	11	12/14	(100)%	11	363	-	-	-
Referral to TB DOTS (completion unkr	-	-	-	-	17		(100)%	17	67	-	-	-
Referral to TB DOTS (completion un	-	-	-	-	17		(100)%	17	67	-	-	-
<b>South Africa</b>										<b>2,625,403</b>	<b>94,550</b>	<b>2,719,954</b>
CD4 Tests Provided to HIV+ Clients	-	9	4,936	-	59		8266%	59	4,995	-	-	-
CD4 Tests Provided to HIV+ Clients	-	9	4,936	-	59		8,266%	59	4,995	-	-	-
Condom	3,498,396	3,751,813	40,500,889	52,739,076	48,943,658		(17)%	48,943,658	695,015,360	816,384	36,972	853,356
Lovers Plus	477,144	323,131	4,152,412	5,474,844	5,140,551	10/92	(19)%	5,140,551	166,186,792	83,701	3,791	87,492
Lovers Plus C&F	292,176	264,404	2,927,475	4,796,064	4,117,957	1/08	(29)%	4,117,957	55,771,486	59,010	2,672	61,682
Lovers Plus Extra Play	39,960	36,712	367,236	679,752	458,103	9/13	(20)%	458,103	2,598,498	7,402	335	7,738
Lovers Plus R&S	145,656	160,047	1,979,032	3,036,168	2,915,143	4/07	(32)%	2,915,143	37,485,556	39,892	1,807	41,698
Trust	1,303,884	1,564,176	14,408,550	19,931,304	19,643,191	5/01	(27)%	19,643,191	221,311,870	290,436	13,153	303,589
Trust Studded	1,239,576	1,403,343	16,666,184	18,820,944	16,668,713	4/04	-%	16,668,713	211,661,158	335,943	15,214	351,157
Female Condom	-	-	(2,880)	-	(35,316)		0%	(35,316)	974,999	(58)	(2)	(60)
LP Condom - Inner Condom	-	-	(2,880)	-	(35,316)	9/13	-%	(35,316)	974,999	(58)	(2)	(60)
Free Condom	9,686,700	6,314,700	62,638,800	45,000,000	67,505,600		(7)%	67,505,600	1,066,140,576	1,262,622	57,181	1,319,803
Military Condom	-	-	5,000,000	-	5,000,000	3/13	-%	5,000,000	20,800,016	100,786	4,564	105,350
Public Distribution	9,686,700	6,314,700	57,638,800	45,000,000	62,505,600	1/04	(8)%	62,505,600	1,045,340,560	1,161,836	52,617	1,214,452
Free Female Condom	104,400	59,833	569,000	1,000,000	555,800		2%	555,800	5,034,100	11,469	400	11,869
FC2 Female Condom	-	-	-	1,000,000	-	5/12	-%	-	1,112,000	-	-	-
Female Condom GOSA	104,400	59,833	569,000	-	555,800	10/13	2%	555,800	3,922,100	11,469	400	11,869
HIV Testing Services	161,614	10,616	529,619	515,489	262,513		102%	262,513	1,869,181	37,533	-	37,533
VCT Concordant Couple (HIV-Nega	-	-	-	-	20,004	12/09	(100)%	20,004	89,520	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	895	12/09	(100)%	895	3,545	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Discordant Couple (HIV-Negati	-	-	-	-	1,306	12/09	(100)%	1,306	2,989	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	1,306	12/09	(100)%	1,306	2,989	-	-	-
VCT Individual (HIV-Negative)	149,892	10,178	479,154	444,746	217,903	12/09	120%	217,903	1,623,187	33,957	-	33,957
VCT Individual (HIV-Positive)	11,722	438	50,465	70,743	21,100	12/09	139%	21,100	146,952	3,576	-	3,576
<b>Lubricant</b>	<b>180</b>	<b>67</b>	<b>4,821</b>	-	<b>118,584</b>		<b>(96)%</b>	<b>118,584</b>	<b>536,957</b>	-	-	-
Lovers Plus Lube Natural (100mL)	180	67	6,057	-	4,512	1/13	34%	4,512	83,421	-	-	-
Lovers Plus Lube Natural (50mL)	-	-	(1,236)	-	(32,928)	1/13	-%	(32,928)	46,536	-	-	-
Lovers Plus Lube Natural (5mL)	-	-	-	-	147,000	3/13	(100)%	147,000	407,000	-	-	-
<b>Male Circumcision (HIV-Positive)</b>	-	-	-	-	<b>1,521</b>		<b>(100)%</b>	<b>1,521</b>	<b>6,118</b>	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	1,521	3/16	(100)%	1,521	6,118	-	-	-
<b>Referral to CD4/Clinical Staging</b>	-	-	-	-	<b>1,960</b>		<b>(100)%</b>	<b>1,960</b>	<b>3,364</b>	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	1,960	12/14	(100)%	1,960	3,364	-	-	-
<b>Referral to Clinical Staging</b>	-	-	-	-	<b>1,960</b>		<b>(100)%</b>	<b>1,960</b>	<b>3,364</b>	-	-	-
Referral to Clinical Staging	-	-	-	-	1,960	12/14	(100)%	1,960	3,364	-	-	-
<b>Referral to STI Treatment (unknown)</b>	-	-	-	-	<b>890</b>		<b>(100)%</b>	<b>890</b>	<b>1,690</b>	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	890	12/14	(100)%	890	1,690	-	-	-
<b>Referral to Voluntary Medical Male Cir</b>	-	-	-	-	<b>1,153</b>		<b>(100)%</b>	<b>1,153</b>	<b>3,382</b>	-	-	-
Referral to Voluntary Medical Male C	-	-	-	-	1,153		(100)%	1,153	3,382	-	-	-
<b>Voluntary Medical Male Circumcision</b>	<b>33,435</b>	-	<b>70,623</b>	<b>49,922</b>	<b>19,672</b>		<b>259%</b>	<b>19,672</b>	<b>228,047</b>	<b>497,453</b>	-	<b>497,453</b>
Bepelopele (MC HIV-Negative)	-	-	-	-	14,726	3/09	(100)%	14,726	146,696	-	-	-
Bepelopele (MC HIV-Unknown)	-	-	-	-	2,227	3/09	(100)%	2,227	8,009	-	-	-
<b>Voluntary Medical Male Circumcisio</b>	<b>33,435</b>	-	<b>70,623</b>	<b>49,922</b>	<b>2,719</b>		<b>2,497%</b>	<b>2,719</b>	<b>73,342</b>	<b>497,453</b>	-	<b>497,453</b>
<b>Swaziland</b>										<b>736,765</b>	<b>35,243</b>	<b>772,009</b>
Antiretroviral Treatment (Currently Enr	187	230	1,873	-	-		0%	-	1,873	385	-	385
Antiretroviral Treatment (Currently E	187	230	1,873	-	-		-%	-	1,873	385	-	385

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Antiretroviral Treatment (Newly Enrolle	24	36	569	-	-		0%	-	569	-	-	-
Antiretroviral Treatment (Newly Enrc	24	36	569	-	-		-%	-	569	-	-	-
CD4 Tests Provided to HIV+ Clients	53	118	1,318	-	80		1548%	80	1,398	-	-	-
CD4 Tests Provided to HIV+ Clients	53	118	1,318	-	80		1,548%	80	1,398	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-Pap and Refer to ai	-	-	1	-	-		-%	-	1	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	2	-	-		0%	-	2	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	2	-	-		-%	-	2	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		-%	-	1	-	-	-
Condom	1,925,286	519,944	4,868,958	871,752	2,173,060		124%	2,173,060	30,738,453	196,699	10,271	206,970
Lovers Plus	5,184	576	30,672	32,832	31,104	2/01	(1)%	31,104	1,645,378	1,239	65	1,304
Lovers Plus C&F	5,304	2,304	39,864	42,048	43,200	1/05	(8)%	43,200	442,312	1,610	84	1,695
Lovers Plus Extra Play	-	1,152	6,912	-	1,728		300%	1,728	10,368	279	15	294
Lovers Plus R&S	-	2,304	32,832	31,104	31,680	5/10	4%	31,680	307,656	1,326	69	1,396
Trust	20,100	24,648	188,652	130,032	118,800	5/01	59%	118,800	6,878,101	7,621	398	8,019
Trust Regular BGF	-	48	144	-	-	7/08	-%	-	74,187	6	-	6
Trust Studded	133,698	81,912	795,882	635,736	546,048	1/05	46%	546,048	9,606,670	32,153	1,679	33,831
Trust Workplace	1,761,000	407,000	3,774,000	-	1,400,500	2/06	169%	1,400,500	11,773,781	152,465	7,961	160,426
Condom Provided	-	-	-	-	28,574		(100)%	28,574	28,574	-	-	-
Non-PSI Condom Provided	-	-	-	-	28,574		(100)%	28,574	28,574	-	-	-
Emergency Contraception Provided	-	-	1	120	4		(75)%	4	5	-	-	-
Non-PSI Emergency Contraception I	-	-	1	120	4		(75)%	4	5	-	-	-
Female Condom	10,000	9,333	113,000	200,000	140,000		(19)%	140,000	916,227	4,565	183	4,748
Female Condom	10,000	9,333	113,000	200,000	140,000	7/06	(19)%	140,000	916,227	4,565	183	4,748

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Free Condom</b>	<b>210,274</b>	<b>587,000</b>	<b>11,526,274</b>	<b>13,444,915</b>	<b>11,475,600</b>		<b>0%</b>	<b>11,475,600</b>	<b>61,246,418</b>	<b>465,646</b>	<b>24,314</b>	<b>489,960</b>
Generic	210,000	587,000	11,526,000	13,444,915	11,475,600	4/05	-%	11,475,600	50,855,544	465,635	24,313	489,948
Workplace	274	-	274	-	-	10/01	-%	-	10,390,874	11	1	12
<b>HIV Testing Services</b>	<b>4,327</b>	<b>5,399</b>	<b>84,171</b>	<b>62,844</b>	<b>52,093</b>		<b>62%</b>	<b>52,093</b>	<b>594,285</b>	<b>11,444</b>	<b>-</b>	<b>11,444</b>
VCT Concordant Couple (HIV-Nega	-	-	-	-	898	12/09	(100)%	898	9,516	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	126	12/09	(100)%	126	1,050	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	97	12/09	(100)%	97	768	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	97	12/09	(100)%	97	768	-	-	-
VCT Individual (HIV-Negative)	4,033	5,058	78,951	56,046	44,213	12/09	79%	44,213	535,081	10,734	-	10,734
VCT Individual (HIV-Positive)	294	341	5,220	6,798	6,662	12/09	(22)%	6,662	47,102	710	-	710
<b>Hypertension Diagnosis</b>	<b>-</b>	<b>-</b>	<b>684</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>684</b>	<b>-</b>	<b>-</b>	<b>-</b>
Hypertension Diagnosis	-	-	684	-	-		-%	-	684	-	-	-
<b>Hypertension Screening</b>	<b>195</b>	<b>388</b>	<b>5,234</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>5,234</b>	<b>-</b>	<b>-</b>	<b>-</b>
Hypertension Screening	195	388	5,234	-	-		-%	-	5,234	-	-	-
<b>Implant 3 Insertion</b>	<b>2</b>	<b>-</b>	<b>2</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>2</b>	<b>-</b>	<b>3</b>	<b>3</b>
Non-PSI Implant 3 Inserted	2	-	2	-	-		-%	-	2	-	3	3
<b>Implant 5 Insertion</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>50</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Non-PSI Implant 5 Inserted	-	-	-	50	-		-%	-	-	-	-	-
<b>Injectable 1 Provided</b>	<b>27</b>	<b>99</b>	<b>1,087</b>	<b>100</b>	<b>135</b>		<b>705%</b>	<b>135</b>	<b>1,222</b>	<b>-</b>	<b>40</b>	<b>40</b>
Non-PSI Injectable 1 Provided	27	99	1,087	100	135		705%	135	1,222	-	40	40
<b>Injectable 2 Provided</b>	<b>-</b>	<b>-</b>	<b>4</b>	<b>200</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>4</b>	<b>-</b>	<b>-</b>	<b>-</b>
Non-PSI Injectable 2 Provided	-	-	4	200	-		-%	-	4	-	-	-
<b>Injectable 3 Provided</b>	<b>41</b>	<b>95</b>	<b>1,179</b>	<b>370</b>	<b>460</b>		<b>156%</b>	<b>460</b>	<b>1,639</b>	<b>-</b>	<b>130</b>	<b>130</b>
Non-PSI Injectable 3 Provided	41	95	1,179	370	460		156%	460	1,639	-	130	130
<b>Lubricant</b>	<b>85,000</b>	<b>56,000</b>	<b>540,000</b>	<b>-</b>	<b>190,000</b>		<b>184%</b>	<b>190,000</b>	<b>1,341,557</b>	<b>-</b>	<b>-</b>	<b>-</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Assegai Branded (5 mL)	-	-	-	-	58,000	8/11	(100)%	58,000	668,557	-	-	-
Lifestyles Liquid Personal Lubricant	85,000	56,000	540,000	-	132,000	8/11	309%	132,000	673,000	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	117		(100)%	117	230	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	117	3/16	(100)%	117	230	-	-	-
OCs Provided	29	58	887	330	632		40%	632	1,519	-	27	27
Non-PSI OCs Provided	29	58	887	330	632		40%	632	1,519	-	27	27
Referral to CD4/Clinical Staging	-	-	-	6,798	-		0%	-	4,429	-	-	-
Referral to CD4/Clinical Staging	-	-	-	6,798	-	12/14	-%	-	4,429	-	-	-
Referral to HIV Testing Services	-	-	220	2,400	5,736		(96)%	5,736	10,168	15	-	15
Referral to HIV Testing & Counseling	-	-	220	2,400	5,736	12/14	(96)%	5,736	10,168	15	-	15
Referral to Hypertension Management	-	3	39	50	3		1200%	3	42	-	-	-
Referral to Hypertension Management	-	3	39	50	3		1,200%	3	42	-	-	-
Referral to Implant 5 Insertion	-	-	-	20	-		0%	-	-	-	-	-
Referral to Implant 5 Insertion	-	-	-	20	-		-%	-	-	-	-	-
Referral to Injectable 1	8	60	332	100	16		1975%	16	348	-	6	6
Referral to Injectable 1	8	60	332	100	16		1,975%	16	348	-	6	6
Referral to Injectable 2	-	-	-	200	-		0%	-	-	-	-	-
Referral to Injectable 2	-	-	-	200	-		-%	-	-	-	-	-
Referral to Injectable 3	14	78	546	370	45		1113%	45	591	-	30	30
Referral to Injectable 3	14	78	546	370	45		1,113%	45	591	-	30	30
Referral to IUD 5 Insertion	-	-	-	30	-		0%	-	-	-	-	-
Referral to IUD 5 Insertion	-	-	-	30	-		-%	-	-	-	-	-
Referral to Linkage to HIV Care	163	246	3,632	6,798	430		745%	430	4,062	2,373	-	2,373
Referral to Linkage to HIV Care	163	246	3,632	6,798	430		745%	430	4,062	2,373	-	2,373
Referral to OCs	24	17	396	330	75		428%	75	471	-	6	6

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to OCs	24	17	396	330	75		428%	75	471	-	6	6
Referral to STI Screening (syndromic)	-	-	-	338	3		(100)%	3	3	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	338	3		(100)%	3	3	-	-	-
Referral to STI Treatment (unknown)	1	3	48	-	22		118%	22	221	-	-	-
Referral to STI Treatment (unknown)	1	3	48	-	22	12/14	118%	22	221	-	-	-
Referral to TB Diagnosis	-	-	19	6,750	-		0%	-	3,639	-	-	-
Referral to TB Diagnosis	-	-	19	6,750	-	12/14	-%	-	3,639	-	-	-
Referral to TB Screening	163	246	3,296	-	433		661%	433	3,729	-	-	-
Referrals to TB Screening	163	246	3,296	-	433		661%	433	3,729	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	5	3		(100)%	3	3	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	5	3		(100)%	3	3	-	-	-
Referral to Treatment for Vaginitis	-	-	-	5	4		(100)%	4	4	-	-	-
Referral to Treatment for Vaginitis	-	-	-	5	4		(100)%	4	4	-	-	-
Referral to Vasectomy	-	-	-	3	-		0%	-	-	-	-	-
Referral to Vasectomy	-	-	-	3	-		-%	-	-	-	-	-
Referral to Voluntary Medical Male Circumcision	-	1	122	449	171		(29)%	171	4,718	852	-	852
Referral to Voluntary Medical Male Circumcision	-	1	122	449	171	12/14	(29)%	171	4,718	852	-	852
STI Kit (Non-Ulcerative)	-	-	-	241	749		(100)%	749	3,764	-	-	-
Inguinal Bubo	-	-	-	5	2	4/10	(100)%	2	2	-	-	-
Urethral Discharge	-	-	-	12	273	3/10	(100)%	273	1,552	-	-	-
Vaginal Discharge	-	-	-	224	474	3/10	(100)%	474	2,210	-	-	-
STI Kit (Ulcerative)	-	-	-	184	119		(100)%	119	464	-	-	-
Genital Herpes	-	-	-	12	-	3/10	-%	-	20	-	-	-
Genital Ulcer Syndrome	-	-	-	172	119	3/10	(100)%	119	444	-	-	-
<b>STI Screening</b>	<b>4,327</b>	<b>5,634</b>	<b>61,887</b>	<b>-</b>	<b>9,589</b>		<b>545%</b>	<b>9,589</b>	<b>71,476</b>	<b>-</b>	<b>-</b>	<b>-</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
STI Screening	4,327	5,634	61,887	-	9,589		545%	9,589	71,476	-	-	-
TB Screening	4,327	5,634	61,903	-	484		12690%	484	62,387	-	-	-
TB Screening	4,327	5,634	61,903	-	484		12,690%	484	62,387	-	-	-
Treatment for Genital Herpes	1	1	25	12	2		1150%	2	27	-	2	2
Treatment for Genital Herpes	1	1	25	12	2		1,150%	2	27	-	2	2
Treatment for Inguinal Bubo	-	1	4	-	-		0%	-	4	-	-	-
Treatment for Inguinal Bubo	-	1	4	-	-		-%	-	4	-	-	-
Treatment for Lower Abdominal Pain	8	4	54	30	1		5300%	1	55	-	-	-
Treatment for Lower Abdominal Pair	8	4	54	30	1		5,300%	1	55	-	-	-
Treatment for Nonherpetic Genital Ulc	8	10	139	80	6		2217%	6	145	-	54	54
Treatment for Nonherpetic Genital U	8	10	139	80	6		2,217%	6	145	-	54	54
Treatment for Urethral Discharge (Mer	13	14	194	2	25		676%	25	219	-	27	27
Treatment for Urethral Discharge (M	13	14	194	2	25		676%	25	219	-	27	27
Treatment for Urethral Discharge (Wor	-	-	1	10	1		0%	1	2	-	-	-
Treatment for Urethral Discharge (W	-	-	1	10	1		-%	1	2	-	-	-
Treatment for Vaginitis	18	40	563	5	23		2348%	23	586	-	149	149
Treatment for Vaginitis	18	40	563	5	23		2,348%	23	586	-	149	149
Type 2 Diabetes Diagnosis	-	-	42	-	-		0%	-	42	-	-	-
Type 2 Diabetes Diagnosis	-	-	42	-	-		-%	-	42	-	-	-
Type 2 Diabetes Screening	13	16	259	-	-		0%	-	259	-	-	-
Type 2 Diabetes Screening	13	16	259	-	-		-%	-	259	-	-	-
Voluntary Medical Male Circumcision	69	237	3,923	4,500	4,240		(7)%	4,240	62,437	54,786	-	54,786
Male Circumcision (HIV-Negative)	-	-	-	-	4,062	6/09	(100)%	4,062	58,336	-	-	-
Voluntary Medical Male Circumcisioi	69	237	3,923	4,500	178		2,104%	178	4,101	54,786	-	54,786
<b>Zambia</b>										<b>746,448</b>	<b>91,962</b>	<b>838,410</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Condom	-	-	-	<b>453,600</b>	<b>836,352</b>		<b>(100)%</b>	<b>836,352</b>	<b>1,739,520</b>	-	-	-
Trust	-	-	-	<b>211,680</b>	<b>418,176</b>	8/16	(100)%	<b>418,176</b>	<b>418,176</b>	-	-	-
Trust Studded	-	-	-	<b>241,920</b>	<b>418,176</b>	1/08	(100)%	<b>418,176</b>	<b>1,321,344</b>	-	-	-
Early Infant Male Circumcision	-	-	-	-	<b>5</b>		<b>(100)%</b>	<b>5</b>	<b>5</b>	-	-	-
Early Infant MC (HIV-Negative)	-	-	-	-	<b>3</b>		(100)%	<b>3</b>	<b>3</b>	-	-	-
Early Infant MC (HIV-Positive)	-	-	-	-	<b>1</b>		(100)%	<b>1</b>	<b>1</b>	-	-	-
Early Infant MC (HIV-Unknown)	-	-	-	-	<b>1</b>		(100)%	<b>1</b>	<b>1</b>	-	-	-
Free Female Condom	<b>2,480</b>	-	<b>2,480</b>	<b>289</b>	-		<b>0%</b>	-	<b>189,180</b>	<b>42</b>	<b>5</b>	<b>46</b>
Free Female Condoms	<b>2,480</b>	-	<b>2,480</b>	<b>289</b>	-	1/12	-%	-	<b>189,180</b>	<b>42</b>	<b>5</b>	<b>46</b>
HIV Self-Testing Kit	<b>6,317</b>	<b>17,944</b>	<b>185,550</b>	-	<b>95,000</b>		<b>95%</b>	<b>95,000</b>	<b>280,550</b>	-	-	-
ORAQUICK HIV Self-Testing Kit (Pc	<b>6,317</b>	<b>17,944</b>	<b>185,550</b>	-	<b>95,000</b>	5/16	95%	<b>95,000</b>	<b>280,550</b>	-	-	-
HIV Testing Services	-	-	-	<b>133,242</b>	-		<b>0%</b>	-	<b>836,505</b>	-	-	-
VCT Individual (HIV-Negative)	-	-	-	<b>133,242</b>	-	12/09	-%	-	<b>836,505</b>	-	-	-
Implant 3 Insertion	<b>246</b>	<b>217</b>	<b>896</b>	-	<b>1</b>		<b>89500%</b>	<b>1</b>	<b>897</b>	-	<b>1,633</b>	<b>1,633</b>
Non-PSI Implant 3 Inserted	<b>246</b>	<b>217</b>	<b>896</b>	-	<b>1</b>		89,500%	<b>1</b>	<b>897</b>	-	<b>1,633</b>	<b>1,633</b>
Implant 4 Insertion	-	-	-	-	<b>116</b>		<b>(100)%</b>	<b>116</b>	<b>116</b>	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	<b>116</b>		(100)%	<b>116</b>	<b>116</b>	-	-	-
Implant 5	-	-	-	-	<b>(310)</b>		<b>0%</b>	<b>(310)</b>	<b>(178,192)</b>	-	-	-
PSI Implant 5 Distributed Inserted (	-	-	-	-	<b>(310)</b>		-%	<b>(310)</b>	<b>(178,192)</b>	-	-	-
Implant 5 Insertion	<b>1,018</b>	<b>2,930</b>	<b>20,719</b>	<b>27,997</b>	<b>2,731</b>		<b>659%</b>	<b>2,731</b>	<b>201,332</b>	-	<b>55,571</b>	<b>55,571</b>
PSI Implant 5 Inserted	-	-	-	-	<b>310</b>		(100)%	<b>310</b>	<b>178,192</b>	-	-	-
Non-PSI Implant 5 Inserted	<b>1,018</b>	<b>2,930</b>	<b>20,719</b>	<b>27,997</b>	<b>2,421</b>		756%	<b>2,421</b>	<b>23,140</b>	-	<b>55,571</b>	<b>55,571</b>
Injectable 2 Provided	<b>887</b>	<b>1,367</b>	<b>9,586</b>	-	-		<b>0%</b>	-	<b>9,586</b>	-	<b>831</b>	<b>831</b>
Non-PSI Injectable 2 Provided	<b>887</b>	<b>1,367</b>	<b>9,586</b>	-	-		-%	-	<b>9,586</b>	-	<b>831</b>	<b>831</b>
Injectable 3 Provided	<b>6,839</b>	<b>11,939</b>	<b>81,842</b>	<b>9,712</b>	<b>1,592</b>		<b>5041%</b>	<b>1,592</b>	<b>83,434</b>	-	<b>10,638</b>	<b>10,638</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Injectable 3 Provided	6,839	11,939	81,842	9,712	1,592		5,041%	1,592	83,434	-	10,638	10,638
IUD 10	3,135	-	3,135	-	(49)		0%	(49)	4,958	-	9,361	9,361
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(49)		-%	(49)	(78,096)	-	-	-
MyChoice IUD-10	3,135	-	3,135	-	-	11/08	-%	-	83,054	-	9,361	9,361
IUD 10 Insertion	104	322	1,857	11,999	135		1276%	135	80,039	-	6,161	6,161
PSI IUD 10 Inserted	-	-	-	-	49		(100)%	49	78,096	-	-	-
Non-PSI IUD 10 Inserted	104	322	1,857	11,999	86		2,059%	86	1,943	-	6,161	6,161
IUD 5 Insertion	-	-	8	150	241		(97)%	241	249	-	20	20
Non-PSI IUD 5 Inserted	-	-	8	150	241		(97)%	241	249	-	20	20
IUS 5	-	167	800	-	-		0%	-	800	-	1,775	1,775
LNG-IUS	-	167	800	-	-		-%	-	800	-	1,775	1,775
IUS 5 Insertion	64	35	178	-	-		0%	-	178	-	439	439
Non-PSI IUS 5 Inserted	64	35	178	-	-		-%	-	178	-	439	439
Male Circumcision (HIV-Positive)	-	-	-	-	143		(100)%	143	297	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	143		(100)%	143	297	-	-	-
OCs Provided	2,862	5,030	33,324	2,242	90		36927%	90	33,414	-	1,173	1,173
Non-PSI OCs Provided	2,862	5,030	33,324	2,242	90		36,927%	90	33,414	-	1,173	1,173
Safe Water Solution	139,764	119,512	754,860	864,000	754,608		0%	754,608	34,865,363	-	3,015	3,015
Clorin	139,764	119,512	754,860	864,000	754,608	11/98	-%	754,608	34,865,363	-	3,015	3,015
Tubal Ligation	-	17	171	-	-		0%	-	171	-	1,090	1,090
Tubal Ligation	-	17	171	-	-		-%	-	171	-	1,090	1,090
Vasectomy	-	-	29	-	-		0%	-	29	-	188	188
Vasectomy	-	-	29	-	-		-%	-	29	-	188	188
Voluntary Medical Male Circumcision	4,249	2,992	99,988	82,404	80,719		24%	80,719	666,443	745,866	-	745,866
Male Circumcision (HIV-Negative)	-	-	-	-	67,572	4/07	(100)%	67,572	353,786	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Male Circumcision (HIV-Unknown)	-	-	-	-	8,989	4/07	(100)%	8,989	208,511	-	-	-
Voluntary Medical Male Circumcision	4,249	2,992	99,988	82,404	4,158		2,305%	4,158	104,146	745,866	-	745,866
Woman Condom	4,296	2,640	32,232	81,624	9,600		236%	9,600	41,832	541	62	602
MAXIMUM DIVA	4,296	2,640	32,232	81,624	9,600	4/16	236%	9,600	41,832	541	62	602
<b>Zimbabwe</b>										1,794,727	44,951	1,839,677
Antiretroviral Treatment (Currently Enr	7,123	7,707	82,481	76,596	5,010		1546%	5,010	87,491	14,374	-	14,374
Antiretroviral Treatment (Currently E	7,123	7,707	82,481	76,596	5,010		1,546%	5,010	87,491	14,374	-	14,374
Antiretroviral Treatment (Newly Enrolle	255	578	8,806	-	5,283		67%	5,283	14,089	-	-	-
Antiretroviral Treatment (Newly Enrc	255	578	8,806	-	5,283		67%	5,283	14,089	-	-	-
CD4 Tests Provided to HIV+ Clients	259	431	6,833	-	639		969%	639	7,472	-	-	-
CD4 Tests Provided to HIV+ Clients	259	431	6,833	-	639		969%	639	7,472	-	-	-
Cervical Cancer-HPV DNA and Refer 1	-	-	11	-	-		0%	-	11	-	3	3
Cervical Cancer-HPV DNA and Refe	-	-	11	-	-		-%	-	11	-	3	3
Cervical Cancer-HPV DNA and Refer 1	-	-	9	-	-		0%	-	9	-	2	2
Cervical Cancer-HPV DNA and Refe	-	-	9	-	-		-%	-	9	-	2	2
Cervical Cancer-Pap and Refer to any	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-Pap and Refer to ai	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-Pap and Refer to Con	-	-	-	-	7		(100)%	7	9	-	-	-
Cervical Cancer-Pap and Refer to C	-	-	-	-	7		(100)%	7	9	-	-	-
Cervical Cancer-Pap Smear Screening	-	-	-	-	116		(100)%	116	116	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	116		(100)%	116	116	-	-	-
Cervical Cancer-VIA and Conization	1	7	168	185	10		1580%	10	178	-	48	48
Cervical Cancer-VIA and Conization	1	7	168	185	10		1,580%	10	178	-	48	48
Cervical Cancer-VIA and Cryotherapy	28	41	497	278	1,181		(58)%	1,181	3,555	-	138	138
Cervical Cancer-VIA and Cryotherap	28	41	497	278	1,181	11/13	(58)%	1,181	3,555	-	138	138

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-VIA and Refer to any	-	4	38	-	17		124%	17	286	-	5	5
Cervical Cancer-VIA and Refer to ar	-	4	38	-	17	1/15	124%	17	286	-	5	5
Cervical Cancer-VIA and Refer to Con	-	-	69	200	402		(83)%	402	1,936	-	10	10
Cervical Cancer-VIA and Refer to Ci	-	-	69	200	402	12/14	(83)%	402	1,936	-	10	10
Cervical Cancer-VIA and Refer to Cryc	-	-	16	-	33		(52)%	33	449	-	2	2
Cervical Cancer-VIA and Refer to Ci	-	-	16	-	33	12/14	(52)%	33	449	-	2	2
Cervical Cancer-VIA/VILI Screening	945	1,385	15,981	-	26,594		(40)%	26,594	67,316	-	-	-
Cervical Cancer-VIA/VILI Screening	945	1,385	15,981	-	26,594		(40)%	26,594	67,316	-	-	-
Condom	1,255,080	1,969,400	15,996,240	18,200,000	25,178,622		(36)%	25,178,622	309,577,585	343,148	21,827	364,975
PSI Condom Distributed Provided	-	-	-	-	(43,698)		-%	(43,698)	(61,465)	-	-	-
Protector Plus	366,960	563,760	5,713,200	7,280,000	11,649,920	1/08	(51)%	11,649,920	273,068,890	122,558	7,796	130,354
Protector Plus Flavors	888,120	1,405,640	10,283,040	10,920,000	13,572,400	3/14	(24)%	13,572,400	36,570,160	220,590	14,032	234,621
Condom Provided	-	-	-	-	167,928		(100)%	167,928	235,493	-	-	-
PSI Condom Provided	-	-	-	-	43,698		(100)%	43,698	61,465	-	-	-
Non-PSI Condom Provided	-	-	-	-	124,230		(100)%	124,230	174,028	-	-	-
Emergency Contraception	(2)	(4)	57,685	120,000	197,597		(71)%	197,597	785,052	-	297	297
PSI Emergency Contraception Distr	(2)	(4)	(60)	-	(219)		-%	(219)	(443)	-	-	-
Pregnon	-	-	57,745	120,000	124,037	9/10	(53)%	124,037	702,195	-	297	297
Revoke-72	-	-	-	-	73,779	12/15	(100)%	73,779	83,300	-	-	-
Emergency Contraception Provided	2	4	92	-	313		(71)%	313	628	-	1	1
PSI Emergency Contraception Prov	2	4	60	-	219		(73)%	219	443	-	-	-
Non-PSI Emergency Contraception I	-	-	32	-	94		(66)%	94	185	-	-	-
Female Condom	56,400	23,240	515,560	600,000	1,017,642		(49)%	1,017,642	23,861,688	11,060	541	11,601
PSI Female Condom Distributed Pr	-	-	-	-	(11,058)		-%	(11,058)	(16,366)	-	-	-
Care	56,400	23,240	515,560	600,000	1,028,700	6/97	(50)%	1,028,700	23,878,054	11,060	541	11,601

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom Provided	-	-	-	-	21,730		(100)%	21,730	30,088	-	-	-
PSI Female Condom Provided	-	-	-	-	11,058		(100)%	11,058	16,366	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	10,672		(100)%	10,672	13,722	-	-	-
Free Female Condom	-	-	-	-	14,000		(100)%	14,000	338,000	-	-	-
Care (Free Distribution)	-	-	-	-	14,000	12/11	(100)%	14,000	338,000	-	-	-
HIV Testing Services	7,376	10,161	209,441	220,000	316,961		(34)%	316,961	2,878,981	13,883	-	13,883
VCT Concordant Couple (HIV-Nega	-	-	-	-	34,800	12/09	(100)%	34,800	334,640	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	1,364	12/09	(100)%	1,364	24,938	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	1,549	12/09	(100)%	1,549	14,482	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	1,549	12/09	(100)%	1,549	14,482	-	-	-
VCT Individual (HIV-Negative)	5,497	7,699	186,648	203,500	251,984	12/09	(26)%	251,984	2,215,255	12,372	-	12,372
VCT Individual (HIV-Positive)	1,879	2,462	22,793	16,500	25,715	12/09	(11)%	25,715	275,184	1,511	-	1,511
Hypertension Diagnosis	22	29	276	-	4		6800%	4	280	-	-	-
Hypertension Diagnosis	22	29	276	-	4		6,800%	4	280	-	-	-
Hypertension Screening	7,131	10,450	321,263	-	12,961		2379%	12,961	334,224	-	-	-
Hypertension Screening	7,131	10,450	321,263	-	12,961		2,379%	12,961	334,224	-	-	-
Hypertension_Controlled Condition	5	3	63	-	3		2000%	3	66	-	-	-
Hypertension_Controlled Condition	5	3	63	-	3		2,000%	3	66	-	-	-
Implant 3	(3)	57	(50)	-	(122)		0%	(122)	323	-	(45)	(45)
PSI Implant 3 Distributed Inserted ('	(3)	(30)	(410)	-	(622)		-%	(622)	(2,341)	-	(370)	(370)
Implanon	-	87	360	-	500	9/15	(28)%	500	2,664	-	325	325
Implant 3 Insertion	4	142	1,459	1,151	3,480		(58)%	3,480	9,056	-	1,464	1,464
PSI Implant 3 Inserted	3	30	410	-	622		(34)%	622	2,341	-	411	411
Non-PSI Implant 3 Inserted	1	112	1,049	1,151	2,858	3/16	(63)%	2,858	6,715	-	1,052	1,052
Implant 5	(206)	(148)	(2,429)	-	(667)		0%	(667)	(29,423)	-	(3,230)	(3,230)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Distributed Inserted (	(206)	(148)	(2,429)	-	(667)		-%	(667)	(29,423)	-	(3,230)	(3,230)
Implant 5 Insertion	657	496	7,965	9,240	17,413		(54)%	17,413	82,478	-	11,769	11,769
PSI Implant 5 Inserted	206	148	2,429	-	667		264%	667	29,423	-	3,589	3,589
Non-PSI Implant 5 Inserted	451	348	5,536	9,240	16,746	1/14	(67)%	16,746	53,055	-	8,180	8,180
Injectable 3	4,579	1,619	17,514	12,000	19,378		(10)%	19,378	887,969	-	1,126	1,126
PSI Injectable 3 Distributed Provide	(496)	(743)	(9,431)	-	(1,158)		-%	(1,158)	(39,887)	-	(606)	(606)
Depo-Provera	5,075	2,362	26,945	-	2,575	9/00	946%	2,575	697,721	-	1,732	1,732
Petogen	-	-	-	12,000	17,961	9/09	(100)%	17,961	230,135	-	-	-
Injectable 3 Provided	2,765	3,277	49,552	39,150	68,505		(28)%	68,505	176,205	-	3,540	3,540
PSI Injectable 3 Provided	496	743	9,431	-	1,158		714%	1,158	39,887	-	674	674
Non-PSI Injectable 3 Provided	2,269	2,535	40,121	39,150	67,347		(40)%	67,347	136,318	-	2,866	2,866
IUD 10	(32)	48	212	-	(281)		0%	(281)	2,446	-	349	349
PSI IUD 10 Distributed Inserted (1)	(112)	(125)	(1,538)	-	(2,031)	3/16	-%	(2,031)	(7,545)	-	(2,534)	(2,534)
TCU 380A IUCD Copper T	80	173	1,750	-	1,750	4/12	-%	1,750	9,991	-	2,884	2,884
IUD 10 Insertion	112	127	1,559	1,253	2,033		(23)%	2,033	7,746	-	2,854	2,854
PSI IUD 10 Inserted	112	125	1,538	-	2,031	3/16	(24)%	2,031	7,545	-	2,816	2,816
Non-PSI IUD 10 Inserted	-	2	21	1,253	2		950%	2	201	-	38	38
IUS 5	(4)	(6)	154	-	-		0%	-	154	-	188	188
PSI IUS 5 Distributed Inserted (1)	(4)	(27)	(171)	(500)	-		-%	-	(171)	-	(209)	(209)
LNG-IUS	-	22	325	500	-		-%	-	325	-	397	397
IUS 5 Insertion	4	27	188	500	-		0%	-	188	-	255	255
PSI IUS 5 Inserted	4	27	171	500	-		-%	-	171	-	232	232
Non-PSI IUS 5 Inserted	-	-	17	-	-		-%	-	17	-	23	23
LLIN	-	-	-	322,644	863,993		(100)%	863,993	5,332,182	-	-	-
Interceptor	-	-	-	322,644	863,993	10/10	(100)%	863,993	5,332,182	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	71,000	35,750	454,550	-	-		0%	-	454,550	-	-	-
Personal lubricants water based 4.5	71,000	35,750	454,550	-	-	2/17	-%	-	454,550	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	1,227		(100)%	1,227	3,214	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	1,227		(100)%	1,227	3,214	-	-	-
OCs	(528)	(967)	(11,606)	-	(9,514)		0%	(9,514)	3,664,377	-	(202)	(202)
PSI OCs Distributed Provided	(528)	(967)	(11,606)	-	(17,254)		-%	(17,254)	(232,415)	-	(202)	(202)
Control Combined OC	-	-	-	-	2,880	4/12	(100)%	2,880	561,777	-	-	-
Marvelon	-	-	-	-	4,860	2/99	(100)%	4,860	3,335,015	-	-	-
OCs Provided	4,010	5,825	137,245	112,800	390,702		(65)%	390,702	901,639	-	2,655	2,655
PSI OCs Provided	528	967	11,606	-	17,254		(33)%	17,254	232,415	-	224	224
Non-PSI OCs Provided	3,482	4,858	125,639	112,800	373,448		(66)%	373,448	669,224	-	2,430	2,430
PrEP	50	264	2,713	19,960	403		573%	403	3,116	88	-	88
PrEP	50	264	2,713	19,960	403		573%	403	3,116	88	-	88
Referral to Advanced Cervical Cancer	1	5	57	85	142		(60)%	142	400	-	-	-
Referral to Advanced Cervical Canc	1	5	57	85	142	12/14	(60)%	142	400	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,400	2,373		(100)%	2,373	4,459	-	-	-
Referral to CD4/Clinical Staging	-	-	-	2,400	2,373		(100)%	2,373	4,459	-	-	-
Referral to Clinical Staging	-	-	-	-	497		(100)%	497	671	-	-	-
Referral to Clinical Staging	-	-	-	-	497	3/16	(100)%	497	671	-	-	-
Referral to Diabetes Management (nor	-	-	1	-	-		0%	-	1	-	-	-
Referral to Diabetes Management (r	-	-	1	-	-		-%	-	1	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	8		(100)%	8	66	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	8		(100)%	8	66	-	-	-
Referral to Emergency Contraception	-	-	-	-	6		(100)%	6	8	-	-	-
Referral to Emergency Contraceptio	-	-	-	-	6		(100)%	6	8	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to HIV Testing Services	-	17	51	-	718		(93)%	718	1,231	2	-	2
Referral to HIV Testing & Counseling	-	17	51	-	718		(93)%	718	1,231	2	-	2
Referral to Hypertension Management	22	16	497	-	24		1971%	24	521	-	-	-
Referral to Hypertension Management	22	16	497	-	24		1,971%	24	521	-	-	-
Referral to Implant 3 Insertion	2	1	8	-	1		700%	1	9	-	4	4
Referral to Implant 3 Insertion	2	1	8	-	1		700%	1	9	-	4	4
Referral to Implant 5 Insertion	1	3	16	-	-		0%	-	990	-	12	12
Referral to Implant 5 Insertion	1	3	16	-	-	12/13	-%	-	990	-	12	12
Referral to Injectable 1	-	-	-	-	16		(100)%	16	16	-	-	-
Referral to Injectable 1	-	-	-	-	16		(100)%	16	16	-	-	-
Referral to Injectable 3	11	2	18	-	-		0%	-	750	-	1	1
Referral to Injectable 3	11	2	18	-	-		-%	-	750	-	1	1
Referral to IUD 10 Insertion	2	2	40	-	7		471%	7	204	-	37	37
Referral to IUD 10 Insertion	2	2	40	-	7	12/13	471%	7	204	-	37	37
Referral to IUD Insertion (duration unknown)	-	-	5	-	2		150%	2	7	-	3	3
Referral to IUD Insertion (duration unknown)	-	-	5	-	2		150%	2	7	-	3	3
Referral to IUS 3 Insertion	-	-	26	-	-		0%	-	26	-	13	13
Referral to IUS 3 Insertion	-	-	26	-	-		-%	-	26	-	13	13
Referral to Linkage to HIV Care	505	371	6,094	-	2,082		193%	2,082	8,176	3,373	-	3,373
Referral to Linkage to HIV Care	505	371	6,094	-	2,082		193%	2,082	8,176	3,373	-	3,373
Referral to OCs	-	-	-	-	4		(100)%	4	851	-	-	-
Referral to OCs	-	-	-	-	4	1/15	(100)%	4	851	-	-	-
Referral to Pre-Exposure Prophylaxis (PEP)	-	36	230	-	-		0%	-	230	4	-	4
Referral to Pre-Exposure Prophylaxis (PEP)	-	36	230	-	-		-%	-	230	4	-	4
Referral to STI Screening (syndromic)	9	6	97	-	5		1840%	5	102	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referrals to STI Screening (syndromic)	9	6	97	-	5		1,840%	5	102	-	-	-
Referral to STI Treatment (unknown)	-	-	7	-	12		(42)%	12	2,244	-	-	-
Referral to STI Treatment (unknown)	-	-	7	-	12	1/15	(42)%	12	2,244	-	-	-
Referral to TB Diagnosis	7	25	233	-	11		2018%	11	244	-	-	-
Referral to TB Diagnosis	7	25	233	-	11		2,018%	11	244	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	1	-	2		(50)%	2	17	-	1	1
Referral to TB DOTS (completion confirmed)	-	-	1	-	2		(50)%	2	17	-	1	1
Referral to TB DOTS (completion unknown)	22	14	244	300	467		(48)%	467	2,630	-	135	135
Referral to TB DOTS (completion unknown)	22	14	244	300	467	12/13	(48)%	467	2,630	-	135	135
Referral to TB Screening	-	1,892	12,335	-	1		1233400%	1	12,336	-	-	-
Referrals to TB Screening	-	1,892	12,335	-	1		1,233,400%	1	12,336	-	-	-
Referral to Treatment for Cervicitis	4	3	46	-	4		1050%	4	69	-	2	2
Referral to Treatment for Cervicitis	4	3	46	-	4	1/15	1,050%	4	69	-	2	2
Referral to Treatment for Genital Herpes	-	-	3	-	-		0%	-	3	-	-	-
Referral to Treatment for Genital Herpes	-	-	3	-	-		-%	-	3	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	4	-	8		(50)%	8	27	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	4	-	8		(50)%	8	27	-	-	-
Referral to Treatment for Urethral Discharge	1	1	4	-	32		(88)%	32	60	-	-	-
Referral to Treatment for Urethral Discharge	1	1	4	-	32		(88)%	32	60	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	3		(100)%	3	8	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	3	1/15	(100)%	3	8	-	-	-
Referral to Tubal Ligation	-	-	1	-	-		0%	-	1	-	2	2
Referral to Tubal Ligation	-	-	1	-	-		-%	-	1	-	2	2
Referral to Tx for Nonherpetic Genital Infection	-	-	25	-	13		92%	13	47	-	4	4
Referral to Tx for Nonherpetic Genital Infection	-	-	25	-	13		92%	13	47	-	4	4

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Tx for Urethral Discharge (1	2	-	100	-	156		(36)%	156	499	-	9	9
Referral to Tx for Urethral Discharge	2	-	100	-	156		(36)%	156	499	-	9	9
Referral to Voluntary Medical Male Cir	64	13	340	1,800	2,351		(86)%	2,351	10,695	1,152	-	1,152
Referral to Voluntary Medical Male C	64	13	340	1,800	2,351	12/14	(86)%	2,351	10,695	1,152	-	1,152
Safe Water Solution	-	-	133,066	150,000	120,121		11%	120,121	1,697,655	-	779	779
WaterGuard	-	-	-	150,000	-	9/10	-%	-	1,049,801	-	-	-
WaterGuard Solution 150mL SI	-	-	133,066	-	120,121	4/14	11%	120,121	647,854	-	779	779
STI Screening	64	357	3,917	-	3,655		7%	3,655	9,338	-	-	-
STI Screening	64	357	3,917	-	3,655		7%	3,655	9,338	-	-	-
TB Diagnosis	25	30	414	-	336		23%	336	1,149	-	-	-
TB Diagnosis	25	30	414	-	336		23%	336	1,149	-	-	-
TB DOTS	2	-	8	-	11		(27)%	11	50	-	11	11
TB DOTS	2	-	8	-	11	7/14	(27)%	11	50	-	11	11
TB Screening	14,263	18,603	236,661	-	283,969		(17)%	283,969	768,981	-	-	-
TB Screening	14,263	18,603	236,661	-	283,969		(17)%	283,969	768,981	-	-	-
Treatment for Cervicitis	2	4	270	120	20		1250%	20	290	-	25	25
Treatment for Cervicitis	2	4	270	120	20		1,250%	20	290	-	25	25
Treatment for Genital Herpes	-	1	22	-	3		633%	3	25	-	1	1
Treatment for Genital Herpes	-	1	22	-	3		633%	3	25	-	1	1
Treatment for Inguinal Bubo	-	1	5	-	5		0%	5	10	-	-	-
Treatment for Inguinal Bubo	-	1	5	-	5		-%	5	10	-	-	-
Treatment for Lower Abdominal Pain	1	2	15	-	2		650%	2	17	-	-	-
Treatment for Lower Abdominal Pair	1	2	15	-	2		650%	2	17	-	-	-
Treatment for Nonherpetic Genital Ulc	18	23	355	70	45		689%	45	400	-	127	127
Treatment for Nonherpetic Genital U	18	23	355	70	45		689%	45	400	-	127	127

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Urethral Discharge (Mer	10	9	226	70	25		804%	25	251	-	28	28
Treatment for Urethral Discharge (M	10	9	226	70	25		804%	25	251	-	28	28
Treatment for Urethral Discharge (Wor	18	37	867	330	83		945%	83	950	-	160	160
Treatment for Urethral Discharge (W	18	37	867	330	83		945%	83	950	-	160	160
Treatment for Vaginitis	-	-	1	-	-		0%	-	1	-	-	-
Treatment for Vaginitis	-	-	1	-	-		-%	-	1	-	-	-
Type 2 Diabetes Diagnosis	-	-	5	-	-		0%	-	5	-	-	-
Type 2 Diabetes Diagnosis	-	-	5	-	-		-%	-	5	-	-	-
Type 2 Diabetes Screening	392	455	6,076	-	-		0%	-	6,076	-	-	-
Type 2 Diabetes Screening	392	455	6,076	-	-		-%	-	6,076	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	6	-	-		0%	-	6	-	-	-
Type 2 Diabetes_Controlled Conditic	-	-	6	-	-		-%	-	6	-	-	-
Voluntary Medical Male Circumcision	13,135	19,165	207,743	180,000	139,719		49%	139,719	896,356	1,407,643	-	1,407,643
Male Circumcision (HIV-Negative)	-	-	-	-	128,675	1/09	(100)%	128,675	674,924	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	93	1/09	(100)%	93	2,738	-	-	-
Voluntary Medical Male Circumcision	13,135	19,165	207,743	180,000	10,951		1,797%	10,951	218,694	1,407,643	-	1,407,643

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Southern Africa</b>														
<b>Angola</b>							\$0		\$0	\$0	NA			
<b>Medicines &amp; Supplies</b>														
IUD Insertion Kit	12/2017	0	1,009	0	1,009	100%	\$0	NA	\$0	\$0	NA	16,529	987	16.75
MVA Kit	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	82	0	NA
<b>Condom</b>														
Sensual Champagne	12/2017	0	73,620	0	73,620	100%	\$0	NA	\$0	\$0	NA	349,416	75,612	4.62
Sensual Chocolate	12/2017	0	119,880	0	119,880	100%	\$0	NA	\$0	\$0	NA	507,816	130,068	3.90
Sensual Maracuja	12/2017	0	109,224	0	109,224	100%	\$0	NA	\$0	\$0	NA	802,080	98,868	8.11
Sensual Menta	12/2017	0	129,960	0	129,960	100%	\$0	NA	\$0	\$0	NA	1,138,688	139,932	8.14
Sensual Morango	12/2017	0	122,436	0	122,436	100%	\$0	NA	\$0	\$0	NA	628,488	123,396	5.09
<b>LLIN</b>														
Generic LLINs	12/2017	0	293,566	0	293,566	100%	\$0	NA	\$0	\$0	NA	56,558	353,413	0.16
Joia	12/2017	0	369	0	369	100%	\$0	NA	\$0	\$0	NA	7,648	4,379	1.75
<b>Malaria PPT (ACT)</b>														
ALU 20mg/120mg, 12's, 3-8Yrs (15	12/2017	0	3,293	0	3,293	100%	\$0	NA	\$0	\$0	NA	573	2,451	0.23
ALU 20mg/120mg, 18's, 9-14Yrs (2	12/2017	0	4,826	0	4,826	100%	\$0	NA	\$0	\$0	NA	15,155	3,157	4.80
ALU 20mg/120mg, 24's, >14Yrs (>	12/2017	0	12,350	0	12,350	100%	\$0	NA	\$0	\$0	NA	2,754	7,147	0.39
ALU 20mg/120mg, 6's, >3Yrs (5-14	12/2017	0	6,313	0	6,313	100%	\$0	NA	\$0	\$0	NA	1,372	4,735	0.29
<b>Malaria RDK</b>														
Bioline (RDT)	12/2017	0	150	0	150	100%	\$0	NA	\$0	\$0	NA	3,175	1,883	1.69
<b>Misoprostol for PAC (Sublingual)</b>														
ACE Miso (Misoprostol 200mcg tab	12/2017	0	1,732	0	1,732	100%	\$0	NA	\$0	\$0	NA	1,072	1,867	0.57
<b>Water Treatment Tablets</b>														
Certeza Water Tabs	12/2017	0	1,320,500	0	1,320,500	100%	\$0	NA	\$0	\$0	NA	3,680,388	863,467	4.26
<b>Implant 5</b>														
Jadelle	12/2017	0	500	0	500	100%	\$0	NA	\$0	NA	NA	4,500	NA	NA
<b>IUD 10</b>														
Coper T 380 A – ENOVA	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,786	0	NA
<b>OCs</b>														
MEURI	12/2017	0	8,493	0	8,493	100%	\$0	NA	\$0	\$0	NA	140,507	4,124	34.07

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Lesotho</b>							\$0		\$422	\$0	NA				
<b>Condom</b>															
Lovers Plus C&F	12/2017	0	0	0	0	NA	\$0	NA	\$97	\$0	NA	0	0	NA	
Trust	12/2017	0	0	0	0	NA	\$0	NA	\$76	\$0	NA	0	0	NA	
Trust Studded	12/2017	0	0	0	0	NA	\$0	NA	\$249	\$0	NA	0	0	NA	
<b>Female Condom</b>															
Generic	12/2017	0	2,454	0	2,454	100%	\$0	NA	\$0	\$0	NA	97,854	7,073	13.83	
<b>Free Condom</b>															
Camouflage Free	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	819,600	22,800	35.95	
Vibe Condom	12/2017	0	139,365	0	139,365	100%	\$0	NA	\$0	\$0	NA	12,913,556	398,963	32.37	
<b>Madagascar</b>							\$0		\$40,239	\$0	NA				
<b>Medicines &amp; Supplies</b>															
ACTELLIC 300 CS 833mL Bottle	12/2017	0	25,020	0	25,020	100%	\$0	NA	\$0	\$0	NA	499,992	8,440	59.24	
Alphacypermethrin 5% WP, 150 m	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	8,871	0	NA	
Sulfadoxine 500mg/ Pyrimethamin	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	204,000	291,667	0.70	
Syringe IPAS MVA Plus Aspirator	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	64	1	96.00	
<b>Condom</b>															
Protector Plus	12/2017	533,184	1,392	0	534,576	0%	\$0	NA	\$0	\$0	NA	322,753	411,200	0.78	
YES	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	60	610	0.10	
<b>Female Condom</b>															
Feeling	12/2017	984	54	0	1,038	5%	\$0	NA	\$0	\$0	NA	300	2,097	0.14	
<b>Free Condom</b>															
Generic	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,100	167	18.60	
Generic Condom	12/2017	0	24,014	0	24,014	100%	\$0	NA	\$0	\$0	NA	25,952	54,202	0.48	
<b>Lubricant A</b>															
Gel Lubricant 5 mL	12/2017	0	72,200	700	72,900	100%	\$0	NA	\$0	\$0	NA	812,000	65,301	12.43	
<b>LLIN</b>															
Generic net "PERMANET WHITE"	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	8,552	157	54.59	
Global Fund Free Nets	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	19,378	0	NA	
Net Protect	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,403	0	NA	
PermaNet-White	12/2017	0	4	0	4	100%	\$0	NA	\$0	\$0	NA	48,870	418	116.82	
Permanet Blue	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	137	0	411.00	
Super Moustiquaire-Blue	12/2017	1,368	0	2	1,370	0%	\$0	NA	\$0	\$0	NA	490	1,358	0.36	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$0		\$40,239	\$0	NA				
<b>LLIN</b>															
Super Moustiquaire-White	12/2017	262,485	0	10	262,495	0%	\$0	NA	\$0	\$0	NA	318,561	87,497	3.64	
Yorkool Blue (Generic Net)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	333,918	1	500,877.00	
Yorkool White (Generic Net)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,001,650	0	NA	
<b>Malaria PPT (ACT)</b>															
ACT 100 mg (1x3's)	12/2017	0	0	443	443	NA	\$0	NA	\$0	\$0	NA	15,050	0	NA	
ACT 100 mg (1x6's)	12/2017	0	78,125	0	78,125	100%	\$0	NA	\$0	\$0	NA	21,350	26,050	0.82	
ACT 25 mg (1x3's)	12/2017	0	3,300	13,094	16,394	100%	\$0	NA	\$0	\$0	NA	3,500	1,100	3.18	
ACT 50 mg (1x3's)	12/2017	0	207,800	0	207,800	100%	\$0	NA	\$0	\$0	NA	0	69,267	NA	
AL for Adolescent, 20/120mg, 18's	12/2017	0	10,469	-10,469	0	100%	\$0	NA	\$0	\$0	NA	0	3,490	NA	
AL for Adult, 20/120mg, 24's	12/2017	0	15,398	-15,398	0	100%	\$0	NA	\$0	\$0	NA	0	5,133	NA	
AL for Infant, 20/120mg, 6's	12/2017	0	8,267	-8,267	0	100%	\$0	NA	\$0	\$0	NA	0	2,756	NA	
AL for Toddler, 20/120mg, 12's	12/2017	0	10,729	-10,729	0	100%	\$0	NA	\$0	\$0	NA	0	3,576	NA	
Artesunate Amodiaquine 25 mg	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
Artesunate Amodiaquine combo 50	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
ASAQ for Adolescent, 100/270mg,	12/2017	0	130,272	-130,272	0	100%	\$0	NA	\$0	\$0	NA	0	43,424	NA	
ASAQ for Adult, 100/270mg, 6's	12/2017	0	171,423	-171,423	0	100%	\$0	NA	\$0	\$0	NA	0	57,141	NA	
ASAQ for Infant, 25/67.5mg, 3's	12/2017	0	34,042	-34,042	0	100%	\$0	NA	\$0	\$0	NA	0	11,347	NA	
ASAQ for Toddler, 50/135mg, 3's	12/2017	0	180,744	-180,744	0	100%	\$0	NA	\$0	\$0	NA	0	60,248	NA	
<b>Malaria RDK</b>															
RDT Malaria	12/2017	0	0	0	0	NA	\$0	NA	\$6,994	\$0	NA	506,525	0	NA	
<b>Chlorhexidine</b>															
Arofoitra	12/2017	270	1	0	271	0%	\$0	NA	\$0	\$0	NA	121,421	267	454.76	
<b>Diarrhea Treatment Kit</b>															
Hydrazinc	12/2017	17,550	0	3,002	20,552	0%	\$0	NA	\$4,711	\$0	NA	14,254	11,160	1.28	
ORS-Zinc	12/2017	400	0	0	400	0%	\$0	NA	\$0	\$0	NA	8,580	133	64.35	
Viasur	12/2017	900	0	14,536	15,436	0%	\$0	NA	\$0	\$0	NA	11,433	2,483	4.60	
<b>Micronutrient Powder</b>															
ZAZATOMADY (ZZT)	12/2017	29,490	0	0	29,490	0%	\$0	NA	\$533	\$0	NA	5,818,920	18,700	311.17	
<b>Safe Water Solution</b>															
Sur Eau 40 mL	12/2017	6,630	0	200	6,830	0%	\$0	NA	\$0	\$0	NA	11,850	2,370	5.00	



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$0		\$40,239	\$0	NA				
<u>Safe Water Solution</u>															
Sur Eau Vaovao	12/2017	39,491	0	4,029	43,520	0%	\$0	NA	\$0	\$0	NA	1,841,228	63,277	29.10	
<u>Water Treatment Tablets</u>															
SUR EAU PILINA (67mg tablet)	12/2017	157,680	75,920	0	233,600	33%	\$0	NA	\$0	\$0	NA	1,488,620	263,833	5.64	
<u>Implant 3</u>															
Implanon	12/2017	122	0	0	122	0%	\$0	NA	\$0	\$0	NA	2,007	41	48.95	
Implanon NXT	12/2017	237	0	0	237	0%	\$0	NA	\$0	\$0	NA	2,233	425	5.26	
<u>Implant 4</u>															
Implant Zarin	12/2017	0	0	34	34	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<u>Implant 5</u>															
Jadelle	12/2017	207	0	0	207	0%	\$0	NA	\$0	\$0	NA	117	69	1.70	
<u>Injectable 3</u>															
Confiance Injectable	12/2017	125,285	0	3	125,288	0%	\$0	NA	\$4,985	\$0	NA	114,029	155,560	0.73	
Sayana Press	12/2017	48,530	0	0	48,530	0%	\$0	NA	\$0	\$0	NA	93,155	34,428	2.71	
<u>IUD 10</u>															
Copper T	12/2017	70	0	0	70	0%	\$0	NA	\$0	\$0	NA	362	30	11.93	
IUD 1 x 5	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	55	0	NA	
Pregna T Cu 380A	12/2017	1,400	80	0	1,480	5%	\$0	NA	\$0	\$0	NA	25,243	1,020	24.74	
<u>OCs</u>															
Pilplan	12/2017	225,719	0	20,061	245,780	0%	\$0	NA	\$23,016	\$0	NA	240,973	267,261	0.90	
<u>SDM (Cycle Beads)</u>															
Rojo	12/2017	0	190	26	216	100%	\$0	NA	\$0	\$0	NA	6,498	148	44.00	
<u>Pneumonia PPT</u>															
PneumoStop Tablet (6 x 480 mg)	12/2017	2,220	0	0	2,220	0%	\$0	NA	\$0	\$0	NA	70	1,140	0.06	
Pneumox 250 (10's) for Children u	12/2017	12,240	8,520	0	20,760	41%	\$0	NA	\$0	\$0	NA	20,858	13,193	1.58	
<b>Mozambique</b>							\$58,998		\$424,199	\$89,436	4.74				
<u>LLIC</u>															
Serena Curtina	12/2017	0	7,188	0	7,188	100%	\$0	NA	-\$657	\$0	NA	1,724	2,403	0.72	
<u>Medicines &amp; Supplies</u>															
JV (Finger Vibes)	12/2017	0	7,782	0	7,782	100%	\$0	NA	\$12	\$0	NA	0	3,096	NA	
Teste Glicemia	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,324	0	NA	
<u>Condom</u>															
J0.1	12/2017	0	0	0	0	NA	\$0	NA	\$72,686	\$23,656	3.07	0	576,000	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Mozambique</b>							\$58,998		\$424,199	\$89,436	4.74				
<b>Condom</b>															
J1	12/2017	0	52,248	528	52,776	100%	\$0	NA	\$78,118	\$12,440	6.28	202,704	593,440	0.34	
J14	12/2017	216	6,336	0	6,552	97%	\$25	0%	-\$455	\$8	-55.45	0	2,184	NA	
J2	12/2017	-115,200	3,744	0	-111,456	-3%	-\$4,070	100%	\$12,473	-\$1,357	-9.19	116,280	-37,152	-3.13	
J24	12/2017	0	0	0	0	NA	\$0	NA	\$72,686	\$23,656	3.07	864,000	576,000	1.50	
J3	12/2017	979,200	0	0	979,200	0%	\$34,597	100%	\$149,030	\$11,532	12.92	1,368	326,400	0.00	
Jeito 4	12/2017	0	0	288	288	NA	\$0	NA	\$6,264	\$0	NA	44,568	0	NA	
Jeito 5	12/2017	0	504	360	864	100%	\$0	NA	\$2,443	\$0	NA	3,384	168	20.14	
Jzero	12/2017	0	0	0	0	NA	\$0	NA	-\$12	\$0	NA	0	0	NA	
<b>Free Condom</b>															
No Logo Condom Lubricant Comb	12/2017	0	8,928	0	8,928	100%	\$0	NA	\$0	\$0	NA	33,135	20,539	1.61	
<b>Free Female Condom</b>															
Female Condom Free	12/2017	0	0	0	0	NA	\$0	NA	-\$3,910	\$0	NA	0	4	NA	
<b>Lubricant E</b>															
J8 (60 ml tube)	12/2017	137	0	0	137	0%	\$180	0%	\$138	\$60	2.30	6,934	46	151.84	
<b>LLIN</b>															
Serena	12/2017	0	18	0	18	100%	\$0	NA	\$10,956	\$1,430	7.66	695	1,753	0.40	
<b>Malaria RDK</b>															
Teste Malaria Rapido	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,062	0	NA	
<b>Micronutrient Powder</b>															
Super Bebe	12/2017	0	0	0	0	NA	\$0	NA	-\$228	\$0	NA	0	0	NA	
VITA MAIS	12/2017	0	0	49,900	49,900	NA	\$0	NA	\$6,043	\$0	NA	0	50,893	NA	
<b>Safe Water Solution</b>															
Certeza Commercial ISM	12/2017	0	51	-2,699	-2,648	100%	\$0	NA	-\$2,890	\$275	-10.51	14,388	1,249	11.52	
Certeza Free ISM	12/2017	47,840	100	0	47,940	0%	\$28,266	0%	\$20,924	\$18,359	1.14	298,635	47,162	6.33	
<b>Water Treatment Tablets</b>															
Certeza Comprimido 20L	12/2017	0	0	0	0	NA	\$0	NA	-\$164	-\$623	0.26	90,720	-19,040	-4.76	
Certeza Comprimido 5L	12/2017	0	0	0	0	NA	\$0	NA	\$507	\$0	NA	1,680	0	NA	
Certeza Free Comprimido 20L	12/2017	0	0	0	0	NA	\$0	NA	-\$135	\$0	NA	246,000	0	NA	
<b>Implant 5</b>															
Jadelle	12/2017	0	181	0	181	100%	\$0	NA	\$0	\$0	NA	39,460	170	231.66	
<b>Injectable 3</b>															
Enaf Injectable	12/2017	0	590	0	590	100%	\$0	NA	\$0	\$0	NA	49,587	435	114.08	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Mozambique</b>							\$58,998		\$424,199	\$89,436	4.74				
<u><b>IUD 10</b></u>															
DIU Copper T 380A	12/2017	0	18,848	0	18,848	100%	\$0	NA	\$0	\$0	NA	3,023	6,283	0.48	
<u><b>OCs</b></u>															
Microginon Mobiz	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	24,252	0	NA	
Microlynyn 30 Combined OC	12/2017	0	3,772	0	3,772	100%	\$0	NA	\$0	\$0	NA	226,866	3,831	59.21	
Progestyn OC	12/2017	0	1,195	0	1,195	100%	\$0	NA	\$0	\$0	NA	36,616	1,205	30.40	
<u><b>SDM (Cycle Beads)</b></u>															
Missangas Ciclo	12/2017	0	7,647	0	7,647	100%	\$0	NA	\$369	\$0	NA	13	2,549	0.01	
<b>Namibia</b>							\$0		\$0	\$0	NA				
<u><b>Free Condom</b></u>															
Smile	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	164,035	0	NA	
<u><b>Free Female Condom</b></u>															
Femidom Free	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	55,455	0	NA	
<u><b>Lubricant A</b></u>															
Condom Lubricant (Water Based)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,809,869	0	NA	
<b>Swaziland</b>							\$0		-\$1,928	\$0	NA				
<u><b>Other Revenues</b></u>															
VCT Fees	12/2017	0	4,331	0	4,331	100%	\$0	NA	\$0	\$0	NA	0	5,040	NA	
<u><b>Condom</b></u>															
Lovers Plus	12/2017	0	0	0	0	NA	\$0	NA	-\$703	\$0	NA	0	0	NA	
Lovers Plus C&F	12/2017	0	120	0	120	100%	\$0	NA	\$1,466	\$0	NA	309	40	7.73	
Lovers Plus R&S	12/2017	0	0	0	0	NA	\$0	NA	-\$102	\$0	NA	0	0	NA	
Trust	12/2017	0	2,820	0	2,820	100%	\$0	NA	-\$863	\$0	NA	780	1,252	0.62	
Trust Regular BGF	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	732	48	15.25	
Trust Studded	12/2017	0	642	0	642	100%	\$0	NA	-\$1,806	\$0	NA	2,697	526	5.13	
Trust Workplace	12/2017	0	1,761,000	0	1,761,000	100%	\$0	NA	\$16	\$0	NA	5,064,000	918,000	5.52	
<u><b>Female Condom</b></u>															
Care	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Female Condom	12/2017	0	10,000	0	10,000	100%	\$0	NA	\$64	\$0	NA	4,000	8,333	0.48	
<u><b>Free Condom</b></u>															
Generic	12/2017	0	210,000	0	210,000	100%	\$0	NA	\$0	\$0	NA	0	546,000	NA	
Workplace	12/2017	0	274	0	274	100%	\$0	NA	\$0	NA	NA	1,974	NA	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Swaziland</b>							\$0		-\$1,928	\$0	NA				
<u>Lubricant A</u>															
Lifestyles Liquid Personal Lubrican	12/2017	0	85,000	0	85,000	100%	\$0	NA	\$0	\$0	NA	327,000	65,000	5.03	



# Latin America & the Caribbean

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Americas	2,842	18	-	648	661,549	68	144,456	34	112	-	-	825
Caribbean	1	-	-	-	68	-	10	-	-	-	-	-
Costa Rica	50	-	-	-	13,936	-	1,997	-	-	-	-	-
Dominican Republic	388	-	-	-	94,240	6	13,573	-	-	-	-	-
El Salvador	133	-	-	-	60,920	4	14,826	-	-	-	-	-
Guatemala	374	-	-	-	255,565	24	69,743	-	-	-	-	9
Haiti	843	18	-	648	14,167	7	3,896	34	112	-	-	813
Honduras	354	-	-	-	32,393	3	4,681	-	-	-	-	-
Nicaragua	155	-	-	-	69,334	11	15,347	-	-	-	-	1
Panama	142	-	-	-	31,327	2	4,488	-	-	-	-	-
Paraguay	402	-	-	-	89,599	11	15,896	-	-	-	-	2

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>									<b>27</b>	<b>5</b>	<b>33</b>
<b>Free Condom</b>	-	<b>474</b>	<b>8,215</b>	-	<b>11,779</b>	<b>(30)%</b>	<b>11,779</b>	<b>402,397</b>	<b>23</b>	<b>5</b>	<b>28</b>
<b>HIV Testing Services</b>	-	<b>79</b>	<b>645</b>	-	<b>636</b>	<b>1%</b>	<b>636</b>	<b>7,358</b>	<b>5</b>	-	<b>5</b>
<b>Lubricant</b>	-	<b>237</b>	<b>4,300</b>	-	<b>939</b>	<b>358%</b>	<b>939</b>	<b>95,365</b>	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>									<b>49,608</b>	<b>36,667</b>	<b>86,275</b>
Cervical Cancer-Pap Sme:	20	72	236	-	-	-%	-	236	-	-	-
Condom	1,681,273	2,533,330	29,246,295	31,715,405	27,549,084	6%	27,549,084	346,541,522	49,393	10,070	59,463
Condom Provided	-	-	-	-	466,816	(100)%	466,816	612,770	-	-	-
Emergency Contraception	-	-	6	-	6	-%	6	12	-	-	-
Family Planning Counseli	-	-	-	-	3,787	(100)%	3,787	3,787	-	-	-
Female Condom Provided	-	-	-	-	1	(100)%	1	1	-	-	-
Free Condom	-	-	-	-	6,917,715	(100)%	6,917,715	6,983,994	-	-	-
Free Female Condom	-	-	-	-	167,978	(100)%	167,978	183,380	-	-	-
HIV Testing Services	385	1,192	17,077	12,485	16,648	3%	16,648	135,339	36	-	36
Hypertension Diagnosis	-	1	2	-	-	-%	-	2	-	-	-
Hypertension Screening	1	1	3	-	-	-%	-	3	-	-	-
Hypertension_Controlled	-	1	2	-	-	-%	-	2	-	-	-
Implant 3	(1)	(6)	(119)	100	333	(136)%	333	557	-	(29)	(29)
Implant 3 Insertion	12	13	238	311	797	(70)%	797	1,214	-	62	62
Implant 5	(886)	39	(1,420)	558	(333)	-%	(333)	12,012	-	(898)	(898)
Implant 5 Insertion	1,586	883	9,220	2,372	4,862	90%	4,862	35,605	-	4,415	4,415
Injectable 1	(154)	2,978	30,936	54,269	30,791	-%	30,791	227,713	-	223	223
Injectable 1 Provided	1,919	2,925	30,658	42	11,222	173%	11,222	47,935	-	245	245
Injectable 2 Provided	377	776	7,110	-	6,869	4%	6,869	21,710	-	114	114
Injectable 3	-	(1)	(2)	-	(7)	-%	(7)	(9)	-	-	-
Injectable 3 Provided	3,957	6,958	70,550	58	37,200	90%	37,200	136,062	-	1,697	1,697



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	117	527	2,993	2,083	4,537	(34)%	4,537	96,655	-	610	610
IUD 10 Insertion	1,260	1,675	19,440	25,173	18,956	3%	18,956	186,229	-	10,475	10,475
IUD 5	50	17	310	50	591	(48)%	591	901	-	105	105
IUD 5 Insertion	5	2	12	800	154	(92)%	154	166	-	4	4
IUS 5 Insertion	1	-	1	-	-	-%	-	1	-	-	-
Lubricant	67,728	70,924	914,014	-	641,646	42%	641,646	4,930,504	-	-	-
Manual Vacuum Aspiratio	409	251	5,793	780	5,421	7%	5,421	11,214	-	129	129
Micronutrient Powder	-	-	-	-	395,910	(100)%	395,910	546,420	-	-	-
Misoprostol for PAC (Oral	14,331	8,008	58,420	118,920	2,042	2,761%	2,042	75,972	-	425	425
Misoprostol for PAC (oral]	591	499	11,136	600	36	30,833%	36	11,172	-	86	86
Misoprostol for PPH	-	-	880	-	79,680	(99)%	79,680	181,252	-	2	2
OCs	3,374	7,381	121,382	173,120	152,685	(21)%	152,685	746,739	-	571	571
OCs Provided	854	2,630	26,674	40	12,463	114%	12,463	53,966	-	174	174
Referral to HIV Testing Se	-	-	-	-	27	(100)%	27	27	-	-	-
Referral to Linkage to HIV	314	-	314	-	292	8%	292	606	179	-	179
Repellant	9,325	-	9,325	-	1,835	408%	1,835	11,160	-	-	-
SDM (Cycle Beads) Provic	-	-	13	-	39	(67)%	39	117	-	3	3
STI Screening	10	10	39	-	-	-%	-	2,635	-	-	-
Treatment for Cervicitis	3	4	15	-	-	-%	-	15	-	-	-
Treatment for Genital Herp	-	3	8	-	-	-%	-	8	-	-	-
Treatment for Nonherpetic	-	1	2	-	-	-%	-	2	-	-	-
Treatment for Urethral Dis	-	2	7	-	-	-%	-	7	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Treatment for Vaginitis</b>	<b>3</b>	<b>-</b>	<b>3</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>3</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Tubal Ligation</b>	<b>1,269</b>	<b>442</b>	<b>4,899</b>	<b>-</b>	<b>1,982</b>	<b>147%</b>	<b>1,982</b>	<b>15,509</b>	<b>-</b>	<b>7,670</b>	<b>7,670</b>
<b>Type 2 Diabetes Screenin</b>	<b>-</b>	<b>1</b>	<b>2</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>2</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Vasectomy</b>	<b>48</b>	<b>44</b>	<b>312</b>	<b>-</b>	<b>14</b>	<b>2,129%</b>	<b>14</b>	<b>583</b>	<b>-</b>	<b>497</b>	<b>497</b>
<b>Zika Prevention Kit</b>	<b>21</b>	<b>280</b>	<b>966</b>	<b>-</b>	<b>112,890</b>	<b>(99)%</b>	<b>112,890</b>	<b>113,856</b>	<b>-</b>	<b>14</b>	<b>14</b>

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>									<b>82,096</b>	<b>63,956</b>	<b>146,052</b>
Antiretroviral Treatment (C	-	22,602	269,998	8,000	-	-%	-	269,998	45,829	-	45,829
Antiretroviral Treatment (I	-	387	4,301	-	-	-%	-	4,301	-	-	-
CD4 Tests Provided to HIV	115	53	386	-	118	227%	118	504	-	-	-
Cervical Cancer-VIA and C	-	3	78	-	-	-%	-	118	-	7	7
Cervical Cancer-VIA/VILI §	1	7	360	-	-	-%	-	782	-	-	-
Condom	1,138,105	1,281,366	13,269,354	12,981,520	11,295,344	17%	11,295,344	357,083,713	31,996	5,385	37,381
Diarrhea Treatment Kit	-	-	-	40,000	-	-%	-	-	-	-	-
Emergency Contraception	30,105	22,766	298,962	336,500	308,976	(3)%	308,976	2,512,152	-	413	413
Fever Cases Attended	1,352	1,304	36,368	-	1,187	2,964%	1,187	37,555	-	-	-
Fever Cases Tested with H	5,531	5,554	115,576	-	4,934	2,242%	4,934	120,510	-	-	-
Fever Cases Tested with F	18,982	28,547	522,476	-	23,956	2,081%	23,956	546,432	-	-	-
Free Condom	16,000	60,000	1,952,000	7,684,000	1,150,000	70%	1,150,000	9,318,472	2,572	727	3,299
HIV Testing Services	7,203	20,904	237,241	155,000	337,775	(30)%	337,775	616,673	1,698	-	1,698
Implant 3	-	-	2,016	350	-	-%	-	2,016	-	1,938	1,938
Implant 3 Insertion	24	25	322	-	-	-%	-	3,951	-	264	264
Injectable 2 Provided	-	3	82	-	-	-%	-	158	-	1	1
Injectable 3	-	-	-	57,500	-	-%	-	-	-	-	-
Injectable 3 Provided	39	49	279	-	-	-%	-	547	-	16	16
IUD 10	-	8	873	100	88	892%	88	2,247	-	1,528	1,528
IUD 10 Insertion	9	17	215	-	-	-%	-	471	-	395	395
LLIN	680,940	-	680,940	375,000	-	-%	-	3,668,840	-	2,338	2,338

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	71,000	9,667	206,020	-	360,000	(43)%	360,000	1,510,992	-	-	-
Malaria PPT (Non-ACT)	-	-	-	11,000	-	-%	-	316,240	-	-	-
Multivitamin	177,660	160,530	2,195,100	2,476,080	1,789,770	23%	1,789,770	35,035,350	-	162	162
OCs	50,305	53,612	678,800	927,500	749,197	(9)%	749,197	7,655,085	-	3,176	3,176
OCs Provided	60	59	403	-	-	-%	-	2,882	-	7	7
ORS	-	-	300,000	330,000	300,000	-%	300,000	10,047,338	-	10,285	10,285
Positive RDTs	1,226	1,251	30,261	-	1,069	2,731%	1,069	31,330	-	-	-
Referral to Linkage to HIV	-	-	-	-	41	(100)%	41	41	-	-	-
STI Screening	-	14,784	185,813	-	222,184	(16)%	222,184	407,997	-	-	-
TB Diagnosis	-	-	9,484	-	11,406	(17)%	11,406	20,890	-	-	-
TB DOTS	-	-	10,637	10,000	9,997	6%	9,997	20,634	-	36,409	36,409
TB Screening	-	-	11,507	-	12,026	(4)%	12,026	23,533	-	-	-
Treatment for Nonherpetic	-	368	5,427	-	1,290	321%	1,290	6,717	-	905	905

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>										<b>27</b>	<b>5</b>	<b>33</b>
<b>Caribbean</b>										<b>27</b>	<b>5</b>	<b>33</b>
Free Condom	-	<b>474</b>	<b>8,215</b>	-	<b>11,779</b>		<b>(30)%</b>	<b>11,779</b>	<b>402,397</b>	<b>23</b>	<b>5</b>	<b>28</b>
GIGI (Got it? Get it!) Free Condom	-	<b>474</b>	<b>8,215</b>	-	<b>11,779</b>	10/09	<b>(30)%</b>	<b>11,779</b>	<b>402,397</b>	<b>23</b>	<b>5</b>	<b>28</b>
HIV Testing Services	-	<b>79</b>	<b>645</b>	-	<b>636</b>		<b>1%</b>	<b>636</b>	<b>7,358</b>	<b>5</b>	-	<b>5</b>
VCT Individual (HIV-Negative)	-	<b>74</b>	<b>618</b>	-	<b>584</b>	12/10	<b>6%</b>	<b>584</b>	<b>7,222</b>	<b>4</b>	-	<b>4</b>
VCT Individual (HIV-Positive)	-	<b>4</b>	<b>27</b>	-	<b>52</b>	12/10	<b>(48)%</b>	<b>52</b>	<b>136</b>	-	-	-
Lubricant	-	<b>237</b>	<b>4,300</b>	-	<b>939</b>		<b>358%</b>	<b>939</b>	<b>95,365</b>	-	-	-
GIGI (Got it? Get it!) Lube Sachet	-	<b>237</b>	<b>4,300</b>	-	<b>939</b>	10/09	<b>358%</b>	<b>939</b>	<b>95,365</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>										<b>49,608</b>	<b>36,667</b>	<b>86,275</b>
<b>Belize</b>										-	-	-
Condom	-	-	-	-	2,325		(100)%	2,325	994,749	-	-	-
GIGI (Got it? Get it!) Condom	-	-	-	-	2,325	3/10	(100)%	2,325	994,749	-	-	-
Free Condom	-	-	-	-	2,606		(100)%	2,606	68,885	-	-	-
GIGI (Got it? Get it!) Free Condom	-	-	-	-	2,606	3/10	(100)%	2,606	68,885	-	-	-
Free Female Condom	-	-	-	-	104		(100)%	104	15,506	-	-	-
GIGI (Got it? Get it!) Free Female C	-	-	-	-	104	3/10	(100)%	104	15,506	-	-	-
HIV Testing Services	-	-	-	-	481		(100)%	481	8,061	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	455	12/10	(100)%	455	7,962	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	26	12/10	(100)%	26	99	-	-	-
Lubricant	-	-	-	-	868		(100)%	868	8,715	-	-	-
GIGI (Got it? Get it!) Lube Sachet	-	-	-	-	868	3/10	(100)%	868	8,715	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	8		(100)%	8	8	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	8		(100)%	8	8	-	-	-
<b>Costa Rica</b>										<b>1,785</b>	<b>126</b>	<b>1,911</b>
Condom	124,265	151,152	1,672,308	1,405,851	1,518,375		10%	1,518,375	17,498,803	1,785	126	1,911
Combo Pack	-	-	-	2,695	13,354	5/05	(100)%	13,354	53,757	-	-	-
Combo-Mix Lub Fresa	-	-	1,646	2,695	4,556	6/12	(64)%	4,556	16,718	2	-	2
Combo-Mix Lub Natural	-	-	-	2,282	1,112	6/12	(100)%	1,112	5,342	-	-	-
Combo-Pack Lub Fresa	(592)	2,599	15,414	-	10,212	10/10	51%	10,212	56,523	16	1	18
Tira Multilinea	-	-	132,342	-	173,439	8/16	(24)%	173,439	305,781	141	10	151
Vive	14,007	19,969	259,546	203,664	257,825	12/97	1%	257,825	4,659,415	277	20	297
Vive Amor	87,840	63,984	765,552	525,667	633,204	6/04	21%	633,204	7,439,993	817	58	875
Vive Colors/Mas Colors	15,843	35,533	293,160	370,049	239,085	5/03	23%	239,085	3,185,871	313	22	335

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Mas Fuerte /Retardante	2,814	10,538	55,905	134,182	73,401	6/04	(24)%	73,401	643,635	60	4	64
Vive Mas Natural /Sensitivo	4,353	18,530	134,103	131,936	94,586	6/04	42%	94,586	823,492	143	10	153
Vive Mas/Texturizado	-	-	14,640	32,681	17,601	6/04	(17)%	17,601	308,276	16	1	17
Lubricant	2,298	3,924	30,276	-	18,606		63%	18,606	139,507	-	-	-
Vive Lub Natural (sachet)	974	1,176	7,850	-	5,235	5/11	50%	5,235	48,982	-	-	-
Vive Lub Natural (tube)	330	601	5,749	-	4,540	5/11	27%	4,540	17,922	-	-	-
Vive Lub Sachet Fresa 5 mL	724	1,369	7,929	-	3,879	5/12	104%	3,879	54,379	-	-	-
Vive Lub Tubo Fresa 120 mL	270	777	8,748	-	4,952	1/12	77%	4,952	18,224	-	-	-
<b>El Salvador</b>										4,811	2,594	7,405
Cervical Cancer-Pap Smear Screening	20	72	236	-	-		0%	-	236	-	-	-
Cervical Cancer-Pap Smear Screeni	20	72	236	-	-		-%	-	236	-	-	-
Condom	202,920	192,843	3,232,320	3,244,205	2,668,520		21%	2,668,520	37,017,875	4,751	667	5,418
Combo-Mix Lub Fresa	-	-	1,840	9,861	3,424	10/10	(46)%	3,424	26,664	3	-	3
Combo-Mix Lub Natural	-	11	2,784	9,861	784	10/10	255%	784	19,384	4	1	5
Combo-Pack Lub Fresa	-	-	320	-	-	5/12	-%	-	5,328	-	-	1
Vive	24,192	38,096	881,760	879,791	747,792	4/98	18%	747,792	14,465,836	1,296	182	1,478
Vive Amor	112,896	84,640	1,400,064	991,402	1,086,000	7/04	29%	1,086,000	12,924,241	2,058	289	2,347
Vive Colors/Mas Colors	39,408	45,488	590,832	826,840	539,424	10/03	10%	539,424	6,706,266	868	122	990
Vive Mas Fuerte /Retardante	17,280	12,936	190,896	254,193	156,312	7/04	22%	156,312	1,348,412	281	39	320
Vive Mas Natural /Sensitivo	7,656	9,712	90,864	172,952	62,784	7/04	45%	62,784	712,856	134	19	152
Vive Mas/Texturizado	1,488	1,960	72,960	99,305	72,000	7/04	1%	72,000	808,888	107	15	122
Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Non-PSI Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Family Planning Counseling	-	-	-	-	3,787		(100)%	3,787	3,787	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Family Planning Counseling	-	-	-	-	3,787		(100)%	3,787	3,787	-	-	-
Free Condom	-	-	-	-	6,915,109		(100)%	6,915,109	6,915,109	-	-	-
Free Condom	-	-	-	-	6,915,109	11/15	(100)%	6,915,109	6,915,109	-	-	-
Free Female Condom	-	-	-	-	167,874		(100)%	167,874	167,874	-	-	-
Free Female Condoms	-	-	-	-	167,874	11/15	(100)%	167,874	167,874	-	-	-
HIV Testing Services	180	360	4,669	2,551	1,283		264%	1,283	41,859	7	-	7
VCT Individual (HIV-Negative)	176	348	4,528	2,412	1,207	12/09	275%	1,207	41,329	6	-	6
VCT Individual (HIV-Positive)	4	12	141	139	76	12/09	86%	76	530	-	-	-
Hypertension Diagnosis	-	1	2	-	-		0%	-	2	-	-	-
Hypertension Diagnosis	-	1	2	-	-		-%	-	2	-	-	-
Hypertension Screening	1	1	3	-	-		0%	-	3	-	-	-
Hypertension Screening	1	1	3	-	-		-%	-	3	-	-	-
Hypertension_Controlled Condition	-	1	2	-	-		0%	-	2	-	-	-
Hypertension_Controlled Condition	-	1	2	-	-		-%	-	2	-	-	-
Implant 3 Insertion	-	-	-	-	169		(100)%	169	169	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	169		(100)%	169	169	-	-	-
Implant 5	(8)	193	776	550	126		516%	126	4,388	-	156	156
PSI Implant 5 Distributed Inserted (	(28)	(16)	(184)	-	(74)		-%	(74)	(892)	-	(37)	(37)
Jadelle	20	209	960	550	200	12/08	380%	200	5,280	-	193	193
Implant 5 Insertion	28	16	202	-	77		162%	77	913	-	45	45
PSI Implant 5 Inserted	28	16	184	-	74		149%	74	892	-	41	41
Non-PSI Implant 5 Inserted	-	-	18	-	3		500%	3	21	-	4	4
Injectable 1	-	-	(8)	-	(2)		0%	(2)	(10)	-	-	-
PSI Injectable 1 Distributed Provide	-	-	(8)	-	(2)		-%	(2)	(10)	-	-	-
Injectable 1 Provided	7	-	41	-	20		105%	20	61	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 1 Provided	-	-	8	-	2		300%	2	10	-	-	-
Non-PSI Injectable 1 Provided	7	-	33	-	18		83%	18	51	-	-	-
Injectable 3 Provided	-	-	1	-	-		0%	-	1	-	-	-
Non-PSI Injectable 3 Provided	-	-	1	-	-		-%	-	1	-	-	-
<b>IUD 10</b>	<b>399</b>	<b>401</b>	<b>2,752</b>	<b>816</b>	<b>902</b>		<b>205%</b>	<b>902</b>	<b>32,304</b>	-	<b>683</b>	<b>683</b>
PSI IUD 10 Distributed Inserted (1)	(271)	(176)	(1,650)	(6,932)	(1,850)		-%	(1,850)	(24,420)	-	(409)	(409)
Copper T 380	670	577	4,402	7,748	2,752	12/08	60%	2,752	56,724	-	1,092	1,092
<b>IUD 10 Insertion</b>	<b>271</b>	<b>289</b>	<b>3,270</b>	<b>6,932</b>	<b>3,266</b>		<b>0%</b>	<b>3,266</b>	<b>35,298</b>	-	<b>901</b>	<b>901</b>
PSI IUD 10 Inserted	271	176	1,650	6,932	1,850		(11)%	1,850	24,420	-	455	455
Non-PSI IUD 10 Inserted	-	113	1,620	-	1,416	11/13	14%	1,416	10,878	-	446	446
<b>Lubricant</b>	<b>15,309</b>	<b>14,632</b>	<b>368,841</b>	-	<b>173,765</b>		<b>112%</b>	<b>173,765</b>	<b>1,252,468</b>	-	-	-
Vive Lub (sachet)	6,800	4,533	169,700	-	73,750	12/06	130%	73,750	707,490	-	-	-
Vive Lub (tube)	380	828	9,226	-	7,105	12/06	30%	7,105	54,975	-	-	-
Vive Lub Natural (sachet)	8,000	8,900	182,090	-	88,705	1/10	105%	88,705	467,152	-	-	-
Vive Lub Natural (tube)	129	371	7,825	-	4,205	1/10	86%	4,205	22,851	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	<b>78</b>	<b>75</b>	<b>1,277</b>	<b>155</b>	<b>1,280</b>		<b>0%</b>	<b>1,280</b>	<b>2,557</b>	-	<b>19</b>	<b>19</b>
MVA for PAC	78	75	1,277	155	1,280	8/16	-%	1,280	2,557	-	19	19
<b>Micronutrient Powder</b>	-	-	-	-	<b>395,910</b>		<b>(100)%</b>	<b>395,910</b>	<b>546,420</b>	-	-	-
VitalDia Kids	-	-	-	-	395,910	10/14	(100)%	395,910	546,420	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>284</b>	-	<b>1,527</b>	<b>30,200</b>	<b>738</b>		<b>107%</b>	<b>738</b>	<b>17,775</b>	-	<b>7</b>	<b>7</b>
PSI Misoprostol for PAC Oral Dist F	-	-	(39)	-	(12)		-%	(12)	(51)	-	-	-
Misoprostol for PAC (oral)	284	-	1,566	30,200	750	10/13	109%	750	17,826	-	7	7
<b>Misoprostol for PAC (oral) Provided</b>	-	-	<b>186</b>	-	<b>12</b>		<b>1450%</b>	<b>12</b>	<b>198</b>	-	<b>1</b>	<b>1</b>
PSI Misoprostol for PAC (oral) Prov	-	-	39	-	12		225%	12	51	-	-	-
Non-PSI Misoprostol for PAC (oral) I	-	-	147	-	-		-%	-	147	-	1	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>OCs</b>	<b>2,252</b>	<b>2,524</b>	<b>38,300</b>	<b>42,360</b>	<b>15,361</b>		<b>149%</b>	<b>15,361</b>	<b>149,080</b>	-	<b>101</b>	<b>101</b>
PSI OCs Distributed Provided	-	-	(5)	-	(4)		-%	(4)	(9)	-	-	-
Segura Plus	2,252	2,524	38,305	42,360	15,365	2/12	149%	15,365	149,089	-	101	101
<b>OCs Provided</b>	<b>3</b>	-	<b>8</b>	-	<b>7</b>		<b>14%</b>	<b>7</b>	<b>15</b>	-	-	-
PSI OCs Provided	-	-	5	-	4		25%	4	9	-	-	-
Non-PSI OCs Provided	3	-	3	-	3		-%	3	6	-	-	-
<b>Referral to Linkage to HIV Care</b>	<b>107</b>	-	<b>107</b>	-	<b>42</b>		<b>155%</b>	<b>42</b>	<b>149</b>	<b>53</b>	-	<b>53</b>
Referral to Linkage to HIV Care	107	-	107	-	42		155%	42	149	53	-	53
<b>STI Screening</b>	<b>10</b>	<b>10</b>	<b>39</b>	-	-		<b>0%</b>	-	<b>2,635</b>	-	-	-
STI Screening	10	10	39	-	-		-%	-	2,635	-	-	-
<b>Treatment for Cervicitis</b>	<b>3</b>	<b>4</b>	<b>15</b>	-	-		<b>0%</b>	-	<b>15</b>	-	-	-
Treatment for Cervicitis	3	4	15	-	-		-%	-	15	-	-	-
<b>Treatment for Genital Herpes</b>	-	<b>3</b>	<b>8</b>	-	-		<b>0%</b>	-	<b>8</b>	-	-	-
Treatment for Genital Herpes	-	3	8	-	-		-%	-	8	-	-	-
<b>Treatment for Nonherpetic Genital Ulc</b>	-	<b>1</b>	<b>2</b>	-	-		<b>0%</b>	-	<b>2</b>	-	-	-
Treatment for Nonherpetic Genital U	-	1	2	-	-		-%	-	2	-	-	-
<b>Treatment for Urethral Discharge (Wor</b>	-	<b>2</b>	<b>7</b>	-	-		<b>0%</b>	-	<b>7</b>	-	-	-
Treatment for Urethral Discharge (W	-	2	7	-	-		-%	-	7	-	-	-
<b>Treatment for Vaginitis</b>	<b>3</b>	-	<b>3</b>	-	-		<b>0%</b>	-	<b>3</b>	-	-	-
Treatment for Vaginitis	3	-	3	-	-		-%	-	3	-	-	-
<b>Tubal Ligation</b>	-	-	<b>1</b>	-	-		<b>0%</b>	-	<b>1</b>	-	<b>1</b>	<b>1</b>
Tubal Ligation	-	-	1	-	-		-%	-	1	-	1	1
<b>Type 2 Diabetes Screening</b>	-	<b>1</b>	<b>2</b>	-	-		<b>0%</b>	-	<b>2</b>	-	-	-
Type 2 Diabetes Screening	-	1	2	-	-		-%	-	2	-	-	-
<b>Zika Prevention Kit</b>	<b>21</b>	<b>280</b>	<b>966</b>	-	<b>930</b>		<b>4%</b>	<b>930</b>	<b>1,896</b>	-	<b>14</b>	<b>14</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Zika Prevention Kit	21	280	966	-	930	7/16	4%	930	1,896	-	14	14
<b>Guatemala</b>										15,520	27,099	42,619
Condom	807,656	1,201,294	11,905,520	12,755,737	10,980,589		8%	10,980,589	133,845,873	15,452	5,471	20,923
PSI Condom Distributed Provided	-	-	-	-	(11,755)		-%	(11,755)	(11,804)	-	-	-
Bodyguard	88,272	-	88,272	-	77,328	10/15	14%	77,328	347,760	115	41	155
Combo Pack	3,200	6,094	52,928	34,548	32,960	4/05	61%	32,960	418,504	69	24	93
Vive	197,760	429,488	3,910,272	3,628,203	3,856,224	4/98	1%	3,856,224	53,961,741	5,075	1,797	6,872
Vive Amor	446,688	581,584	6,053,040	3,839,268	5,796,576	7/04	4%	5,796,576	60,834,063	7,856	2,782	10,638
Vive Colors/Mas Colors	42,936	106,432	1,162,992	3,472,854	778,296	4/02	49%	778,296	13,579,894	1,509	534	2,044
Vive Mas Fuerte /Retardante	18,600	62,480	374,856	1,382,019	312,576	7/04	20%	312,576	2,768,528	487	172	659
Vive Mas Natural /Sensitivo	9,456	12,776	104,280	368,803	76,080	7/04	37%	76,080	996,157	135	48	183
Vive Mas/Texturizado	744	2,440	158,880	30,042	62,304	7/04	155%	62,304	951,030	206	73	279
Condom Provided	-	-	-	-	466,815		(100)%	466,815	612,769	-	-	-
PSI Condom Provided	-	-	-	-	11,755		(100)%	11,755	11,804	-	-	-
Non-PSI Condom Provided	-	-	-	-	455,060		(100)%	455,060	600,965	-	-	-
Emergency Contraception Provided	-	-	6	-	6		0%	6	12	-	-	-
Non-PSI Emergency Contraception I	-	-	6	-	6		-%	6	12	-	-	-
Female Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
HIV Testing Services	92	376	5,883	4,672	8,883		(34)%	8,883	49,143	15	-	15
VCT Individual (HIV-Negative)	90	363	5,677	4,433	8,640	12/09	(34)%	8,640	48,464	15	-	15
VCT Individual (HIV-Positive)	2	13	206	239	243	12/09	(15)%	243	679	1	-	1
Implant 3 Insertion	-	-	-	-	11		(100)%	11	33	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	11		(100)%	11	33	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5	(909)	(232)	(3,059)	108	(723)		0%	(723)	5,725	-	(1,362)	(1,362)
PSI Implant 5 Distributed Inserted (1)	(995)	(411)	(4,629)	(972)	(2,859)		-%	(2,859)	(13,343)	-	(2,061)	(2,061)
Jadelle	86	179	1,570	1,080	2,136	12/08	(26)%	2,136	19,068	-	699	699
Implant 5 Insertion	1,400	752	8,073	972	4,553		77%	4,553	31,706	-	3,995	3,995
PSI Implant 5 Inserted	995	411	4,629	972	2,859		62%	2,859	13,343	-	2,291	2,291
Non-PSI Implant 5 Inserted	405	341	3,444	-	1,694		103%	1,694	18,363	-	1,704	1,704
Injectable 1	(154)	2,978	30,946	54,269	30,798		0%	30,798	227,730	-	223	223
PSI Injectable 1 Distributed Provide	(850)	(407)	(3,780)	-	(1,826)		-%	(1,826)	(6,203)	-	(27)	(27)
Cyclofem	696	3,386	34,726	54,269	32,624	5/11	6%	32,624	233,933	-	251	251
Injectable 1 Provided	1,885	2,901	30,372	-	11,103		174%	11,103	47,530	-	244	244
PSI Injectable 1 Provided	850	407	3,780	-	1,826		107%	1,826	6,203	-	30	30
Non-PSI Injectable 1 Provided	1,035	2,494	26,592	-	9,277		187%	9,277	41,327	-	213	213
Injectable 2	-	-	-	-	(7)		0%	(7)	(7)	-	-	-
PSI Injectable 2 Distributed Provide	-	-	-	-	(7)		-%	(7)	(7)	-	-	-
Injectable 2 Provided	377	776	7,110	-	6,869		4%	6,869	21,710	-	114	114
PSI Injectable 2 Provided	-	-	-	-	7		(100)%	7	7	-	-	-
Non-PSI Injectable 2 Provided	377	776	7,110	-	6,862		4%	6,862	21,703	-	114	114
Injectable 3	-	-	-	-	(407)		0%	(407)	(593)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(407)		-%	(407)	(593)	-	-	-
Injectable 3 Provided	3,946	6,952	70,477	-	37,157		90%	37,157	135,946	-	1,695	1,695
PSI Injectable 3 Provided	-	-	-	-	407		(100)%	407	593	-	-	-
Non-PSI Injectable 3 Provided	3,946	6,952	70,477	-	36,750		92%	36,750	135,353	-	1,695	1,695
IUD 10	(64)	(72)	(1,647)	517	(618)		0%	(618)	27,123	-	(905)	(905)
PSI IUD 10 Distributed Inserted (1)	(423)	(896)	(11,020)	(12,226)	(11,625)		-%	(11,625)	(86,398)	-	(6,057)	(6,057)
Copper T 380	300	815	9,181	12,743	11,007	12/08	(17)%	11,007	113,329	-	5,046	5,046

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Copper T 380 Postpartum	59	9	192	-	-	1/17	-%	-	192	-	106	106
IUD 10 Insertion	764	1,174	13,691	12,226	13,400		2%	13,400	108,519	-	8,361	8,361
PSI IUD 10 Inserted	423	896	11,020	12,226	11,625		(5)%	11,625	86,398	-	6,730	6,730
Non-PSI IUD 10 Inserted	341	278	2,671	-	1,775		50%	1,775	22,121	-	1,631	1,631
IUD 5	-	-	43	-	530		(92)%	530	573	-	18	18
IUD Sleek	-	-	43	-	530	5/16	(92)%	530	573	-	18	18
IUD 5 Insertion	-	-	-	-	147		(100)%	147	147	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	147		(100)%	147	147	-	-	-
Lubricant	30,464	30,970	173,323	-	192,313		(10)%	192,313	1,435,228	-	-	-
Vive Lub (sachet)	3,000	19,461	70,259	-	107,228	4/05	(34)%	107,228	944,738	-	-	-
Vive Lub (tube)	367	2,967	18,932	-	19,302	4/05	(2)%	19,302	132,770	-	-	-
Vive Lub Natural (sachet)	21,009	6,822	61,943	-	46,983	1/10	32%	46,983	272,577	-	-	-
Vive Lub Natural (tube)	6,088	1,720	22,189	-	18,800	1/10	18%	18,800	85,143	-	-	-
Manual Vacuum Aspiration for PAC	273	158	4,029	300	3,716		8%	3,716	7,745	-	94	94
MVA for PAC	273	158	4,029	300	3,716	5/16	8%	3,716	7,745	-	94	94
Misoprostol for PAC (Oral)	13,857	7,399	50,249	59,720	(24)		0%	(24)	50,225	-	351	351
PSI Misoprostol for PAC Oral Dist F	(543)	(388)	(5,991)	(600)	(24)		-%	(24)	(6,015)	-	(42)	(42)
Misoprostol for PAC (oral)	14,400	7,787	56,240	60,320	-	7/13	-%	-	56,240	-	392	392
Misoprostol for PAC (oral) Provided	549	496	10,782	600	24		44825%	24	10,806	-	84	84
PSI Misoprostol for PAC (oral) Prov	543	388	5,991	600	24		24,863%	24	6,015	-	46	46
Non-PSI Misoprostol for PAC (oral) I	6	108	4,791	-	-		-%	-	4,791	-	37	37
Misoprostol for PPH	-	-	880	-	79,680		(99)%	79,680	181,252	-	2	2
Misoprostol for PPH	-	-	880	-	79,680	7/13	(99)%	79,680	181,252	-	2	2
OCs	1,122	4,857	68,649	39,760	60,581		13%	60,581	492,698	-	402	402
PSI OCs Distributed Provided	(290)	(243)	(2,918)	-	(906)		-%	(906)	(3,968)	-	(17)	(17)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Oralcon-F (28 tablets Blister)	-	-	-	-	40,212	8/10	(100)%	40,212	366,801	-	-	-
Segura Plus	1,412	5,100	71,567	39,760	21,275	5/14	236%	21,275	129,865	-	420	420
<b>OCs Provided</b>	<b>841</b>	<b>2,606</b>	<b>26,517</b>	<b>-</b>	<b>12,390</b>		<b>114%</b>	<b>12,390</b>	<b>53,736</b>	<b>-</b>	<b>173</b>	<b>173</b>
PSI OCs Provided	290	243	2,918	-	906		222%	906	3,968	-	19	19
Non-PSI OCs Provided	551	2,363	23,599	-	11,484		105%	11,484	49,768	-	154	154
Referral to Linkage to HIV Care	76	-	76	-	90		(16)%	90	166	53	-	53
Referral to Linkage to HIV Care	76	-	76	-	90		(16)%	90	166	53	-	53
Repellant	9,325	-	9,325	-	1,835		408%	1,835	11,160	-	-	-
Repellant	9,325	-	9,325	-	1,835	12/16	408%	1,835	11,160	-	-	-
SDM (Cycle Beads)	-	-	-	-	(2)		0%	(2)	(2)	-	-	-
PSI SDM (Cycle Beads) Distributed	-	-	-	-	(2)		-%	(2)	(2)	-	-	-
<b>SDM (Cycle Beads) Provided</b>	<b>-</b>	<b>-</b>	<b>13</b>	<b>-</b>	<b>39</b>		<b>(67)%</b>	<b>39</b>	<b>117</b>	<b>-</b>	<b>3</b>	<b>3</b>
PSI SDM (Cycle Beads) Provided	-	-	-	-	2		(100)%	2	2	-	-	-
Non-PSI SDM (Cycle Beads) Provid	-	-	13	-	37		(65)%	37	115	-	3	3
Tubal Ligation	1,264	437	4,875	-	1,982		146%	1,982	15,485	-	7,640	7,640
Tubal Ligation	1,264	437	4,875	-	1,982	7/12	146%	1,982	15,485	-	7,640	7,640
Vasectomy	48	44	312	-	14		2129%	14	583	-	497	497
Vasectomy	48	44	312	-	14	7/12	2,129%	14	583	-	497	497
<b>Honduras</b>										<b>14,955</b>	<b>1,185</b>	<b>16,140</b>
<b>Condom</b>	<b>134,616</b>	<b>263,368</b>	<b>3,863,296</b>	<b>4,290,217</b>	<b>4,121,656</b>		<b>(6)%</b>	<b>4,121,656</b>	<b>46,503,512</b>	<b>14,900</b>	<b>1,168</b>	<b>16,068</b>
Bodyguard	-	-	2,208	-	98,592	7/16	(98)%	98,592	100,800	9	1	9
Combo Pack	-	-	-	-	(256)	4/05	-%	(256)	153,800	-	-	-
Combo-Mix Lub Fresa	-	-	-	1,259	848	10/10	(100)%	848	10,864	-	-	-
Combo-Mix Lub Natural	-	-	-	1,111	1,216	10/10	(100)%	1,216	9,984	-	-	-
Combo-Pack Lub Fresa	400	731	9,168	4,852	-	2/16	-%	-	9,168	35	3	38

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Combo-Pack Lub Natural	80	133	1,264	6,219	4,160	10/10	(70)%	4,160	26,960	5	-	5
Vive	24,576	39,424	975,792	720,013	657,168	9/00	48%	657,168	14,332,099	3,763	295	4,058
Vive Amor	88,320	165,120	1,911,888	2,760,149	2,619,312	8/04	(27)%	2,619,312	21,789,944	7,374	578	7,952
Vive Colors/Mas Colors	13,776	39,840	701,904	589,161	537,168	4/02	31%	537,168	8,158,438	2,707	212	2,919
Vive Mas Fuerte /Retardante	5,592	10,400	140,208	117,089	131,064	8/04	7%	131,064	975,576	541	42	583
Vive Mas Natural /Sensitivo	1,200	2,808	40,224	35,859	38,448	8/04	5%	38,448	444,722	155	12	167
Vive Mas/Texturizado	672	4,912	80,640	54,505	33,936	8/04	138%	33,936	491,157	311	24	335
HIV Testing Services	2	380	4,299	2,725	3,717		16%	3,717	11,863	10	-	10
VCT Individual (HIV-Negative)	1	370	4,185	2,589	3,659	4/12	14%	3,659	11,687	9	-	9
VCT Individual (HIV-Positive)	1	10	114	136	58	4/14	97%	58	176	-	-	-
Implant 3	-	(3)	(4)	-	-		0%	-	(4)	-	(1)	(1)
PSI Implant 3 Distributed Inserted (	-	(3)	(4)	-	-		-%	-	(4)	-	(1)	(1)
Implant 3 Insertion	3	6	38	11	5		660%	5	43	-	8	8
PSI Implant 3 Inserted	-	3	4	-	-		-%	-	4	-	1	1
Non-PSI Implant 3 Inserted	3	3	34	11	5		580%	5	39	-	8	8
Injectable 1	-	(1)	(2)	-	(5)		0%	(5)	(7)	-	-	-
PSI Injectable 1 Distributed Provide	-	(1)	(2)	-	(5)		-%	(5)	(7)	-	-	-
Injectable 1 Provided	3	2	32	42	24		33%	24	56	-	-	-
PSI Injectable 1 Provided	-	1	2	-	5		(60)%	5	7	-	-	-
Non-PSI Injectable 1 Provided	3	2	30	42	19		58%	19	49	-	-	-
Injectable 3	-	(1)	(2)	-	(7)		0%	(7)	(9)	-	-	-
PSI Injectable 3 Distributed Provide	-	(1)	(2)	-	(7)		-%	(7)	(9)	-	-	-
Injectable 3 Provided	2	4	40	58	26		54%	26	66	-	1	1
PSI Injectable 3 Provided	-	1	2	-	7		(71)%	7	9	-	-	-
Non-PSI Injectable 3 Provided	2	3	38	58	19		100%	19	57	-	1	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	-	(1)	(2)	-	(1)		0%	(1)	(3)	-	(1)	(1)
PSI IUD 10 Distributed Inserted (1)	-	(1)	(2)	-	(1)		-%	(1)	(3)	-	(1)	(1)
IUD 10 Insertion	1	4	24	15	7		243%	7	31	-	10	10
PSI IUD 10 Inserted	-	1	2	-	1		100%	1	3	-	1	1
Non-PSI IUD 10 Inserted	1	3	22	15	6		267%	6	28	-	9	9
IUD 5	-	-	-	-	(4)		0%	(4)	(4)	-	-	-
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	(4)		-%	(4)	(4)	-	-	-
IUD 5 Insertion	-	-	-	-	7		(100)%	7	7	-	-	-
PSI IUD 5 Inserted	-	-	-	-	4		(100)%	4	4	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	3		(100)%	3	3	-	-	-
Lubricant	1,290	12,999	140,330	-	67,107		109%	67,107	793,271	-	-	-
Vive Lub (sachet)	-	6,667	92,570	-	27,717	3/05	234%	27,717	529,877	-	-	-
Vive Lub (tube)	665	680	7,020	-	14,698	3/05	(52)%	14,698	80,749	-	-	-
Vive Lub Natural (sachet)	-	4,090	26,940	-	16,191	1/10	66%	16,191	136,716	-	-	-
Vive Lub Natural (tube)	625	1,563	13,800	-	8,501	1/10	62%	8,501	45,929	-	-	-
OCs	-	-	(1)	-	(20)		0%	(20)	(21)	-	-	-
PSI OCs Distributed Provided	-	-	(1)	-	(20)		-%	(20)	(21)	-	-	-
OCs Provided	-	-	8	40	26		(69)%	26	34	-	-	-
PSI OCs Provided	-	-	1	-	20		(95)%	20	21	-	-	-
Non-PSI OCs Provided	-	-	7	40	6		17%	6	13	-	-	-
Referral to HIV Testing Services	-	-	-	-	27		(100)%	27	27	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	27		(100)%	27	27	-	-	-
Referral to Linkage to HIV Care	72	-	72	-	24		200%	24	96	45	-	45
Referral to Linkage to HIV Care	72	-	72	-	24		200%	24	96	45	-	45
<b>Nicaragua</b>										<b>6,873</b>	<b>4,800</b>	<b>11,673</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Condom</b>	<b>314,280</b>	<b>154,105</b>	<b>4,813,626</b>	<b>5,632,395</b>	<b>4,590,438</b>		<b>5%</b>	<b>4,590,438</b>	<b>70,916,288</b>	<b>6,871</b>	<b>1,775</b>	<b>8,646</b>
Bodyguard	-	(1,743)	79,538	30,000	111,568	2/04	(29)%	111,568	11,097,090	114	29	143
Combo-Pack Lub Fresa	1,296	1,296	12,288	14,041	9,152	5/11	34%	9,152	54,552	18	5	22
Combo-Pack Lub Natural	-	432	5,152	6,797	5,904	10/10	(13)%	5,904	26,992	7	2	9
Vive	219,696	84,240	3,307,968	4,182,330	2,984,352	4/98	11%	2,984,352	45,530,480	4,722	1,220	5,942
Vive Colors/Mas Colors	67,776	48,640	909,816	916,570	998,172	4/02	(9)%	998,172	10,739,756	1,299	335	1,634
Vive Mas Fuerte /Retardante	18,528	13,432	318,672	308,902	333,384	6/04	(4)%	333,384	1,829,054	455	117	572
Vive Mas Natural /Sensitivo	6,864	5,856	109,872	126,853	95,868	6/04	15%	95,868	899,771	157	41	197
Vive Mas/Texturizado	120	1,952	70,320	46,902	52,038	6/04	35%	52,038	738,593	100	26	126
<b>HIV Testing Services</b>	<b>20</b>	<b>9</b>	<b>93</b>	<b>-</b>	<b>616</b>		<b>(85)%</b>	<b>616</b>	<b>7,031</b>	<b>-</b>	<b>-</b>	<b>-</b>
VCT Individual (HIV-Negative)	19	8	86	-	567	12/09	(85)%	567	6,939	-	-	-
VCT Individual (HIV-Positive)	1	1	7	-	49	12/09	(86)%	49	92	-	-	-
<b>Implant 3</b>	<b>(1)</b>	<b>(3)</b>	<b>(115)</b>	<b>100</b>	<b>333</b>		<b>(135)%</b>	<b>333</b>	<b>561</b>	<b>-</b>	<b>(28)</b>	<b>(28)</b>
PSI Implant 3 Distributed Inserted (	(1)	(3)	(179)	(300)	(612)	3/16	-%	(612)	(948)	-	(44)	(44)
Implanon	-	-	64	400	945	7/15	(93)%	945	1,509	-	16	16
<b>Implant 3 Insertion</b>	<b>9</b>	<b>7</b>	<b>200</b>	<b>300</b>	<b>612</b>		<b>(67)%</b>	<b>612</b>	<b>969</b>	<b>-</b>	<b>54</b>	<b>54</b>
PSI Implant 3 Inserted	1	3	179	300	612	3/16	(71)%	612	948	-	48	48
Non-PSI Implant 3 Inserted	8	4	21	-	-		-%	-	21	-	6	6
<b>Implant 5</b>	<b>31</b>	<b>78</b>	<b>863</b>	<b>(100)</b>	<b>264</b>		<b>227%</b>	<b>264</b>	<b>1,899</b>	<b>-</b>	<b>308</b>	<b>308</b>
PSI Implant 5 Distributed Inserted (	(158)	(116)	(945)	(1,400)	(232)		-%	(232)	(2,986)	-	(338)	(338)
Jadelle	189	194	1,808	1,300	496	12/08	265%	496	4,885	-	646	646
<b>Implant 5 Insertion</b>	<b>158</b>	<b>116</b>	<b>945</b>	<b>1,400</b>	<b>232</b>		<b>307%</b>	<b>232</b>	<b>2,986</b>	<b>-</b>	<b>375</b>	<b>375</b>
PSI Implant 5 Inserted	158	116	945	1,400	232		307%	232	2,986	-	375	375
<b>Injectable 1 Provided</b>	<b>24</b>	<b>21</b>	<b>213</b>	<b>-</b>	<b>75</b>		<b>184%</b>	<b>75</b>	<b>288</b>	<b>-</b>	<b>1</b>	<b>1</b>
Non-PSI Injectable 1 Provided	24	21	213	-	75		184%	75	288	-	1	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Injectable 3 Provided	9	3	32	-	17		88%	17	49	-	1	1
Non-PSI Injectable 3 Provided	9	3	32	-	17		88%	17	49	-	1	1
IUD 10	(218)	199	1,890	750	4,254		(56)%	4,254	37,231	-	834	834
PSI IUD 10 Distributed Inserted (1)	(224)	(208)	(2,455)	(6,000)	(2,283)		-%	(2,283)	(42,381)	-	(1,083)	(1,083)
Copper T 380	6	407	4,335	6,750	6,485	12/08	(33)%	6,485	79,550	-	1,913	1,913
Copper-T 380-A IUD	-	-	10	-	52	3/16	(81)%	52	62	-	4	4
IUD 10 Insertion	224	208	2,455	6,000	2,283		8%	2,283	42,381	-	1,203	1,203
PSI IUD 10 Inserted	224	208	2,455	6,000	2,283		8%	2,283	42,381	-	1,203	1,203
IUD 5	50	17	267	50	61		338%	61	328	-	88	88
PSI IUD 5 Distributed Inserted (1)	(5)	(2)	(12)	(800)	-		-%	-	(12)	-	(4)	(4)
Copper T375 Sleek	55	19	279	850	61	3/16	357%	61	340	-	92	92
IUD 5 Insertion	5	2	12	800	-		0%	-	12	-	4	4
PSI IUD 5 Inserted	5	2	12	800	-		-%	-	12	-	4	4
IUS 5 Insertion	1	-	1	-	-		0%	-	1	-	-	-
Non-PSI IUS 5 Inserted	1	-	1	-	-		-%	-	1	-	-	-
Lubricant	7,696	3,474	137,004	-	141,496		(3)%	141,496	855,871	-	-	-
Vive Lub (sachet)	2,511	585	47,404	-	60,504	3/05	(22)%	60,504	391,943	-	-	-
Vive Lub (tube)	1,998	1,111	22,241	-	16,332	3/05	36%	16,332	108,325	-	-	-
Vive Lub Natural (sachet)	2,025	1,294	49,860	-	52,175	1/10	(4)%	52,175	288,645	-	-	-
Vive Lub Natural (tube)	1,162	484	17,499	-	12,485	1/10	40%	12,485	66,958	-	-	-
Manual Vacuum Aspiration for PAC	58	19	487	325	425		15%	425	912	-	16	16
MVA for PAC	58	19	487	325	425	5/16	15%	425	912	-	16	16
Misoprostol for PAC (Oral)	190	609	6,644	29,000	1,328		400%	1,328	7,972	-	67	67
PSI Misoprostol for PAC Oral Dist F	(42)	(3)	(144)	-	-		-%	-	(144)	-	(1)	(1)
Misoprostol for PAC (oral)	232	612	6,788	29,000	1,328	10/16	411%	1,328	8,116	-	69	69

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol for PAC (oral) Provided	42	3	168	-	-		0%	-	168	-	2	2
PSI Misoprostol for PAC (oral) Prov	42	3	144	-	-		-%	-	144	-	2	2
Non-PSI Misoprostol for PAC (oral) I	-	-	24	-	-		-%	-	24	-	-	-
<b>OCs</b>	<b>-</b>	<b>-</b>	<b>14,434</b>	<b>91,000</b>	<b>76,754</b>		<b>(81)%</b>	<b>76,754</b>	<b>104,973</b>	<b>-</b>	<b>68</b>	<b>68</b>
PSI OCs Distributed Provided	-	-	-	-	(9)		-%	(9)	(9)	-	-	-
Segura Plus	-	-	14,434	91,000	76,763	7/15	(81)%	76,763	104,982	-	68	68
<b>OCs Provided</b>	<b>10</b>	<b>24</b>	<b>141</b>	<b>-</b>	<b>40</b>		<b>253%</b>	<b>40</b>	<b>181</b>	<b>-</b>	<b>1</b>	<b>1</b>
PSI OCs Provided	-	-	-	-	9		(100)%	9	9	-	-	-
Non-PSI OCs Provided	10	24	141	-	31		355%	31	172	-	1	1
Referral to Linkage to HIV Care	2	-	2	-	35		(94)%	35	37	1	-	1
Referral to Linkage to HIV Care	2	-	2	-	35		(94)%	35	37	1	-	1
Tubal Ligation	5	5	23	-	-		0%	-	23	-	29	29
Tubal Ligation	5	5	23	-	-		-%	-	23	-	29	29
<b>Panama</b>										<b>5,664</b>	<b>864</b>	<b>6,528</b>
Condom	97,536	570,568	3,759,225	4,387,000	3,655,170		3%	3,655,170	39,906,418	5,633	864	6,497
Bodyguard	-	-	-	-	3,700	12/14	(100)%	3,700	27,460	-	-	-
Vive	72,000	536,304	3,064,704	3,552,285	3,056,256	7/00	-%	3,056,256	33,173,201	4,592	704	5,296
Vive Colors/Mas Colors	2,664	8,136	331,539	470,962	270,696	3/05	22%	270,696	3,773,820	497	76	573
Vive Mas Fuerte /Retardante	20,400	15,200	210,024	207,076	201,110	3/05	4%	201,110	1,522,999	315	48	363
Vive Mas Natural /Sensitivo	-	6,848	92,409	94,353	73,632	3/05	26%	73,632	766,961	138	21	160
Vive Mas/Texturizado	2,472	4,080	60,549	62,324	49,776	3/05	22%	49,776	641,977	91	14	105
<b>HIV Testing Services</b>	<b>91</b>	<b>68</b>	<b>2,133</b>	<b>2,537</b>	<b>1,668</b>		<b>28%</b>	<b>1,668</b>	<b>17,382</b>	<b>4</b>	<b>-</b>	<b>4</b>
VCT Individual (HIV-Negative)	78	63	2,025	2,417	1,502	12/11	35%	1,502	16,841	4	-	4
VCT Individual (HIV-Positive)	13	5	108	120	166	12/11	(35)%	166	541	-	-	-
Lubricant	10,671	4,925	64,240	-	47,491		35%	47,491	445,444	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Lub (sachet)	7,500	1,717	16,250	-	22,573	2/09	(28)%	22,573	259,026	-	-	-
Vive Lub (tube)	121	575	12,498	-	8,965	2/09	39%	8,965	65,440	-	-	-
Vive Lub Natural (sachet)	2,550	1,750	17,650	-	5,400	5/11	227%	5,400	60,255	-	-	-
Vive Lub Natural (tube)	500	883	17,842	-	10,553	5/11	69%	10,553	60,723	-	-	-
Referral to Linkage to HIV Care	57	-	57	-	93		(39)%	93	150	27	-	27
Referral to Linkage to HIV Care	57	-	57	-	93		(39)%	93	150	27	-	27
Zika Prevention Kit	-	-	-	-	111,960		(100)%	111,960	111,960	-	-	-
Zika Prevention Kit	-	-	-	-	111,960	7/16	(100)%	111,960	111,960	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>										<b>82,096</b>	<b>63,956</b>	<b>146,052</b>
<b>Dominican Republic</b>										<b>14,938</b>	<b>4,233</b>	<b>19,172</b>
CD4 Tests Provided to HIV+ Clients	115	53	386	-	118		227%	118	504	-	-	-
CD4 Tests Provided to HIV+ Clients	115	53	386	-	118		227%	118	504	-	-	-
Condom	718,120	781,123	9,313,124	8,669,760	8,230,724		13%	8,230,724	181,367,441	12,273	3,468	15,741
Pante	718,120	781,123	9,313,124	8,669,760	8,230,724	9/03	13%	8,230,724	181,367,441	12,273	3,468	15,741
Free Condom	16,000	60,000	1,952,000	684,000	1,150,000		70%	1,150,000	9,318,472	2,572	727	3,299
No Logo	16,000	60,000	1,952,000	684,000	1,150,000	4/10	70%	1,150,000	9,318,472	2,572	727	3,299
HIV Testing Services	7,203	4,903	38,049	-	24,360		56%	24,360	76,832	92	-	92
VCT Individual (HIV-Negative)	6,972	4,759	37,054	-	23,751	9/13	56%	23,751	74,984	90	-	90
VCT Individual (HIV-Positive)	231	144	995	-	609	9/13	63%	609	1,848	2	-	2
Implant 3 Insertion	-	3	100	-	-		0%	-	3,729	-	27	27
Non-PSI Implant 3 Inserted	-	3	100	-	-	11/13	-%	-	3,729	-	27	27
Injectable 2 Provided	-	3	82	-	-		0%	-	158	-	1	1
Non-PSI Injectable 2 Provided	-	3	82	-	-		-%	-	158	-	1	1
Injectable 3 Provided	-	3	91	-	-		0%	-	359	-	2	2
Non-PSI Injectable 3 Provided	-	3	91	-	-	3/16	-%	-	359	-	2	2
IUD 10 Insertion	-	2	16	-	-		0%	-	272	-	8	8
Non-PSI IUD 10 Inserted	-	2	16	-	-	11/13	-%	-	272	-	8	8
Lubricant	71,000	9,667	206,020	-	360,000		(43)%	360,000	1,510,992	-	-	-
No Logo Lubricant (4.5 gram sachet)	71,000	9,667	206,020	-	360,000	3/13	(43)%	360,000	1,510,992	-	-	-
OCs Provided	-	1	61	-	-		0%	-	2,540	-	-	-
Non-PSI OCs Provided	-	1	61	-	-	3/16	-%	-	2,540	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	41		(100)%	41	41	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	41		(100)%	41	41	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Haiti</b>										<b>48,868</b>	<b>54,677</b>	<b>103,545</b>
Antiretroviral Treatment (Currently Enr	-	22,602	269,998	8,000	-		0%	-	269,998	45,829	-	45,829
Antiretroviral Treatment (Currently E	-	22,602	269,998	8,000	-		-%	-	269,998	45,829	-	45,829
Antiretroviral Treatment (Newly Enrolle	-	387	4,301	-	-		0%	-	4,301	-	-	-
Antiretroviral Treatment (Newly Enrc	-	387	4,301	-	-		-%	-	4,301	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	3	78	-	-		0%	-	118	-	7	7
Cervical Cancer-VIA and Cryotherap	-	3	78	-	-		-%	-	118	-	7	7
Cervical Cancer-VIA/VILI Screening	1	7	360	-	-		0%	-	782	-	-	-
Cervical Cancer-VIA/VILI Screening	1	7	360	-	-		-%	-	782	-	-	-
Condom	-	142,848	428,544	250,000	-		0%	-	135,779,208	1,433	623	2,056
Feeling Plus	-	142,848	428,544	-	-	3/17	-%	-	428,544	1,433	623	2,056
Pante	-	-	-	250,000	-	11/90	-%	-	135,350,664	-	-	-
Diarrhea Treatment Kit	-	-	-	40,000	-		0%	-	-	-	-	-
Salusel & Saluzinc	-	-	-	40,000	-	3/17	-%	-	-	-	-	-
Emergency Contraception	-	-	-	17,500	-		0%	-	-	-	-	-
Pronta1	-	-	-	17,500	-	3/17	-%	-	-	-	-	-
Fever Cases Attended	1,352	1,304	36,368	-	1,187		2964%	1,187	37,555	-	-	-
Fever Cases Attended	1,352	1,304	36,368	-	1,187		2,964%	1,187	37,555	-	-	-
Fever Cases Tested with Microscopy	5,531	5,554	115,576	-	4,934		2242%	4,934	120,510	-	-	-
Fever Cases Tested with Microscop	5,531	5,554	115,576	-	4,934		2,242%	4,934	120,510	-	-	-
Fever Cases Tested with RDTs	18,982	28,547	522,476	-	23,956		2081%	23,956	546,432	-	-	-
Fever Cases Tested with RDTs	18,982	28,547	522,476	-	23,956		2,081%	23,956	546,432	-	-	-
Free Condom	-	-	-	7,000,000	-		0%	-	-	-	-	-
Generic Condom	-	-	-	7,000,000	-	3/17	-%	-	-	-	-	-
HIV Testing Services	-	16,000	199,192	155,000	313,415		(36)%	313,415	539,841	1,606	-	1,606

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Negative)	-	<b>16,000</b>	<b>177,923</b>	<b>150,000</b>	<b>306,390</b>	4/10	(42)%	<b>306,390</b>	<b>510,939</b>	<b>1,435</b>	-	<b>1,435</b>
VCT Individual (HIV-Positive)	-	-	<b>21,269</b>	<b>5,000</b>	<b>7,025</b>	4/10	203%	<b>7,025</b>	<b>28,902</b>	<b>171</b>	-	<b>171</b>
Implant 3	-	-	<b>2,016</b>	<b>350</b>	-		<b>0%</b>	-	<b>2,016</b>	-	<b>1,938</b>	<b>1,938</b>
Implanon	-	-	-	<b>350</b>	-	3/17	-%	-	-	-	-	-
Implanon NXT	-	-	<b>2,016</b>	-	-	7/17	-%	-	<b>2,016</b>	-	<b>1,938</b>	<b>1,938</b>
Implant 3 Insertion	<b>24</b>	<b>22</b>	<b>222</b>	-	-		<b>0%</b>	-	<b>222</b>	-	<b>237</b>	<b>237</b>
Non-PSI Implant 3 Inserted	<b>24</b>	<b>22</b>	<b>222</b>	-	-		-%	-	<b>222</b>	-	<b>237</b>	<b>237</b>
Injectable 3	-	-	-	<b>57,500</b>	-		<b>0%</b>	-	-	-	-	-
Saluplan Piki	-	-	-	<b>50,000</b>	-	3/17	-%	-	-	-	-	-
Sayana Press	-	-	-	<b>7,500</b>	-	3/17	-%	-	-	-	-	-
Injectable 3 Provided	<b>39</b>	<b>46</b>	<b>188</b>	-	-		<b>0%</b>	-	<b>188</b>	-	<b>14</b>	<b>14</b>
Non-PSI Injactable 3 Provided	<b>39</b>	<b>46</b>	<b>188</b>	-	-		-%	-	<b>188</b>	-	<b>14</b>	<b>14</b>
IUD 10	-	<b>8</b>	<b>873</b>	<b>100</b>	<b>88</b>		<b>892%</b>	<b>88</b>	<b>2,247</b>	-	<b>1,528</b>	<b>1,528</b>
Confiance Plus IUD	-	<b>8</b>	<b>873</b>	<b>100</b>	<b>88</b>	12/13	892%	<b>88</b>	<b>2,247</b>	-	<b>1,528</b>	<b>1,528</b>
IUD 10 Insertion	<b>9</b>	<b>15</b>	<b>199</b>	-	-		<b>0%</b>	-	<b>199</b>	-	<b>387</b>	<b>387</b>
Non-PSI IUD 10 Inserted	<b>9</b>	<b>15</b>	<b>199</b>	-	-		-%	-	<b>199</b>	-	<b>387</b>	<b>387</b>
LLIN	<b>680,940</b>	-	<b>680,940</b>	<b>375,000</b>	-		<b>0%</b>	-	<b>3,668,840</b>	-	<b>2,338</b>	<b>2,338</b>
LLIN Free	<b>680,940</b>	-	<b>680,940</b>	<b>375,000</b>	-	1/08	-%	-	<b>3,668,840</b>	-	<b>2,338</b>	<b>2,338</b>
Malaria PPT (Non-ACT)	-	-	-	<b>11,000</b>	-		<b>0%</b>	-	<b>316,240</b>	-	-	-
Chloroquine	-	-	-	<b>11,000</b>	-	3/12	-%	-	<b>316,240</b>	-	-	-
OCs	-	-	-	<b>117,500</b>	-		<b>0%</b>	-	-	-	-	-
MEURI	-	-	-	<b>17,500</b>	-	3/17	-%	-	-	-	-	-
Saluplan Grenn	-	-	-	<b>100,000</b>	-	3/17	-%	-	-	-	-	-
OCs Provided	<b>60</b>	<b>58</b>	<b>342</b>	-	-		<b>0%</b>	-	<b>342</b>	-	<b>7</b>	<b>7</b>
Non-PSI OCs Provided	<b>60</b>	<b>58</b>	<b>342</b>	-	-		-%	-	<b>342</b>	-	<b>7</b>	<b>7</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ORS	-	-	300,000	330,000	300,000		0%	300,000	10,047,338	-	10,285	10,285
Salusel	-	-	-	80,000	-	3/17	-%	-	-	-	-	-
Sel Lavi	-	-	300,000	250,000	300,000	10/99	-%	300,000	10,047,338	-	10,285	10,285
Positive RDTs	1,226	1,251	30,261	-	1,069		2731%	1,069	31,330	-	-	-
Positive RDTs	1,226	1,251	30,261	-	1,069		2,731%	1,069	31,330	-	-	-
STI Screening	-	14,784	185,813	-	222,184		(16)%	222,184	407,997	-	-	-
STI Screening	-	14,784	185,813	-	222,184		(16)%	222,184	407,997	-	-	-
TB Diagnosis	-	-	9,484	-	11,406		(17)%	11,406	20,890	-	-	-
TB Diagnosis	-	-	9,484	-	11,406		(17)%	11,406	20,890	-	-	-
TB DOTS	-	-	10,637	10,000	9,997		6%	9,997	20,634	-	36,409	36,409
TB DOTS	-	-	10,637	10,000	9,997		6%	9,997	20,634	-	36,409	36,409
TB Screening	-	-	11,507	-	12,026		(4)%	12,026	23,533	-	-	-
TB Screening	-	-	11,507	-	12,026		(4)%	12,026	23,533	-	-	-
Treatment for Nonherpetic Genital Ulc	-	368	5,427	-	1,290		321%	1,290	6,717	-	905	905
Treatment for Nonherpetic Genital U	-	368	5,427	-	1,290		321%	1,290	6,717	-	905	905
<b>Paraguay</b>										18,290	5,046	23,335
Condom	419,985	357,395	3,527,686	4,061,760	3,064,620		15%	3,064,620	39,937,064	18,290	1,294	19,584
Pantera	187,857	164,714	1,763,402	1,982,400	1,649,108	8/98	7%	1,649,108	35,139,287	9,143	647	9,789
Pantera Banana	22,722	18,258	163,435	240,000	69,557	9/16	135%	69,557	232,992	847	60	907
Pantera Chocolate	33,781	24,107	235,722	278,400	234,083	2/14	1%	234,083	792,700	1,222	86	1,309
Pantera Frutilla	-	-	-	326,400	-		-%	-	-	-	-	-
Pantera Retardant	73,422	63,063	552,003	598,560	528,012	2/14	5%	528,012	1,698,800	2,862	202	3,064
Pantera Ribbed	23,397	16,686	172,901	180,000	169,989	2/14	2%	169,989	631,204	896	63	960
Pantera Strawberry	35,033	32,861	298,287	-	280,297	2/14	6%	280,297	966,571	1,547	109	1,656
Pantera Tachas	17,367	17,297	148,500	216,000	61,081	9/16	143%	61,081	209,581	770	54	824

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Pantera Tutti Frutti	26,406	20,409	193,436	240,000	72,493	9/16	167%	72,493	265,929	1,003	71	1,074
Emergency Contraception	30,105	22,766	298,962	319,000	308,976		(3)%	308,976	2,512,152	-	413	413
Pronta	30,105	22,766	298,962	319,000	308,976	2/04	(3)%	308,976	2,512,152	-	413	413
Multivitamin	177,660	160,530	2,195,100	2,476,080	1,789,770		23%	1,789,770	35,035,350	-	162	162
VitalDia	177,660	160,530	2,195,100	2,476,080	1,789,770	11/00	23%	1,789,770	35,035,350	-	162	162
OCs	50,305	53,612	678,800	810,000	749,197		(9)%	749,197	7,655,085	-	3,176	3,176
Segura	48,230	50,139	643,181	750,000	706,380	4/01	(9)%	706,380	7,449,619	-	3,009	3,009
Segura Plus	2,075	3,473	35,619	60,000	42,817	3/11	(17)%	42,817	205,466	-	167	167

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Americas - Central America</b>															
<b>Belize</b>							\$0		\$109	\$0	NA				
<u>Condom</u>															
GiGi (Got it? Get it!) Condom	12/2017	0	0	0	0	NA	\$0	NA	\$109	\$0	NA	0	0	NA	
<u>Free Female Condom</u>															
GiGi (Got it? Get it!) Free Female	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4	0	NA	
<u>Lubricant A</u>															
GiGi (Got it? Get it!) Lube Sachet	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	70	0	NA	
<b>Costa Rica</b>							\$0		\$34,807	\$0	NA				
<u>Condom</u>															
Combo Pack	12/2017	0	0	0	0	NA	\$0	NA	\$41	\$0	NA	0	0	NA	
Combo-Mix Lub Fresa	12/2017	0	0	0	0	NA	\$0	NA	\$176	\$0	NA	0	0	NA	
Combo-Pack Lub Fresa	12/2017	-616	24	0	-592	-4%	\$0	NA	\$84	\$0	NA	26,554	1,519	17.48	
Tira Multilinea	12/2017	0	0	0	0	NA	\$0	NA	\$9,663	\$0	NA	0	0	NA	
Vive	12/2017	13,911	96	0	14,007	1%	\$0	NA	\$4,306	\$0	NA	205,242	18,160	11.30	
Vive Amor	12/2017	86,832	1,008	0	87,840	1%	\$0	NA	\$0	\$0	NA	605,328	73,920	8.19	
Vive Colors/Mas Colors	12/2017	15,753	90	0	15,843	1%	\$0	NA	\$6,808	\$0	NA	394,185	31,634	12.46	
Vive Mas Fuerte /Retardante	12/2017	2,814	0	0	2,814	0%	\$0	NA	\$2,187	\$0	NA	233,652	8,762	26.67	
Vive Mas Natural /Sensitivo	12/2017	4,353	0	0	4,353	0%	\$0	NA	\$5,775	\$0	NA	127,785	15,908	8.03	
Vive Mas/Texturizado	12/2017	0	0	0	0	NA	\$0	NA	\$519	\$0	NA	0	16	NA	
<u>Lubricant A</u>															
Vive Lub Natural (sachet)	12/2017	750	224	0	974	23%	\$0	NA	\$74	\$0	NA	9,132	1,476	6.19	
Vive Lub Sachet Fresa 5 mL	12/2017	500	224	0	724	31%	\$0	NA	\$108	\$0	NA	4,550	1,377	3.30	
<u>Lubricant E</u>															
Vive Lub Natural (tube)	12/2017	330	0	0	330	0%	\$0	NA	\$1,442	\$0	NA	10,660	599	17.80	
Vive Lub Tubo Fresa 120 mL	12/2017	270	0	0	270	0%	\$0	NA	\$3,625	\$0	NA	6,876	717	9.59	
<b>EI Salvador</b>							\$42,081		\$141,811	\$46,437	3.05				
<u>Medicines &amp; Supplies</u>															
Intrauterine Vacuum cleaner for p	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Accessories for the vacuum cleane	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<u>Condom</u>															
Combo-Mix Lub Natural	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$4	NA	48	11	4.50	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>El Salvador</b>							\$42,081		\$141,811	\$46,437	3.05				
<b>Condom</b>															
Combo-Pack Lub Fresa	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	33,440	0	NA	
Vive	12/2017	24,192	0	2,160	26,352	0%	\$4,737	99%	\$23,484	\$7,568	3.10	745,536	38,624	19.30	
Vive Amor	12/2017	110,736	816	0	111,552	1%	\$14,972	75%	\$27,900	\$13,750	2.03	1,070,544	100,176	10.69	
Vive Colors/Mas Colors	12/2017	39,408	0	864	40,272	0%	\$9,011	83%	\$39,576	\$10,047	3.94	1,042,848	39,584	26.35	
Vive Mas Fuerte /Retardante	12/2017	17,280	0	0	17,280	0%	\$4,668	88%	\$9,035	\$3,612	2.50	414,480	13,368	31.01	
Vive Mas Natural /Sensitivo	12/2017	7,632	24	8	7,664	0%	\$2,065	94%	\$18,436	\$2,577	7.16	206,448	9,528	21.67	
Vive Mas/Texturizado	12/2017	1,488	0	0	1,488	0%	\$394	0%	\$98	\$401	0.24	41,184	1,496	27.53	
<b>Lubricant A</b>															
Vive Lub (sachet)	12/2017	6,800	0	0	6,800	0%	\$1,030	73%	\$4,800	\$1,007	4.77	20,900	6,667	3.14	
Vive Lub Natural (sachet)	12/2017	8,000	0	0	8,000	0%	\$1,209	81%	\$6,975	\$1,692	4.12	1,250	11,250	0.11	
<b>Lubricant E</b>															
Vive Lub (tube)	12/2017	380	0	0	380	0%	\$915	98%	\$5,340	\$1,795	2.97	4,781	747	6.40	
Vive Lub Natural (tube)	12/2017	129	0	0	129	0%	\$326	74%	\$480	\$540	0.89	4,723	224	21.12	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	0	0	2,368	2,368	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<b>Zika Prevention Kit</b>															
Zika Prevention Kit	12/2017	0	21	5	26	100%	\$0	NA	\$0	\$0	NA	730	287	2.54	
<b>Implant 5</b>															
Jadelle	12/2017	4	2	0	6	33%	\$67	0%	\$0	\$50	NA	154	5	28.88	
<b>IUD 10</b>															
Copper T 380	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<b>OCs</b>															
Segura Plus	12/2017	2,240	6	3	2,249	0%	\$2,688	100%	\$5,688	\$3,395	1.68	17,288	2,831	6.11	
<b>El Salvador SA</b>							\$4,078		\$2,235	\$2,511	0.89				
<b>Medicines &amp; Supplies</b>															
Intrauterine Vacuum cleaner for p	12/2017	47	0	1	48	0%	\$2,912	32%	\$1,673	\$1,260	1.33	151	20	7.43	
<b>Condom</b>															
Vive Amor	12/2017	1,344	0	288	1,632	0%	\$177	0%	\$189	\$223	0.85	8,880	1,744	5.09	
<b>Lubricant E</b>															
Vive Lub Natural (tube)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	12	0	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	284	0	0	284	0%	\$121	51%	\$62	\$40	1.53	19,716	95	208.27	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>El Salvador SA</b>							\$4,078		\$2,235	\$2,511	0.89				
<b>Implant 5</b>															
Jadelle	12/2017	14	0	10	24	0%	\$257	0%	\$0	\$440	NA	176	24	7.33	
<b>IUD 10</b>															
Copper T 380	12/2017	670	0	127	797	0%	\$601	52%	\$312	\$529	0.59	15,135	461	32.85	
<b>OCs</b>															
Segura Plus	12/2017	6	0	0	6	0%	\$11	0%	\$0	\$19	NA	44	10	4.26	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<b>HIV Test Kit</b>															
Determine	12/2017	0	400	0	400	100%	\$0	NA	\$0	\$0	NA	0	133	NA	
<b>Condom</b>															
Bodyguard	12/2017	0	88,272	0	88,272	100%	\$0	NA	\$0	\$0	NA	0	29,424	NA	
Combo Pack	12/2017	3,200	0	0	3,200	0%	\$0	NA	\$0	\$0	NA	46,432	3,120	14.88	
Vive	12/2017	195,840	48	0	195,888	0%	\$0	NA	\$0	\$0	NA	4,101,069	386,128	10.62	
Vive Amor	12/2017	444,240	0	0	444,240	0%	\$0	NA	\$0	\$0	NA	5,835,888	552,672	10.56	
Vive Colors/Mas Colors	12/2017	42,936	0	0	42,936	0%	\$0	NA	\$0	\$0	NA	2,564,808	93,744	27.36	
Vive Mas Fuerte /Retardante	12/2017	18,600	0	0	18,600	0%	\$0	NA	\$0	\$0	NA	570,120	54,760	10.41	
Vive Mas Natural /Sensitivo	12/2017	8,400	1,056	0	9,456	11%	\$0	NA	\$0	\$0	NA	195,936	12,584	15.57	
Vive Mas/Texturizado	12/2017	0	744	0	744	100%	\$0	NA	\$0	\$0	NA	21,456	1,512	14.19	
<b>Lubricant A</b>															
Vive Lub (sachet)	12/2017	3,000	0	0	3,000	0%	\$0	NA	\$0	\$0	NA	210,420	20,395	10.32	
Vive Lub Natural (sachet)	12/2017	21,009	0	0	21,009	0%	\$0	NA	\$0	\$0	NA	44,300	13,100	3.38	
<b>Lubricant E</b>															
Vive Lub (tube)	12/2017	359	0	0	359	0%	\$0	NA	\$0	\$0	NA	12,790	2,450	5.22	
Vive Lub Natural (tube)	12/2017	6,080	0	1	6,081	0%	\$0	NA	\$0	\$0	NA	23,924	3,111	7.69	
<b>Repellant</b>															
Repellant	12/2017	0	9,325	0	9,325	100%	\$0	NA	\$0	\$0	NA	0	3,108	NA	
<b>Implant 5</b>															
Jadelle	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,210	0	NA	
<b>Injectable 1</b>															
Cyclofem	12/2017	550	0	0	550	0%	\$0	NA	\$0	\$0	NA	73,156	2,857	25.60	
<b>IUD 10</b>															
Copper T 380	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	207	0	NA	
Copper T 380 Postpartum	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	62	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<u>IUD 5</u>															
IUD Sleek	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	57	0	NA	
<u>OCs</u>															
Oralcon-F (28 tablets Blister)	12/2017	0	0	5	5	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Segura Plus	12/2017	1,411	1	7	1,419	0%	\$0	NA	\$0	\$0	NA	9,449	5,210	1.81	
<b>Guatemala SA</b>							\$0		\$0	\$0	NA				
<u>Condom</u>															
Vive	12/2017	1,872	0	0	1,872	0%	\$0	NA	\$0	\$0	NA	50,832	4,752	10.70	
Vive Amor	12/2017	2,448	0	0	2,448	0%	\$0	NA	\$0	\$0	NA	6,480	5,952	1.09	
<u>Lubricant E</u>															
Vive Lub (tube)	12/2017	8	0	0	8	0%	\$0	NA	\$0	\$0	NA	88	7	13.20	
Vive Lub Natural (tube)	12/2017	8	0	0	8	0%	\$0	NA	\$0	\$0	NA	94	7	14.10	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	12/2017	14,400	0	0	14,400	0%	\$0	NA	\$0	\$0	NA	6,280	9,800	0.64	
<u>Implant 5</u>															
Jadelle	12/2017	86	0	0	86	0%	\$0	NA	\$0	\$0	NA	472	184	2.57	
<u>Injectable 1</u>															
Cyclofem	12/2017	146	0	0	146	0%	\$0	NA	\$0	\$0	NA	1,130	233	4.85	
<u>IUD 10</u>															
Copper T 380	12/2017	300	0	0	300	0%	\$0	NA	\$0	\$0	NA	29,919	766	39.08	
Copper T 380 Postpartum	12/2017	59	0	0	59	0%	\$0	NA	\$0	\$0	NA	2,607	29	89.90	
<u>IUD 5</u>															
IUD Sleek	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,370	0	NA	
<b>Honduras</b>							\$0		\$0	\$0	NA				
<u>Condom</u>															
Combo-Mix Lub Fresa	12/2017	0	0	288	288	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Combo-Mix Lub Natural	12/2017	0	0	320	320	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Combo-Pack Lub Fresa	12/2017	400	0	32	432	0%	\$0	NA	\$0	\$0	NA	27,856	837	33.27	
Combo-Pack Lub Natural	12/2017	80	0	0	80	0%	\$0	NA	\$0	\$0	NA	3,680	112	32.86	
Vive	12/2017	24,576	0	0	24,576	0%	\$0	NA	\$0	\$0	NA	1,343,760	38,960	34.49	
Vive Amor	12/2017	88,320	0	96	88,416	0%	\$0	NA	\$0	\$0	NA	2,236,272	169,968	13.16	
Vive Colors/Mas Colors	12/2017	13,776	0	4,944	18,720	0%	\$0	NA	\$0	\$0	NA	450,192	37,592	11.98	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Honduras</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Vive Mas Fuerte /Retardante	12/2017	5,592	0	120	5,712	0%	\$0	NA	\$0	\$0	NA	154,008	8,792	17.52	
Vive Mas Natural /Sensitivo	12/2017	1,200	0	24	1,224	0%	\$0	NA	\$0	\$0	NA	21,360	2,632	8.12	
Vive Mas/Texturizado	12/2017	672	0	480	1,152	0%	\$0	NA	\$0	\$0	NA	26,064	4,440	5.87	
<b>Lubricant A</b>															
Vive Lub (sachet)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5,352	6,633	0.81	
Vive Lub Natural (sachet)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,512	4,043	3.84	
<b>Lubricant E</b>															
Vive Lub (tube)	12/2017	665	0	5	670	0%	\$0	NA	\$0	\$0	NA	14,550	837	17.38	
Vive Lub Natural (tube)	12/2017	625	0	0	625	0%	\$0	NA	\$0	\$0	NA	3,776	1,749	2.16	
<b>Nicaragua</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Bodyguard	12/2017	0	0	93	93	NA	\$0	NA	\$0	\$0	NA	112,615	0	NA	
Combo-Pack Lub Fresa	12/2017	1,296	0	0	1,296	0%	\$0	NA	\$0	\$0	NA	26,720	864	30.93	
Combo-Pack Lub Natural	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,792	0	NA	
Vive	12/2017	216,240	3,456	0	219,696	2%	\$0	NA	\$0	\$0	NA	3,601,347	140,896	25.56	
Vive Colors/Mas Colors	12/2017	60,096	7,680	0	67,776	11%	\$0	NA	\$0	\$0	NA	790,956	57,400	13.78	
Vive Mas Fuerte /Retardante	12/2017	18,144	384	0	18,528	2%	\$0	NA	\$0	\$0	NA	275,640	16,992	16.22	
Vive Mas Natural /Sensitivo	12/2017	6,480	384	0	6,864	6%	\$0	NA	\$0	\$0	NA	102,025	6,344	16.08	
Vive Mas/Texturizado	12/2017	0	120	0	120	100%	\$0	NA	\$0	\$0	NA	12,871	808	15.93	
<b>Lubricant A</b>															
Vive Lub (sachet)	12/2017	2,511	0	3	2,514	0%	\$0	NA	\$0	\$0	NA	13,276	1,422	9.34	
Vive Lub Natural (sachet)	12/2017	2,025	0	0	2,025	0%	\$0	NA	\$0	\$0	NA	6,731	1,969	3.42	
<b>Lubricant E</b>															
Vive Lub (tube)	12/2017	1,998	0	0	1,998	0%	\$0	NA	\$0	\$0	NA	3,605	1,738	2.07	
Vive Lub Natural (tube)	12/2017	1,162	0	0	1,162	0%	\$0	NA	\$0	\$0	NA	5,069	847	5.98	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	232	0	0	232	0%	\$0	NA	\$0	\$0	NA	25,884	531	48.78	
<b>Implant 5</b>															
Jadelle	12/2017	182	7	0	189	4%	\$0	NA	\$0	\$0	NA	1,195	216	5.52	
<b>IUD 10</b>															
Copper T 380	12/2017	6	0	0	6	0%	\$0	NA	\$0	\$0	NA	9	299	0.03	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nicaragua</b>							\$0		\$0	\$0	NA				
<u>IUD 10</u>															
Copper-T 380-A IUD	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,938	0	NA	
<u>IUD 5</u>															
Copper T375 Slek	12/2017	35	20	0	55	36%	\$0	NA	\$0	\$0	NA	4,660	35	131.89	
<u>OCs</u>															
Segura Plus	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	17	0	NA	
<b>Panama</b>							\$0		\$0	\$0	NA				
<u>HIV Test Kit</u>															
Uni Gold Kit	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	975	107	9.14	
<u>Condom</u>															
Vive	12/2017	72,000	0	0	72,000	0%	\$0	NA	\$0	\$0	NA	5,054,688	447,584	11.29	
Vive Colors/Mas Colors	12/2017	2,664	0	-1,200	1,464	0%	\$0	NA	\$0	\$0	NA	1,284,072	4,896	262.27	
Vive Mas Fuerte /Retardante	12/2017	20,400	0	-1,200	19,200	0%	\$0	NA	\$0	\$0	NA	261,624	14,000	18.69	
Vive Mas Natural /Sensitivo	12/2017	0	0	1,200	1,200	NA	\$0	NA	\$0	\$0	NA	230,232	2,800	82.23	
Vive Mas/Texturizado	12/2017	2,472	0	1,200	3,672	0%	\$0	NA	\$0	\$0	NA	67,680	2,824	23.97	
<u>Lubricant A</u>															
Vive Lub (sachet)	12/2017	7,500	0	0	7,500	0%	\$0	NA	\$0	\$0	NA	9,200	4,183	2.20	
Vive Lub Natural (sachet)	12/2017	2,550	0	0	2,550	0%	\$0	NA	\$0	\$0	NA	12,750	1,700	7.50	
<u>Lubricant E</u>															
Vive Lub (tube)	12/2017	121	0	0	121	0%	\$0	NA	\$0	\$0	NA	10,859	549	19.79	
Vive Lub Natural (tube)	12/2017	500	0	0	500	0%	\$0	NA	\$0	\$0	NA	2,557	967	2.65	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Americas - Other</b>														
<b>Haiti</b>							\$0		\$13,230	\$2	5,460.48			
<b>Malaria PPT (Non-ACT) P</b>														
Primaquine Tablet	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	26,018	0	NA
<b>Medicines &amp; Supplies</b>														
MVA Kit	12/2017	0	0	0	0	NA	\$0	NA	\$2,258	\$0	NA	0	0	NA
<b>Condom</b>														
Feeling Plus	12/2017	0	0	0	0	NA	\$0	NA	\$404	\$0	NA	167,835	0	NA
<b>LLIN</b>														
LLIN Free	12/2017	0	680,940	0	680,940	100%	\$0	NA	\$0	NA	NA	271,760	NA	NA
<b>Malaria PPT (Non-ACT)</b>														
Chloroquine	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	200	0	NA
<b>Emergency Contraception</b>														
Levonorgestrel 1.5 mg Tablet	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,300	0	NA
<b>Implant 3</b>														
Implanon NXT	12/2017	0	0	0	0	NA	\$0	NA	\$10,567	\$0	NA	0	0	NA
<b>IUD 10</b>														
Confiance Plus IUD	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$2	NA	553	2	331.80
Copper-T 380-A IUD	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	993	0	NA
<b>OCs</b>														
MEURI	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	84,802	0	NA
<b>Paraguay</b>							\$185,798		\$0	\$175,927	NA			
<b>Condom</b>														
Pantera	12/2017	187,497	360	5	187,862	0%	\$49,475	77%	\$0	\$31,550	NA	1,805,885	189,940	9.51
Pantera Banana	12/2017	22,662	60	1	22,723	0%	\$0	NA	\$0	\$0	NA	198,389	19,293	10.28
Pantera Chocolate	12/2017	33,591	190	-6	33,775	1%	\$0	NA	\$0	\$0	NA	215,292	26,800	8.03
Pantera Retardant	12/2017	72,852	570	29	73,451	1%	\$0	NA	\$0	\$0	NA	460,850	70,110	6.57
Pantera Ribbed	12/2017	23,397	0	6	23,403	0%	\$0	NA	\$0	\$0	NA	88,728	19,183	4.63
Pantera Strawberry	12/2017	34,878	155	4	35,037	0%	\$0	NA	\$0	\$0	NA	185,351	32,430	5.72
Pantera Tachas	12/2017	17,307	60	1	17,368	0%	\$0	NA	\$0	\$0	NA	221,808	17,340	12.79
Pantera Tutti Frutti	12/2017	26,346	60	2	26,408	0%	\$0	NA	\$0	\$0	NA	165,989	22,574	7.35
<b>Multivitamin</b>														
VitalDia	12/2017	177,660	0	0	177,660	0%	\$13,496	95%	\$0	\$12,490	NA	337,650	167,620	2.01



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Paraguay</b>							\$185,798		\$0	\$175,927	NA				
<u>Emergency Contraception</u>															
Pronta	12/2017	30,105	0	-75	30,030	0%	\$66,922	94%	\$0	\$71,926	NA	152,976	32,410	4.72	
<u>OCs</u>															
Segura	12/2017	48,230	0	2	48,232	0%	\$53,887	89%	\$0	\$57,674	NA	615,568	51,663	11.91	
Segura Plus	12/2017	2,075	0	0	2,075	0%	\$2,018	89%	\$0	\$2,286	NA	40,240	3,027	13.30	
<b>SFH Dominican Republic</b>							\$0		\$9,019	\$0	NA				
<u>Condom</u>															
Pante	12/2017	509,200	208,920	980	719,100	29%	\$0	NA	\$9,019	\$0	NA	18,737,181	772,763	24.25	
<u>Free Condom</u>															
No Logo	12/2017	0	16,000	0	16,000	100%	\$0	NA	\$0	\$0	NA	6,093,534	55,333	110.12	
<u>Lubricant A</u>															
No Logo Lubricant (4.5 gram sach	12/2017	0	71,000	2,002	73,002	100%	\$0	NA	\$0	\$0	NA	1,862,978	32,667	57.03	



# Asia & Eastern Europe

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 12/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Asia and Eastern Eur	8,948	-	85	4,200	6,200,107	1,354	1,586,933	2,501	620	-	-	8,962
Cambodia	1,847	-	-	-	726,564	114	176,035	51	12	-	-	470
India	-	-	-	979	512,147	141	214,494	-	400	-	-	1,377
India LLC	4,271	-	-	-	1,326,700	256	270,032	-	69	-	-	894
Kazakhstan	7	-	-	-	99	-	13	-	-	-	-	-
Kyrgyzstan	12	-	-	-	-	-	-	-	-	-	-	-
Laos	61	-	-	35	109,896	19	34,190	1	-	-	-	75
Myanmar	2,068	-	-	1,751	628,882	106	135,599	322	137	-	-	2,210
Nepal	30	-	-	-	128,212	46	43,876	-	-	-	-	141
Pakistan	575	-	-	1,436	2,757,201	670	710,832	-	-	-	-	1,580
Papua New Guinea	43	-	-	-	5,685	1	797	2,127	1	-	-	2,128
Tajikistan	34	-	85	-	2,520	-	361	-	-	-	-	85
Viet Nam	-	-	-	-	2,202	-	703	-	1	-	-	2
<b>Total</b>	<b>253,180</b>	<b>48</b>	<b>85</b>	<b>4,851</b>	<b>19,902,226</b>	<b>11,637</b>	<b>4,867,772</b>	<b>125,851</b>	<b>3,862</b>	<b>5,579</b>	<b>-</b>	<b>154,414</b>

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 12  
 Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>									<b>437,945</b>	<b>1,699,416</b>	<b>2,137,361</b>
Antiretroviral Treatment (C	4,927	4,638	45,990	36,450	1,661	2,669%	1,661	47,651	8,034	-	8,034
Antiretroviral Treatment (I	188	242	2,917	2,100	1,042	180%	1,042	3,959	-	-	-
Cervical Cancer-Pap Sme:	-	-	304	-	4,743	(94)%	4,743	5,047	-	-	-
Cervical Cancer-VIA and C	-	-	420	-	2,718	(85)%	2,718	4,013	-	115	115
Cervical Cancer-VIA and F	-	-	79	-	48	65%	48	127	-	11	11
Cervical Cancer-VIA and F	-	-	419	-	446	(6)%	446	865	-	57	57
Cervical Cancer-VIA/VILI §	7	6	5,629	-	98,040	(94)%	98,040	107,354	-	-	-
Clean Delivery Kit	-	-	-	-	400	(100)%	400	260,026	-	-	-
Condom	26,359,602	17,660,709	215,658,647	293,359,477	232,147,502	(7)%	232,147,502	6,376,333,468	362,996	193,303	556,299
Condom Provided	-	-	-	-	63,111	(100)%	63,111	85,090	-	-	-
Diarrhea Treatment Kit	7,048	4,744	77,204	92,360	443,466	(83)%	443,466	5,937,941	-	2,139	2,139
Emergency Contraception	464,396	227,122	2,346,810	1,784,252	2,360,728	(1)%	2,360,728	19,046,610	-	9,581	9,581
Emergency Contraception	357	500	8,692	-	9,101	(4)%	9,101	29,308	-	37	37
Fecal Sludge Managemen	23	38	661	670	921	(28)%	921	1,582	-	-	-
Fecal Sludge Managemen	1,310,000	130,000	4,125,200	1,571,000	3,021,000	37%	3,021,000	7,146,200	-	228	228
Female Condom	7,917	17,364	134,294	152,960	108,934	23%	108,934	1,729,264	493	91	584
Fever Cases Attended	136,702	139,419	1,237,217	-	657,831	88%	657,831	1,895,048	-	-	-
Fever Cases Tested with F	136,699	139,414	1,237,181	-	657,831	88%	657,831	1,895,012	-	-	-
Free Condom	18,300	28,424	839,917	5,034,034	681,034	23%	681,034	7,016,540	2,347	551	2,898
Free Female Condom	-	190	4,570	34,000	20,000	(77)%	20,000	24,570	4	1	5
HIV Testing Services	9,888	10,367	112,911	113,553	70,109	61%	70,109	402,925	172	-	172

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Hypertension Diagnosis	17,294	6,286	42,374	-	-	-%	-	42,374	-	-	-
Hypertension Screening	199,388	8,944	236,728	-	-	-%	-	236,728	-	-	-
Hypertension_Controlled	20,255	2,376	32,418	-	-	-%	-	32,418	-	-	-
Implant 3	365	191	7,713	11,000	2,657	190%	2,657	10,370	-	2,277	2,277
Implant 3 Insertion	1,982	862	12,080	6,730	4,155	191%	4,155	16,511	-	5,558	5,558
Implant 5	499	461	4,874	3,250	21,275	(77)%	21,275	46,603	-	3,570	3,570
Implant 5 Insertion	262	260	3,556	2,525	3,146	13%	3,146	31,601	-	2,481	2,481
Injectable 1	6,724	7,293	84,751	79,473	85,224	(1)%	85,224	1,603,408	-	1,462	1,462
Injectable 1 Provided	2,276	2,310	34,249	-	30,476	12%	30,476	89,405	-	656	656
Injectable 2	5,391	18,680	276,802	225,406	299,852	(8)%	299,852	6,950,055	-	9,548	9,548
Injectable 2 Provided	1,329	1,400	21,738	-	22,868	(5)%	22,868	67,869	-	833	833
Injectable 3	124,657	106,702	1,574,193	1,857,118	1,598,677	(2)%	1,598,677	17,828,441	-	56,049	56,049
Injectable 3 Provided	7,855	9,206	290,172	9,500	39,569	633%	39,569	350,812	-	15,937	15,937
IUD 10	4,906	6,817	131,049	154,558	161,261	(19)%	161,261	381,846	-	167,089	167,089
IUD 10 Insertion	7,860	5,541	132,256	38,056	47,793	177%	47,793	427,002	-	155,056	155,056
IUD 5	5,842	8,419	151,835	399,227	34,252	343%	34,252	4,258,235	-	122,521	122,521
IUD 5 Insertion	13,123	13,107	173,907	-	202,186	(14)%	202,186	1,001,965	-	175,618	175,618
IUS 5	-	-	-	3,500	-	-%	-	-	-	-	-
LLIN	-	143	15,800	15,800	22,280	(29)%	22,280	38,080	-	1,225	1,225
LLIN (Hammock net)	45	-	45	550	-	-%	-	45	-	-	-
Lubricant	51,738	70,576	839,393	-	712,089	18%	712,089	9,448,363	-	-	-
Malaria PPT (ACT)	249,926	198,238	1,026,089	1,230,330	466,511	120%	466,511	4,182,124	-	220,154	220,154

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Malaria PPT (Non-ACT)	(180)	87	1,261	344	3,078	(59)%	3,078	106,226	-	176	176
Malaria RDK	218,711	513,145	2,690,851	1,386,516	1,231,291	119%	1,231,291	10,738,271	-	-	-
Manual Vacuum Aspiratio	3,024	2,745	28,649	-	31,135	(8)%	31,135	59,784	-	1,469	1,469
Medical Abortion	74,701	94,016	863,391	954,436	390,924	121%	390,924	3,650,852	-	77,690	77,690
Medical Abortion Provider	718	716	7,970	-	-	-%	-	7,970	-	681	681
Micronutrient Powder	-	917,734	7,401,710	-	97,980	7,454%	97,980	7,499,690	-	-	-
Misoprostol for PAC (Oral	22,570	8,333	123,570	156,000	124,500	(1)%	124,500	393,470	-	2,146	2,146
Misoprostol for PAC (Subl	298,800	-	298,800	-	-	-%	-	298,800	-	6,893	6,893
Multivitamin	45,090	59,657	433,510	-	-	-%	-	433,510	-	104	104
Naloxone	600	282	3,511	5,892	-	-%	-	14,143	4,790	-	4,790
Needle & Syringe	1,011,864	619,873	6,912,895	6,082,749	4,903,605	41%	4,903,605	21,662,312	57,424	-	57,424
OCs	1,467,042	1,206,273	14,139,175	17,157,537	9,152,550	54%	9,152,550	131,797,830	-	118,212	118,212
OCs Provided	10,362	12,129	567,917	23,434	91,978	517%	91,978	718,277	-	8,538	8,538
ORS	52,525	76,960	767,528	2,370,620	568,984	35%	568,984	26,452,663	-	17,798	17,798
Pneumonia PPT	-	-	-	-	127,866	(100)%	127,866	1,057,411	-	-	-
Positive RDTs	5,105	5,688	39,332	-	13,201	198%	13,201	52,533	-	-	-
Positive RDTs Given First	4,834	5,397	36,641	-	10,870	237%	10,870	47,511	-	-	-
PUR	6,547	13,129	846,731	1,110,000	2,080,716	(59)%	2,080,716	16,460,293	-	20	20
QAACs Provided after Ci	4,971	5,005	32,965	10,513	7,361	348%	7,361	40,326	-	4,701	4,701
Referral to Emergency Co	-	25	76	-	-	-%	-	76	-	-	-
Referral to HIV Testing Se	1	9	5,229	2,935	10,424	(50)%	10,424	34,964	8	-	8
Referral to Implant 3 Inser	-	-	-	-	636	(100)%	636	636	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Implant 5 Inse	7	17	194	-	114	70%	114	781	-	68	68
Referral to Injectable 3	12	23	159	5,478	1,248	(87)%	1,248	2,237	-	3	3
Referral to IUD 10 Insertio	57	45	517	55,834	2,010	(74)%	2,010	10,732	-	222	222
Referral to Linkage to HIV	113	97	1,859	1,172	834	123%	834	2,693	1,676	-	1,676
Referral to Manual Vacuur	-	-	-	-	46	(100)%	46	46	-	-	-
Referral to Medication Abi	-	-	-	-	24	(100)%	24	24	-	-	-
Referral to OCs	15	4	93	-	1,280	(93)%	1,280	1,726	-	-	-
Referral to Opioid Treatme	7	13	201	-	136	48%	136	337	-	-	-
Referral to PAC Service (u	-	-	-	-	488	(100)%	488	488	-	-	-
Referral to TB Diagnosis	-	156	2,762	13,044	1,435	92%	1,435	14,911	-	-	-
Referral to TB DOTS (com	-	129	1,104	9,502	771	43%	771	1,875	-	1,582	1,582
Referral to TB DOTS (com	-	128	2,233	6,796	1,268	76%	1,268	3,682	-	3,346	3,346
Referral to TB Screening	24	2,292	50,482	12,177	35,261	43%	35,261	85,743	-	-	-
Safe Water Solution	-	-	-	-	6,973	(100)%	6,973	655,267	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	43,388	(100)%	43,388	548,483	-	-	-
STI Kit (Ulcerative)	-	-	-	-	3,679	(100)%	3,679	60,473	-	-	-
STI Screening	2,930	2,792	33,643	-	221	15,123%	221	34,447	-	-	-
TB Diagnosis	3,801	5,536	64,019	-	40,546	58%	40,546	128,167	-	-	-
TB DOTS	2,492	3,167	34,732	22,517	23,790	46%	23,790	296,664	-	177,784	177,784
TB Screening	11,331	15,034	197,010	-	109,755	79%	109,755	371,493	-	-	-
Toilets Constructed	-	-	12,802	-	-	-%	-	12,802	-	-	-
Toilets Sold	311	207	124,497	105,137	73,282	70%	73,282	197,779	-	16,114	16,114

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Tubal Ligation</b>	<b>3,761</b>	<b>1,848</b>	<b>29,781</b>	<b>67,302</b>	<b>18,281</b>	<b>63%</b>	<b>18,281</b>	<b>262,861</b>	-	<b>108,559</b>	<b>108,559</b>
<b>Vasectomy</b>	<b>88</b>	<b>65</b>	<b>1,798</b>	<b>2,112</b>	<b>1,870</b>	<b>(4)%</b>	<b>1,870</b>	<b>3,668</b>	-	<b>6,743</b>	<b>6,743</b>
<b>Vivax Treatment after Con</b>	<b>209</b>	<b>189</b>	<b>2,175</b>	<b>3,443</b>	<b>3,796</b>	<b>(43)%</b>	<b>3,796</b>	<b>5,971</b>	-	<b>358</b>	<b>358</b>
<b>Water Treatment Tablets</b>	-	<b>433</b>	<b>16,300</b>	<b>50,000</b>	<b>268,130</b>	<b>(94)%</b>	<b>268,130</b>	<b>3,641,923</b>	-	<b>1</b>	<b>1</b>
<b>Zinc</b>	-	-	<b>8,490</b>	<b>8,490</b>	<b>5,050</b>	<b>68%</b>	<b>5,050</b>	<b>32,844</b>	-	<b>58</b>	<b>58</b>



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>										<b>437,945</b>	<b>1,699,416</b>	<b>2,137,361</b>
<b>Cambodia</b>										<b>73,608</b>	<b>123,595</b>	<b>197,203</b>
Condom	1,323,618	1,039,248	11,569,716	12,238,560	10,681,429		8%	10,681,429	375,393,742	73,608	7,499	81,107
PSI Condom Distributed Provided	-	-	-	-	(2,117)		-%	(2,117)	(3,043)	-	-	-
Number One	700,488	442,128	4,477,896	4,829,760	3,632,976	12/94	23%	3,632,976	264,831,253	28,489	2,902	31,391
OK Condom	623,130	597,120	7,091,820	7,408,800	7,050,570	2/04	1%	7,050,570	110,565,532	45,119	4,597	49,716
Condom Provided	-	-	-	-	2,117		(100)%	2,117	3,043	-	-	-
PSI Condom Provided	-	-	-	-	2,117		(100)%	2,117	3,043	-	-	-
Diarrhea Treatment Kit	7,040	4,727	57,490	72,360	115,160		(50)%	115,160	873,250	-	1,133	1,133
Orasel Kit	7,040	4,727	57,490	72,360	115,160	3/09	(50)%	115,160	873,250	-	1,133	1,133
Emergency Contraception	5,989	6,446	65,719	58,800	51,970		26%	51,970	228,587	-	161	161
PSI Emergency Contraception Distr	(1)	(1)	(11)	-	(10)		-%	(10)	(33)	-	-	-
NEXT 72 EC	5,990	6,447	65,730	58,800	51,980	8/13	26%	51,980	228,620	-	161	161
Emergency Contraception Provided	1	1	11	-	10		10%	10	33	-	-	-
PSI Emergency Contraception Prov	1	1	11	-	10		10%	10	33	-	-	-
Fever Cases Attended	19,230	20,161	150,601	-	-		0%	-	150,601	-	-	-
Fever Cases Attended	19,230	20,161	150,601	-	-		-%	-	150,601	-	-	-
Fever Cases Tested with RDTs	19,229	20,159	150,579	-	-		0%	-	150,579	-	-	-
Fever Cases Tested with RDTs	19,229	20,159	150,579	-	-		-%	-	150,579	-	-	-
Implant 5	435	400	3,710	3,250	2,801		32%	2,801	13,897	-	2,326	2,326
PSI Implant 5 Distributed Inserted (	(260)	(254)	(3,449)	(2,500)	(3,061)		-%	(3,061)	(28,859)	-	(2,163)	(2,163)
Implant 5	695	654	7,159	5,750	5,862	5/09	22%	5,862	42,756	-	4,489	4,489
Implant 5 Insertion	260	254	3,449	2,525	3,064		13%	3,064	28,886	-	2,403	2,403
PSI Implant 5 Inserted	260	254	3,449	2,500	3,061		13%	3,061	28,859	-	2,403	2,403
Non-PSI Implant 5 Inserted	-	-	-	25	3		(100)%	3	27	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 3</b>	<b>42,103</b>	<b>34,205</b>	<b>373,073</b>	<b>376,000</b>	<b>349,694</b>		<b>7%</b>	<b>349,694</b>	<b>5,263,525</b>	-	<b>11,393</b>	<b>11,393</b>
PSI Injectable 3 Distributed Provide	(397)	(328)	(4,102)	-	(3,446)		-%	(3,446)	(10,834)	-	(125)	(125)
OK Injection-3	42,500	34,533	377,175	376,000	353,140	2/02	7%	353,140	5,274,359	-	11,518	11,518
<b>Injectable 3 Provided</b>	<b>397</b>	<b>328</b>	<b>4,102</b>	<b>-</b>	<b>3,448</b>		<b>19%</b>	<b>3,448</b>	<b>10,836</b>	-	<b>139</b>	<b>139</b>
PSI Injectable 3 Provided	397	328	4,102	-	3,446		19%	3,446	10,834	-	139	139
Non-PSI Injectable 3 Provided	-	-	-	-	2		(100)%	2	2	-	-	-
<b>IUD 10</b>	<b>700</b>	<b>723</b>	<b>11,736</b>	<b>10,000</b>	<b>12,935</b>		<b>(9)%</b>	<b>12,935</b>	<b>71,747</b>	-	<b>9,070</b>	<b>9,070</b>
PSI IUD 10 Distributed Inserted (1)	(1,660)	(1,672)	(21,109)	(19,000)	(15,805)		-%	(15,805)	(124,063)	-	(16,314)	(16,314)
IUD Copper T	2,360	2,395	32,845	29,000	28,740	1/10	14%	28,740	195,810	-	25,384	25,384
<b>IUD 10 Insertion</b>	<b>1,660</b>	<b>1,672</b>	<b>21,109</b>	<b>19,190</b>	<b>15,819</b>		<b>33%</b>	<b>15,819</b>	<b>124,427</b>	-	<b>18,126</b>	<b>18,126</b>
PSI IUD 10 Inserted	1,660	1,672	21,109	19,000	15,805		34%	15,805	124,063	-	18,126	18,126
Non-PSI IUD 10 Inserted	-	-	-	190	14		(100)%	14	364	-	-	-
<b>Lubricant</b>	<b>48,480</b>	<b>67,500</b>	<b>817,380</b>	<b>-</b>	<b>676,860</b>		<b>21%</b>	<b>676,860</b>	<b>8,656,760</b>	-	<b>-</b>	<b>-</b>
OK Plus Lubricant	48,480	67,500	817,380	-	676,860	6/09	21%	676,860	8,656,760	-	-	-
<b>Malaria PPT (ACT)</b>	<b>988</b>	<b>523</b>	<b>12,627</b>	<b>50,000</b>	<b>70,406</b>		<b>(82)%</b>	<b>70,406</b>	<b>411,866</b>	-	<b>1,447</b>	<b>1,447</b>
PSI QAActs Distributed Provided	(3,744)	(4,086)	(24,817)	-	-		-%	-	(24,817)	-	(2,845)	(2,845)
ASMQ for Adolescent	-	191	1,321	1,156	-		-%	-	1,321	-	151	151
ASMQ for Adult	4,224	4,148	27,929	23,802	17,673	5/16	58%	17,673	45,602	-	3,202	3,202
ASMQ for Children	508	264	1,501	1,042	357	10/16	320%	357	1,858	-	172	172
DHA-PIP For Adolescent	-	-	541	1,067	6,049	8/12	(91)%	6,049	40,822	-	62	62
DHA-PIP For Adult	-	7	5,691	21,971	41,229	8/12	(86)%	41,229	312,107	-	652	652
DHA-PIP For Children	-	-	461	962	5,098	8/12	(91)%	5,098	34,973	-	53	53
<b>Malaria RDK</b>	<b>32,700</b>	<b>31,467</b>	<b>321,025</b>	<b>500,000</b>	<b>401,875</b>		<b>(20)%</b>	<b>401,875</b>	<b>5,392,220</b>	-	<b>-</b>	<b>-</b>
MalaCheck	-	-	-	500,000	-	2/03	-%	-	3,772,420	-	-	-
Malaria RDT (Diagnosis)	32,700	31,467	321,025	-	401,875	6/15	(20)%	401,875	1,619,800	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Medical Abortion	23,974	29,333	283,725	255,000	250,187		13%	250,187	1,411,355	-	21,822	21,822
PSI Medical Abortion Distributed Pr	(718)	(716)	(7,970)	-	-		-%	-	(7,970)	-	(613)	(613)
Medabon	24,692	30,048	291,695	255,000	250,187	11/09	17%	250,187	1,419,325	-	22,435	22,435
Medical Abortion Provided	718	716	7,970	-	-		0%	-	7,970	-	681	681
PSI Medical Abortion Provided	718	716	7,970	-	-		-%	-	7,970	-	681	681
OCs	589,001	452,506	5,286,302	5,168,040	4,871,331		9%	4,871,331	54,734,268	-	43,712	43,712
PSI OCs Distributed Provided	(356)	(367)	(4,130)	-	(2,648)		-%	(2,648)	(8,735)	-	(34)	(34)
Marvelon	105,445	41,665	645,220	488,040	419,255	12/12	54%	419,255	1,455,555	-	5,335	5,335
OK Pills	483,912	411,208	4,645,212	4,680,000	4,454,724	9/97	4%	4,454,724	53,287,448	-	38,411	38,411
OCs Provided	356	367	4,130	-	2,649		56%	2,649	8,736	-	38	38
PSI OCs Provided	356	367	4,130	-	2,648		56%	2,648	8,735	-	38	38
Non-PSI OCs Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Positive RDTs	3,888	4,231	26,033	-	-		0%	-	26,033	-	-	-
Positive RDTs	3,888	4,231	26,033	-	-		-%	-	26,033	-	-	-
Positive RDTs Given First Line Treatm	3,744	4,086	24,817	-	-		0%	-	24,817	-	-	-
Positive RDTs Given First Line Trea	3,744	4,086	24,817	-	-		-%	-	24,817	-	-	-
QAACTs Provided after Confirmatory I	3,744	4,092	24,848	-	-		0%	-	24,848	-	3,351	3,351
PSI QAACTs Provided after Confirm	3,744	4,086	24,817	-	-		-%	-	24,817	-	3,347	3,347
Non-PSI QAACTs Provided after Co	-	5	31	-	-		-%	-	31	-	4	4
Referral to Emergency Contraception	-	25	76	-	-		0%	-	76	-	-	-
Referral to Emergency Contraceptio	-	25	76	-	-		-%	-	76	-	-	-
Referral to Implant 5 Insertion	7	17	194	-	114		70%	114	781	-	68	68
Referral to Implant 5 Insertion	7	17	194	-	114		70%	114	781	-	68	68
Referral to Injectable 3	12	23	159	-	250		(36)%	250	1,239	-	3	3
Referral to Injectable 3	12	23	159	-	250		(36)%	250	1,239	-	3	3

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to IUD 10 Insertion	57	45	517	-	825		(37)%	825	8,802	-	222	222
Referral to IUD 10 Insertion	57	45	517	-	825	12/11	(37)%	825	8,802	-	222	222
Referral to OCs	15	4	93	-	105		(11)%	105	551	-	-	-
Referral to OCs	15	4	93	-	105		(11)%	105	551	-	-	-
<b>India</b>										(2)	172,365	172,363
Cervical Cancer-Pap Smear Screening	-	-	304	-	4,743		(94)%	4,743	5,047	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	304	-	4,743		(94)%	4,743	5,047	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	419	-	2,696		(84)%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Cryotherap	-	-	419	-	2,696		(84)%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Refer to any	-	-	79	-	48		65%	48	127	-	11	11
Cervical Cancer-VIA and Refer to ar	-	-	79	-	48		65%	48	127	-	11	11
Cervical Cancer-VIA and Refer to Cryc	-	-	419	-	446		(6)%	446	865	-	57	57
Cervical Cancer-VIA and Refer to Ci	-	-	419	-	446		(6)%	446	865	-	57	57
Cervical Cancer-VIA/VILI Screening	-	-	5,504	-	97,406		(94)%	97,406	102,910	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	5,504	-	97,406		(94)%	97,406	102,910	-	-	-
Clean Delivery Kit	-	-	-	-	400		(100)%	400	260,026	-	-	-
NewBorn	-	-	-	-	400	7/02	(100)%	400	260,026	-	-	-
Condom	-	-	(900)	-	17,665,520		(100)%	17,665,520	2,907,664,828	(2)	(1)	(2)
Masti	-	-	(900)	-	17,655,020	9/88	(100)%	17,655,020	1,966,656,606	(2)	(1)	(2)
Nirodh	-	-	-	-	10,500	5/88	(100)%	10,500	941,008,222	-	-	-
Condom Provided	-	-	-	-	50,644		(100)%	50,644	50,644	-	-	-
Non-PSI Condom Provided	-	-	-	-	50,644		(100)%	50,644	50,644	-	-	-
Diarrhea Treatment Kit	-	-	-	-	(4,574)		0%	(4,574)	546,681	-	-	-
Neotral Zinc Kit	-	-	-	-	(3,611)	7/13	-%	(3,611)	267,989	-	-	-
ORS + Zinc (Generic)	-	-	-	-	(963)	9/12	-%	(963)	278,692	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fecal Sludge Management (Household)	23	38	661	670	921		(28)%	921	1,582	-	-	-
Fecal Sludge Management (Household)	23	38	661	670	921		(28)%	921	1,582	-	-	-
Fecal Sludge Management (Liters)	1,310,000	130,000	4,125,200	1,571,000	3,021,000		37%	3,021,000	7,146,200	-	228	228
Fecal Sludge Management (Liters)	1,310,000	130,000	4,125,200	1,571,000	3,021,000		37%	3,021,000	7,146,200	-	228	228
Injectable 3	-	-	(414)	-	37,194		(101)%	37,194	266,201	-	(16)	(16)
Freedom Inject (3-month)	-	-	(414)	-	37,478	7/13	(101)%	37,478	152,577	-	(16)	(16)
Procosteron 150	-	-	-	-	(284)	6/10	-%	(284)	113,624	-	-	-
Injectable 3 Provided	1,699	1,879	18,762	-	16,188		16%	16,188	34,950	-	786	786
Non-PSI Injectable 3 Provided	1,699	1,879	18,762	-	16,188		16%	16,188	34,950	-	786	786
Iron Folic Acid Tablet	-	-	-	-	(5,412)		0%	(5,412)	48,228,558	-	-	-
Vitalet-Preg	-	-	-	-	(5,412)	8/02	-%	(5,412)	48,228,558	-	-	-
IUD 10	-	-	(174)	-	4,370		(104)%	4,370	4,196	-	(166)	(166)
PSI IUD 10 Distributed Inserted (1)	-	-	(174)	-	-		-%	-	(174)	-	(166)	(166)
Freedom 10	-	-	-	-	4,370	7/16	(100)%	4,370	4,370	-	-	-
IUD 10 Insertion	17	51	1,051	-	1,608		(35)%	1,608	2,659	-	1,114	1,114
PSI IUD 10 Inserted	-	-	174	-	-		-%	-	174	-	184	184
Non-PSI IUD 10 Inserted	17	51	877	-	1,608		(45)%	1,608	2,485	-	930	930
IUD 5	-	-	(4,537)	-	20,146		(123)%	20,146	995,119	-	(3,231)	(3,231)
PSI IUD 5 Distributed Inserted (1)	-	-	(3,406)	-	-		-%	-	(3,406)	-	(2,425)	(2,425)
Freedom 5	-	-	(1,131)	-	20,146	7/08	(106)%	20,146	998,525	-	(805)	(805)
IUD 5 Insertion	3,823	4,053	43,042	-	26,529		62%	26,529	69,571	-	34,055	34,055
PSI IUD 5 Inserted	-	-	3,406	-	-		-%	-	3,406	-	2,695	2,695
Non-PSI IUD 5 Inserted	3,823	4,053	39,636	-	26,529		49%	26,529	66,165	-	31,360	31,360
Medical Abortion	-	-	(1,258)	-	72,708		(102)%	72,708	1,482,093	-	(117)	(117)
Safe Abort kit	-	-	(1,258)	-	72,708	11/09	(102)%	72,708	1,482,093	-	(117)	(117)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
OCs	-	-	(11,250)	-	(642,408)		0%	(642,408)	115,515,319	-	(115)	(115)
Mala-D	-	-	-	-	(33,833)	5/97	-%	(33,833)	67,283,904	-	-	-
Pearl 3	-	-	(11,250)	-	(608,575)	1/02	-%	(608,575)	48,231,415	-	(115)	(115)
OCs Provided	3,008	2,833	35,422	9,434	28,714		23%	28,714	64,136	-	402	402
Non-PSI OCs Provided	3,008	2,833	35,422	9,434	28,714		23%	28,714	64,136	-	402	402
ORS	-	-	(12,625)	-	306,053		(104)%	306,053	25,409,579	-	(237)	(237)
Neotral Orange 1000ml	-	-	(12,625)	-	306,053	7/98	(104)%	306,053	25,409,579	-	(237)	(237)
Referral to Injectable 3	-	-	-	5,478	-		0%	-	-	-	-	-
Referral to Injectable 3	-	-	-	5,478	-		-%	-	-	-	-	-
Referral to IUD 10 Insertion	-	-	-	35,834	-		0%	-	-	-	-	-
Referral to IUD 10 Insertion	-	-	-	35,834	-		-%	-	-	-	-	-
Referral to TB Diagnosis	-	145	2,505	13,044	1,393		80%	1,393	3,898	-	-	-
Referral to TB Diagnosis	-	145	2,505	13,044	1,393		80%	1,393	3,898	-	-	-
Referral to TB DOTS (completion confi	-	61	902	7,328	437		106%	437	1,339	-	1,513	1,513
Referral to TB DOTS (completion co	-	61	902	7,328	437		106%	437	1,339	-	1,513	1,513
Referral to TB DOTS (completion unkr	-	122	2,213	5,716	1,268		75%	1,268	3,481	-	3,340	3,340
Referral to TB DOTS (completion un	-	122	2,213	5,716	1,268		75%	1,268	3,481	-	3,340	3,340
Referral to TB Screening	-	2,292	50,453	12,177	35,095		44%	35,095	85,548	-	-	-
Referrals to TB Screening	-	2,292	50,453	12,177	35,095		44%	35,095	85,548	-	-	-
TB Diagnosis	-	1,519	21,022	-	6,769		211%	6,769	27,791	-	-	-
TB Diagnosis	-	1,519	21,022	-	6,769		211%	6,769	27,791	-	-	-
TB DOTS	-	366	3,530	8,533	880		301%	880	4,410	-	11,839	11,839
TB DOTS	-	366	3,530	8,533	880		301%	880	4,410	-	11,839	11,839
TB Screening	-	3,024	64,007	-	44,185		45%	44,185	108,192	-	-	-
TB Screening	-	3,024	64,007	-	44,185		45%	44,185	108,192	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Toilets Constructed	-	-	12,802	-	-		0%	-	12,802	-	-	-
Toilet Type 1	-	-	3,067	-	-	10/16	-%	-	3,067	-	-	-
Toilet Type 2	-	-	7,308	-	-	10/16	-%	-	7,308	-	-	-
Toilet Type 3	-	-	2,427	-	-	10/16	-%	-	2,427	-	-	-
Toilets Sold	-	-	122,599	99,647	73,282		67%	73,282	195,881	-	16,061	16,061
Toilet Type 1, Direct Sales	-	-	36,613	27,800	17,812		106%	17,812	54,425	-	8,007	8,007
Toilet Type 2, Direct Sales	-	-	62,456	50,387	30,789		103%	30,789	93,245	-	7,683	7,683
Toilet Type 3, Direct Sales	-	-	6,020	8,687	7,307		(18)%	7,307	13,327	-	370	370
Toilet Type 3, Microfinance	-	-	17,510	12,773	17,374		1%	17,374	34,884	-	-	-
Tubal Ligation	3,761	1,848	27,037	67,302	16,209		67%	16,209	43,246	-	99,982	99,982
Tubal Ligation	3,761	1,848	27,037	67,302	16,209		67%	16,209	43,246	-	99,982	99,982
Vasectomy	88	65	1,798	2,112	1,870		(4)%	1,870	3,668	-	6,743	6,743
Vasectomy	88	65	1,798	2,112	1,870		(4)%	1,870	3,668	-	6,743	6,743
Zinc	-	-	-	-	(3,758)		0%	(3,758)	478,970	-	-	-
BIBZinC	-	-	-	-	(1,000)	11/09	-%	(1,000)	420,928	-	-	-
NeoZinc (50ml zinc acetate syrup)	-	-	-	-	(2,758)	7/13	-%	(2,758)	58,042	-	-	-
<b>India LLC</b>										176,973	234,452	411,425
Condom	9,455,360	7,558,661	91,337,907	185,784,321	48,873,945		87%	48,873,945	140,211,852	176,973	73,135	250,108
Masti Classic 10's	493,200	1,313,200	4,432,800	-	-	10/17	-%	-	4,432,800	8,589	3,549	12,138
Masti Classic 10's (Flavoured)	1,411,200	1,244,200	9,209,640	47,902,315	-		-%	-	9,209,640	17,844	7,374	25,218
Masti Classic 3's	3,492,240	1,439,234	36,142,507	57,434,459	29,023,320	12/16	25%	29,023,320	65,165,827	70,029	28,939	98,968
Masti Classic 3's (Flavoured)	2,635,200	2,191,133	14,086,360	24,194,683	-		-%	-	14,086,360	27,293	11,279	38,572
Masti Classic 6's	-	2,280	9,651,360	7,210,944	17,442,120	12/16	(45)%	17,442,120	27,093,480	18,700	7,728	26,428
Masti Premium 10's (Flavoured)	370,920	448,040	4,249,920	12,006,720	-		-%	-	4,249,920	8,235	3,403	11,637

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Masti Premium 3's	-	-	6,552,520	9,459,504	2,408,505	12/16	172%	2,408,505	8,961,025	12,696	5,247	17,943
Masti Premium 3's (Flavoured)	1,052,600	920,573	7,012,800	25,575,696	-		-%	-	7,012,800	13,588	5,615	19,203
Vive 10's (X Dotted + Flavour)	-	-	-	500,000	-		-%	-	-	-	-	-
Vive 10's (X Time + Flavour)	-	-	-	200,000	-		-%	-	-	-	-	-
Vive 3's (X Dotted + Flavour)	-	-	-	1,000,000	-		-%	-	-	-	-	-
Vive 3's (X Time + Flavour)	-	-	-	300,000	-		-%	-	-	-	-	-
Emergency Contraception	-	-	-	250,000	-		0%	-	-	-	-	-
Pronta	-	-	-	250,000	-		-%	-	-	-	-	-
Injectable 3	5,256	10,820	69,081	298,848	-		0%	-	69,081	-	2,606	2,606
Freedom Inject (3-month)	5,256	10,820	69,081	298,848	-	12/16	-%	-	69,081	-	2,606	2,606
IUD 5	6,055	11,873	100,714	150,000	-		0%	-	100,714	-	71,717	71,717
Freedom 5	6,055	11,873	100,714	150,000	-	12/16	-%	-	100,714	-	71,717	71,717
IUS 5	-	-	-	3,500	-		0%	-	-	-	-	-
Freedom LNG-IUS	-	-	-	3,500	-		-%	-	-	-	-	-
Medical Abortion	43,030	60,485	514,936	606,936	-		0%	-	514,936	-	47,794	47,794
Safe Abort kit	43,030	60,485	514,936	606,936	-	12/16	-%	-	514,936	-	47,794	47,794
OCs	263,040	249,960	3,238,860	6,069,120	431,100		651%	431,100	3,669,960	-	33,085	33,085
MEURI	-	-	-	96,000	-		-%	-	-	-	-	-
Pearl	263,040	249,960	3,238,860	5,973,120	431,100	12/16	651%	431,100	3,669,960	-	33,085	33,085
ORS	7,200	15,158	326,428	2,001,120	-		0%	-	326,428	-	6,116	6,116
Neotral Orange 1000ml	7,200	15,158	326,428	2,001,120	-	12/16	-%	-	326,428	-	6,116	6,116
<b>Kazakhstan</b>										412	3	415
Free Condom	-	455	7,365	178,420	619,800		(99)%	619,800	627,165	7	2	9
Generic Male Condom	-	455	7,365	178,420	619,800	8/16	(99)%	619,800	627,165	7	2	9
Free Female Condom	-	190	4,570	34,000	20,000		(77)%	20,000	24,570	4	1	5

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Generic Female Condom	-	190	4,570	34,000	20,000	8/16	(77)%	20,000	24,570	4	1	5
HIV Testing Services	223	302	2,452	2,200	367		568%	367	3,530	4	-	4
VCT Individual (HIV-Negative)	216	294	2,395	2,200	367		553%	367	3,473	4	-	4
VCT Individual (HIV-Positive)	7	8	57	-	-		-%	-	57	-	-	-
Referral to HIV Testing Services	-	9	893	635	1,273		(30)%	1,273	5,148	1	-	1
Referral to HIV Testing & Counseling	-	9	893	635	1,273	12/13	(30)%	1,273	5,148	1	-	1
Referral to Linkage to HIV Care	16	19	438	450	281		56%	281	719	396	-	396
Referral to Linkage to HIV Care	16	19	438	450	281		56%	281	719	396	-	396
Referral to Opioid Treatment	-	5	67	-	-		0%	-	67	-	-	-
Referral to Opioid Treatment	-	5	67	-	-		-%	-	67	-	-	-
Referral to TB Diagnosis	-	4	73	-	-		0%	-	1,335	-	-	-
Referral to TB Diagnosis	-	4	73	-	-	12/14	-%	-	1,335	-	-	-
Referral to TB Screening	6	-	10	-	-		0%	-	10	-	-	-
Referrals to TB Screening	6	-	10	-	-		-%	-	10	-	-	-
TB Screening	468	156	2,073	-	447		364%	447	3,038	-	-	-
TB Screening	468	156	2,073	-	447		364%	447	3,038	-	-	-
<b>Kyrgyzstan</b>										639	-	639
HIV Testing Services	1,718	1,173	11,071	13,700	1,502		637%	1,502	13,468	20	-	20
VCT Individual (HIV-Negative)	1,691	1,151	10,835	13,700	1,502		621%	1,502	13,232	20	-	20
VCT Individual (HIV-Positive)	27	22	236	-	-		-%	-	236	-	-	-
Referral to HIV Testing Services	-	-	7	-	7,517		(100)%	7,517	14,518	-	-	-
Referral to HIV Testing & Counseling	-	-	7	-	7,517	12/13	(100)%	7,517	14,518	-	-	-
Referral to Linkage to HIV Care	29	30	589	568	473		25%	473	1,062	618	-	618
Referral to Linkage to HIV Care	29	30	589	568	473		25%	473	1,062	618	-	618
Referral to Opioid Treatment	2	-	15	-	131		(89)%	131	146	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Opioid Treatment	2	-	15	-	131		(89)%	131	146	-	-	-
Referral to TB Diagnosis	-	6	128	-	-		0%	-	4,428	-	-	-
Referral to TB Diagnosis	-	6	128	-	-	12/14	-%	-	4,428	-	-	-
Referral to TB Screening	12	-	12	-	-		0%	-	12	-	-	-
Referrals to TB Screening	12	-	12	-	-		-%	-	12	-	-	-
TB Screening	163	122	1,571	-	1,868		(16)%	1,868	5,173	-	-	-
TB Screening	163	122	1,571	-	1,868		(16)%	1,868	5,173	-	-	-
<b>Laos</b>										2,187	21,866	24,052
Condom	422,211	191,232	2,146,335	3,200,000	2,935,872		(27)%	2,935,872	27,460,782	2,183	1,496	3,679
No 1 Condom Grp	110,085	19,008	353,550	600,000	452,736	11/10	(22)%	452,736	4,280,452	360	246	606
No 1 Condom Strw	178,518	97,920	1,044,219	1,800,000	1,410,048	8/08	(26)%	1,410,048	14,165,880	1,062	728	1,790
Number One Rose	133,608	74,304	748,566	800,000	1,073,088	4/08	(30)%	1,073,088	9,014,450	761	522	1,283
Fever Cases Attended	1,741	1,267	11,061	-	-		0%	-	11,061	-	-	-
Fever Cases Attended	1,741	1,267	11,061	-	-		-%	-	11,061	-	-	-
Fever Cases Tested with RDTs	1,739	1,264	11,047	-	-		0%	-	11,047	-	-	-
Fever Cases Tested with RDTs	1,739	1,264	11,047	-	-		-%	-	11,047	-	-	-
HIV Testing Services	477	489	5,030	2,740	195		2479%	195	14,052	4	-	4
VCT Individual (HIV-Negative)	475	487	5,001	2,728	192	2/10	2,505%	192	13,915	4	-	4
VCT Individual (HIV-Positive)	2	2	29	12	3	4/10	867%	3	137	-	-	-
Implant 3 Insertion	1,611	503	8,435	6,700	4,152		103%	4,152	12,863	-	4,285	4,285
Non-PSI Implant 3 Inserted	1,611	503	8,435	6,700	4,152	3/16	103%	4,152	12,863	-	4,285	4,285
Injectable 3 Provided	2,200	3,822	14,976	9,500	-		0%	-	17,709	-	547	547
Non-PSI Injectable 3 Provided	2,200	3,822	14,976	9,500	-	3/16	-%	-	17,709	-	547	547
IUD 10 Insertion	2,253	815	14,315	-	10,848		32%	10,848	34,684	-	13,014	13,014
Non-PSI IUD 10 Inserted	2,253	815	14,315	-	10,848		32%	10,848	34,684	-	13,014	13,014

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	-	-	-	-	6,024		(100)%	6,024	38,836	-	-	-
Number One Lubricant (20 cc)	-	-	-	-	6,024	7/12	(100)%	6,024	38,836	-	-	-
Misoprostol for PAC (Oral)	22,570	8,333	123,570	156,000	124,500		(1)%	124,500	393,470	-	2,146	2,146
Misoprostol for PAC (oral)	22,570	8,333	123,570	156,000	124,500	8/13	(1)%	124,500	393,470	-	2,146	2,146
OCs Provided	3,413	4,962	19,945	14,000	-		0%	-	24,047	-	197	197
Non-PSI OCs Provided	3,413	4,962	19,945	14,000	-	3/16	-%	-	24,047	-	197	197
Positive RDTs	95	56	563	-	-		0%	-	563	-	-	-
Positive RDTs	95	56	563	-	-		-%	-	563	-	-	-
Positive RDTs Given First Line Treatm	95	56	563	-	-		0%	-	563	-	-	-
Positive RDTs Given First Line Trea	95	56	563	-	-		-%	-	563	-	-	-
QAACts Provided after Confirmatory I	563	-	563	-	-		0%	-	563	-	105	105
Non-PSI QAACts Provided after Co	563	-	563	-	-		-%	-	563	-	105	105
Referral to HIV Testing Services	-	-	-	-	195		(100)%	195	195	-	-	-
Referral to HIV Testing & Counselin	-	-	-	-	195		(100)%	195	195	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	636		(100)%	636	636	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	636		(100)%	636	636	-	-	-
Referral to Injectable 3	-	-	-	-	998		(100)%	998	998	-	-	-
Referral to Injectable 3	-	-	-	-	998		(100)%	998	998	-	-	-
Referral to IUD 10 Insertion	-	-	-	20,000	1,185		(100)%	1,185	1,930	-	-	-
Referral to IUD 10 Insertion	-	-	-	20,000	1,185	12/11	(100)%	1,185	1,930	-	-	-
Referral to Manual Vacuum Aspiration	-	-	-	-	46		(100)%	46	46	-	-	-
Referral to Manual Vacuum Aspiratic	-	-	-	-	46		(100)%	46	46	-	-	-
Referral to Medication Abortion	-	-	-	-	24		(100)%	24	24	-	-	-
Referral to Medication Abortion	-	-	-	-	24		(100)%	24	24	-	-	-
Referral to OCs	-	-	-	-	1,175		(100)%	1,175	1,175	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to OCs	-	-	-	-	1,175		(100)%	1,175	1,175	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	488		(100)%	488	488	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	488		(100)%	488	488	-	-	-
Referral to TB Diagnosis	-	-	-	-	42		(100)%	42	42	-	-	-
Referral to TB Diagnosis	-	-	-	-	42		(100)%	42	42	-	-	-
Referral to TB DOTS (completion confi	-	67	202	120	41		393%	41	243	-	70	70
Referral to TB DOTS (completion co	-	67	202	120	41	3/16	393%	41	243	-	70	70
Referral to TB DOTS (completion unkr	-	7	20	80	-		0%	-	201	-	6	6
Referral to TB DOTS (completion un	-	7	20	80	-	12/13	-%	-	201	-	6	6
Referral to TB Screening	-	-	-	-	166		(100)%	166	166	-	-	-
Referrals to TB Screening	-	-	-	-	166		(100)%	166	166	-	-	-
TB Diagnosis	-	15	224	-	218		3%	218	604	-	-	-
TB Diagnosis	-	15	224	-	218		3%	218	604	-	-	-
TB DOTS	-	-	-	-	121		(100)%	121	231	-	-	-
TB DOTS	-	-	-	-	121	11/11	(100)%	121	231	-	-	-
TB Screening	-	64	731	-	782		(7)%	782	2,262	-	-	-
TB Screening	-	64	731	-	782		(7)%	782	2,262	-	-	-
<b>Myanmar</b>										99,925	184,293	284,219
Antiretroviral Treatment (Currently Enr	4,927	4,638	45,990	36,450	1,661		2669%	1,661	47,651	8,034	-	8,034
Antiretroviral Treatment (Currently E	4,927	4,638	45,990	36,450	1,661		2,669%	1,661	47,651	8,034	-	8,034
Antiretroviral Treatment (Newly Enrolle	188	242	2,917	2,100	1,042		180%	1,042	3,959	-	-	-
Antiretroviral Treatment (Newly Enrc	188	242	2,917	2,100	1,042		180%	1,042	3,959	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	1	-	22		(95)%	22	898	-	-	-
Cervical Cancer-VIA and Cryothera	-	-	1	-	22	11/12	(95)%	22	898	-	-	-
Cervical Cancer-VIA/VILI Screening	7	6	125	-	634		(80)%	634	4,444	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-VIA/VILI Screening	7	6	125	-	634		(80)%	634	4,444	-	-	-
<b>Condom</b>	<b>666,241</b>	<b>1,123,555</b>	<b>16,611,972</b>	<b>16,200,001</b>	<b>21,386,624</b>		<b>(22)%</b>	<b>21,386,624</b>	<b>399,807,257</b>	<b>78,613</b>	<b>7,795</b>	<b>86,408</b>
Aphaw	114,060	273,243	2,762,308	5,755,658	6,364,593	7/96	(57)%	6,364,593	188,750,399	13,072	1,296	14,368
Aphaw - Natural Touch	53,301	72,427	2,798,322	2,423,695	2,680,116	8/12	4%	2,680,116	13,738,575	13,243	1,313	14,556
Aphaw Flavors	390,544	728,103	7,758,456	4,504,599	4,981,175	10/01	56%	4,981,175	170,894,415	36,716	3,640	40,356
Aphaw Studded	5,100	33,630	3,040,650	3,316,049	3,666,879	7/12	(17)%	3,666,879	17,397,687	14,389	1,427	15,816
Generic Male Condom	91,500	9,000	134,000	-	3,551,661	1/08	(96)%	3,551,661	3,888,529	634	63	697
OK Condom	11,736	7,152	118,236	200,000	142,200	5/03	(17)%	142,200	5,137,652	560	55	615
<b>Diarrhea Treatment Kit</b>	<b>8</b>	<b>18</b>	<b>17,471</b>	<b>5,000</b>	<b>322,860</b>		<b>(95)%</b>	<b>322,860</b>	<b>5,046,455</b>	<b>-</b>	<b>940</b>	<b>940</b>
Orasel DTK	8	18	17,471	5,000	322,860	2/09	(95)%	322,860	5,046,455	-	940	940
<b>Emergency Contraception</b>	<b>-</b>	<b>-</b>	<b>42</b>	<b>-</b>	<b>1,084</b>		<b>(96)%</b>	<b>1,084</b>	<b>177,864</b>	<b>-</b>	<b>-</b>	<b>-</b>
OK EC	-	-	42	-	1,084	8/07	(96)%	1,084	177,864	-	-	-
<b>Female Condom</b>	<b>7,917</b>	<b>6,277</b>	<b>71,234</b>	<b>90,000</b>	<b>89,174</b>		<b>(20)%</b>	<b>89,174</b>	<b>1,390,825</b>	<b>337</b>	<b>26</b>	<b>363</b>
Generic Female Condom	7,917	6,277	71,234	90,000	89,174	5/08	(20)%	89,174	1,390,825	337	26	363
<b>Fever Cases Attended</b>	<b>115,731</b>	<b>117,990</b>	<b>1,075,555</b>	<b>-</b>	<b>657,831</b>		<b>64%</b>	<b>657,831</b>	<b>1,733,386</b>	<b>-</b>	<b>-</b>	<b>-</b>
Fever Cases Attended	115,731	117,990	1,075,555	-	657,831		64%	657,831	1,733,386	-	-	-
<b>Fever Cases Tested with RDTs</b>	<b>115,731</b>	<b>117,990</b>	<b>1,075,555</b>	<b>-</b>	<b>657,831</b>		<b>64%</b>	<b>657,831</b>	<b>1,733,386</b>	<b>-</b>	<b>-</b>	<b>-</b>
Fever Cases Tested with RDTs	115,731	117,990	1,075,555	-	657,831		64%	657,831	1,733,386	-	-	-
<b>Free Condom</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,000,000</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>4,285,491</b>	<b>-</b>	<b>-</b>	<b>-</b>
Generic	-	-	-	4,000,000	-	8/01	-%	-	4,285,491	-	-	-
<b>HIV Testing Services</b>	<b>4,996</b>	<b>6,232</b>	<b>74,728</b>	<b>63,000</b>	<b>68,045</b>		<b>10%</b>	<b>68,045</b>	<b>351,404</b>	<b>89</b>	<b>-</b>	<b>89</b>
VCT Concordant Couple (HIV-Nega)	-	-	-	-	42	12/09	(100)%	42	2,090	-	-	-
VCT Concordant Couple (HIV-Positi)	-	-	-	-	94	12/09	(100)%	94	1,800	-	-	-
VCT Discordant Couple (HIV-Negati)	-	-	-	-	27	12/09	(100)%	27	752	-	-	-
VCT Discordant Couple (HIV-Positiv)	-	-	-	-	27	12/09	(100)%	27	752	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Negative)	4,604	5,843	69,966	60,000	64,256	12/09	9%	64,256	321,245	84	-	84
VCT Individual (HIV-Positive)	392	389	4,762	3,000	3,599	12/09	32%	3,599	24,765	6	-	6
Hypertension Diagnosis	5,751	3,097	16,041	-	-		0%	-	16,041	-	-	-
Hypertension Diagnosis	5,751	3,097	16,041	-	-		-%	-	16,041	-	-	-
Hypertension Screening	12,455	6,826	34,514	-	-		0%	-	34,514	-	-	-
Hypertension Screening	12,455	6,826	34,514	-	-		-%	-	34,514	-	-	-
Hypertension_Controlled Condition	4,272	2,376	12,310	-	-		0%	-	12,310	-	-	-
Hypertension_Controlled Condition	4,272	2,376	12,310	-	-		-%	-	12,310	-	-	-
Implant 3	320	148	7,496	6,000	2,660		182%	2,660	10,156	-	2,319	2,319
PSI Implant 3 Distributed Inserted (	(350)	(351)	(3,481)	-	-		-%	-	(3,481)	-	(1,077)	(1,077)
Implanon NXT	670	500	10,977	6,000	2,660	12/15	313%	2,660	13,637	-	3,396	3,396
Implant 3 Insertion	350	351	3,481	-	-		0%	-	3,481	-	1,197	1,197
PSI Implant 3 Inserted	350	351	3,481	-	-		-%	-	3,481	-	1,197	1,197
Implant 5	-	-	(2)	-	107		(102)%	107	(998)	-	(1)	(1)
PSI Implant 5 Distributed Inserted (	-	-	(2)	-	-		-%	-	(1,105)	-	(1)	(1)
Jadelle	-	-	-	-	107	5/16	(100)%	107	107	-	-	-
Implant 5 Insertion	-	-	2	-	-		0%	-	1,105	-	1	1
PSI Implant 5 Inserted	-	-	2	-	-		-%	-	1,105	-	1	1
Injectable 3	51,700	43,169	557,444	650,000	584,852		(5)%	584,852	9,358,892	-	12,324	12,324
OK-3 Injection	51,700	43,169	557,444	650,000	584,852	9/01	(5)%	584,852	9,358,892	-	12,324	12,324
IUD 10	-	(1)	1,501	-	50		2902%	50	3,148	-	841	841
PSI IUD 10 Distributed Inserted (1)	-	(1)	(92)	-	-		-%	-	(92)	-	(52)	(52)
OK IUD (Copper T Cu 380A)	-	-	1,593	-	50	10/14	3,086%	50	3,240	-	892	892
IUD 10 Insertion	-	1	92	-	-		0%	-	92	-	57	57
PSI IUD 10 Inserted	-	1	92	-	-		-%	-	92	-	57	57

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 5	70	50	895	4,000	6,528		(86)%	6,528	140,930	-	374	374
PSI IUD 5 Distributed Inserted (1)	(117)	(117)	(1,470)	-	-		-%	-	(56,697)	-	(614)	(614)
OK IUD	187	167	2,365	4,000	6,528	5/03	(64)%	6,528	197,627	-	988	988
IUD 5 Insertion	117	117	1,470	-	-		0%	-	56,697	-	682	682
PSI IUD 5 Inserted	117	117	1,470	-	-		-%	-	56,697	-	682	682
LLIN	-	143	15,800	15,800	22,280		(29)%	22,280	38,080	-	1,225	1,225
LLIN	-	143	15,800	15,800	22,280	11/16	(29)%	22,280	38,080	-	1,225	1,225
Lubricant	3,258	3,076	22,013	-	29,205		(25)%	29,205	752,767	-	-	-
Aphaw Gel - Tube 20 cc	3,258	3,076	21,383	-	-	10/06	-%	-	630,069	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	-	-	630	-	29,205	10/14	(98)%	29,205	122,698	-	-	-
Malaria PPT (ACT)	1,060	6,304	191,354	244,409	392,739		(51)%	392,739	2,932,563	-	26,761	26,761
PSI QAACTs Distributed Provided ε	(647)	(903)	(7,492)	(10,088)	(7,361)		-%	(7,361)	(14,853)	-	(1,048)	(1,048)
AL 1	1	89	1,206	-	1,386	7/12	(13)%	1,386	13,589	-	169	169
AL 2	11	123	1,331	-	1,285	7/12	4%	1,285	14,363	-	186	186
AL 3	186	187	1,862	-	2,304	1/11	(19)%	2,304	48,924	-	260	260
AL 4	789	958	8,211	4,497	11,892	1/11	(31)%	11,892	262,758	-	1,148	1,148
Arte+1	-	8	2,266	3,375	2,762	8/14	(18)%	2,762	22,279	-	317	317
Arte+2	-	8	2,266	3,375	3,660	8/14	(38)%	3,660	23,178	-	317	317
Arte+3	720	-	3,861	4,500	3,630	8/14	6%	3,630	26,542	-	540	540
Arte+4	-	4,808	77,036	101,250	143,957	8/14	(46)%	143,957	466,688	-	10,773	10,773
Supa Arte 1	-	329	3,457	4,125	14,120	9/12	(76)%	14,120	120,711	-	483	483
Supa Arte 2	-	329	2,340	4,125	16,436	9/12	(86)%	16,436	116,552	-	327	327
Supa Arte 3	-	360	5,799	5,500	15,611	9/12	(63)%	15,611	196,459	-	811	811
Supa Arte 4	-	8	89,211	123,750	183,057	9/12	(51)%	183,057	1,635,373	-	12,476	12,476

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Malaria PPT (Non-ACT)	(180)	87	1,261	344	3,078		(59)%	3,078	106,226	-	176	176
PSI Vivax Tx Distributed Provided a	(209)	(186)	(2,166)	(3,443)	(3,796)		-%	(3,796)	(5,962)	-	(303)	(303)
Vivax Treatment Kit	29	273	3,427	3,787	6,874	6/11	(50)%	6,874	112,188	-	479	479
Malaria RDK	46,180	111,779	1,120,295	886,516	829,416		35%	829,416	3,988,564	-	-	-
Malaria RDT (Diagnosis)	46,180	111,779	1,120,295	886,516	829,416	3/11	35%	829,416	3,988,564	-	-	-
Micronutrient Powder	-	917,734	7,401,710	-	97,980		7454%	97,980	7,499,690	-	-	-
Happy Kid (Micronutrient powder)	-	917,734	7,401,710	-	97,980	9/16	7,454%	97,980	7,499,690	-	-	-
Multivitamin	45,090	59,657	433,510	-	-		0%	-	433,510	-	104	104
May May Vita Plus	45,090	59,657	433,510	-	-	6/17	-%	-	433,510	-	104	104
Needle & Syringe	445,264	85,400	1,565,364	500,000	303,605		416%	303,605	1,945,969	12,851	-	12,851
Needle & Syringe (LDS)	445,264	85,400	1,565,364	500,000	303,605	10/15	416%	303,605	1,945,969	12,851	-	12,851
OCs	447,366	459,194	4,618,758	5,070,000	3,337,534		38%	3,337,534	21,296,699	-	27,648	27,648
OK Pills	445,951	455,895	4,607,137	5,070,000	3,337,534	9/01	38%	3,337,534	21,285,078	-	27,578	27,578
OK Pills (Zinnia F)	1,415	3,299	11,621	-	-	11/16	-%	-	11,621	-	70	70
ORS	45,325	61,802	453,725	369,500	262,931		73%	262,931	716,656	-	11,919	11,919
ORS	45,325	61,802	453,725	369,500	262,931	1/08	73%	262,931	716,656	-	11,919	11,919
Pneumonia PPT	-	-	-	-	127,866		(100)%	127,866	1,057,411	-	-	-
Pneumox 125 mg (15 tabs)	-	-	-	-	75,684	2/11	(100)%	75,684	431,561	-	-	-
Pneumox 250 mg (15 tabs)	-	-	-	-	52,182	2/11	(100)%	52,182	625,850	-	-	-
Positive RDTs	1,064	1,374	12,558	-	13,201		(5)%	13,201	25,759	-	-	-
Positive RDTs	1,064	1,374	12,558	-	13,201		(5)%	13,201	25,759	-	-	-
Positive RDTs Given First Line Treatm	978	1,245	11,196	-	10,870		3%	10,870	22,066	-	-	-
Positive RDTs Given First Line Trea	978	1,245	11,196	-	10,870		3%	10,870	22,066	-	-	-
PUR	6,547	13,129	846,731	1,110,000	1,502,076		(44)%	1,502,076	15,224,481	-	20	20
Purifier of Water	6,547	13,129	846,731	1,110,000	1,502,076	4/14	(44)%	1,502,076	15,224,481	-	20	20

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
QAACTs Provided after Confirmatory I	647	903	7,492	10,088	7,361		2%	7,361	14,853	-	1,233	1,233
PSI QAACTs Provided after Confirm	647	903	7,492	10,088	7,361		2%	7,361	14,853	-	1,233	1,233
Referral to TB DOTS (completion confi	-	-	-	2,054	293		(100)%	293	293	-	-	-
Referral to TB DOTS (completion co	-	-	-	2,054	293		(100)%	293	293	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	43,388		(100)%	43,388	548,483	-	-	-
Cure U for Urethritis & Cervicitis	-	-	-	-	38,888	8/09	(100)%	38,888	514,283	-	-	-
Cure U Vaginitis	-	-	-	-	4,500	5/11	(100)%	4,500	34,200	-	-	-
STI Kit (Ulcerative)	-	-	-	-	3,679		(100)%	3,679	60,473	-	-	-
Cure U for Non-Herpetic Ulcer	-	-	-	-	3,679	8/09	(100)%	3,679	60,473	-	-	-
STI Screening	2,862	2,760	33,288	-	-		0%	-	33,288	-	-	-
STI Screening	2,862	2,760	33,288	-	-		-%	-	33,288	-	-	-
TB Diagnosis	1,480	1,444	14,182	-	15,499		(8)%	15,499	44,674	-	-	-
TB Diagnosis	1,480	1,444	14,182	-	15,499		(8)%	15,499	44,674	-	-	-
TB DOTS	942	1,402	14,235	13,984	15,133		(6)%	15,133	204,560	-	88,297	88,297
TB DOTS	942	1,402	14,235	13,984	15,133	12/04	(6)%	15,133	204,560	-	88,297	88,297
TB Screening	7,068	7,283	72,800	-	60,830		20%	60,830	194,218	-	-	-
TB Screening	7,068	7,283	72,800	-	60,830		20%	60,830	194,218	-	-	-
Vivax Treatment after Confirmatory Di	209	186	2,166	3,443	3,796		(43)%	3,796	5,962	-	356	356
PSI Vivax Treatment after Confirme	209	186	2,166	3,443	3,796		(43)%	3,796	5,962	-	356	356
<b>Nepal</b>										1,183	32,759	33,942
Emergency Contraception	-	-	14,464	14,700	15		96327%	15	14,479	-	38	38
Emergency Contraception	-	-	14,464	14,700	15	9/16	96,327%	15	14,479	-	38	38
Free Condom	-	-	530,200	568,070	41,934		1164%	41,934	572,134	1,183	367	1,550
Generic Condom	-	-	530,200	568,070	41,934	1/16	1,164%	41,934	572,134	1,183	367	1,550
Implant 5	-	(1)	(6)	-	18,088		(100)%	18,088	19,371	-	(4)	(4)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 12**  
**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Distributed Inserted (1)	-	(1)	(6)	-	(7)		-%	(7)	(1,343)	-	(4)	(4)
Jadelle	-	-	-	-	18,095	8/09	(100)%	18,095	20,714	-	-	-
Implant 5 Insertion	2	6	105	-	82		28%	82	1,610	-	77	77
PSI Implant 5 Inserted	-	1	6	-	7		(14)%	7	1,343	-	4	4
Non-PSI Implant 5 Inserted	2	5	99	-	75		32%	75	267	-	73	73
Injectable 3	-	-	-	-	61,975		(100)%	61,975	62,000	-	-	-
Depo-Provera	-	-	-	-	61,975	6/16	(100)%	61,975	62,000	-	-	-
IUD 10	(1,104)	(625)	(3,927)	-	1,190		(430)%	1,190	9,686	-	(3,169)	(3,169)
PSI IUD 10 Distributed Inserted (1)	(3,704)	(2,882)	(28,640)	(18,596)	(18,982)		-%	(18,982)	(188,961)	-	(23,112)	(23,112)
IUD	-	-	10,343	18,596	20,172	8/03	(49)%	20,172	180,377	-	8,346	8,346
OK IUD	2,600	2,250	14,350	-	-	5/04	-%	-	18,250	-	11,580	11,580
Pregna T Cu 380A	-	7	20	-	-	7/17	-%	-	20	-	16	16
IUD 10 Insertion	3,924	2,983	29,982	18,596	19,489		54%	19,489	199,404	-	26,883	26,883
PSI IUD 10 Inserted	3,704	2,882	28,640	18,596	18,982		51%	18,982	188,961	-	25,680	25,680
Non-PSI IUD 10 Inserted	220	102	1,342	-	507		165%	507	10,442	-	1,203	1,203
Medical Abortion	7,697	4,198	65,988	92,500	68,029		(3)%	68,029	242,468	-	8,191	8,191
Medabon	7,697	4,198	65,988	92,500	68,029	12/08	(3)%	68,029	242,468	-	8,191	8,191
OCs	-	-	42,624	43,083	8		532700%	8	143,172	-	376	376
Zinnia	-	-	42,624	43,083	8	8/15	532,700%	8	143,172	-	376	376
PUR	-	-	-	-	578,640		(100)%	578,640	1,235,812	-	-	-
PuR	-	-	-	-	578,640	6/15	(100)%	578,640	1,235,812	-	-	-
STI Screening	68	32	355	-	221		61%	221	1,159	-	-	-
STI Screening	68	32	355	-	221		61%	221	1,159	-	-	-
<b>Pakistan</b>										<b>30,093</b>	<b>736,805</b>	<b>766,898</b>
Condom	14,492,172	7,736,317	93,374,502	75,326,595	129,964,527		(28)%	129,964,527	2,517,772,661	30,093	102,546	132,639

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Condom Distributed Provided	-	-	-	-	(10,350)		-%	(10,350)	(31,403)	-	-	-
Do	79,200	36,240	1,168,920	-	-	8/17	-%	-	1,168,920	377	1,284	1,660
Generic Male Condom	-	-	1,778,241	1,218,430	1,710,632		4%	1,710,632	3,488,873	573	1,953	2,526
Sathi	13,100,232	6,278,796	77,894,894	62,763,591	113,482,837	1/87	(31)%	113,482,837	2,272,378,435	25,104	85,546	110,650
Sathi Plus	86,400	223,200	1,116,000	-	-	8/17	-%	-	1,116,000	360	1,226	1,585
Touch	1,183,140	1,134,601	10,542,007	11,344,574	14,781,408	4/96	(29)%	14,781,408	238,777,396	3,397	11,578	14,975
Touch Delay	43,200	63,480	874,440	-	-	8/17	-%	-	874,440	282	960	1,242
Condom Provided	-	-	-	-	10,350		(100)%	10,350	31,403	-	-	-
PSI Condom Provided	-	-	-	-	10,350		(100)%	10,350	31,403	-	-	-
Emergency Contraception	458,459	220,676	2,266,637	1,460,752	2,307,659		(2)%	2,307,659	18,625,732	-	9,383	9,383
PSI Emergency Contraception Distr	(304)	(407)	(7,190)	-	(9,091)		-%	(9,091)	(27,784)	-	(30)	(30)
ECP	458,763	167,371	1,999,333	1,460,752	2,316,750	9/14	(14)%	2,316,750	6,867,924	-	8,276	8,276
Postinor II	-	53,711	274,494	-	-	6/01	-%	-	11,785,592	-	1,136	1,136
Emergency Contraception Provided	304	407	8,020	-	9,091		(12)%	9,091	28,614	-	37	37
PSI Emergency Contraception Prov	304	407	7,190	-	9,091		(21)%	9,091	27,784	-	33	33
Non-PSI Emergency Contraception I	-	-	830	-	-		-%	-	830	-	4	4
Implant 3	-	-	(87)	-	-		0%	-	(87)	-	(63)	(63)
PSI Implant 3 Distributed Inserted (	-	-	(87)	-	-		-%	-	(87)	-	(63)	(63)
Implant 3 Insertion	-	-	87	-	-		0%	-	87	-	70	70
PSI Implant 3 Inserted	-	-	87	-	-		-%	-	87	-	70	70
Implant 5	64	61	1,172	-	279		320%	279	14,333	-	1,249	1,249
Jadelle	64	61	1,172	-	279	12/11	320%	279	14,333	-	1,249	1,249
Injectable 1	6,726	7,293	84,753	79,473	85,224		(1)%	85,224	1,603,410	-	1,462	1,462
PSI Injectable 1 Distributed Provide	(2,274)	(2,307)	(33,347)	-	(30,476)		-%	(30,476)	(88,503)	-	(575)	(575)
Femi-ject	9,000	9,600	118,100	79,473	115,700	6/03	2%	115,700	1,691,913	-	2,037	2,037

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 1 Provided</b>	<b>2,274</b>	<b>2,307</b>	<b>34,207</b>	-	<b>30,476</b>		<b>12%</b>	<b>30,476</b>	<b>89,363</b>	-	<b>656</b>	<b>656</b>
PSI Injectable 1 Provided	2,274	2,307	33,347	-	30,476		9%	30,476	88,503	-	639	639
Non-PSI Injectable 1 Provided	-	-	860	-	-		-%	-	860	-	16	16
<b>Injectable 2</b>	<b>5,391</b>	<b>18,680</b>	<b>276,802</b>	<b>225,406</b>	<b>299,852</b>		<b>(8)%</b>	<b>299,852</b>	<b>6,950,055</b>	-	<b>9,548</b>	<b>9,548</b>
PSI Injectable 2 Distributed Provide (1,329)	(1,329)	(1,400)	(20,558)	-	(22,868)		-%	(22,868)	(66,689)	-	(709)	(709)
Novaject	6,720	20,080	297,360	225,406	322,720	12/96	(8)%	322,720	7,016,744	-	10,258	10,258
<b>Injectable 2 Provided</b>	<b>1,329</b>	<b>1,400</b>	<b>21,738</b>	-	<b>22,868</b>		<b>(5)%</b>	<b>22,868</b>	<b>67,869</b>	-	<b>833</b>	<b>833</b>
PSI Injectable 2 Provided	1,329	1,400	20,558	-	22,868		(10)%	22,868	66,689	-	788	788
Non-PSI Injectable 2 Provided	-	-	1,180	-	-		-%	-	1,180	-	45	45
<b>Injectable 3</b>	<b>25,610</b>	<b>18,498</b>	<b>574,771</b>	<b>520,270</b>	<b>564,683</b>		<b>2%</b>	<b>564,683</b>	<b>2,922,133</b>	-	<b>29,741</b>	<b>29,741</b>
PSI Injectable 3 Distributed Provide (3,510)	(3,510)	(3,076)	(24,700)	-	(19,928)		-%	(19,928)	(59,680)	-	(1,278)	(1,278)
Depo-Provera	29,120	21,573	374,136	293,030	372,600	7/11	-%	372,600	2,544,467	-	19,359	19,359
Generic 3-month Injectable	-	-	225,335	227,240	212,011		6%	212,011	437,346	-	11,660	11,660
<b>Injectable 3 Provided</b>	<b>3,510</b>	<b>3,076</b>	<b>251,515</b>	-	<b>19,928</b>		<b>1162%</b>	<b>19,928</b>	<b>286,495</b>	-	<b>14,460</b>	<b>14,460</b>
PSI Injectable 3 Provided	3,510	3,076	24,700	-	19,928		24%	19,928	59,680	-	1,420	1,420
Non-PSI Injectable 3 Provided	-	-	226,815	-	-		-%	-	226,815	-	13,040	13,040
<b>IUD 10</b>	<b>5,310</b>	<b>6,720</b>	<b>121,915</b>	<b>144,558</b>	<b>142,645</b>		<b>(15)%</b>	<b>142,645</b>	<b>293,000</b>	-	<b>160,514</b>	<b>160,514</b>
Generic IUD 10	-	-	63,505	115,708	81,552		(22)%	81,552	145,057	-	83,611	83,611
Safeload	5,310	6,720	58,410	28,850	61,093	8/14	(4)%	61,093	147,943	-	76,903	76,903
<b>IUD 10 Insertion</b>	<b>-</b>	<b>-</b>	<b>65,510</b>	-	<b>-</b>		<b>0%</b>	<b>-</b>	<b>65,510</b>	-	<b>95,834</b>	<b>95,834</b>
Non-PSI IUD 10 Inserted	-	-	65,510	-	-		-%	-	65,510	-	95,834	95,834
<b>IUD 5</b>	<b>(283)</b>	<b>(3,504)</b>	<b>54,763</b>	<b>245,227</b>	<b>7,578</b>		<b>623%</b>	<b>7,578</b>	<b>3,021,472</b>	-	<b>53,662</b>	<b>53,662</b>
PSI IUD 5 Distributed Inserted (1)	(9,183)	(8,937)	(124,075)	-	(175,657)		-%	(175,657)	(870,377)	-	(121,580)	(121,580)
Generic IUD 5	-	-	12,138	15,627	15,035		(19)%	15,035	27,173	-	11,894	11,894
Multiload	8,900	5,433	166,700	229,600	168,200	12/95	(1)%	168,200	3,864,676	-	163,347	163,347

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 5 Insertion	9,183	8,937	129,395	-	175,657		(26)%	175,657	875,697	-	140,881	140,881
PSI IUD 5 Inserted	9,183	8,937	124,075	-	175,657		(29)%	175,657	870,377	-	135,088	135,088
Non-PSI IUD 5 Inserted	-	-	5,320	-	-		-%	-	5,320	-	5,792	5,792
Manual Vacuum Aspiration for PAC	3,024	2,745	28,649	-	31,135		(8)%	31,135	59,784	-	1,469	1,469
MVA for PAC	3,024	2,745	28,649	-	31,135		(8)%	31,135	59,784	-	1,469	1,469
Misoprostol for PAC (Sublingual)	298,800	-	298,800	-	-		0%	-	298,800	-	6,893	6,893
Misoprostol for PAC (Sublingual)	298,800	-	298,800	-	-	12/17	-%	-	298,800	-	6,893	6,893
OCs	167,752	44,614	963,998	807,294	1,121,152		(14)%	1,121,152	3,722,433	-	13,506	13,506
PSI OCs Distributed Provided	(3,468)	(3,846)	(53,811)	-	(60,615)		-%	(60,615)	(166,749)	-	(754)	(754)
Generic OC	-	-	447,869	389,165	364,567		23%	364,567	812,436	-	6,275	6,275
Novadol	171,220	48,460	569,940	418,129	817,200	1/08	(30)%	817,200	3,076,746	-	7,985	7,985
OCs Provided	3,468	3,846	507,470	-	60,615		737%	60,615	620,408	-	7,900	7,900
PSI OCs Provided	3,468	3,846	53,811	-	60,615		(11)%	60,615	166,749	-	838	838
Non-PSI OCs Provided	-	-	453,659	-	-		-%	-	453,659	-	7,062	7,062
TB Diagnosis	2,189	2,511	27,844	-	15,666		78%	15,666	50,161	-	-	-
TB Diagnosis	2,189	2,511	27,844	-	15,666		78%	15,666	50,161	-	-	-
TB DOTS	1,550	1,399	16,967	-	7,656		122%	7,656	87,463	-	77,648	77,648
TB DOTS	1,550	1,399	16,967	-	7,656	4/05	122%	7,656	87,463	-	77,648	77,648
TB Screening	3,626	4,109	53,521	-	-		0%	-	53,521	-	-	-
TB Screening	3,626	4,109	53,521	-	-		-%	-	53,521	-	-	-
Tubal Ligation	-	-	2,744	-	2,072		32%	2,072	219,615	-	8,577	8,577
VSC	-	-	2,744	-	2,072	6/01	32%	2,072	219,615	-	8,577	8,577
Water Treatment Tablets	-	-	-	-	241,500		(100)%	241,500	2,754,300	-	-	-
Aquatabs 33 mg (10 L)	-	-	-	-	167,380	2/12	(100)%	167,380	2,166,780	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	-	74,120	2/12	(100)%	74,120	587,520	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Papua New Guinea</b>										<b>1,683</b>	<b>192,970</b>	<b>194,652</b>
Condom	-	11,696	619,115	610,000	627,118		(1)%	627,118	7,987,900	1,527	833	2,360
Seif Raida	-	7,856	113,216	160,000	427,780	1/08	(74)%	427,780	6,909,453	279	152	432
Seif Raida Orange Plus	-	3,840	505,899	450,000	199,338	8/13	154%	199,338	1,078,447	1,248	680	1,928
Diarrhea Treatment Kit	-	-	2,243	15,000	5,446		(59)%	5,446	18,236	-	67	67
DTK	-	-	2,243	15,000	5,446	2/15	(59)%	5,446	18,236	-	67	67
Female Condom	-	11,087	63,060	62,960	19,760		219%	19,760	338,439	156	65	221
Stap Seif	-	11,087	63,060	62,960	19,760	2/09	219%	19,760	338,439	156	65	221
Malaria PPT (ACT)	247,878	191,410	822,108	935,921	3,366		24324%	3,366	837,695	-	191,945	191,945
Coartem 1x12's for 1-5 years old	7,465	38,260	122,245	305,007	660	8/15	18,422%	660	125,698	-	28,542	28,542
Coartem 1x18's for 6-13 years old	133,225	45,560	269,905	140,358	338	8/15	79,754%	338	271,435	-	63,017	63,017
Coartem 1x24's for 14+ years old	53,680	66,270	252,490	290,534	1,590	8/15	15,780%	1,590	258,462	-	58,951	58,951
Coartem 1x6's for 2-11 months	53,508	41,320	177,468	200,022	778	8/15	22,711%	778	182,100	-	41,435	41,435
Malaria RDK	139,831	369,900	1,249,531	-	-		0%	-	1,357,487	-	-	-
Carestart Malaria HRP2/pLDH (pf/PfPR)	139,831	369,900	1,249,531	-	-	10/13	-%	-	1,357,487	-	-	-
Water Treatment Tablets	-	433	16,300	50,000	26,630		(39)%	26,630	887,623	-	1	1
Aquatab	-	433	16,300	50,000	26,630	12/11	(39)%	26,630	887,623	-	1	1
Zinc	-	-	8,490	8,490	5,050		68%	5,050	32,844	-	58	58
Zinc 20 mg	-	-	8,490	8,490	5,050	12/11	68%	5,050	32,844	-	58	58
<b>Tajikistan</b>										<b>22,474</b>	<b>182</b>	<b>22,655</b>
Free Condom	18,300	27,969	302,352	287,544	19,300		1467%	19,300	1,531,750	1,158	182	1,339
Generic Condom	-	-	-	287,544	-	8/10	-%	-	1,210,098	-	-	-
Generic Male Condom	18,300	27,969	302,352	-	19,300	8/16	1,467%	19,300	321,652	1,158	182	1,339
HIV Testing Services	1,791	1,645	14,406	21,913	-		0%	-	15,247	46	-	46
VCT Individual (HIV-Negative)	1,749	1,603	14,027	21,913	-		-%	-	14,868	45	-	45

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	42	42	379	-	-		-%	-	379	1	-	1
Naloxone	600	282	3,511	5,892	-		0%	-	14,143	4,790	-	4,790
Naloxone	600	282	3,511	5,892	-	1/11	-%	-	14,143	4,790	-	4,790
Needle & Syringe	200,000	162,307	1,259,681	1,482,749	-		0%	-	2,168,953	15,811	-	15,811
Needle/Syringe	200,000	162,307	1,259,681	1,482,749	-	1/11	-%	-	2,168,953	15,811	-	15,811
Referral to HIV Testing Services	1	1	4,329	2,300	1,439		201%	1,439	15,103	7	-	7
Referral to HIV Testing & Counseling	1	1	4,329	2,300	1,439	12/13	201%	1,439	15,103	7	-	7
Referral to Linkage to HIV Care	68	48	832	154	80		940%	80	912	662	-	662
Referral to Linkage to HIV Care	68	48	832	154	80		940%	80	912	662	-	662
Referral to Opioid Treatment	5	8	119	-	5		2280%	5	124	-	-	-
Referral to Opioid Treatment	5	8	119	-	5		2,280%	5	124	-	-	-
Referral to TB Diagnosis	-	-	56	-	-		0%	-	5,208	-	-	-
Referral to TB Diagnosis	-	-	56	-	-	12/14	-%	-	5,208	-	-	-
Referral to TB Screening	6	-	7	-	-		0%	-	7	-	-	-
Referrals to TB Screening	6	-	7	-	-		-%	-	7	-	-	-
TB Screening	6	276	2,307	-	1,643		40%	1,643	5,089	-	-	-
TB Screening	6	276	2,307	-	1,643		40%	1,643	5,089	-	-	-
<b>Viet Nam</b>										<b>28,771</b>	<b>127</b>	<b>28,898</b>
Emergency Contraception	(52)	-	(52)	-	-		0%	-	(52)	-	-	-
PSI Emergency Contraception Distr	(52)	-	(52)	-	-		-%	-	(52)	-	-	-
Emergency Contraception Provided	52	93	661	-	-		0%	-	661	-	-	-
PSI Emergency Contraception Prov	52	-	52	-	-		-%	-	52	-	-	-
Non-PSI Emergency Contraception I	-	93	609	-	-		-%	-	609	-	-	-
HIV Testing Services	683	525	5,224	10,000	-		0%	-	5,224	8	-	8
VCT Individual (HIV-Negative)	641	493	4,824	10,000	-		-%	-	4,824	8	-	8

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	42	33	400	-	-		-%	-	400	1	-	1
Hypertension Diagnosis	11,543	3,189	26,333	-	-		0%	-	26,333	-	-	-
Hypertension Diagnosis	11,543	3,189	26,333	-	-		-%	-	26,333	-	-	-
Hypertension Screening	186,933	2,118	202,214	-	-		0%	-	202,214	-	-	-
Hypertension Screening	186,933	2,118	202,214	-	-		-%	-	202,214	-	-	-
Hypertension_Controlled Condition	15,983	-	20,108	-	-		0%	-	20,108	-	-	-
Hypertension_Controlled Condition	15,983	-	20,108	-	-		-%	-	20,108	-	-	-
Implant 3	45	43	304	5,000	(3)		0%	(3)	301	-	21	21
PSI Implant 3 Distributed Inserted (	(16)	(2)	(32)	-	(3)		-%	(3)	(35)	-	(2)	(2)
Implanon NXT	61	45	336	5,000	-	2/17	-%	-	336	-	23	23
Implant 3 Insertion	21	7	77	30	3		2467%	3	80	-	6	6
PSI Implant 3 Inserted	16	2	32	-	3		967%	3	35	-	2	2
Non-PSI Implant 3 Inserted	5	5	45	30	-		-%	-	45	-	3	3
Injectable 1	(2)	-	(2)	-	-		0%	-	(2)	-	-	-
PSI Injectable 1 Distributed Provide	(2)	-	(2)	-	-		-%	-	(2)	-	-	-
Injectable 1 Provided	2	3	42	-	-		0%	-	42	-	-	-
PSI Injectable 1 Provided	2	-	2	-	-		-%	-	2	-	-	-
Non-PSI Injectable 1 Provided	-	3	40	-	-		-%	-	40	-	-	-
Injectable 3	(12)	10	238	12,000	(5)		0%	(5)	233	-	1	1
PSI Injectable 3 Distributed Provide	(12)	(46)	(233)	-	(5)		-%	(5)	(238)	-	(1)	(1)
Depoteron	-	57	471	12,000	-	2/17	-%	-	471	-	2	2
Injectable 3 Provided	49	101	817	-	5		16240%	5	822	-	4	4
PSI Injectable 3 Provided	12	46	233	-	5		4,560%	5	238	-	1	1
Non-PSI Injectable 3 Provided	37	54	584	-	-		-%	-	584	-	3	3
IUD 10	-	(1)	(2)	-	71		(103)%	71	69	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 12

Year: 2017

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 10 Distributed Inserted (1)	-	(1)	(2)	-	(29)		-%	(29)	(31)	-	-	-
Copper-T 380-A IUD	-	-	-	-	100	9/16	(100)%	100	100	-	-	-
IUD 10 Insertion	6	20	197	270	29		579%	29	226	-	27	27
PSI IUD 10 Inserted	-	1	2	-	29		(93)%	29	31	-	-	-
Non-PSI IUD 10 Inserted	6	19	195	270	-		-%	-	195	-	27	27
LLIN (Hammock net)	45	-	45	550	-		0%	-	45	-	-	-
Tana Nets	45	-	45	550	-		-%	-	45	-	-	-
Needle & Syringe	366,600	372,167	4,087,850	4,100,000	4,600,000		(11)%	4,600,000	17,547,390	28,763	-	28,763
B-braun Omnican 40 (U-40 Insulin)	366,600	372,167	4,087,850	-	4,584,000	9/13	(11)%	4,584,000	17,524,900	28,763	-	28,763
Needle & Syringe (LDS)	-	-	-	4,100,000	16,000	4/13	(100)%	16,000	22,490	-	-	-
OCs	(117)	-	(117)	-	-		0%	-	(117)	-	-	-
PSI OCs Distributed Provided	(117)	-	(117)	-	-		-%	-	(117)	-	-	-
OCs Provided	117	121	950	-	-		0%	-	950	-	1	1
PSI OCs Provided	117	-	117	-	-		-%	-	117	-	-	-
Non-PSI OCs Provided	-	121	833	-	-		-%	-	833	-	1	1
Positive RDTs	58	28	178	-	-		0%	-	178	-	-	-
Positive RDTs	58	28	178	-	-		-%	-	178	-	-	-
Positive RDTs Given First Line Treatm	17	10	65	-	-		0%	-	65	-	-	-
Positive RDTs Given First Line Trea	17	10	65	-	-		-%	-	65	-	-	-
QAACTs Provided after Confirmatory I	17	10	62	425	-		0%	-	62	-	12	12
Non-PSI QAACTs Provided after Co	17	10	62	425	-		-%	-	62	-	12	12
Referral to TB DOTS (completion unkr	-	-	-	1,000	-		0%	-	-	-	-	-
Referral to TB DOTS (completion un	-	-	-	1,000	-		-%	-	-	-	-	-
Safe Water Solution	-	-	-	-	6,973		(100)%	6,973	655,267	-	-	-
SafeWat	-	-	-	-	6,973	11/05	(100)%	6,973	655,267	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 12**

**Year: 2017**

	DISTRIBUTION 12/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB Diagnosis	<b>132</b>	<b>47</b>	<b>747</b>	-	<b>2,394</b>		<b>(69)%</b>	<b>2,394</b>	<b>4,937</b>	-	-	-
TB Diagnosis	<b>132</b>	<b>47</b>	<b>747</b>	-	<b>2,394</b>		(69)%	<b>2,394</b>	<b>4,937</b>	-	-	-
Toilets Sold	<b>311</b>	<b>207</b>	<b>1,898</b>	<b>5,490</b>	-		<b>0%</b>	-	<b>1,898</b>	-	<b>53</b>	<b>53</b>
Toilet Type 1, Direct Sales	<b>311</b>	<b>207</b>	<b>1,898</b>	<b>4,740</b>	-		-%	-	<b>1,898</b>	-	<b>53</b>	<b>53</b>
Toilet Type 2, Direct Sales	-	-	-	<b>750</b>	-		-%	-	-	-	-	-
Vivax Treatment after Confirmatory Di	-	<b>3</b>	<b>9</b>	-	-		<b>0%</b>	-	<b>9</b>	-	<b>2</b>	<b>2</b>
Non-PSI Vivax Treatment after Conf	-	<b>3</b>	<b>9</b>	-	-		-%	-	<b>9</b>	-	<b>2</b>	<b>2</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Asia and Eastern Europe - Asia</b>														
<b>Cambodia</b>							\$0		\$0	\$0	NA			
<b>Condom</b>														
Number One	12/2017	691,920	8,568	0	700,488	1%	\$0	NA	\$0	\$0	NA	1,760,976	572,064	3.08
OK Condom	12/2017	622,890	240	0	623,130	0%	\$0	NA	\$0	\$0	NA	5,668,713	628,130	9.02
<b>Lubricant A</b>														
OK Plus Lubricant	12/2017	48,420	60	0	48,480	0%	\$0	NA	\$0	\$0	NA	505,760	62,120	8.14
<b>Malaria PPT (ACT)</b>														
ASMQ for Adult	12/2017	3,693	531	0	4,224	13%	\$0	NA	\$0	\$0	NA	776	3,793	0.20
ASMQ for Children	12/2017	507	1	0	508	0%	\$0	NA	\$0	\$0	NA	175	418	0.42
<b>Malaria RDK</b>														
Malaria RDT (Diagnosis)	12/2017	25,250	7,450	0	32,700	23%	\$0	NA	\$0	\$0	NA	276,500	35,100	7.88
<b>Diarrhea Treatment Kit</b>														
Orasel Kit	12/2017	5,550	1,490	0	7,040	21%	\$0	NA	\$0	\$0	NA	57,190	6,697	8.54
<b>Medical Abortion</b>														
Medabon	12/2017	24,686	6	0	24,692	0%	\$0	NA	\$0	\$0	NA	62,310	30,278	2.06
<b>Emergency Contraception</b>														
NEXT 72 EC	12/2017	5,970	20	0	5,990	0%	\$0	NA	\$0	\$0	NA	21,238	6,803	3.12
<b>Implant 5</b>														
Implant 5	12/2017	695	0	0	695	0%	\$0	NA	\$0	\$0	NA	4,624	710	6.51
<b>Injectable 3</b>														
OK Injection-3	12/2017	42,475	25	0	42,500	0%	\$0	NA	\$0	\$0	NA	57,875	37,492	1.54
<b>IUD 10</b>														
IUD Copper T	12/2017	2,360	0	0	2,360	0%	\$0	NA	\$0	\$0	NA	12,760	2,542	5.02
<b>OCs</b>														
Marvelon	12/2017	102,400	3,045	0	105,445	3%	\$0	NA	\$0	\$0	NA	148,368	48,122	3.08
OK Pills	12/2017	483,888	24	0	483,912	0%	\$0	NA	\$0	\$0	NA	2,427,048	435,552	5.57
<b>India</b>							\$0		\$0	\$0	NA			
<b>Condom</b>														
Masti	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,960	0	NA
<b>ORS</b>														
Neotral Orange 1000ml	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	355	0	NA
<b>Injectable 3</b>														
Freedom Inject (3-month)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	68	0	NA

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>India</b>							\$0		\$0	\$0	NA				
<u><b>IUD 10</b></u>															
Freedom 10	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	65,560	0	NA	
<b>India LLC</b>							\$447,698		\$82,595	\$421,504	0.20				
<u><b>Condom</b></u>															
Masti Classic 10's	12/2017	493,200	0	0	493,200	0%	\$15,239	0%	\$0	\$45,500	NA	3,845,920	1,477,600	2.60	
Masti Classic 10's (Flavoured)	12/2017	1,411,200	0	3,600	1,414,800	0%	\$49,106	11%	\$5,634	\$43,422	0.13	8,392,040	1,270,440	6.61	
Masti Classic 3's	12/2017	3,492,000	240	7,185	3,499,425	0%	\$102,438	17%	\$17,717	\$68,953	0.26	25,571,903	2,378,834	10.75	
Masti Classic 3's (Flavoured)	12/2017	2,635,200	0	46,800	2,682,000	0%	\$93,783	17%	\$15,675	\$81,486	0.19	9,099,070	2,355,320	3.86	
Masti Classic 6's	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	960	0	NA	
Masti Premium 10's (Flavoured)	12/2017	370,920	0	27,000	397,920	0%	\$20,505	22%	\$4,511	\$20,500	0.22	5,502,120	387,920	14.18	
Masti Premium 3's	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	12,856	0	NA	
Masti Premium 3's (Flavoured)	12/2017	1,052,600	0	14,400	1,067,000	0%	\$61,262	29%	\$18,018	\$54,292	0.33	7,503,671	966,427	7.76	
<u><b>Medical Abortion</b></u>															
Safe Abort kit	12/2017	43,030	0	0	43,030	0%	\$34,125	13%	\$4,438	\$32,244	0.14	453,454	48,003	9.45	
<u><b>ORS</b></u>															
Neotral Orange 1000ml	12/2017	7,200	0	0	7,200	0%	\$861	0%	\$0	\$1,171	NA	1,208,945	11,700	103.33	
<u><b>Injectable 3</b></u>															
Freedom Inject (3-month)	12/2017	4,884	372	0	5,256	7%	\$4,517	24%	\$1,076	\$7,680	0.14	130,471	9,924	13.15	
<u><b>IUD 5</b></u>															
Freedom 5	12/2017	6,055	0	0	6,055	0%	\$6,222	0%	\$0	\$10,140	NA	46,421	10,036	4.63	
<u><b>OCs</b></u>															
Pearl	12/2017	263,040	0	1,590	264,630	0%	\$59,641	26%	\$15,527	\$56,116	0.28	2,664,680	256,140	10.40	
<b>Kazakhstan</b>							\$0		\$0	\$0	NA				
<u><b>HIV Test Kit</b></u>															
OraQuick	12/2017	0	77	0	77	100%	\$0	NA	\$0	\$0	NA	4,079	74	55.37	
<u><b>Free Condom</b></u>															
Generic Male Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	246,835	455	542.49	
<u><b>Free Female Condom</b></u>															
Generic Female Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	12,430	190	65.42	
<b>Kyrgyzstan</b>							\$0		\$0	\$0	NA				
<u><b>HIV Test Kit</b></u>															
Alere Determine	12/2017	0	1,700	0	1,700	100%	\$0	NA	\$0	\$0	NA	3,600	1,833	1.96	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Kyrgyzstan</b>							\$0		\$0	\$0	NA				
<b>Free Condom</b>															
Generic Male Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	227,000	NA	NA	
<b>Free Female Condom</b>															
Generic Female Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	13,000	NA	NA	
<b>Laos</b>							\$4,372		\$15,324	\$5,111	3.00				
<b>Condom</b>															
No 1 Condom Grp	12/2017	0	110,085	-107,559	2,526	100%	\$0	NA	\$173	\$58	3.00	337,533	37,847	8.92	
No 1 Condom Strw	12/2017	0	178,518	-159,717	18,801	100%	\$0	NA	\$1,299	\$434	3.00	931,788	68,146	13.67	
Number One Rose	12/2017	0	133,608	-116,670	16,938	100%	\$0	NA	\$5,108	\$1,704	3.00	58,905	78,520	0.75	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	12/2017	20,000	2,570	0	22,570	11%	\$4,372	100%	\$8,743	\$2,915	3.00	24,000	14,190	1.69	
<b>IUD 5</b>															
IUD Cu375	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	8,000	0	NA	
<b>Myanmar</b>							\$196,585		\$83	\$159,294	0.00				
<b>Condom</b>															
Aphaw	12/2017	110,340	3,720	5	114,065	3%	\$5,425	0%	\$0	\$6,533	NA	5,349,138	154,623	34.59	
Aphaw - Natural Touch	12/2017	51,321	1,980	0	53,301	4%	\$3,154	0%	\$0	\$2,305	NA	1,846,937	45,774	40.35	
Aphaw Flavors	12/2017	181,248	209,296	6,000	396,544	54%	\$8,267	0%	\$0	\$9,500	NA	5,568,909	518,178	10.75	
Aphaw Studded	12/2017	4,860	240	9	5,109	5%	\$299	0%	\$0	\$452	NA	1,041,915	12,490	83.42	
Generic Male Condom	12/2017	0	91,500	0	91,500	100%	\$0	NA	\$0	\$0	NA	2,587,000	39,500	65.49	
OK Condom	12/2017	11,736	0	0	11,736	0%	\$72	0%	\$0	\$49	NA	97,160	7,968	12.19	
<b>Female Condom</b>															
Generic Female Condom	12/2017	0	7,917	0	7,917	100%	\$0	NA	\$0	\$0	NA	160,744	7,111	22.60	
<b>Lubricant B</b>															
Aphaw Gel - Tube 20 cc	12/2017	0	3,258	0	3,258	100%	\$0	NA	\$0	\$0	NA	64,039	3,178	20.15	
Aphaw Gel - Tube 20 cc - Flavors	12/2017	0	0	4	4	NA	\$0	NA	\$0	\$0	NA	20,480	0	NA	
<b>Needle &amp; Syringe</b>															
Needle & Syringe (LDS)	12/2017	0	445,264	0	445,264	100%	\$0	NA	\$0	\$0	NA	10,100	199,488	0.05	
<b>Malaria PPT (ACT)</b>															
AL 1	12/2017	0	1	250	251	100%	\$0	NA	\$0	\$0	NA	11,208	65	173.32	
AL 2	12/2017	0	11	1,121	1,132	100%	\$0	NA	\$0	\$0	NA	9,552	104	92.14	
AL 3	12/2017	0	186	1,740	1,926	100%	\$0	NA	\$0	\$0	NA	26,283	221	118.93	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Myanmar</b>							\$196,585		\$83	\$159,294	0.00				
<b><u>Malaria PPT (ACT)</u></b>															
AL 4	12/2017	0	789	1,231	2,020	100%	\$0	NA	\$0	\$0	NA	14,078	983	14.32	
Arte+1	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	620	0	NA	
Arte+2	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,198	0	NA	
Arte+3	12/2017	720	0	0	720	0%	\$83	100%	\$83	\$28	3.00	1,575	240	6.56	
Arte+4	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	600	8	72.00	
Supa Arte 1	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	952	0	NA	
Supa Arte 2	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,207	0	NA	
Supa Arte 3	12/2017	0	0	56	56	NA	\$0	NA	\$0	\$0	NA	2,428	9	260.14	
Supa Arte 4	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	151	8	18.12	
<b><u>Malaria PPT (Non-ACT)</u></b>															
Vivax Treatment Kit	12/2017	0	29	0	29	100%	\$0	NA	\$0	\$0	NA	2,128	213	10.01	
<b><u>Malaria RDK</u></b>															
Malaria RDT (Diagnosis)	12/2017	0	46,180	0	46,180	100%	\$0	NA	\$0	\$0	NA	87,550	88,460	0.99	
<b><u>Diarrhea Treatment Kit</u></b>															
Orasel DTK	12/2017	0	8	0	8	100%	\$0	NA	\$0	\$0	NA	0	17	NA	
<b><u>Multivitamin</u></b>															
May May Vita Plus	12/2017	43,140	1,950	0	45,090	4%	\$2,608	0%	\$0	\$2,823	NA	1,019,300	49,277	20.69	
<b><u>ORS</u></b>															
ORS	12/2017	45,271	54	200	45,525	0%	\$3,933	0%	\$0	\$4,065	NA	142,475	46,962	3.03	
<b><u>PUR</u></b>															
Purifier of Water	12/2017	3,177	3,370	560	7,107	51%	\$92	0%	\$0	\$71	NA	646,532	7,359	87.86	
<b><u>Emergency Contraception</u></b>															
OK EC	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5	0	15.00	
<b><u>Implant 3</u></b>															
Implanon NXT	12/2017	655	15	0	670	2%	\$6,096	0%	\$0	\$5,003	NA	8,363	541	15.46	
<b><u>Implant 5</u></b>															
Jadelle	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	93	0	NA	
<b><u>Injectable 3</u></b>															
OK-3 Injection	12/2017	51,600	100	0	51,700	0%	\$25,878	0%	\$0	\$18,088	NA	677,832	43,238	15.68	
<b><u>IUD 10</u></b>															
OK IUD (Copper T Cu 380A)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	259	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Myanmar</b>							\$196,585		\$83	\$159,294	0.00				
<u><b>IUD 5</b></u>															
OK IUD	12/2017	187	0	0	187	0%	\$69	0%	\$0	\$67	NA	14,087	183	76.84	
<u><b>OCs</b></u>															
OK Pills	12/2017	445,883	68	0	445,951	0%	\$140,169	0%	\$0	\$109,481	NA	611,963	348,387	1.76	
OK Pills (Zinnia F)	12/2017	1,415	0	0	1,415	0%	\$440	0%	\$0	\$829	NA	3,379	2,727	1.24	
<b>Nepal</b>							\$17,102		\$0	\$10,943	NA				
<u><b>Free Condom</b></u>															
Generic Condom	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,148	0	NA	
<u><b>Medical Abortion</b></u>															
Medabon	12/2017	7,697	0	0	7,697	0%	\$16,861	0%	\$0	\$10,783	NA	22,535	6,331	3.56	
<u><b>Emergency Contraception</b></u>															
i-pill	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	221	0	NA	
<u><b>IUD 10</b></u>															
OK IUD	12/2017	2,600	0	0	2,600	0%	\$241	0%	\$0	\$160	NA	35,162	2,550	13.79	
Pregna T Cu 380A	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,914	7	287.10	
<u><b>OCs</b></u>															
Zinnia	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	554	0	NA	
Zinnia - F	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	14,580	0	NA	
<b>Pakistan</b>							\$663,067		\$331,913	\$464,061	0.72				
<u><b>Medicines &amp; Supplies</b></u>															
ViCal+ (Ossein Mineral Complex &	12/2017	720,000	0	0	720,000	0%	\$49,953	100%	\$32,795	NA	NA	519,420	NA	NA	
<u><b>Condom</b></u>															
Do	12/2017	79,200	0	0	79,200	0%	\$19,161	100%	\$13,734	\$7,171	1.92	1,831,080	29,640	61.78	
Sathi	12/2017	13,100,232	0	0	13,100,232	0%	\$297,048	100%	\$135,041	\$212,018	0.64	115,807,255	8,668,344	13.36	
Sathi Plus	12/2017	86,400	0	0	86,400	0%	\$6,968	100%	\$21,590	\$17,422	1.24	3,384,000	216,000	15.67	
Touch	12/2017	1,183,140	0	0	1,183,140	0%	\$89,486	100%	\$61,239	\$82,890	0.74	21,906,387	1,069,441	20.48	
Touch Delay	12/2017	43,200	0	0	43,200	0%	\$5,226	100%	\$14,242	\$3,978	3.58	2,125,560	32,880	64.65	
<u><b>Misoprostol for PAC (Sublingual)</b></u>															
Misoprostol for PAC (Sublingual)	12/2017	298,800	0	0	298,800	0%	\$21,445	100%	\$14,675	NA	NA	18,360	NA	NA	
<u><b>Water Treatment Tablets</b></u>															
Aquatabs 33 mg (10 L)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,016	0	NA	
Aquatabs 67 mg (20 L)	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,246	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Pakistan</b>							\$663,067		\$331,913	\$464,061	0.72				
<u>Emergency Contraception</u>															
ECP	12/2017	458,763	0	0	458,763	0%	\$49,389	100%	\$4,463	\$34,486	0.13	9,066	320,292	0.03	
Postinor II	12/2017	0	0	0	0	NA	\$0	NA	\$4,039	\$0	NA	21	0	NA	
<u>Implant 5</u>															
Jadelle	12/2017	64	0	0	64	0%	\$121	0%	\$0	\$134	NA	18,214	71	257.75	
<u>Injectable 1</u>															
Femi-ject	12/2017	9,000	0	0	9,000	0%	\$3,294	100%	\$2,220	\$3,722	0.60	310,226	10,167	30.51	
<u>Injectable 2</u>															
Novaject	12/2017	6,720	0	0	6,720	0%	\$3,280	100%	\$5,159	\$7,148	0.72	114,614	14,640	7.83	
<u>Injectable 3</u>															
Depo-Provera	12/2017	29,120	0	0	29,120	0%	\$31,965	100%	\$14,207	\$29,448	0.48	264,955	26,800	9.89	
<u>IUD 10</u>															
Safeload	12/2017	5,310	0	0	5,310	0%	\$4,484	100%	\$4,760	\$5,624	0.85	96,578	6,660	14.50	
<u>IUD 5</u>															
Multiload	12/2017	8,900	0	0	8,900	0%	\$7,515	100%	\$422	\$7,094	0.06	521,229	8,400	62.05	
<u>OCs</u>															
Novadol	12/2017	171,220	0	0	171,220	0%	\$73,733	100%	\$3,329	\$29,126	0.11	385,611	88,753	4.34	
<b>Papua New Guinea</b>							\$0		\$1,868	\$2,967	0.63				
<u>Condom</u>															
Seif Raida	12/2017	0	0	0	0	NA	\$0	NA	\$42	\$661	0.06	59,552	6,016	9.90	
Seif Raida Orange Plus	12/2017	0	0	0	0	NA	\$0	NA	\$320	\$379	0.84	2,667	2,480	1.08	
<u>Female Condom</u>															
Stap Seif	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$1,926	NA	120	11,087	0.01	
<u>Lubricant A</u>															
Glide Lubricant	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	256	0	NA	
<u>Malaria PPT (ACT)</u>															
Coartem 1x12's for 1-5 years old	12/2017	0	7,465	0	7,465	100%	\$0	NA	\$0	\$0	NA	95	24,928	0.00	
Coartem 1x18's for 6-13 years old	12/2017	0	133,225	0	133,225	100%	\$0	NA	\$0	\$0	NA	4,535	64,868	0.07	
Coartem 1x24's for 14+ years old	12/2017	0	53,680	0	53,680	100%	\$0	NA	\$0	\$0	NA	1,490	58,763	0.03	
Coartem 1x6's for 2-11 months	12/2017	0	53,508	0	53,508	100%	\$0	NA	\$0	\$0	NA	1,662	39,506	0.04	
<u>Malaria RDK</u>															
Carestart Malaria HRP2/pLDH (pf/	12/2017	0	139,831	0	139,831	100%	\$0	NA	\$0	\$0	NA	4,469	416,510	0.01	
<u>Diarrhea Treatment Kit</u>															
DTK	12/2017	0	0	1,377	1,377	NA	\$0	NA	\$57	\$0	NA	0	0	NA	



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Papua New Guinea</b>							\$0		\$1,868	\$2,967	0.63				
<u>ORS</u>															
ORS	12/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	14,940	NA	NA	
<u>Water Treatment Tablets</u>															
Aquatab	12/2017	0	0	200	200	NA	\$0	NA	\$1,450	\$0	NA	484,020	433	1,116.97	
<u>Zinc</u>															
Zinc 20 mg	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,590	0	NA	
<b>Tajikistan</b>							\$0		\$0	\$0	NA				
<u>HIV Test Kit</u>															
HIV Test Kit	12/2017	0	900	0	900	100%	\$0	NA	\$0	\$0	NA	2,394	1,233	1.94	
<u>Free Condom</u>															
Generic Male Condom	12/2017	0	18,300	0	18,300	100%	\$0	NA	\$0	\$0	NA	743,770	24,217	30.71	
<u>Needle &amp; Syringe</u>															
Needle/Syringe-1 ml (0.45x16mm)	12/2017	0	30,000	0	30,000	100%	\$0	NA	\$0	\$0	NA	0	43,000	NA	
Needle/Syringe-2 ml (0.46x25mm)	12/2017	0	60,000	0	60,000	100%	\$0	NA	\$0	\$0	NA	0	20,000	NA	
Needle/Syringe-5 ml (0.6x32mm)	12/2017	0	110,000	0	110,000	100%	\$0	NA	\$0	\$0	NA	0	95,200	NA	
<u>Naloxone</u>															
Naloxone	12/2017	0	600	0	600	100%	\$0	NA	\$0	\$0	NA	0	432	NA	
<b>Viet Nam</b>							\$139		\$0	\$46	NA				
<u>Needle &amp; Syringe</u>															
B-braun Omnican 40 (U-40 Insulin/	12/2017	0	366,600	-366,600	0	100%	\$0	NA	\$0	\$0	NA	1,150	372,267	0.00	
<u>LLIN (Hammock net)</u>															
Tana Nets	12/2017	45	0	0	45	0%	\$139	0%	\$0	NA	NA	1,954	NA	NA	
<u>Malaria RDK</u>															
On-site Malaria Pf/Pv Ag Rapid Te	12/2017	0	0	1,440	1,440	NA	\$0	NA	\$0	\$0	NA	4,210	0	NA	
<u>Implant 3</u>															
Implanon NXT	12/2017	0	61	-61	0	100%	\$0	NA	\$0	\$0	NA	0	33	NA	
<u>IUD 10</u>															
Copper-T 380-A IUD	12/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	544	0	NA	